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Following traumatic brain injury (TBI), ~80% of individuals will experience cognitive deficits, 
and ~50% will experience post-TBI depression (PTD). Identifying individual risk patterns for 
these complications is important for preventive treatment and early intervention. In uninjured 
populations, individuals with depression have distinct accompanying cognitive deficits. 
Importantly, dysregulation of fronto-limbic regions may, in part, explain the co-occurrence of both 
depressive and cognitive symptoms. The work presented investigates biological factors that 
influence survival after severe TBI, and among survivors, the presence and severity of PTD and/or 
cognitive deficits. The scientific framework under which this work was completed proposes 
targeted interactions between monoaminergic and neurotrophic gene variation that may lead to 
cognitive deficits and depressive symptoms. In addition to cognition, serotonergic (5-HT) and 
dopaminergic (DA) signaling both contribute to depressed mood and anhedonia, suggesting 
genetic variation in their signaling pathways may modulate PTD risk. Brain-derived neurotrophic 
factor (BDNF), a ubiquitous neurotrophin involved in neuronal survival and synaptic plasticity, is 
implicated in depression and cognitive dysfunction, and BDNF interacts with 5-HT/DA signaling 
in mood and cognitive processes. The work presented examines monoaminergic-neurotrophic 
biomarkers for predicting PTD risk and cognitive deficits. Serum and cerebrospinal fluid (CSF) 
BDNF levels, and fronto-limbic atrophy, were examined as possible biomarkers of PTD and 
cognitive deficits. A battery of targeted genes were examined for their proposed roles in survival, 
depression, cognition, and/or modulation of fronto-limbic connectivity. The data show variation 
within monoaminergic genes was associated with PTD incidence (serotonin transporter, 5-
HTTLPR) and cognitive deficits post-TBI (dopamine D2 receptor, DRD2 and COMT). When 
investigating BDNF associations with PTD, we discovered that variation in BDNF interacts with 
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age to influence TBI survival, and acute BDNF levels were consistent biomarkers for TBI survival. 
Among TBI survivors, acute BDNF levels were associated with chronic cognitive performance 
and depressive symptoms severity, suggesting early neurotrophic support may facilitate chronic 
recovery. Investigating fronto-limbic regional brain volumes identified significant relationships to 
PTD and suggested non-uniform fronto-limbic atrophy patterns that may explain PTD 
susceptibility. Overall, this work supports that monoaminergic-neurotrophin genetic variability 
affects individual risk for PTD and related cognitive deficits, possibly through relationships with 
fronto-limbic circuitry. 
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1.0  INTRODUCTION 
Traumatic brain injury (TBI) results in either a transient or permanent neurological deficit resulting 
from mechanical insult to the brain due to an external force. Approximately 1.7 million people per 
year in the US sustain a TBI (“CDC - Injury - TBI - TBI in the US Report,” n.d.). An estimated 
5.3 million Americans are currently living with disabilities resulting from TBI, with an estimated 
national cost to society of $48.3 billion per year. As there is a spike in incidence during late 
adolescence/young adulthood (“CDC - Injury - TBI - TBI in the US Report,” n.d.), the incurred 
difficulties resulting from a TBI can lead to decades of lost opportunities for employment and 
productivity, significantly burdening survivors and their families. Several factors influence patient 
reintegration in society and quality of life following injury, but cognitive deficits and depressive 
symptoms can have the greatest impact on recovery. Following a TBI, 80% of individuals will 
experience cognitive deficits (McCullagh and Feinstein, 2004). Similarly, individuals with TBI 
are at a significantly greater risk for depression compared to the general population. In the U.S., 
6.7% of the general population will experience an episode of major depression each year (Kessler 
et al., 2005), while the rate of depression in TBI ranges from 10-77% within the first year post-
injury(Rosenthal et al., 1998); a recent, well characterized study reported a rate of 53% 
(Bombardier et al., 2010a). Further, those with PTD are at increased risk for suicide (León-Carrión 
et al., 2001). With the addition of an increasing rise in TBI among the U.S. military population, 
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where TBI has become the ‘signature wound’, understanding cognitive deficits and depression 
following injury will be increasingly important.  
Identifying risk for complications in an individual’s recovery is integral in development of 
effective treatment and early intervention. Risk assessment tools are currently lacking and clinical 
and injury-related variables provide little insight. In the work described in this narrative, survival, 
mood, and cognitive recovery post-TBI is studied across multiple disciplines and modalities to 
discern relevant biological mechanisms behind post-TBI depression (PTD) and associative 
cognitive deficits, in order to aid in identifying and treating an at-risk, highly complex, population. 
The results of this work will advance both clinical investigation into monoaminergic and 
neurotrophin pathology of TBI as well as basic research into fronto-limbic structural 
vulnerabilities and their involvement in depressive symptomology and cognitive impairments 
post-TBI.  
1.1 CHRONIC RECOVERY FOLLOWING TBI  
The effects of TBI are heterogeneous, and in addition to damage from the direct injury, the 
mechanical disruptions associated with TBI facilitates the development of secondary pathologic 
processes in the brain, including inflammation, excitotoxicity, ischemia, edema, and many chronic 
secondary signaling changes (Park et al., 2008). Traditionally, treatments and translational 
research in TBI, has focused primarily on acute neurological injury and neuroprotection. Yet, 
therapies that are neuroprotective in experimental TBI, have consistently failed to translate into 
successful treatments in the clinical setting (Ikonomidou and Turski, 2002; Narayan et al., 2002). 
This apparent disconnect may be due to heterogeneity in injury as well as a lack of consideration 
  3 
in preclinical studies for important covariates like age or sex. However, one of the most critical 
limitations of successfully translating experimental research to clinical trials is the lack of 
understanding of TBI as a chronic, yet rehabilitation sensitive, disease.  
 To date, there has been a lack of emphasis in the literature on mechanisms of chronic 
dysfunction after TBI. Contemporary research now suggests that TBI, even mild, concussive 
injuries, is not simply a transient and static syndrome from which people recover, but rather a 
chronic and evolving disease state. Our own work suggests that TBI pathology has a dynamic time 
course in which secondary complications and symptoms can arise and require ongoing 
management(Failla et al., 2014). Within this chronic disease framework, therapeutic plasticity and 
recovery mechanisms interplay with ongoing neurodegenerative and other chronic state pathology 
to affect symptoms, complications, and function (Dixon et al., 1999; S.N. Niogi et al., 2008; 
Sidaros et al., 2008). Common functional impairment and disability following TBI can vary and 
lead to faster recovery patterns (months for motor function (Katz et al., 1998)) compared to longer 
recovery patterns (years for cognitive/mood recovery (Hammond et al., 2004)). This evolving 
understanding of the dynamic nature of TBI requires a paradigm shift in both experimental and 
clinical TBI studies and understanding of chronic states of TBI pathology and associated sequelae. 
The work described here focuses on closed head traumatic brain injuries, (as opposed to 
those that penetrate the skull), and most of the resultant injuries are wide-spread with complex, 
evolving diffuse axonal injury (DAI). Thus, these injuries tend to follow a multi-stage 
injury/recovery time-line with three important stages: primary injury (disruption and physical 
injuries to brain tissue), secondary injury (induction of biochemical cascades resulting in 
dysfunction and apoptosis), and a chronic repair state characterized by both degeneration and 
reorganization of the brain. The timeline for these phases is likely tied to severity of injury. The 
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primary injury complex TBI itself is the result of biomechanical forces, complicated by contact 
between the brain tissue and the skull (resulting in compression of tissue at the impact and 
stretching of tissue at the opposite pole), and angular rotation. Angular rotation occurs even with 
linear blows to the head as the brain is tethered to the base of the skull at medial, inferior frontal 
regions at the base of the brain (near and including the pituitary stalk) (Bayly et al., 2005). This 
rotational force often results in DAI. DAI results from microstructural damage of axons resulting 
in axonal disruptions and disconnections (Carrera and Tononi, 2014; Hernández, 2006). 
Importantly, longer axonal tracts in the brain are more susceptible to these rotational forces (Sabet 
et al., 2008). Due to the inherent vulnerability in the brain, it is likely that injury severity plays a 
role in the development and degree of the resulting DAI. Severity of injury is classically measured 
by the Glasgow Coma Scale (GCS (Teasdale and Jennett, 1974a)) score, taken acutely at varying 
time-points following the injury. While GCS has been shown to be related to a number of acute 
and chronic dysfunctions (McNett, 2007; Udekwu et al., 2004a), there is no significant evidence 
of injury severity relating to PTD (Maller et al., 2010). 
Even with the association between injury severity and chronic complications, there is 
difficulty with chronic complication prognostication that precludes clinician abilities to define 
early interventions. The population with TBI can be quite heterogeneous; individuals can have 
markedly different outcomes despite similar injury types and/or clinical management complicating 
standard treatment development. This is especially true when examining chronic complications 
like mood and cognitive recovery post-TBI, where dynamic and temporal variation in the 
pathophysiology associated with TBI can alter the mechanisms associated with recovery.  
  5 
1.1.1 Post-TBI Depression 
PTD sufferers comprise a large subset of those with depression. Importantly, there is evidence to 
suggest a unique pathology in PTD compared to major depressive disorder (MDD), yet there is a 
limited understanding of the unique underlying biological mechanisms that lead to PTD. Many 
features of major depression, including apathy, insomnia, psychomotor agitation or retardation, 
slowed thinking, poor concentration, and fatigue are reported frequently after TBI. As these 
symptoms can also be features of TBI, MDD, pre-injury functioning, or medication side effects, it 
can be difficult to discern causation. Several hypotheses have been produced regarding this 
alarming rate of depressive symptoms following TBI including the presence of premorbid 
depression/mood disorders, location of the injury (damage to fronto-limbic or serotonergic 
neurons), and/or a psychogenic reaction to the injury. While individuals with premorbid mood 
disorders are at greater risk for depression following TBI (Chapter 2, 3), this does not explain the 
substantial risk seen in individuals with no history of mood disorders and may suggest different 
risk factors stratified by premorbid history. Several other factors have been suggested to indicate 
risk for PTD such as lower education, unemployment, and minority status (Jorge and Arciniegas, 
2014). Yet, again, this does not explain the still increased risk in individuals with none of these 
identified risk factors. 
Interestingly, there has not been conclusive evidence to suggest that location of injury 
predicates PTD development. While some studies support the notion that injury foci in left 
frontal/medial regions relate to PTD development (Jorge et al., 2004), this is not conclusive and, 
again, does not explain susceptibility in a large number of PTD sufferers (Maller et al., 2010). In 
the experimental literature, there is a lack of anatomical relationships to mood complications post-
TBI, but this may be due to the paucity of research specifically assessing mood complications post-
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TBI. One study has shown depressive-like behavior following frontal lobe damage in an 
experimental TBI model (Moritz et al., 2014). 
Other theories posit that a subject’s awareness of their injury induced deficits predicts 
development of PTD (Malec et al., 2010). Yet, this theory of a proposed reactive PTD has been 
called into question. Interestingly, PTD can develop at early chronic time-points (1 month post-
injury) before a patient may fully realize cognitive/functional deficits (Bombardier et al., 2010a). 
Consistent with the clinical studies, there is evidence in experimental models that depressive-like 
symptoms are present early after injury (Cope et al., 2011; Fenn et al., 2013) and persist 
(Washington et al., 2012). While awareness of deficits may be a factor in PTD, it does not fully 
explain the etiology of PTD. Similarly, current leaders in the field have hypothesized that, due to 
awareness of deficits theory, subjects with more mild injuries would have greater incidence of 
PTD, but this has not had consistent support in the literature (Maller et al., 2010). In experimental 
TBI, there is also no supported relationship between injury severity and development or severity 
of depression or anxiety (Washington et al., 2012).  
As there is not conclusive evidence supporting PTD mechanisms or risk, it is not surprising 
that there is a severe lack of efficacious treatment paradigms for PTD. Treatments used for Major 
Depressive Disorders (MDD) are not necessarily effective in the context of PTD (Warden et al., 
2006). The most common treatments include antidepressants, yet, recent studies show reduced 
efficacy and increased adverse events, especially with selective serotonin reuptake inhibitors 
(SSRI) (Fann et al., 2009a; Lanctôt et al., 2010; Lee et al., 2005). Recent work examining physical 
activity as a possible therapeutic in PTD has shown promising results (Hoffman et al., 2010; Wise 
et al., 2012). This lack of effective treatments may indicate unique pathologies involved in PTD 
  7 
development compared to MDD, emphasizing the need for a greater understanding of the 
underlying mechanisms of PTD in order to aid treatment.  
1.1.2 Post-TBI Cognition 
Cognitive impairment post-TBI can impact return to work and community reintegration (Jennifer 
Fleming, Leigh Tooth, Mary, 1999). Cognitive dysfunction following TBI is the most common 
complaint cited, even years after TBI (Hoofien et al., 2001). Multiple neuropsychological domains 
of cognition are impaired following TBI, including attention, arousal, memory, and executive 
control. Cognitive deficits mirror severity of injury as indicated by the extent of DAI, generalized 
atrophy, and the location and extent of focal injuries (Katz and Alexander, 1994; Wilson et al., 
1995).  
Studies have demonstrated that following TBI, individuals with depressive symptomology 
perform worse on a number of cognitive measures (Bornstein et al., 1989; Gfeller et al., 1994; 
Rapoport et al., 2002; Satz et al., 1998), across domains (attention, memory, and executive 
function). We report important findings regarding unique patterns of PTD-associated cognitive 
deficits in Chapter 2. Many symptoms overlap between TBI-related cognitive deficits and PTD 
like slowed thinking and poor concentration. Similarly, symptoms like apathy, insomnia, 
psychomotor agitation or retardation, and fatigue are reported frequently after TBI and can 
influence mood and cognition. For individuals with TBI, remittance of depressive symptoms may 
lead to improved cognitive performance (Fann et al., 2001), suggesting overlapping biological 
pathways or at least interacting symptomology.  
Memory problems are common following TBI. Explicit memory involves the conscious 
acquisition and retention of new information, while implicit learning involves skill or knowledge 
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acquisition without explicit awareness of how the material is learned. Explicit learning-memory is 
hippocampal dependent (Brandeis et al., 1989), and hippocampal damage is associated with 
reproducible deficits in spatial and temporal memory processing. Explicit learning-memory is 
vulnerable to the effects of TBI, while implicit learning-memory relatively resistant to impairment 
because it is hippocampal independent and involves both cortical and subcortical regions (Buckley, 
2005; Vakil, 2005). Implicitly learned information is often considered relatively “inflexible”, 
where carry-over of implicitly learned knowledge can be limited (Schmitter-Edgecombe, 2006). 
Cognitive rehabilitation interventions appear to improve attention, memory, social communication 
skills, and executive function (Cicerone et al., 2011). In the clinical population, cognitive 
rehabilitation paradigms have shown significant promise but have not been subjected to the rigor 
of experimental studies to characterize their mechanisms of action, effectiveness, or capacity to 
enhance efficacy of other interventions (Cicerone et al., 2011). Importantly, implicit tasks are more 
resistant to external factors like anxiety or fatigue, yet interference with explicit feedback during 
implicit learning can adversely affect task performance after TBI (Vakil, 2005). Thus, 
understanding how mood can impact cognitive rehabilitation will be important for successful 
cognitive rehabilitation. 
In uninjured populations, individuals with depression also have distinct accompanying 
cognitive deficits, likely due to common pathology. Individuals with depression consistently show 
working memory deficits and reduced cognitive flexibility and complain of memory problems and 
difficulty concentrating (Gotlib and Joormann, 2010). Several studies suggest an attentional bias 
to negative stimuli, consistent with an emotional congruence theory (Peckham et al., 2010). 
Importantly, individuals with depression show greater attention or distractibility by negative 
stimuli, possibly explaining propensity for rumination (Joormann et al., 2006). Similarly, this lack 
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of task-switching ability may indicate a loss of cognitive control in individuals with depression 
(Fales et al., 2008). Individuals in TBI often exhibit difficulties in cognitive control (cognitive 
flexibility, inhibition, and task switching) that could further aggravate these predispositions to 
negative stimuli or explain relationships to PTD.  
While the resultant cognitive impairments following TBI have been well-studied (Levin et 
al., 1982), identifying individual patterns in recovery and response to rehabilitation is still difficult. 
In fact, the recent international guidelines for cognitive rehabilitation post-TBI (Bayley et al., 
2014), emphasize the need for individualized cognitive rehabilitation paradigms. With regard to 
cognitive recovery post-TBI, numerous acute care clinical trials have been negative, yet all of these 
trials failed to examine how genetic factors interplay in TBI recovery. Understanding the unique 
relationships between cognition and mood recovery may aid in treatment identification. 
1.2 INTERACTING MONOAMINERGIC AND NEUROTROPHIC SIGNALING: 
IMPLICATIONS FOR PTD AND COGNITIVE DEFICITS POST-TBI 
The overall goal of the work presented here to identify individual factors that influence the 
presence and severity of cognitive deficits and/or PTD concurrently. In this vein, we examined 
genetic variation that, through modulation of monoaminergic or neurotrophic signaling, may 
impact fronto-limbic circuitry, and thus, influence mood or cognition post-TBI. Factors underlying 
individual variation in recovery, both in depression and cognition, following TBI are poorly 
understood. We specifically targeted monoaminergic signaling due to the role of serotonin (5-HT) 
and dopamine (DA) in the hallmark symptoms of PTD, depressed mood and anhedonia (Dunlop 
and Nemeroff, 2007; Martinowich and Lu, 2008). Similarly, 5-HT and DA signaling modulates 
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cognitive function(Olvera-Cortés et al., 2008). As TBI induces a hypo-monoaminergic state, 
genetic variation in 5-HT/DA pathways may then be relevant to recovery. Brain-derived 
neurotrophic factor (BDNF), a neurotrophin involved in neuronal survival and synaptic plasticity, 
is implicated in depression and cognition and interacts with 5-HT/DA signaling (Nibuya et al., 
1996),(Guillin et al., 2001). There are major gaps in our understanding of how these pathways 
converge to influence PTD and associated cognitive deficits post-TBI. We suggest that without 
studying these interacting pathways, treatments and prevention measures for PTD and cognitive 
recovery will remain fragmentary and inadequate.   
 
1.2.1 Dopaminergic functioning in TBI recovery 
Dopaminergic signaling is critically important for attention and cognitive control. A number of 
studies implicate DAergic signaling in attention, response inhibition, and working memory (Braver 
and Cohen, 2000).  DA neurons project from the ventral tegmental area (VTA) to subcortical areas 
like the nucleus accumbens (NAc, also called the ventral striatum) and amygdala, as well as fronto-
limbic cortical areas like the dorsolateral prefrontal cortex (DLPFC).  DA has long been implicated 
in reward processing, with strong associations with attentional properties, prediction, stimulus-
reward pairing (learning (Graybiel, 2005)), and motivational states for reward acquisition 
(Berridge and Kringelbach, 2008) that may underlie an organisms ability to experience pleasure. 
As such, there is mounting evidence supporting a role for DA in depressive symptomology. Some 
current antidepressants may partially act through improving DA function (bupropion (Cooper et 
al., 1980)) and some evidence that serotoninergic targeting antidepressants can have partial affinity 
for DA targets (Damsa et al., 2004). Similarly, there is comorbidity of depression and Parkinson’s 
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disease (with loss of DAergic neurons) (Santamaría et al., 1986). Studies show conflicting results 
in positron emission tomography (PET) studies of striatal DAT binding (Laasonen-Balk et al., 
1999; Meyer et al., 2001) but do tend to suggest reduced DA neurotransmission in depression 
(Nutt, 2006). Given this evidence, DA is an attractive link between depressive symptomology and 
cognitive function post-TBI. 
Dysregulated DAergic signaling may explain many of the persistent cognitive deficits in 
TBI (James W Bales et al., 2009). The facets of cognition that seem most influenced by TBI are 
often associated with frontal lobe areas that have dense projections to the striatum. PET studies 
characterizing DA function showed D2 binding was correlated to several aspects of cognition, 
such as working memory in healthy populations (Aalto et al., 2005). Overall, TBI induces a chronic 
hypo-DAergic state that relates to cognitive deficits even outside of overt damage to DA neurons 
(James W Bales et al., 2009).  
TBI studied have demonstrated a number of lines of DA dysfunction. Single photon 
emission tomography studies in adult TBI show reduced binding of the dopamine transporter 
(DAT) at 4-5 months post-TBI (Donnemiller et al., 2000; Scanlon et al., 2009). DAT regulates 
action of DA neurotransmission, taking up extracellular DA into presynaptic terminals following 
DA release (Torres et al., 2003); studies in mice lacking DAT suggest DAT is determinant of 
extracellular DA levels (Perona et al., 2008). Decreased levels of DAT in the prefrontal cortex 
have also been confirmed in a rat model of TBI (H.Q. Yan et al., 2002), suggesting a compensatory 
action by DA neurons in order to increase DA signaling post-TBI. In TBI, tyrosine hydroxylase 
(TH), a rate-limiting enzyme in the synthesis of DA is upregulated in presynaptic terminals in the 
frontal cortex (Yan et al., 2001) and in the striatum after very severe injury (James W Bales et al., 
2009). This finding is also suggestive of a compensatory mechanism in presynaptic DA neurons 
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trying to increase DA neurotransmission post-TBI. Interestingly, real time neurotransmission 
studies evaluating stimulated DA release in the striatum still demonstrate decreased evoked DA 
overflow and altered DA clearance kinetics. The dopamine receptor D2 serves an auto-receptor 
function in the striatum (Tang et al., 1994). Human single photon emission tomography studies 
show reduced binding of D2 post-TBI (Donnemiller et al., 2000). Catechol-O-methyl transferase 
(COMT), an enzyme involved in degradation of DA in the synapse, can also impact DA signaling 
by modulating active DA. In addition, there is evidence for COMT in executive function following 
TBI (Lipsky et al., 2005a). Multiple DA agonists, including Methylphenidate, Amantadine, and 
Bromocriptine have beneficial effects on cognition and place learning post-TBI (James W Bales 
et al., 2009; Frenette et al., 2012). While methylphenidate (MPD) has been used primarily to aid 
in attentional processes and overall cognitive recovery post-TBI, there is new evidence of a 
positive effect on mood in TBI (Kim et al., 2011). Similarly, methylphenidate has shown promise 
in treating post-stroke depression (Grade et al., 1998; Lazarus et al., 1992). 
1.2.2 Serotonergic functioning in TBI recovery 
Serotonin (5-hydroxytryptamine, 5-HT) has long been implicated in cognition and mood. 
Serotonergic projections from the raphe nucleus of the brainstem have wide-spread connections 
throughout the brain, especially in regions important for mood and cognition. Serotonergic 
function has long been implicated in depressive symptomology; individuals with depression have 
reduced 5-HT metabolites in CSF, decreases in serotonin uptake and transporter binding in post-
mortem brain tissue and platelets, changes in expression of serotonergic receptors(Owens and 
Nemeroff, 1994). Similarly, SSRIs target the serotonin transporter (5-HTT), blocking 5-HTT, and 
effectively increasing 5-HT levels. Acute tryptophan (precursor for serotonin) depletion in humans 
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results in depressive symptoms (Toker et al., 2010) and cognitive deficits (response inhibition) 
(Drueke et al., 2013; Rubia et al., 2005). Targeted serotonergic depletion in the marmoset results 
in deficits in reversal learning (Clarke et al., 2007) and other studies show serotonergic modulation 
of task-switching and cognitive control (Lamar et al., 2012).  Transcription of the 5-HTT gene, 
coded by SLC6A4, is modulated by a variation in the serotonin transporter linked polymorphic 
region (5-HTTLPR). The SLC6A4 S-allele (44 bp deletion in the promoter region, 5-HTTLPR) is 
a risk allele for depression, though results from meta-analyses are mixed (Karg et al., 2011; Risch 
et al., 2009). The 5-HTTLPR is thought to modulate amygdala reactivity and amygdala 
connectivity with the anterior cingulate and orbitomedial prefrontal cortex such that S-carriers 
have increased reactivity of the amygdala and decreased orbitomedial prefrontal cortex control 
over amygdala activity (Pezawas et al., 2005). However, S-carriers also so show greater cognitive 
resilience in healthy subjects, performing better in social cognitive measures and attention tasks 
(Canli and Lesch, 2007).  
A recent study implicated 5-HTTLPR in resiliency following TBI (Graham et al., 2013). 
Trait resiliency refers to individual variation with stress management and mood regulation and 
reaction within challenging and stressful situations.  Serotoninergic signaling impacts resiliency 
in conjunction with the modulation of the stress response (and thus, modulation of cortisol) (Lesch, 
2011; Pariante and Lightman, 2008). Much of the literature on resiliency has focused on stress and 
reactivity of the HPA Axis. Activation of the HPA axis during stress results in increased levels of 
cortisol and glucocorticoids that act on the hippocampus (Jacobson and Sapolsky, 1991). Increased 
exposure of the brain to stress hormones can have lasting depressive effects, immunosuppression, 
and cognitive impairments (Lupien et al., 2009; Pariante and Lightman, 2008).  Importantly, 
resiliency in individuals is associated with rapid induction of the HPA axis with subsequent 
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adaptation and termination of this response (de Kloet et al., 2005). This literature suggests that 
adaptability of this biological signaling could have lasting effects on depressive symptomology 
and cognitive resiliency.  
There is a paucity of literature on how TBI effects the serotonergic system, and relationship 
of serotonergic function to both mood and cognitive performance post-TBI has not been well 
studied.  Several studies suggest a hypo-neurotransmission state following TBI, including 
monoaminergic neurotransmitter systems, that likely impacts chronic TBI pathology and cognitive 
dysfunction (James W Bales et al., 2009).  In the acute stages of TBI, rapid increase in extracellular 
serotonin are followed by a chronic hypo-neurotransmission state(Busto et al., 1997). One study 
showed serum serotonin profiles in TBI suffers fall below control subject levels during recovery, 
with even lower levels observed in PTD (Wozniak et al., 2010). While agonists targeting the 
serotonin 5-HT1a receptor seem to confer some benefit in cognitive recovery in experimental TBI 
(Kline et al., 2002), SSRIs do not seem to enhance cognitive recovery in animal models, nor do 
they tend to improve depressive behaviors (Wang et al., 2011). In PTD, some studies have 
suggested that anatomic location of injury, specifically left orbitomedial frontal lobe lesions that 
directly affect serotonergic innervation (Jorge et al., 1993), is a major contributor to PTD 
development, but this pathology is not apparent in a number of PTD cases (Maller et al., 2010). 
1.2.3 Neurotrophic support: impact on monoaminergic function and TBI recovery 
BDNF, a neurotrophin involved in neuronal survival and synaptic plasticity, affects depression, 
cognition, and TBI pathology (Martinowich and Lu, 2008). BDNF has a significant role in 
cognitive and behavioral processes. BDNF is ubiquitous in the hippocampus where it plays a 
critical role in synaptogenesis and maintenance, particularly in long-term potentiation with 
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activity-dependent secretion of BDNF (Kovalchuk et al., 2002). Similarly, BDNF may be an 
underlying substrate for persistent long-term memory storage (Bekinschtein et al., 2008a, 2008b). 
As such, animal studies with conditional BDNF knock-out mice show impairment in hippocampal-
dependent cognition and behavior, but there is a much less established role for BDNF in 
hippocampal-independent cognition (Bath and Lee, 2006). 
In depression, serum BDNF levels are decreased in untreated depression but increase with 
antidepressant treatment, indicating the viability for BDNF serum levels as a biomarker of 
depression (Hashimoto, 2010; Karege et al., 2002; Sen et al., 2008). Yet, serum BDNF may be 
more reflective of BDNF function in the hippocampus and BDNF signaling has differing roles in 
the hippocampus compared to mesolimbic reward circuits. In the hippocampus, BDNF expression 
levels are decreased in correlation with stress and depression (Pittenger and Duman, 2007). BDNF 
signaling in the hippocampus is also implicated in mechanisms of antidepressant treatment (D’Sa 
and Duman, 2002). In rat models, intracerebral BDNF infusions have antidepressant effects, while 
decreased BDNF signaling results in decreased hippocampal neurogenesis (Siuciak et al., 1997). 
In TBI, serum BDNF is acutely decreased, correlating with severity of injury (Kalish and 
Phillips, 2010). Hippocampal BDNF is chronically decreased in TBI (Chen et al., 2005). 
Importantly, therapies thought to increase BDNF expression in the brain, like environmental 
enrichment (Chen et al., 2005) and exercise (Griesbach et al., 2009) are promising therapies for 
cognitive recovery post-TBI. Hippocampal BDNF expression is linked to spatial memory in 
experimental TBI studies (Griesbach et al., 2009).  
BDNF interacts with monoaminergic signaling. BDNF can mediate DAergic synaptic 
plasticity in the striatum, and nucleus accumbens (Guillin et al., 2001).  BDNF injections during 
reward cueing can have a ‘stamping-in’ effect and can induce reward-seeking behaviors(Lu et al., 
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2004). Similarly, BDNF signaling also interacts with serotonergic function.  TrkB receptor 
activation by BDNF increases 5-HT neurotransmission and dendritic branching (Mamounas et al., 
2000),(Horch and Katz, 2002). As increased synaptic 5-HT increases 5-HT receptor activation, 
these receptors signal phosphorylation of cAMP response element binding protein (CREB) 
(Martinowich and Lu, 2008),(Conti et al., 2002) and induce CREB-mediated increases in BDNF 
transcription and neuronal survival (Tao et al., 1998),(Walton and Dragunow, 2000). 
1.3 NEUROCIRCUITRY UNDERLYING POST-TBI COGNITION AND 
DEPRESSION 
Alterations in fronto-limbic networks are implicated in depression and TBI (Kraus et al., 2007; 
Maller et al., 2010). In uninjured populations, significant dysregulation in an anatomically 
interconnected network of fronto-limbic regions are hypothesized to contribute to depression 
pathology and successful remittance of depression implicates a coordinated restructuring of this 
circuit (Mayberg, 2003). Consistent with this hypothesis, individuals with major depressive 
disorder have reduced fronto-limbic volumes in structures like the hippocampus (Sheline et al., 
2003), anterior cingulate, and orbitomedial frontal cortex (Koolschijn et al., 2009). 
Atrophy is a common issue in TBI (MacKenzie et al., 2002). In PTD, a few studies have 
examined regionally  specific atrophy in fronto-limbic regions like the hippocampus (David F. 
Tate and Bigler, 2000) and the anterior cingulate (Chen et al., 2008a). Recent work has shown in 
moderate-severe TBI, the degree of fronto-limbic structure atrophy for the hippocampus and other 
regions, was associated with PTD (Hudak et al., 2011). Interestingly, their work also shows 
regional grey matter atrophy is closely linked to damaged WM tracts post-TBI (Warner et al., 
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2010) suggesting overall reductions in fronto-limbic connectivity. Recent reviews suggest 
overlapping brain regions of vulnerability between depression and TBI, including decreased white 
matter integrity in tracts within fronto-limbic circuits (uncinate fasciculus (UF), cingulum gyrus 
(CG), and fimbria-fornix (Maller et al., 2010)). The CG, UF, and superior longitudinal fasciculus 
(SLF) have all been studied in cognitive deficits post-TBI (Turken et al., 2008) and are implicated 
in circuits relating to depression (Hamani et al., 2011; Mayberg, 2003; Mettenburg et al., 2012). 
With evidence of reduced structural integrity and connectivity in fronto-limbic circuits post-TBI, 
we propose possible alterations in functional connectivity of these circuits. 
Functional MRI (fMRI) studies also support altered fronto-limbic connectivity in 
depression and TBI. In depression, studies have identified altered connectivity in circuits 
containing the anterior cingulate, hippocampus and amygdala (Zeng et al., 2012; Zhu et al., 2012). 
In TBI, disruption of long-range axons may result is a loss of structural connectivity and 
subsequently affect functional connectivity (Sharp et al., 2011). Resting-state fMRI studies have 
identified correlated patterns of activity in a number of brain regions at rest that comprise a default 
mode network (Greicius et al., 2009). While there are no resting-state fMRI studies in PTD, in a 
pair of studies by Palacidos et al., resting-state fMRI post-TBI showed altered patterns of fronto-
limbic connectivity post-TBI. This study suggested that reduced white matter integrity of the 
cingulum disrupted the default mode network and correlated with increased connectivity of the 
frontal portion of the DMN (Eva M Palacios et al., 2013). In this work, cognitive performance 
correlated to the amplitude of low frequency fluctuations during resting state fMRI (Eva M 
Palacios et al., 2013). Interestingly, in this study, hippocampal volume was significantly decreased 
but did not predict cognitive function post-TBI (Eva M. Palacios et al., 2013). 
  18 
In task-dependent fMRI studies, individuals with TBI show consistent hypoactivation in 
the frontal lobe during cognitive tasks, and increased bilateral recruitment, suggesting 
compensatory activation is needed to perform at similar levels to controls on cognitive tasks 
(Ricker et al., 2001; Sánchez-Carrión et al., 2008). One study showed reduced activation in the 
medial orbital frontal cortex of control subjects during a working memory task that was attenuated 
in concussed, depressed individuals (Chen et al., 2008a). These findings may suggest that during 
cognitive tasks there is interference of altered fronto-limbic networks associated with depressive 
symptomology following injury.  
1.4 WORKING TOWARDS A MONOAMINERGIC AND NEUROTROPHIC 
HYPOTHESIS FOR RECOVERY POST-TBI 
Dopamine, serotonin, and BDNF show alterations in signaling post-TBI that may map to TBI 
recovery patterns through alterations in function of fronto-limbic circuits. Studies examining 
targeted monoaminergic-BDNF genes as they relate to regional atrophy and fronto-limbic system 
disruption in TBI recovery may aid in understanding PTD and cognitive impairment risk post-TBI. 
The work presented here sought to understand the role of genetic risk within monoaminergic-
neurotrophic pathways in PTD and how it relates to neurotrophic support and fronto-limbic 
atrophy, providing a possible novel mechanism for PTD.  
Yet, factors underlying individual variation in recovery following TBI, whether in survival, 
depression or cognition, are poorly understood. We suggest genetic variation may explain some of 
this variance. We hypothesize that risk for specific TBI complications (depression and/or cognitive 
impairment) is modulated by alterations in regionally specific gray matter atrophy post-TBI. As 
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such, we have selected a battery of targeted genes for their proposed roles in depression, cognition, 
and/or modulation of fronto-limbic connectivity.  
Importantly, we also aim to determine relationships with BDNF serum levels as these 
levels may be a possible genetically modulated, physiologically relevant biomarker for, survival, 
PTD, and cognition allowing for high translational potential. In addition to survival, we identify 
several genetically-modulated intermediate markers for TBI recovery, including PTD, cognitive 
composite scores, BDNF levels, and structural integrity of fronto-limbic regions.  
1.4.1 Monoaminergic and Neurotrophic Genetic Factors in Mood and Cognition Post-TBI  
Genetic studies of TBI recovery among survivors are important in order to assess how individual 
risk profiles affect multidimensional recovery. Similarly, genetic studies can act as a marker of 
pre-injury risk, though TBI induces a number of epigenetic alterations(Z.-Y. Zhang et al., 2007) 
that make this interpretation of gene-candidate studies complex. There is evidence of important 
gene-injury interactions, which make TBI-specific analyses critical. The work presented here 
proposed exploration of monoaminergic and BDNF genes important for risk in PTD and cognitive 
recovery post-TBI (see Table 1 for complete list). We focused on genetic variants for a number of 
candidate genes thought to be important in monoaminergic function, cognitive function, mood 
regulation, or fronto-limbic connectivity. Importantly, the majority of these genetic effects have 
not been examined in PTD. 
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Table 1. Summary of Monoaminergic and Neurotrophic Candidate Gene Predictions 
  
 
We observe a relationship with DAT1 on PET binding and cognition (Amy K Wagner et al., 2014), 
but this has not been investigated in PTD. The 9 allele is associated with decreased DAT 
expression (Mill et al., 2002) (suggesting a possible reflection of a hypo-dopaminergic state of 
TBI), yet heterozygotes carry the highest risk in depression (Lopez-Leon et al., 2007). We have 
also examined genetic associations of the DAT gene (SLC6A3, but identified as DAT1), 
specifically of the 40bp variable number of tandem repeats (VNTR) in the 3’ UTR in exon 15. The 
most common alleles, 9 and 10 (although it ranges from 3-11 with additional SNPs within alleles 
(Miller et al., 2002)), are associated with DAT expression. Specifically, the 10-allele is associated 
with increased DAT expression(Mill et al., 2002) in control populations. While homozygotes have 
Gene Polymorphism 
Function; 
Implications
  
Prediction to PTD 
Prediction to Cognition 
SLC6A4 5-HTTLPR 
5-HTT expression, 
fronto-limbic circuitry; 
depression risk, TBI 
S-carriers will show 
increased PTD risk  
S-carriers will show better 
overall cognitive 
performance 
DAT1 10/9 VNTR 
Reduced DAT 
expression(VanNess et 
al., 2005); TBI 
9/10 heterozygotes will 
be associated with 
increased PTD 
9- carriers will be 
associated with decreased 
cognitive performance 
COMT Val158Met 
Reduced COMT 
activity(Lotta et al., 
1995); 
depression(Baune et 
al., 2007), TBI(Lipsky et 
al., 2005a) 
Met-homozygotes will be 
at a greater risk for PTD 
Met-homozygotes will 
have better cognitive 
performance 
DRD2 TaqIA1 
Related to D2 binding; 
depression(Opmeer et 
al., 2010), 
TBI(McAllister et al., 
2008) 
A1-carriers will show 
reduced risk for PTD 
A1-carriers will show 
better overall cognitive 
performance 
BDNF Val66Met 
Reduced 
BDNFsecretion(Egan et 
al., 2003); 
depression(Martinowich 
et al., 2007), 
TBI(Krueger et al., 
2011)  
BDNF may interact with 
5-HTTLPR to modulated 
PTD 
Met-carriers show worse 
overall cognitive 
performance 
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been associated with a higher depression risk, 10-homozygotes have higher DA metabolite levels 
as measured in CSF collected in the acute phase after TBI. Imaging studies in our lab using PET 
imaging demonstrate reduced DAT binding in 9-allele subjects as measured by 11C-β-CFT in the 
caudate and putamen. Similarly, 9-allele subjects showed significantly worse performance on 
measures of executive function post-TBI (Scanlon et al., 2007). 
RS4680 is a known functional single nucleotide polymorphism (SNP) in exon 4 of COMT 
that causes a val/met switch, where val (G)=↑activity=↓DA and more metabolite, and Met 
(A)=↓activity=↑DA and less metabolite (J. Chen et al., 2004). The Met allele has been associated 
with depression in a male Swedish population (Åberg et al., 2011), and consistent with the DA 
hypothesis, met/met individuals make fewer cognitive (perseverative) errors after TBI (Lipsky et 
al., 2005a). In the DRD2 Taq1A polymorphism, A1-carriers, with increased basal DA levels 
(Laakso et al., 2005, p. 2), receptor levels is related to cognitive show worse performance on some 
cognitive measures following mild TBI (McAllister et al., 2008). We report DRD2 associations 
with cognitive composites at 6 and 12 months following moderate to severe TBI [see Chapter 4]. 
While genetic associations with depression and DRD2 have not been consistent, A2-homozygotes 
seem to confer the most risk in association with stressful life events (Opmeer et al., 2010), 
suggesting A1-carriers may also be at less risk for PTD.  
We report 5-HTTLPR S-carriers have reduced PTD risk at 6 months post-TBI [see 
Chapter 3]. S-carriers also so show greater cognitive resilience in healthy subjects, performing 
better in social cognitive measures and attention tasks (Canli and Lesch, 2007), which has been 
confirmed in a TBI population (Graham et al., 2013). In this vein, we predict that S-carriers would 
likely show better cognitive performance post-TBI. The BDNF gene polymorphism val66met is 
implicated in several of psychiatric disorders, including major depressive disorder(Martinowich et 
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al., 2007). BDNF has been shown to modulate cognitive recovery post-TBI (Krueger et al., 2011) 
and response to SSRIs in PTD (Lanctôt et al., 2010). Humans with the BDNF Met allele have 
relative deficits in episodic memory and abnormal hippocampus activation compared to Val 
homozygotes (Egan et al., 2003).   
In addition to individual gene associations to cognition/depression, there is evidence of 
epistasis within pairs of targeted genes, suggesting genetic risk profiles that include variation 
within a number of these genes will be increasingly informative in TBI recovery profile prediction. 
There is evidence of epistasis between BDNF and DRD2 in personality traits of harm avoidance 
and novelty seeking (Montag et al., 2010). Similarly, variation within BDNF shows modulation or 
‘rescue’ of 5-HTTLPR effects (Pezawas et al., 2008). 
All of our targeted genes (5-HTTLPR (Pezawas et al., 2005), BDNF (Kim et al., 2013), 
DAT (Bertolino et al., 2009), DRD2 (Bartrés-Faz et al., 2002), and COMT (Honea et al., 2009)) 
have shown associations to volume of fronto-limbic regions in healthy populations, often showing 
epistasis or interacting effects with each other (Montag et al., 2010; Pezawas et al., 2008; Radua 
et al., 2013). Associations with 5-HTTLPR and frontal-limbic tracts are seen in healthy controls, 
modulating white matter integrity in the UF (Pacheco et al., 2009) and functional connectivity in 
fronto-limbic regions (Pezawas et al., 2005). BDNF may also influence WM tracts and functional 
fronto-limbic circuits, but this relationship is less clear (Egan et al., 2003; Kennedy et al., 2009). 
Additionally, there is evidence of epistasis between the BDNF and SLC6A4 genes in moderating 
amygdala activation (Pezawas et al., 2005). Interestingly, hippocampal atrophy in major 
depression tends to be more severe in 5-HTTLPR L-homozygotes (Frodl et al., 2008, 2004) , 
suggesting a potential ‘advantage’ for S-carriers.  
  23 
1.4.2 Biomarker development for PTD and Cognitive Outcomes 
The utilization of serum BDNF as a biomarker for PTD could be extremely helpful for clinical 
evaluation and identification of at-risk subpopulations in TBI. Serum BDNF levels likely provide 
a genetically modulated biomarker for depression, and possibly PTD. Serum BDNF levels are 
consistently decreased in depression (Karege et al., 2005). BDNF is able to cross the blood-brain 
barrier (BBB) in normal conditions (Pan et al., 1998). Consistent with reduced serum BDNF  levels 
being indicative of depressive symptoms, effective antidepressant treatment increases serum 
BDNF (Sen et al., 2008).  Also, the SLC6A4 and BDNF genes influence BDNF levels in both CSF 
and serum (Bhang et al., 2010).  The BDNF Met allele directly affects BDNF secretion, which 
may affect CSF and/or serum BDNF levels (Egan et al., 2003),(Lang et al., 2009). Serum BDNF 
may be an important genetically-modulated tool in understanding neurotrophic support post-
injury.  
Few studies have examined human BDNF levels after TBI. In adult clinical TBI, acute 
serum BDNF levels decrease, with a positive correlation to injury severity, within the first 24 hours 
post-injury (Kalish and Phillips, 2010). Less is known about acute CSF BDNF levels following 
TBI, but one pediatric TBI study found acute increase in CSF (Chiaretti et al., 2003). In 
experimental TBI, there is an acute increase in BDNF transcription, yet our lab shows a chronic 
decrease in hippocampal BDNF protein expression at later time points after experimental TBI 
(Hicks et al., 1997),(Chen et al., 2005). Notably, in a study about depression development 
following stroke, serum BDNF levels were increased during periods of no depressive symptoms, 
but decreased when research participants presented with clinical symptoms associated with 
depression (L. Yang et al., 2010), suggesting BDNF levels could be indicative of emerging 
depressive symptomology in a post-injury state.   
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Studies have begun to show relationships between serum BDNF levels and cognitive 
function (Griffin et al., 2011). Specifically in both patient populations and healthy controls 
(Gunstad et al., 2008), there are relationships to memory and verbal fluency (Dias et al., 2009). 
Interestingly, individuals with schizophrenia have reduced BDNF levels that recover after weeks 
of cognitive plasticity training (Vinogradov et al., 2009). Also, animal TBI models show that 
hippocampal BDNF expression in is correlated to cognitive recovery (Griesbach et al., 2009).   
There is some evidence to suggest BDNF levels may also be associated with neural 
correlates of PTD or cognition. Serum BDNF levels correlates with hippocampal volume in 
depressed subjects (Eker et al., 2010). In healthy controls, serum BDNF levels correlate with N-
acetylaspartate, a marker of neuronal integrity (Lang et al., 2007b).   
1.5 REHABILOMICS IN SURVIVAL, PTD, AND CONGITIVE DEFICITS POST-TBI 
Given the level of complexity in understanding depression and cognition following brain injury, 
we proposed a Rehabilomics (A K Wagner, 2010) approach to understanding how monoaminergic 
and neurotrophic signaling may impact depression and cognition following TBI. While we did not 
intended to examine factors related to survival in this body of work, understanding chronic 
outcomes like depression and cognitive functioning depend on the course of acute care and 
survival. In applying the Rehabilomics approach (A K Wagner, 2010; Wagner and Zitelli, 2012), 
we sought to understand how a wide-range of individual factors (like genetics, age, and sex) that 
interact with injury parameters that could influence response to rehabilitation and alter outcomes 
following TBI. It is imperative for clinical studies, in addition to experimental paradigms, to 
rigorously evaluate important factors in rehabilitation like timing, chronicity of treatment, 
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maintenance of treatment effects and influences of acute management on chronic care. Much of 
the work presented here, supports these important caveats. With an integrative approach, the 
Rehabilomics-framework combined with rigorous experimental models of neurorehabilitation will 
likely yield rapid improvements in the current state of neurorehabilitation research and clinical 
care. 
Thus, in this work we sought to utilize basic research to identify biomarkers within relevant 
mechanistic framework that can inform personalized treatments. This is incredibly relevant to 
understanding complications like depression and cognitive deficits, that are highly interrelated and 
complex. There is a paucity of research into the unique mechanisms of PTD. With the interactions 
of acute and chronic factors, impacting mood and cognition post-injury, it will be imperative to 
examine mood and cognition across recovery utilizing a personalized medicine approach. Novel 
genetic markers as risk factors in PTD may direct future research in mechanisms behind increased 
risk for depressive symptoms in the TBI population, specifically directing future animal studies. 
The work described here we examined genetic risk factors in DA-5-HT-BDNF signaling, allowing 
us to begin to understand how underlying genetic make-up within interacting pathways influences 
TBI recovery.  
There has been a call for genetic studies in TBI. The TBI population can be quite 
heterogeneous: patients can have markedly different outcomes despite similar injury types and/or 
clinical management complicating standard treatment development. This indicates that there is 
likely variation in the neurobiology associated with both TBI pathophysiology, neurotransmission, 
and the mechanisms associated with recovery. However, when identifying candidate genes for 
recovery post-TBI, one important caveat in disease populations, and especially TBI, is to be 
cognizant of mortality effects. Thus, again, applying a holistic Rehabilomics approach can aid in 
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identifying individual variation that can affect acute and chronic outcomes. Genetic studies may 
help to explain some of this heterogeneity and/or aid in identifying particular subsets of the 
population that are more likely to benefit from a particular treatment.  
Results from this work will evaluate how pathways in TBI/PTD interact and allow for new 
therapeutics for PTD that positively influence interacting, complex systems involved. This work 
may also be highly important as many rehabilitation paradigms following TBI utilize behavioral 
and/or cognitive training in PTD therapies. Within this Rehabilomics framework, it is imperative 
to design studies that not only identify subsets of the injured population who may or may not 
benefit from a given treatment, but also aim to understand the biological underpinnings of these 
treatments and disorders as current therapeutics are severely lacking.  
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2.0  EFFECTS OF DEPRESSION AND ANTIDEPRESSANT USE ON COGNITIVE 
DEFICITS AND FUNCTIONAL COGNITION FOLLOWING SEVERE TRAUMATIC 
BRAIN INJURY 
Michelle D. Failla, BS; Shannon B. Juengst, PhD; 
Patricia M. Arenth, PhD; Amy K. Wagner, MD 
2.1 ABSTRACT 
Traumatic brain injury (TBI) results in mood and cognitive complications that impact functional 
recovery. A number of studies have suggested increased presence of cognitive deficits in 
individuals with post-TBI depression (PTD), but have not examined this relationship in the context 
of other demographic, medication, or injury effects. We utilize a Rehabilomics framework, to 
evaluate relationships between PTD and associated demographics (like antidepressant use) on 
cognitive performance and functional cognition in a prospective cohort with severe TBI. 
Participants with TBI (n=154) were evaluated for PTD (Patient Health Questionnaire-9), cognitive 
deficits (cognitive composite score, a battery of 9 neuropsychological assessments) and functional 
cognition (Functional Independence Measure–Cognition, FIM-Cog) at 6 and 12 months post-
injury. Individuals with PTD did not have any measurable cognitive deficits with any of the 
neuropsychological assessments. However, there were consistent negative effects of 
antidepressant use across the cognitive battery. Participants with PTD exhibited lower FIM-Cog 
scores at 12 months post-injury, even after correction for other demographic variables and 
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cognitive performance. PTD is associated with functional cognitive deficits, but not cognitive 
performance, with apathy/motivation as likely etiological factors. 
2.2 INTRODUCTION 
Traumatic brain injury (TBI) is increasingly recognized as a chronic medical condition 
with accompanying mood and cognitive changes. Both cognitive and mood complications can 
greatly impact quality of life for patients and influence return to work or school following TBI 
(Cifu et al., 1997a; Fleming et al., 1999; Juengst et al., 2013; Yasuda et al., 2001). Post-TBI 
depression (PTD) is the most common neurobehavioral complication following TBI. Individuals 
with TBI are 10 times more likely than the general population to experience a depressive episode 
during their first year of recovery (53% (Bombardier et al., 2010a) compared to 6% (Kessler et al., 
2005) per 12 months in the general population) and are at greater risk decades later for recurring 
depressive symptoms (Koponen et al., 2002). Depression can be more debilitating than injury-
induced cognitive deficits as one study found that, compared to cognitive deficits, depression was 
a better predictor of continued disability post-TBI (Whitnall et al., 2006). Importantly, the 
diagnosis of PTD is of significant concern clinically due to overlap of symptomology with TBI 
symptoms (slowed thinking, trouble concentrating, fatigue).  However studies have shown that 
measures like the Patient Health Questionairre-9 can be useful in distinguishing between PTD and 
cognitive deficits (Cook et al., 2011a). Even so, a thorough understanding of the relationship 
between depression and cognitive deficits post-TBI, especially following more severe injuries, is 
important for understanding individual functional recovery.  
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In non-brain injured populations, individuals with depression often have comorbid 
cognitive deficits, likely due to common pathology (Levin et al., 2007). Meta-analyses indicate 
individuals with depression consistently have working memory deficits, reduced cognitive 
flexibility, and complain of memory problems and difficulty concentrating (Gotlib and Joormann, 
2010). While individuals with depression report a number of cognitive difficulties, memory 
deficits are consistently problematic (Burt et al., 1995). Cognitive control, the process defined as 
directing cognitive processing in the face of ever-changing goals and distractions, is particularly 
susceptible to mood and motivation (Kouneiher et al., 2009). Interestingly, individuals with 
depression show the most memory deficits on tasks where cognitive control is necessary 
(additional attentional components, or timed tests) to focus memory (Hertel, 1998; Hertel and 
Rude, 1991), suggesting these specific deficits may manifest in functional cognitive impairment. 
Similar to individuals with depression, individuals with TBI commonly exhibit significant 
memory, cognitive control, attentional difficulties after their injury (Brooks et al., 1999; Sumit N. 
Niogi et al., 2008; Perlstein et al., 2006; Vakil, 2005). Similar to hypotheses in uninjured 
populations, deficits in cognitive control (Fales et al., 2008) (cognitive flexibility, inhibition, and 
task switching) could further aggravate an attentional bias to negative stimuli (Peckham et al., 
2010), increasing risk or duration of depressive symptoms. 
Studies consistently suggest that following TBI, individuals with depressive 
symptomology show worse functional cognition (Bornstein et al., 1989; Gfeller et al., 1994; 
Rapoport et al., 2002). Apathy, insomnia, psychomotor agitation or retardation, and fatigue are 
reported frequently after TBI, even in individuals without depression, and can influence 
cognition(Andersson and Bergedalen, 2002; Bushnik et al., 2008; Larson and Zollman, 2010). For 
individuals with TBI, one study suggests that remittance of depressive symptoms with 
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antidepressant treatment can lead to improved cognitive performance (Fann et al., 2001), 
suggesting overlapping biological pathways or interacting symptomology.  
In this study, we sought to develop an inclusive measure of cognitive performance deficits 
among individuals with PTD, and demonstrate the effect of this relationship on functional 
cognitive measures. Many of the previous studies that demonstrate worse cognitive performance 
among individuals with PTD use raw scores obtained from neuropsychological tests and do not 
correct for demographic or clinical differences in their populations (like age, injury severity, or 
medication use) (Jorge et al., 2004; Rapoport et al., 2005). To begin to address this gap in the 
literature, we utilized normative data from healthy populations to adjust raw neuropsychological 
testing scores for age, education, sex, and race, where appropriate normative were available. 
Within a Rehabilomics (A K Wagner, 2010) framework aimed at understanding how individual 
factors integrate to form unique risk profiles for rehabilitation and recovery following TBI, we 
also examined covariates like age, presence of pre-morbid mood disorders, injury severity, and 
antidepressant use in associations between PTD and neuropsychological tests. In this study, we 
evaluated interrelationships between cognitive deficits as examined with neuropsychological tests, 
functional cognitive impairments, and PTD in the first year following TBI. 
2.3 METHODS 
2.3.1 Participants 
Participants in this study, approved by the University of Pittsburgh’s Institutional Review Board, 
were recruited while receiving care at inpatient and/or outpatient clinics within the University of 
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Pittsburgh Medical Center (UPMC). All participants sustained a non-penetrating traumatic brain 
injury (TBI), with evidence of intracranial injury on Computed Tomography (CT). Exclusion 
criteria included: cardiac arrest prior to admission, documented prolonged hypoxia or hypotension 
prior to admission, or penetrating TBI. All participants survived for at least one year post-injury 
and were a subset of a larger study investigating possible biomarkers and genetic factors related to 
individual recovery following TBI.   
Injury severity was described using the best GCS obtained within the first 24 hours post-
injury, as the best GCS in 24hrs shows better sensitivity in discriminating cognitive outcomes 
(Cifu et al., 1997a; Udekwu et al., 2004a). Demographic information, including age, sex, and 
education, was collected by chart review as well as through participant or caregiver interviews. 
Similarly, anti-depressant use at 6 and 12 months was extracted from both participant interview 
and chart review (see Table 2 for a list of anti-depressants medications considered in this study). 
Additionally, participants on atypical anti-psychotics were excluded from associations with 
cognition due to negative effects of these medications on cognitive functioning post-TBI (Elovic 
et al., 2003; Phelps et al., 2014).  A pre-injury history of mood disorders, including depression, 
bipolar disorder, and anxiety, was established by self-report and chart review.  
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Table 2. Antidepressant Categories and distribution within population. 
Type Generic Trade 6 months 12 months 
Selective Serotonin Reuptake 
Inhibitors (SSRI) 
Fluoxetine Prozac 1 3 
Citalopram Celexa 7 5 
Sertraline Zoloft 3 4 
Escitalopram Lexapro 15 9 
Paroxetine Paxil 3 2 
Serotonin Antagonist and 
Reuptake Inhibitor (SARI) 
Trazodone  4 3 
Serotonin-Norepinephrine 
Reuptake Inhibitors (SNRI) 
Duloxetine Cymbalta 1* 4* 
Venlafaxine Effexor 6 2 
Bupropion Wellbutrin 1** 1 
Noradrenergic and Specific 
Serotonergic Antidepressant 
(NaSSA) 
Mirtazapine Remeron 1 1 
*Individual was also on Citalopram, **Escitalopram. 
 
2.3.2 Cognitive Assessment 
Participants’ functional cognitive impairment was assessed with the FIM-Cog (Dodds et al., 1993) 
at both 6 and 12 months. FIM-Cog has five component scales: expression, comprehension, social 
interaction, problem solving, and memory. Each scale is rated from one to seven, with a 5 or lower 
indicative of need for caregiver assistance. The sum of these five components was considered the 
FIM-Cog Score. 
Cognitive performance was assessed at 6 and 12 months post-injury using a battery of nine 
neuropsychological tests, targeting 4 domains of cognition (attention, language fluency, memory, 
and executive function). Trail Making Tests A and B, where participants draw lines between 
consecutive numbers (Part A) and then between alternating letters and numbers (Part B), was used 
to measure psychomotor processing speed and cognitive flexibility/task-switching, respectively 
(RM Reitan and Wolfson, 1985). Digit span, a sub-test from the Wechsler Adult Intelligence Scale-
R, measures attention and memory by asking participants to repeat a sequence of numbers forward 
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and backwards (Glenn J. Larrabee and Curtiss, 1995). Rey-Osterreith Complex Figure Test 
assesses visuo-spatial episodic memory by asking participants to copy an abstract line drawing 
from memory (PA Osterrieth, 1944). The California Verbal Learning Test-II (CVLT-II (Delis and 
et al., 2000)) is a list learning paradigm, with subtests measuring learning, immediate recall, 
interference, and recognition. Different forms of the CVLT were used at 6 and 12 months to 
minimize practice effects from repeated administration. The Controlled Oral Word Association 
(JG Borkowski et al., 1967) and Delis-Kaplan Executive Function Systems (DKEFS) Verbal 
Fluency assess verbal fluency. In both, participants are asked to name words beginning with a 
letter (phonemic) or within a subject category (semantic); a third condition in the DKEFS assesses 
ability to switch between two semantic categories (Category Switching). The Stroop Task (J. R. 
Stroop, 1935) examines selective attention and cognitive flexibility by asking an individual to 
name the color of ink a word is printed in, suppressing a habitual response (reading the word) to 
produce a more effortful response (naming the color of ink).  Wisconsin Card Sorting Task 
(WCST) (Heaton, 1981) requires individuals to sort a series of cards along one of three dimensions, 
based on verbal accuracy feedback from the administrator, without any information regarding the 
dimension. The dimension requirements were switched every 10 cards. For this study, 
perseverative errors were assessed as a measure of executive function. 
Raw scores from each test were converted into T-scores using appropriate metrics (i.e 
education, age, sex, race) based on norms indicated by the test manufacturer. An overall cognitive 
composite was also utilized, similar to previous studies (see Chapter 4). For the cognitive 
composite, two tests from each domain were used (Attention, Trails A and digit span; Memory, 
Rey delayed copy, CVLT Long Delay Free Recall; Language Fluency, COWA Animals DKEFS 
Letter fluency; Executive function, Trails B, Stroop Interference). These tests were selected as 
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representative measures for their associated domains. T-scores were averaged within each domain 
to create domain specific sub-scores. To calculate a cognitive composite score, participants had to 
complete at least one test in each domain. Mean values across domain sub-scores were calculated 
for the overall cognitive composite score. 
2.3.3 Depressive Symptom Assessment 
At 6 and 12 months, depressive symptoms were evaluated using the Patient Health Questionnaire-
9 (PHQ-9), a brief self-report symptom inventory based on the 9 DSM-IV diagnostic criteria for 
Major Depressive Disorder (MDD). The PHQ-9 asks participants to rate how often they have 
experienced symptoms of depression, on a scale between 0 (None) and 3 (Nearly Every Day), over 
a two-week period.  Higher total scores (PHQ-9 Total) reflect a greater number of and/or greater 
severity of depressive symptoms, with the maximum score being 27.  Participants were grouped 
as “depressed” vs. “non-depressed” using the PHQ-9 questions as they map to DSM diagnostic 
criteria (previously described) (Fann et al., 2005). For a categorization of depression (PTD), 
individuals responded positively to at least five symptom questions on the PHQ-9, with at least 
one pertaining to a cardinal symptom (anhedonia or depression).  Compared to the Structured 
Clinical Interview for DSM Diagnosis (SCID) (Fann et al., 2005), this method has been validated 
in populations with TBI showing a sensitivity of 93% and a specificity of 89%. Importantly, the 
PHQ-9 is reliably able to discriminate between chronic TBI and depression symptoms (Cook et 
al., 2011a). 
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2.3.4 Statistical Analysis 
Data analysis was conducted using Statistical Analysis Software (version 9.4; SAS Institute). 
Descriptive analysis included mean and standard deviation and/or median for continuous and 
ordinal variables such as age, GCS, and education. Frequencies were calculated for categorical 
variables such as sex and antidepressant use. Demographic and relevant clinical information was 
assessed for relationships with cognitive performance using Student’s t-tests or ANOVA to 
compare means. Non-parametric tests (Mann-Whitney and Kruskal-Wallis) were used when 
appropriate. Pearson’s or Spearman’s rho (r) correlations were used to assess relationships between 
two continuous variables. Multivariate linear regression models were used to assess factors 
influencing cognitive performance or functional cognition. Target variables and covariates were 
entered into the model and removed in a backwards step-wise fashion when p>0.2 to generate final 
models. 
2.4 RESULTS 
Specific cohort demographics are shown in Table 3. Overall, participants had a GCS (best in 
24hrs) of 3-15 (mean GCS, 7.7 ± 2.8, median=7). Participants were aged 16-72 (mean age 
34.1±13.8 years) and 18.9% of participants were women. At 6 months post-injury, 38.3% of 
participants with TBI had PTD, while 30.3% had PTD at 12 months. Participants with PTD tended 
to have a higher mean age compared to those without PTD (p=0.061). Participants with PTD at 12 
months tended to have a higher initial best in 24hrs GCS compared to those with no PTD 
(p=0.057), and participants with premorbid mood disorders had higher PTD rates at both 6 (27.9 
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versus 6.0%, p=0.002) and 12 months (31.4 versus 10.0%, p=0.006). At 6 months, 51% of 
participants with PTD were on antidepressants while only 26.1% of participants with no PTD were 
on antidepressants (p=0.007). At 12 months, 40.0% of participants with PTD were taking an 
antidepressant, compared to 25.0% of those with no PTD (p=0.110). 
 
Table 3. Demographic description of study population. 
 
Total 
Population 
6 Months 12 Months 
None 
(n=71) 
PTD 
(n=44) 
p 
value 
None 
(n=83) 
PTD 
(n=36) 
p 
value 
Age, mean±STD 34.1±13.8 32.9±13.8 36.1±13.5 0.061 34.4±13.8 36.5±13.3 0.153 
GCS, median 7 7 8 0.493 7 8 0.057 
Sex, # (%) Males 177 (83.9) 61 (85.9) 33 (75.0) 0.146 67 (80.7) 27 (75.0) 0.482 
Race, # (%) 
Caucasian 
192 (91.9) 67 (94.4) 40 (90.9) 0.485 77 (92.8) 32 (88.9) 0.493 
Education, 
mean±STD 
13.0±1.9 13.1±1.9 12.7±1.9 0.178 13.1±1.8 12.7±2.0 0.246 
Premorbid Mood 
Disorders, # (%) 
 4 (6.0) 12 (27.9) 0.002 8 (10.0) 11 (31.4) 0.006 
Antidepressant  
Use, # (%) 
 18 (26.1) 22 (51.0) 0.007 20 (25.0) 14 (40.0) 0.110 
STD, Standard Deviation; PTD, Post-TBI Depression; GCS, Glasgow Coma Scale 
 
 
Table 4 summarizes bivariate associations between PTD, neuropsychological tests and 
FIM-COG at both time-points. Participants with PTD had no significant cognitive deficits at 6 
months post-TBI in any individual neuropsychological test administered. At 12 months, 
participants with PTD had better cognitive performance on the Rey immediate copy test (p=0.027) 
compared to participants with no PTD. There were no other significant associations between 
neuropsychological tests and PTD at 12 months.  
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Table 4. Bivariate Depression Associations with Cognitive Performance and Cognitive Functioning 
Post-TBI 
   6 MONTHS 12 MONTHS 
Depression None PTD p value None PTD p value 
            Neuropsychological Tests (mean±SEM) 
Overall Composite 40.8±1.0* 40.4±1.1 0.813 41.7±1.1 40.1±1.8 0.459 
CVLT Total 1-5 33.6±1.7 36.5±2 0.280 34.3±1.5 34.7±2.4 0.871 
 SDFR 34±2 37.8±2.5 0.578 36.6±2 36.5±3.2 0.971 
 LDFR 35.1±2.1 37±2.6 0.725 37.9±2.2 33±2.9 0.195 
Stroop Interference 53.7±1.4 53±1.3 0.208 54.2±1.1 51.5±1.9 0.214 
 Color-word 42.9±1.5 39.8±1.7 0.538 42±1.5 39.2±2.1 0.284 
 Color 36.2±1.3 35±1.4 0.725 36.7±1.3 35±1.7 0.455 
 Word 34.4±1.3 31.9±1.5 0.212 34.7±1.2 33±1.7 0.431 
DKEFS Cat Total 39.7±1.5 40.7±1.5 0.676 37.2±1.4 34.8±1.8 0.330 
 Cat Switch 39.9±1.7 38±2.1 0.490 40±1.7 36.1±2.2 0.187 
Rey Immediate 29.4±1.6 30.3±1.7 0.704 29.5±1.3 35.1±2.4 0.027 
 Delay 41.8±1.5 42.1±1.7 0.911 43.8±1.4 44.3±2.1 0.833 
WCST 
Perseverative 
Errors 
49.3±2.3 44.2±2.8 0.163 50±2 52.3±2.9 0.523 
Trails A  36±1.7 36.6±2 0.809 36±1.9 36.8±3.4 0.818 
Trails B  41.6±1.9 39.4±1.9 0.423 40±2.1 38.6±2.7 0.708 
Digit 
Span 
Forwards-
Backwards 
41.7±1 41.8±1.4 0.946 42.4±1.2 41.8±1.9 0.770 
COWA 
Animal 
Category 
33±2 34.8±2.4 0.583 34.3±1.7 33.7±3.1 0.860 
            Functional Independence Measure – Cognition (mean±SEM, median) 
Overall  
 
31.4±0.5, 
33 
30.6±0.4, 
31 
0.018 
31.2±0.5, 
33 
30.4±0.5, 
30.5 
0.015 
Memory 5.9±0.2,  
6 
5.6±0.2,  
6 
0.029 
5.9±0.2,  
6 
5.6±0.2,  
6 
0.020 
Problem Solving 5.9±0.2,  
7 
5.7±0.1, 
5.5 
0.052 
6.1±0.1,  
7 
5.7±0.2,  
6 
0.013 
Social Interaction 6.5±0.1,  
7 
6.3±0.1,  
6 
0.066 
6.4±0.1,  
7 
6.1±0.2,  
6 
0.016 
Expression 6.5±0.1,  
7 
6.5±0.1,  
7 
0.366 
6.5±0.1,  
7 
6.6±0.1,  
7 
0.433 
Comprehension 6.3±0.1,  
7 
6.4±0.1,  
7 
0.389 
6.4±0.1,  
7 
6.5±0.1,  
7 
0.343 
GCS, Glasgow Coma Scale; PTD, Post-TBI Depression; SEM, Standard Error of the Mean; CVLT, 
California Verbal Learning Test; SDFR, Short Delay Free Recall; LDFR, Long Delay Free Recall; 
DKEFS, Delis-Kaplan Executive Function Systems; Cat, Category; WCST, Wisconsin Card Sorting Task; 
COWA, Controlled Oral Word Association. 
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Similarly, there was no association between PTD and overall cognitive composite score at 
either time-point. Participants with PTD had lower FIM-COG scores at 6 (p=0.018, median of 31 
compared to 33) and 12 (p=0.015, median of 30.5 compared to 33) months post-TBI. FIM-COG 
components were examined for associations with PTD. At 6 months, FIM-Memory was lower in 
participants with PTD (p=0.029). At 12 months, PTD was associated with FIM-Memory, FIM-
Problem-Solving, and FIM-Social Interaction (p<0.02 all comparisons).  
As age, GCS, premorbid mood disorders, and antidepressant use were associated with 
PTD, we examined PTD associations after adjusting for these variables. Linear regression models 
were examined for each individual neuropsychological test (Table 5). Age and presence of 
premorbid mood disorders did not prove to be consistent contributors to the models and were 
omitted. Similar to bivariate analysis described in Table 4, PTD was not significantly associated 
with any of the individual neuropsychological tests except for the Stroop Interference score at 12 
months. Interestingly, antidepressant use was a consistent predictor of performance on 
neuropsychological tests, with antidepressant use being associated with worse cognitive 
performance on the CVLT, Stroop Color, DKEFS Category Total, Rey delayed copy, and COWA 
at 6 months (p<0.05 for all comparisons) and the Stroop Word, Trails A, and Trails B  at 12 months 
(p<0.05 for all comparisons). GCS was also a consistent predictor of performance on multiple 
individual neuropsychological tests (Table 5). We then examined neuropsychological test 
performance by both PTD and antidepressant use in order to understand possible interactions in 
predictions of cognitive performance. PTD*Antidepressant Use interactions were examined in the 
linear regression models present in Table 5, but this interaction was not significant in any of the 
examined models (data not shown).   
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Table 5. Linear regression models of neuropsychological tests. 
 
GCS Antidepressant Use* PTD** 
Beta p Beta p Beta p 
6 Months 
CVLT Total 1-5 1.039 0.016 -8.339 0.002 0.093 0.669 
 SDFR 1.207 0.015 -11.417 0.000 0.130 0.607 
 LDFR 0.994 0.059 -12.193 0.000 0.047 0.856 
Stroop Interference -0.184 0.622 -1.128 0.601 -0.059 0.724 
 Color-word 0.346 0.416 -4.375 0.077 -0.062 0.743 
 Color 0.280 0.438 -4.216 0.045 0.054 0.735 
 Word 0.556 0.137 -2.777 0.197 0.023 0.889 
DKEFS Cat Total 0.349 0.345 -6.797 0.005 0.243 0.203 
 Cat Switching 0.569 0.224 -4.916 0.098 -0.066 0.778 
Rey Immediate Copy 0.428 0.332 0.518 0.846 0.227 0.284 
 Delay Copy 0.740 0.066 -4.938 0.042 0.029 0.879 
WCST Perseverative Errors 0.339 0.576 -4.217 0.293 -0.366 0.267 
Trails A 1.026 0.025 -2.759 0.326 0.085 0.697 
Trails B 1.350 0.005 -3.958 0.171 -0.080 0.720 
Digit Span Forwards-Backwards 1.057 0.001 -2.545 0.142 -0.013 0.923 
COWA Animals Category 0.576 0.317 -8.590 0.010 0.288 0.242 
12 Months 
  Beta p Beta p Beta p 
CVLT Total 1-5 1.16 0.008 -3.274 0.235 -0.042 0.855 
 SDFR 1.454 0.012 -5.814 0.116 -0.416 0.179 
 LDFR 1.593 0.015 -0.397 0.92 -0.514 0.119 
Stroop Interference -0.058 0.886 2.447 0.315 -0.387 0.037 
 Color-word 0.286 0.584 -1.919 0.496 -0.056 0.808 
 Color -0.398 0.375 -2.513 0.299 0.125 0.527 
 Word 0.012 0.976 -4.612 0.036 0.058 0.742 
DKEFS Cat Total 0.031 0.938 -2.713 0.292 0.063 0.772 
 Cat Switching 0.222 0.65 -3.241 0.301 0.089 0.735 
Rey Immediate Copy 0.767 0.084 -2.769 0.306 0.149 0.516 
 Delay Copy 0.85 0.059 -1.647 0.546 0.011 0.962 
WCST Perseverative Errors 0.023 0.971 -1.704 0.668 0.15 0.647 
Trails A 1.327 0.05 -10.459 0.01 0.551 0.067 
Trails B 0.677 0.32 -10.543 0.013 0.497 0.111 
Digit Span 
Forwards-Backwards 
 
0.197 0.644 -3.548 0.155 0.17 0.383 
COWA Animals Category 0.045 0.947 -7.097 0.064 0.381 0.198 
*Reference category is no antidepressant;**Reference category is no PTD;  
GCS, Glasgow Coma Scale; PTD, Post-TBI Depression; CVLT, California Verbal Learning Test; 
SDFR, Short Delay Free Recall; LDFR, Long Delay Free Recall; DKEFS, Delis-Kaplan Executive 
Function Systems; Cat, Category; WCST, Wisconsin Card Sorting Task; COWA, Controlled Oral Word 
Association. 
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Figure 1. Cognitive composite scores (T score on y-axis) are shown in groups of participants based on 
PTD and antidepressant use at 6 and 12 months post-injury.  
At 6 months, participants with no PTD, but who are on antidepressants perform worse on cognitive composite 
measures, compared to all other groups (**compared to no PTD, no antidepressant use, p=0.002, compared to PTD, 
no antidepressant use, p=0.048, compared to PTD, antidepressant use, p=0.050). At 12 months, there were no 
significant differences. 
 
 
We examined overall cognitive composite total scores by both PTD and antidepressant use 
in order to understand possible interactions in predictions of cognitive performance. Figure 1 
shows cognitive performance on cognitive composite scores by PTD and antidepressant use at 6 
and 12 months post-TBI. Within subjects with no PTD, those on antidepressants had significantly 
worse cognitive performance at 6 months (p=0.002). There were no significant effects at 12 
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months. This interaction, PTD*Antidepressant use, was a trend in our model of cognitive 
composite scores at 6 months post-injury (Table 6), meeting criteria of p<0.2 to stay in the model. 
Our multivariate linear regression model also demonstrated that age, GCS, and education were 
also associated with cognitive composite scores. At 12 months, only age, GCS, and education were 
associated with cognitive composites.  
 
Table 6. Linear regression models for overall cognitive composites at 6 and 12 months post-injury. 
Variable Beta 
Standard 
Error 
t value p value 
     6 Months 
Age -0.08478 0.05354 -1.58 0.1168 
GCS 0.7464 0.25265 2.95 0.004 
Education 0.89902 0.36506 2.46 0.0157 
PTD -1.32184 1.87498 -0.7 0.4826 
Antidepressant Use -5.95378 2.06092 -2.89 0.0048 
PTD*Antidepressant Use 5.5098 3.03042 1.82 0.0724 
     12 months 
Age -0.12801 0.06335 -2.02 0.0475 
GCS 0.94555 0.31182 3.03 0.0035 
Education 1.23474 0.50676 2.44 0.0176 
GCS, Glasgow Coma Scale; PTD, Post-traumatic brain injury depression 
 
 
Effects of antidepressant use, PTD, cognitive deficits on functional cognitive impairment 
were then investigated. In Figure 2, we show that participants with no PTD, who are also taking 
antidepressants, have worse FIM-Cog scores compared to participants with no PTD who are not 
on antidepressants (6 months, p<0.0001; 12 months, p=0.008).  
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Figure 2. Functional cognition scores (mean score on y-axis) are shown in groups of participants based 
on PTD and antidepressant use at 6 and 12 months post-injury.  
At 6 and 12 months, participants with no PTD, but who are on antidepressant, have lower functional cognition 
compared to no PTD, no antidepressant use (*p<0.0001, **p=0.008). 
 
 
In Table 7, models predicting functional cognition were examined. At 6 months, after 
adjusting for race, cognitive composites and the interaction of PTD*Antidepressant Use remained 
in the model, with cognitive composites being significant component. At 12 months, age, GCS, 
education, cognitive composites and PTD predicted functional cognition. There were no 
significant interactions at 12 months.   
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Table 7. Linear regression models for functional cognition (FIM-Cog Total) at 6 and 12 months post-
injury. 
Variable Beta 
Standard 
Error 
t value p value 
     6 Months 
Race 1.26773 0.49389 2.57 0.0119 
Cognitive Composite 0.24908 0.03725 6.69 <0.0001 
PTD -1.27808 0.72994 -1.75 0.0833 
Antidepressant Use -1.95009 0.84102 -2.32 0.0226 
PTD*Antidepressant Use 1.69613 1.19088 1.42 0.1577 
     12 months 
Age -0.05802 0.02753 -2.11 0.0393 
GCS 0.23944 0.1382 1.73 0.0883 
Education -0.34395 0.21436 -1.6 0.1138 
Cognitive Composite 0.31099 0.048 6.48 <0.0001 
PTD -1.31959 0.76733 -1.72 0.0906 
GCS, Glasgow Coma Scale; PTD, Post-traumatic brain injury depression 
 
2.5 DISCUSSION 
This study sought to identify cognitive performance susceptible to effects of PTD and the 
relationship of these deficits and PTD in functional cognition. In this study, there was no 
significant evidence that cognitive performance deficits associated with PTD, yet individuals with 
PTD had significantly more functional cognitive impairment. Importantly, cognitive performance 
was highly associated with antidepressant use, where individuals on antidepressants performed 
significantly worse on neuropsychological tests, even when correcting for injury severity and PTD.  
While some studies demonstrate that individuals with depressive symptomology following 
TBI perform worse on a number of cognitive measures (Bornstein et al., 1989; Gfeller et al., 1994; 
Rapoport et al., 2002), other studies report no significant relationship (Satz et al., 1998). Similar 
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to previous literature, we show no PTD-associated cognitive performance deficits (as measured by 
neuropsychological cognitive composite scores), but confirm a significant impact on functional 
cognitive impairment (as measured by the FIM-Cog). In the context of Rehabilomics, we aimed 
to understand how cognitive deficits and PTD as “complications” from the injury that might impact 
functional cognition. We had hypothesized that depression might induce or worsen cognitive 
deficits, but instead, PTD is more important in functional cognition.  
 It is important to note, participants with PTD were still cognitively impaired (greater than 
one standard deviation below average), but exhibited no greater cognitive impairment compared 
to participants with no PTD. Given this finding, it may implicate the lack of motivation present in 
individuals with PTD, who, despite having comparatively similar cognitive performance, still 
demonstrated more functional impairment compared to those without PTD. Individuals with PTD 
may not feel able or motivated to compensate for cognitive deficits as much as their non-PTD 
counterparts, requiring greater assistance in daily tasks. Of note, the FIM is a measure of functional 
performance, capturing what an individual does in his or her daily life, not what he or she is capable 
of doing.  Neuropsychological tests of memory more specifically measure an individual’s actual 
cognitive capacity, but do not necessarily translate to functional daily tasks in real life. Our 
findings suggest that those who develop PTD may have comparable cognitive capacity, but as a 
result of depressive symptomology, this capacity does not translate into similar functional 
performance. While individuals with depression also tend to complain of cognitive difficulties 
more, after controlling for depressive symptoms, complaints of cognitive difficulties was 
significantly associated with lower performance on neuropsychological assessments, suggesting 
the perception of cognitive abilities may play a role in functional cognitive impairment (Chamelian 
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and Feinstein, 2006). These findings highlight the need to address PTD, as it may exacerbate the 
functional consequences of cognitive deficits.  
The relationship between PTD and functional cognition, even without significant cognitive 
impairment, may be due to other symptoms associated with PTD. Symptoms like apathy, insomnia, 
psychomotor agitation or retardation, and fatigue are reported frequently after TBI and can 
influence cognitive function. This overlapping symptomology could greatly influence functional 
cognition without manifesting in cognitive deficits. Importantly, these overlapping symptoms can 
also make identification of PTD difficult, though the PHQ-9 has been shown to differentiate 
between cognitive symptoms and PTD (Fann et al., 2005). Identifying relationships between mood 
and cognitive difficulties may also help to delineate risk for PTD with or without cognitive deficits. 
Multiple studies have suggested that individuals with PTD have worse cognitive deficits 
compared to individuals without PTD (Bornstein et al., 1989; Gfeller et al., 1994; Jorge et al., 
2004; Rapoport et al., 2002, 2005). However, many of these studies examined raw 
neuropsychological data (Jorge et al., 2004; Rapoport et al., 2005). As age, sex, education, and 
race can all affect cognitive performance on these neuropsychological evaluations, the previous 
literature may overestimate cognitive deficits in individuals with PTD, as many of these studies 
suggest older age as a contributing factor to PTD (Rapoport et al., 2005). Similarly, these studies 
do not incorporate factors like injury severity and antidepressant use into cognitive performance 
associations. This study demonstrate that both injury severity and antidepressant use are likely 
important contributors to consider in understanding associations with cognitive performance and 
PTD. 
Severity of injury has not been consistently associated with depression development post-
TBI. Many researchers work under the hypothesis that PTD is due to increased awareness of 
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deficits (Malec et al., 2010). In this case, some studies show increased depressive symptoms in 
subjects with less severe injuries (Hudak et al., 2012; Jorge et al., 2004) where there is likely a 
heightened awareness of TBI-related difficulties. Our study does add some support to this finding 
as individuals with PTD tended to have higher GCS scores. Participants with PTD also tended to 
be older than their non-PTD counterparts, similar to previous studies (Rapoport et al., 2005).  
In this study, antidepressant use is consistently associated with worse cognitive 
performance on neuropsychological tests, across domains, as well as increased functional 
cognitive impairment as measured with the FIM-Cog. In some cases, like the CVLT at 6 months, 
this finding was associated with nearly a one standard deviation decline in cognitive performance. 
It is unclear if participants who are not depressed but are on antidepressants were previously 
depressed or were being treated for other common complications post-TBI like sleep disturbances 
(Larson and Zollman, 2010). In a study of individuals with moderate to severe TBI, sertraline did 
not improve cognition when administered early in recovery (first three months) and demonstrated 
a possible negative effect (though this was not significant) (Baños et al., 2010). Fluoxetine 
increases hippocampal neurogenesis in animal models of TBI, without any improvement in 
memory performance (Wang et al., 2011; Wilson and Hamm, 2002). While future studies will 
need to examine this relationship in a priori designed studies to examine the relationship of 
depression remittance on cognitive performance, one study in a much more mild TBI population 
suggests that antidepressant treatment, with remittance of depression, actually improves cognitive 
performance (Fann et al., 2001). Another small study supported this finding (Horsfield et al., 
2002), but other studies have shown no effects of antidepressants on cognitive improvement (Lee 
et al., 2005). While treatment with antidepressants are common for PTD, there is even limited 
evidence of efficacy in regard to remittance of depressive symptoms (Ashman et al., 2009; Fann 
  47 
et al., 2009a; Warden et al., 2006). Thus, if antidepressants are negatively impacting cognitive 
recovery as a side-effect, this could be a reason for the reduced efficacy in PTD. Additionally, 
these initial findings suggests understanding the impact of antidepressants on cognition post-TBI 
may be a deterrent for prescribing antidepressants 
Functional cognition was influenced by multiple covariates in our study. At 6 months, 
covariate effects included cognitive composite scores in addition to a trend for a 
PTD*Antidepressant interaction. As the PTD*Antidepressant interaction also impacted cognitive 
composite scores, it is important to note that this suggests an effect of PTD*Antidepressant on 
FIM-Cog outside of its impact on cognitive deficits. At 12 months, there is no interaction present, 
and antidepressant use is not a significant predictor in the model.  
One important caveat in interpreting functional cognition models is that individuals who 
are on antidepressants or who have reported depression receive an automatic reduction by one 
point on the Social Interaction subscale of the FIM-Cog. Thus, the FIM-Cog total is expected to 
be associated with antidepressant use by at least one point. At 6 months, it is difficult to assess the 
effect of antidepressant use alone, as it interacts with PTD to influence FIM-Cog.  
This study suggests that, while functional cognition is greatly impacted by PTD, 
understanding a number of factors in an individual’s recovery is important to understanding the 
relationship of PTD to outcome. This work, again, supports understanding outcome prediction in 
the context of Rehabilomics, where a number of considerations for covariates can be understood. 
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3.0  VARIANTS OF SLC6A4 IN DEPRESSION RISK FOLLOWING SEVERE TBI 
Published in Brain Injury (2012) 
Michelle D. Failla, BS, Josh N. Burkhardt, BS, Megan A. Miller, BS., Joelle M. Scanlon, 
PhD, Yvette P. Conley, PhD, Robert E. Ferrell, PhD, Amy K. Wagner, MD 
3.1 ABSTRACT  
Post-traumatic depression (PTD), may be a result of several factors like secondary injury chemical 
cascades as well as psycho-social factors following traumatic brain injury (TBI). While the role of 
serotonin in the pathology and treatment of idiopathic major depression may be somewhat 
controversial, it is unclear what role serotonin may play in PTD following a traumatic brain injury 
(TBI). To assess serotonergic function and genetic risk for PTD development over one year 
following TBI, this study examined variation in the serotonin transporter gene [SLC6A4 (5-
HTTLPR, rs25331, and a variable number of tandem repeats variant in Intron 2)] in 109 subjects 
with moderate-severe injury. Depression was assessed using the Patient Health Questionnaire 
(PHQ-9) at 6 and/or 12 months post-injury. At 6 months post-injury, subjects with history of pre-
morbid mood disorders and 5-HTTLPR L-homozygotes were at greater risk for PTD. Contrary to 
major depression, subjects without pre-morbid mood disorders (n=80) and S-carriers were 2.803 
times less likely to be depressed compared to L-homozygotes. At 12 months post-injury, LG-
carriers were also less likely to experience PTD. Temporal analysis also showed 5-HTTLPR 
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associations in PTD development across recovery. This study suggests a unique injury- and 
temporally-specific interaction between TBI and genetic risk for depression. 
3.2 INTRODUCTION 
Post-traumatic depression (PTD) is the most common neurobehavioral complication following 
traumatic brain injury (TBI).  Individuals with TBI are 10 times more likely than the general 
population to suffer from a depressive episode during their first year of recovery (Bombardier et 
al., 2010a).  As individuals with TBI comprise a significantly understudied proportion of the yearly 
major depression disorder (MDD) incidence, examination of this specific population is important 
and novel, and begins to address an important gap in the literature. While studies have examined 
demographic variables [e.g. pre-morbid or family psychiatric illness, substance abuse, or 
socioeconomic class] (Jorge et al., 2004) in PTD development, they do not fully explain this 
increased risk for depression.  For example, several studies suggest that pre-morbid mood disorder 
status is a risk factor for post-TBI depression, yet these studies also show an increased risk for 
subjects with no pre-injury history of mental health disorders (Bombardier et al., 2010a; Gould et 
al., 2011). Other factors, like injury severity, as measured by the Glasgow Coma Scale (Teasdale 
and Jennett, 1974a), do not typically correlate with degree/incidence of depressive symptoms post-
TBI (Maller et al., 2010).   
With an already compromised central neurologic system, the addition of depression 
following injury can further hinder recovery (Jorge et al., 1994).  Depression in TBI has also been 
associated with aggression, anxiety, suicidality, and increased health care costs (Bombardier et al., 
2010a; Fann et al., 2009a; Jorge et al., 2004). Some studies demonstrate that remittance of 
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depressive symptoms allows for greater recuperation of cognitive function post-TBI (Fann et al., 
2001).  These observations suggest that early treatment of PTD may be a key component of 
effective recovery, yet intervention is complicated by a lack of efficacious treatment paradigms 
and a poor understanding of the underlying neuropathology in PTD. 
Decades of research in MDD have explored the role of serotonin (5-HT) in depression 
etiology and treatment (Krishnan and Nestler, 2008). The serotonin transporter (5-HTT), which 
modulates the duration and intensity of 5-HT action on its target receptors through reuptake, has 
been an important and controversial target for genetic studies in major depression. The most 
frequently studied variation of this 5-HTT gene (SLC6A4, located on chromosome 12q11.1-
17q11.2) is a 44 bp insertion/deletion in the promoter region of SLC6A4 and is known as the 
serotonin-transporter-linked polymorphic region (5-HTTLPR). The 5-HTTLPR has two common 
variants: the long (L) and short (S) allele, based on presence and absence of the insertion, 
respectively. The L-allele has a reported threefold higher transcriptional activity in vitro compared 
to the S-allele (Heils et al., 2002), possibly resulting in comparatively less synaptic 5-HT.  One 
meta-analysis showed variation at 5-HTTLPR is implicated in major depression (MDD) risk (Karg 
et al., 2011), but conflicting meta-analyses exist (Risch et al., 2009), potentially due to specific 
methodological differences.  The meta-analysis by Karg et al (Karg et al., 2011) included specific 
physical stressors (e.g. hip-dislocation) and showed the S-allele to be a significant factor in MDD 
risk. S-carriers also show increased emotionality, increased hypothalamic-pituitary-adrenal axis 
reactivity, and show greater reactivity of the amygdala in response to fearful faces (Hariri et al., 
2002). However, as stated in a review by Homberg and Lesch (Homberg and Lesch, 2011), the S-
allele is a conserved polymorphism across evolution (non-human primates also share this 
polymorphism), and likely has an efficacious role as well. Some argue that S-carriers, when 
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compared to L-homozygotes, show better cognitive performance, with some caveats, in areas that 
may be related to increased attention.  There is also a single nucleotide polymorphism (SNP, 
rs25531, A>G), within 5-HTTLPR that is found almost exclusively within the L-allele (Wendland 
et al., 2006). The G-variant results in an additional AP2 transcription factor binding site; in vitro 
studies have shown that the LG-allele is functionally similar to the S-allele (Zalsman et al., 2006). 
Also within SLC6A4, there is a variable number of tandem repeats (VNTR) within Intron 2 that 
results in three variants: 9, 10, and 12 repeats of a 17 bp repeat segment (Ogilvie et al., 1996).  
While it is not clear if the VNTR has a true functional effect on 5-HTT protein expression, the 9-
allele has been associated with unipolar depression (Ogilvie et al., 1996) and the 12-allele with 
bipolar disorder (Rees et al., 1997). From this evidence, it is likely that genetic variation within 
SLC6A4 plays a complex role in depression and mood disorder risk. 
There is a lack of literature on the effects of TBI on the serotonergic system, and the 
relationship between serotonergic function to both mood and cognitive performance post-TBI has 
not been well studied.  Several studies suggest a hypo-neurotransmission state following TBI, 
including monoaminergic neurotransmitter systems, that likely impacts chronic TBI pathology and 
cognitive dysfunction (James W Bales et al., 2009).  Some studies even suggest that anatomic 
location of injury, specifically left orbitomedial frontal lobe lesions that directly affect serotonergic 
innervation (Jorge et al., 1993), is a major contributor to PTD development, but this pathology is 
not apparent in a large number of persons with PTD (Maller et al., 2010). One study showed that 
serum serotonin profiles of subjects with TBI fall below control subject levels during recovery, 
with even lower levels observed in PTD (Wozniak et al., 2010). While serotonergic systems have 
not been fully investigated in TBI, this neurotransmitter system is increasingly important to 
consider as antidepressants like serotonin selective reuptake inhibitors (SSRIs) are a routine part 
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of care for those with MDD, yet seem to have limited effectiveness in PTD (Fann et al., 2009a). 
Interestingly, 5-HT1A receptor agonist administration confers some neuroprotective and cognitive 
benefits when administered acutely in animal models of TBI (Kline et al., 2001)(Kline et al., 2002), 
but their role in PTD has not been studied.   
Considering the increased risk for depressive episodes in the first year post-TBI, and the 
lack of understanding regarding the PTD etiology, we aimed to investigate SLC6A4 genetic 
variation in PTD development. As recovery from TBI is a dynamic and complicated process, we 
examined PTD across the first year of recovery and in relation to pre-morbid mood disorders. We 
hypothesized that genetic variation within SLC6A4 would influence depressive symptomology in 
subjects with TBI.  We expected that subjects with a history of mood disorders may have varied 
temporal onsets and genetic risk factors for PTD. We also hypothesized that genetic associations 
with PTD could differ over time, wherein PTD occurring at early recovery time-points may be 
biologically-driven and reflect a low serotonin environment compared to later time-points, where 
PTD may be driven more heavily by self-awareness of deficits and other environmental stressors.  
To our knowledge only one other study has investigated the role of SLC6A4 in PTD 
incidence at 1 year post-injury, with no significant associations identified (Chan et al., 2008).  
However, in this current study we present novel genetic associations for PTD across the first year 
post-TBI.  Our results show that subjects with pre-morbid mood disorders were more likely to 
develop depression post-TBI, and consistent with major depression, tended to carry the S-allele. 
Subjects with premorbid mood disorders were also more likely to experience a persistent sub-type 
of PTD. Among those without a history of pre-morbid mood disorders, carriage of the S-allele was 
protective against PTD at 6 months post-TBI.  At 12 months post-injury, the S-allele was not 
associated with PTD status, but the LG-allele was protective against PTD. These data suggest a 
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complex and dynamic gene-injury interaction with PTD over time and suggest a need for further 
investigation into the role of SLC6A4 in both PTD and general TBI recovery.  
3.3 METHODS 
3.3.1 Participants 
Included for analysis were 109 Caucasian participants aged 17–71 (mean age 35.33±14 years) 
receiving care at inpatient and/or outpatient clinics within the University of Pittsburgh Medical 
Center (UPMC) after sustaining a moderate to severe, non-penetrating brain injury, with CT 
evidence of intracranial injury. Participants were a subset of a larger study investigating genetic 
factors and recovery in individuals with TBI.  Participants were included in this analysis if they 
were cognitively able to report symptoms on the Patient Health Questionnaire–9 (PHQ-9) at 6 or 
12 months post-injury.  
Participants had a GCS score (Teasdale and Jennett, 1974a) of 3-15 (mean GCS, 7.76 ± 
2.82, median=7) when using the best GCS obtained within the first 24 hours post-injury.  
Demographic information including age, gender and education, was collected through chart review 
as well as subject and caregiver interviews.  Antidepressant usage at 6 and 12 months was extracted 
from both subject interview and chart review. Subjects were not stratified by antidepressant use 
for analysis as many individuals with PTD have a reduced response to SSRIs (Lanctôt et al., 2010) 
or are prescribed SSRIs for reasons other than depressive symptoms (Zafonte et al., 2002). 
However, antidepressant use was considered during multivariate analysis.  A pre-morbid history 
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of mood disorders, including depression, bipolar disorder, and anxiety at each time point, was 
established by self-report and chart review.  
3.3.2 Depressive Symptom Assessment 
Depressive symptomology was evaluated at 6 and 12 months post-injury using the Patient Health 
Questionnaire-9 (PHQ9), a brief self-report symptom inventory based on the 9 DSM-IV diagnostic 
criteria for Major Depressive Disorder (MDD). The PHQ-9 requires participants to rate, on a scale 
between 0 (None) and 3 (Nearly Every Day), how often they experience symptoms of depression 
over a two week period.  A higher total score reflects a greater number of and/or greater severity 
of depressive symptoms, with the maximum score being 27.  The PHQ-9 can be used both as a 
continuous and categorical outcome measure.  Participants with TBI were grouped as “depressed” 
vs. “non-depressed” using the DSM diagnostic criteria as they map to specific PHQ-9 questions 
as previously described (Fann et al., 2005).  Individuals were categorized as depressed if they 
responded positively to at least five symptom based questions on the PHQ-9, with at least one 
pertaining to a cardinal symptom (anhedonia or depression).  This method has been validated in a 
population with TBI showing a sensitivity of 93% and a specificity of 89% compared to the 
Structured Clinical Interview for DSM Diagnosis (SCID), which is also modeled on DSM 
diagnostic criteria (Fann et al., 2005). This method has also been examined for its ability to 
discriminate between chronic TBI and depression symptoms (Cook et al., 2011a). 
Depression was also evaluated across recovery in a subset of participants (n=67) with both 
6 and 12 month depression data.  For this temporal analysis, each participant was categorized into 
a sub-type of PTD as follows: no depression (at either time point), transient depression (depressed 
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at 6 months, but not at 12 months), persistent depression (depressed at both time points), and late-
onset depression (depressed at 12 months only). 
3.3.3 Genotyping 
DNA was isolated from either blood using a simple salting out procedure or from cerebrospinal 
fluid using the Qiamp protocol from Qiagen (Valencia, CA, USA).  For genotyping serotonin 
transporter gene (SLC6A4) promoter polymorphism 5-HTTLPR, flanking primers 5′-
TCCTCCGCTTTGGCGCCTCTTCC-3′ (forward) and 5′-
TGGGGGTTGCAGGGGAGATCCTG-3′ (reverse) were used for DNA amplification (PCR) 
(Wendland et al., 2006).  The rs25531 A>G single nucleotide polymorphism was concurrently 
detected by digesting the amplified fragments with the restriction enzyme MspI (New England 
Biolabs, Beverly, Massachusetts, USA), where the A>G substitution creates an additional MspI 
site.  Amplification products were simultaneously resolved by electrophoresis on 3.5% agarose 
gels and visualized by ethidium bromide staining and UV transillumination (Edenberg and 
Reynolds, 1998).  For genotyping the STin2 VNTR, flanking primers 5′-
GTCAGTATCACAGGCTCGAC-3′ (forward) and 5′-TGTTCCTAGTCTTACGCCAGTG-3′ 
were used.  Sequence confirmed controls of each genotype were run with each plate.  
Genetic variant frequencies did not differ by demographics or clinical variables (data not 
shown).  As this was a genetic association study, the potential for stratification effects was 
examined.  All associations were analyzed in a Caucasian population (n=109). During this study, 
African-American subjects were also recruited and completed PHQ-9 assessments post injury, yet 
the sample size for the African-American population with depression data (n=10) was not 
sufficient for sub-analysis. There is also consistent evidence of race variation in SLC6A4 allele 
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distribution [12], and consistent with the literature, our allelic frequencies for the variants analyzed 
differed by race (Gelernter et al., 1999; Lotrich et al., 2003; Xie et al., 2009) (data not shown).  For 
these reasons, the analyses presented here are limited to the Caucasians sub-population described 
above. 
3.3.4 Statistical Analysis 
The Statistical Package for Social Sciences (SPSS, version 20) was used for data analysis.  
Descriptive analysis included mean and standard deviation for continuous and ordinal variables 
such as age, GCS, and education.  Frequencies were calculated for categorical variables such as 
gender, and antidepressant use.  Genetic information was analyzed and categorized based on 
genotype and allele.  Demographic and relevant clinical information was compared between 
depression groups and variant/genotype groups using Student’s t-tests or an ANOVA to compare 
means and Chi-Square or Fisher’s Exact to compare frequencies.  In order to control for 
demographic/clinical or injury severity information, and control for potential confounders, 
multivariate logistic regression was used when identifying associations with the absence/presence 
of PTD.  Variables were entered in the logistic regression model based on their bivariate 
associations with depression.  Groupings to assess multi-variable interaction effects were avoided 
to limit the possibility of having groups with small numbers in the multivariate regression. 
Variables with a p-value less than 0.3 in bivariate analysis were initially entered in each model.  A 
backward selection method was then used to systematically remove non-significant variables from 
the model (Table 3B/3D).  The final regression model included variables that had a final p-value 
less than 0.2.  However, additional regression analyses incorporated clinically relevant variables 
(gender, injury severity, education) that have been previously associated with TBI outcome risk, 
  57 
regardless of their p-value.  These variables were forced into the model in order to 1) show stability 
of associations across multiple modeling methods, and 2) to add clinical relevance to these models 
(Table 3A/3C). 
3.4 RESULTS 
3.4.1 Population Description 
This study included 109 individuals with both genotype information and at least one PHQ-9 score 
(at 6 or 12 months).  Of these 109 subjects, 35 were categorized as depressed at 6 months (38.46%, 
n=91), while 29 subjects were depressed at 12 months (30.53%, n=95); 46 subjects experienced 
depression at some point during the first year post-injury (42.20%, n=109).  Fifteen subjects 
(13.76%) reported some history of pre-morbid mood disorders, with 14 of these subjects having 
some element of depression as a part of their pre-morbid psychiatric presentation.  The remaining 
subject had a history of anxiety.  Subjects with pre-morbid mood disorders did not differ in age, 
education, or injury severity compared to subjects without any history of mood disorders (data not 
shown). However, more subjects with pre-morbid mood disorders were taking an anti-depressant 
at 6 months (81.8%) compared to subjects with no history of mood disorders (33.8%, X =9.345, 
p=0.003). This effect was reduced at 12 months (53.3% compared to 30%, X=3.079, p=0.075).  
For those with no history of mood disorders, there were no statistically significant differences in 
demographic profiles between depressed and non-depressed groups (Table 8).  
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Table 8. Demographics and allele distribution for subjects with no history of depression (excluding pre-morbid 
subjects)  
 
 
 
 
 
 6 Months (n=80) 12 Months (n=80) 
Variable 
Depressed 
(n=27) 
Not 
Depressed 
(n=53) 
p 
value 
Depressed 
(n=21) 
Not 
Depressed 
(n=59) 
p 
value 
Age(mean ± STD) 
37.8 ± 14.6 33.3 ± 14.4 
0.116 
37.5 ± 14.2 34.0 ± 14.0 0.338 
Education  
(mean ± STD) 
13.0 ± 2.0 13.0 ± 1.9 1.000 
13.2 ± 2.4 13.0 ± 1.7 0.615 
GCS (mean ± STD) 7.9 ± 2.6 7.9 ± 2.8 0.979 8.0 ± 2.5 7.5 ± 2.9 0.549 
Male, # (%) 21 (77.7) 46 (86.8) 0.345 17 (81.0) 47 (79.7) 1.000 
Antidepressant use,  
# (%) 
12 (44.4) 15 (28.3) 0.213 
9 (42.9) 15 (25.8) 0.172 
5-HTTLPR  
S-carriers, # (%) 
11 (40.7) 35 (66.0) 0.035 
13 (61.9) 37 (62.7) 1.000 
5-HTTLPR  
LA-carriers, # (%) 
23 (85.2) 43 (81.1) 0.763 
19 (90.5) 47 (79.7) 0.334 
5-HTTLPR  
LG-carriers, # (%) 
6 (22.2) 7 (13.2) 0.345 
0 (0.0) 12 (20.3) 0.019 
VNTR 9- carriers,  
# (%) 
3 (11.1) 1 (1.9) 0.109 
1 (4.8) 3 (5.1) 1.000 
VNTR 10- carriers,  
# (%) 
16 (59.3) 27 (50.9) 0.636 
12 (57.1) 30 (50.8) 0.800 
VNTR 12- carriers,  
# (%) 
18 (66.6) 45 (84.9) 0.083 
15 (71.4) 47 (79.7) 0.544 
n: sample size; #: number of subjects; %: percent of total subjects; STD: Standard deviation; 
GCS: Glasgow Coma Scale; VNTR, variable number of tandem repeats, refers to VNTR in Intron 
2 of SLC6A4 
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3.4.2 Pre-morbidity and Post-Traumatic Depression 
Table 9. Demographics and Analysis of Pre-morbid history in PTD (6 and 12 months) 
N=109 6 Months (n=91)  12 Months (n=95) 
Variable 
No history  
(n=80) 
Pre-morbid 
(n=11) 
p 
value 
No history  
 (n=80) 
Pre-morbid 
(n=15) 
p 
value 
Age (mean ± STD) 34.8 ± 14.6 38.0 ± 13.6 0.495 34.9 ± 14.0 37.8 ± 12.0 0.462 
Education  
(mean ± STD) 
13.0 ± 2.0 12.1 ± 1.8 0.154 13.0 ± 1.9 12.1 ± 1.7 0.081 
GCS (mean ± STD) 7.9 ± 2.7 6.5 ± 2.3 0.118 7.6 ± 2.8 7.2 ± 2.4 0.570 
Male, # (%) 67 (83.8) 7 (63.3) 0.208 64 (80.0) 10 (66.7) 0.310 
Antidepressant use,  
# (%) 
27 (33.8) 9 (81.8) 0.006 24 (30.0) 8 (53.3) 0.075 
Depressed, # (%) 27 (33.8) 8 (72.7) 0.016 21 (26.3) 8 (53.3) 0.040 
5-HTTLPR  
S-carriers, # (%) 
46 (57.5) 8 (72.7) 0.266 50 (62.5) 11 (73.3) 0.311 
5-HTTLPR  
LA-carriers, # (%) 
66 (82.5) 8 (72.7) 0.336 66 (82.5) 12 (80.0) 0.531 
5-HTTLPR  
LG-carriers, # (%) 
13 (16.3) 1 (9.1) 0.466 12 (15.0) 2 (13.3) 0.615 
VNTR 9- carriers,  
# (%) 
4 (5.0) 0 (0.0) 0.592 4 (5.0) 0 (0.0) 0.497 
VNTR 10- carriers,  
# (%) 
43 (53.8) 5 (45.5) 0.422 42 (52.5) 8 (53.3) 0.589 
VNTR 12- carriers,  
# (%) 
63 (78.8) 9 (81.8) 0.587 62 (77.5) 12 (80.0) 0.567 
n: sample size; #: number of subjects; %: percent of total subjects; p= p value; SEM: standard 
error of mean; STD: Standard deviation 
 
Results comparing pre-morbid mood disorder status and PTD are presented in Table 9.  Those 
with pre-morbid mood disorders were more likely to be depressed at 6 months post-injury 
compared to subjects with no history of mood disorders (p=0.006, n=91, Figure 3A).  This greater 
risk for depression was also observed at 12 months post-injury (p=0.040, Figure 3B). Temporal 
analysis of pre-morbid status showed that subjects with pre-morbid mood disorders had a different 
distribution within temporal PTD subtypes compared to subjects with no history (p=0.036) and 
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were more likely to experience persistent PTD than other temporal sub-types of PTD 
(p=0.015)(Figure 3C). 
 
 
Figure 3. Pre-morbid mood disorder history in PTD risk across recovery.   
(A,B) Subjects with a history of mood disorders prior to a brain injury were more likely to experience PTD at 6 months 
(*A, p=0.016, X2=6.207, n=91) and 12 months (*B, p=0.040, X2=4.369, n=95). (C) There was also a significant 
association for pre-morbid mood disorder status in prediction of PTD subtype (p=0.036, X2=7.308, n=81), such that 
subjects with pre-morbid mood disorders were more likely to have some form of PTD compared to subjects with no 
history (*p=0.047).  This difference was primarily related to an more subjects with pre-morbid history experiencing 
persistent PTD (**p=0.015). 
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When evaluating bivariate associations performed for the entire population, there were no 
significant genetic associations PTD at 6 months or 12 months (Table 8).  While not statistically 
significant, 16.6% of 5-HTTLPR S-carriers in our study reported a history of pre-morbid mood 
disorders (compared to 9.3% of non-carriers, p=0.396, data not shown). As subjects with pre-
morbid mood disorders were more likely to be depressed at 6 and 12 months post-TBI, we 
hypothesized that an interaction between pre-morbid status and genotype might exist for PTD. 
Subjects were evaluated in bivariate analysis using a categorical variable comprising pre-morbid 
and S-carrier status; PTD rates did vary by pre-morbid history by S-carrier status (Fisher’s Exact, 
χ2=10.969, p=0.007, Figure 4A). Post-hoc analysis showed that S-carriers with no pre-morbid 
mood disorders exhibited the lowest depression frequencies (23.9% depressed), while S-carriers 
with pre-morbid mood disorders had the highest depression frequencies, (75.0% depressed, 
p=0.009). Interestingly, at 12 months, the effects of pre-morbid history by S-carrier status on PTD 
status in bivariate analysis was reduced (p=0.123) (Figure 4B).  
Interactions between other variants in SLC6A4 (rs25531, LG, and the VNTR in Intron 2) 
and pre-morbid mood disorder status were evaluated for PTD risk at both time-points, but no 
significant results were observed (data not shown). Multivariate models including pre-morbid 
mood disorder status and also S-carrier status showed these variables were consistently the two 
most important factors in 6 month PTD risk. In a forced entry model with other covariates (age, 
gender, GCS, education level, and antidepressant use) entered, subjects with a history of pre-
morbid mood disorders were still at the greatest risk for PTD (OR: 5.74: CI 1.133-29.092, 
p=0.035), followed by S-carrier status, where L-homozygotes had the next greatest risk (OR: 
3.343, CI: 1.135-9.849, p=0.029) for PTD. In a backwards stepwise model, pre-morbid status and 
S-carrier status were the only variables significantly affecting PTD status. (Tables 10 A, B). 
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Figure 4. Pre-morbid mood disorder history and S-carrier interaction in PTD risk.   
 (A.) Subjects grouped by 5-HTTLPR S-carrier status and pre-morbid mood disorder history show different rates of 
depression at 6 months (n=91; Fisher’s exact, χ2=10.696; p=0.007) based on percent depressed in each group (y-axis). 
Pair-wise contrasts show that subjects with pre-morbid mood disorders and who were also S-carriers, were more likely 
to be depressed, compared to S-carriers with no pre-morbid mood disorder (*p=0.009); within subjects with no history 
of mood disorders, S-carriers were less likely to be depressed (**p=0.035).  (B) At 12 months, 5-HTTLPR S-carrier 
status and pre-morbid mood disorder history did not significantly differ in depression rates (p=0.123). Pair-wise 
contrasts showed trending differences such that subjects with pre-morbid mood disorders and who were non-carriers 
were more likely to be depressed compared to subjects who had no history of mood disorders (with both S-carriers, 
#p=0.089, and non-carriers, #p=0.073, in this group). 
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Table 10. Multivariate Analyses of Genetic Variants in PTD 
A. Pre-morbid Status and 5-HTTLPR in all subjects at 6 months 
post-TBI, forced entry model. 
Variable (n=90*) Odds 
Ratio 
CI (95%) p 
value 
Pre-morbid History 5.740 1.133-29.092 0.035 
5-HTTLPR L-homozygotes 3.343 1.135-9.849 0.029 
Antidepressant Use 1.450 0.478-4.400 0.512 
Age 1.020 0.980-1.063 0.332 
Gender 0.645 0.187-2.226 0.488 
GCS 0.925 0.743-1.151 0.483 
Education 1.069 0.816-1.400 0.629 
B. Pre-morbid Status and 5-HTTLPR in all subjects at 6 months 
post-TBI, backwards conditional step-wise model. 
Variable (n=90*) Odds 
Ratio 
CI (95%) p 
value 
Pre-morbid History 6.943 1.606-30.011 0.009 
5-HTTLPR L-homozygotes 2.715 1.070-6.885 0.035 
All other terms from Model A removed through 5 steps when p>0.2. 
C. 5-HTTLPR in subjects with no history of mood disorders, 
forced entry model. 
Variable (n=79*) Odds 
Ratio 
CI (95%) p 
value 
5-HTTLPR L-homozygotes 2.803 1.032-7.614 0.043 
Antidepressant Use 1.941 0.682-5.521 0.214 
Age 1.014 0.977-1.051 0.466 
Gender 0.537 0.144-2.006 0.355 
GCS 0.983 0.808-1.196 0.865 
Education 1.009 0.774-1.316 0.946 
D. 5-HTTLPR in subjects with no history of mood disorders, 
backwards conditional step-wise model. 
Variable (n=79*) Odds 
Ratio 
CI (95%) p 
value 
5-HTTLPR L-homozygotes 2.932 1.094-7.857 0.033 
Antidepressant Use 1.965 0.716-5.391 0.190 
All other terms from Model C removed through 5 steps if p>0.2. 
*One subject was missing Education information 
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3.4.3 Genetic associations with PTD among those without pre-morbid mood disorders 
Among those with no history of mood disorders, Table 9, (n=94), S-carriers had lower PTD rates 
at 6 months post-injury (Fisher’s exact, p=0.035), with no significant differences by S-carrier 
status at 12 months (p=1.00) (see figure 5A/B).  
 
 
Figure 5. 5-HTTLPR S-carriers in PTD risk across recovery.   
 (A,B) Evaluation of the S-allele carrier frequencies in only subjects with no history of mood disorders shows S-
carriers are less likely to experience PTD at 6 months compared to non-carriers (*p=0.035, A), with no significant 
effect of the S-allele at 12 months (p=1.00, B). (C) There was also a significant association for S-carrier status in 
prediction of PTD subtype (p=0.013), such that S-carriers compared to non-carriers, were less likely to experience 
PTD in any form (*p=0.020).  This difference was primarily related to less S-carriers experiencing transient PTD 
(**p=0.004). 
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LA- and LG-carrier status (rs2553) (LA/LA vs. LA/LG, Fisher’s exact, χ2=0.952, p=0.457) was not 
associated with PTD at 6 months (Figure 6A). However, at 12 months post injury, no LG-carriers 
were depressed (p=0.019, Fischer’s exact, χ2=5.025, n=80) (Figure 6B).  
 
 
 
Figure 6. 5-HTTLPR LG-carriers in PTD risk across recovery.   
(A,B) Evaluation of the LG-allele carrier frequencies in only subjects with no history of mood disorders shows LG-
carriers status was not associated with PTD risk at 6 months (A, p=0.345, X2=6.207, n=91). However, LG-carriers 
were less likely to experience PTD at 12 months compared to non-carriers (*p=0.030, B). (C) There was also a 
significant association for LG-carrier status in prediction of PTD subtype (p=0.011), such that LG-carriers compared 
to non-carriers, were more likely to experience transient PTD (*p=0.005) compared to non-carriers. 
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Genotype and carrier status of the VNTR in Intron 2 of SLC6A4 was also examined in relation to 
PTD risk, with no significant associations (Table 9). All genetic variants were examined as 
modulators of depression severity (PHQ-9 scores) with no significant findings.   
Temporal analysis of PTD showed unique genetic associations in subjects with no history 
of pre-morbid mood disorders. S-carrier status predicted PTD subtype (Fisher’s exact, χ2=10.496, 
p=0.013, Figure 5C), such that S-carriers were less likely to experience PTD in any form 
(compared to L-homozygotes, p=0.020). More specifically, S-carriers were less likely to 
experience a transient depression (compared to L-homozygotes, p=0.004). There was also a 
significant association for LG-carrier status in prediction of PTD subtype (Fisher’s exact, 
χ2=12.856, p=0.011) at 12 months, such that LG-carriers were more likely to experience transient 
PTD compared to non-carriers (p=0.005) (Figure 6C). Temporal analysis of the VNTR in Intron 
2 did not show any significant predictors of PTD subtype. 
Multivariate analysis at 6 months, controlling for antidepressant use, gender, injury 
severity, and education, showed a robust association with 5-HTTLPR such that L-homozygotes 
were 2.803 (95% CI: 1.032-7.614, p=0.043) times more likely to be depressed compared to S-
carriers. Backwards elimination of variables in this model showed that only S-carrier status and 
antidepressant use predicted PTD status at 6 months (Tables 10C/D).  
3.5 DISCUSSION 
This study presents evidence for a temporally-influenced, injury-specific genetic risk profile for 
depression following TBI. While pre-morbid mood disorder history was the most influential 
predictor of PTD, after controlling for this variable, L-homozygotes were at the next greatest risk 
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for PTD 6 months post-injury.  This finding suggests a protective role for the S-allele, which was 
further confirmed in multivariate analysis that included only those without pre-morbid mood 
disorders.  Interestingly, the presence of the LG variant (compared to LG absence) was associated 
with lower PTD risk at 12 months post-TBI.  These PTD genetic risk profiles differ from findings 
reported with MDD and are dependent on time after injury, suggesting a TBI specific genetic risk 
relationship. These unique associations with SLC6A4 in PTD call for further investigation into the 
role of the serotonergic system post-TBI, specifically in earlier recovery periods where 
intervention may be highly beneficial. 
While this study showed a novel, protective association for S-carriers in PTD risk at 6 
months post-TBI, particularly for subjects with no history of pre-injury mood disorders, temporal 
PTD analysis also supported these results by showing that S-carriers were specifically less likely 
to experience a transient depression, with no difference in other PTD-subtypes.  Our findings also 
show a protective association for the LG-allele at 12 months post-injury in these subjects, with LG-
carriers primarily experiencing either no or transient PTD. 
These findings differ from 5-HTTLPR associations in MDD risk, where the S- and LG-
allele are most consistently identified as risk genotypes (Karg et al., 2011), implying a unique 
injury-induced neuropathology in PTD. Temporal PTD-subtype analysis of both S-carrier and LG-
carrier PTD associations show these findings are also temporally-specific during TBI recovery. 
Interestingly, our study found no PTD associations with the VNTR in Intron 2 of SLC6A4.  
However, it has been reported previously that the 5-HTTLPR has a dominant role over 5-HTT 
expression, with the VNTR acting only as a modulator (Hranilovic et al., 2004).  One other study 
has examined S-allele 5-HTTLPR associations with PTD 12 months post-injury with no significant 
results (Chan et al., 2008), findings which are consistent with our results with this allele at 12 
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months. While our study found the LG-allele was associated with no PTD at 12 months, this 
previous study did not examine the LG-allele separate from the S-allele. Also, subjects in that study 
were not stratified by pre-morbid mood disorders; our analysis only showed genetic associations 
with PTD when pre-morbid subjects were excluded or whose effects were adjusted for in 
multivariate analysis (Table 3).  Similarly, studies in post-stroke depression suggest S-
homozygotes show increased rates of depression, but many of these studies did not exclude or 
separately analyze subjects who had a history of pre-injury depression (Mak et al., 2012).  
The results of this study, with 5-HTTLPR genotype PTD risk associations that differ from 
MDD, suggest that depressive symptomology in TBI may arise from a unique, TBI-specific 
pathology. In MDD, several studies show associations between S-carriers and increased risk for 
MDD (particularly in relation to stressful life events (Karg et al., 2011)), yet these findings are 
inconsistent and effect sizes are small (Risch et al., 2009).  Other studies show that the L-allele is 
associated with completed suicide, nicotine dependence, and attention deficit hyperactivity 
disorder (Kenna et al., 2012). While these studies all continue to suggest a role for 5-HTTLPR in 
psychopathology, they remain controversial, in part, due to a lack of a clear underlying mechanism 
for these associations. Some work suggests that cortical 5-HT levels vary by 5-HTTLPR genotype 
when considering both in vitro (Lesch et al., 1996; Little et al., 1998) and in vivo (Praschak-Rieder 
et al., 2007; Reimold et al., 2007) binding studies. However, other conflicting studies exist 
(Erritzoe et al., 2010; Parsey et al., 2006; van Dyck et al., 2004). More consistently, S-carriers 
show increased emotionality with higher amygdala reactivity, as well as a general hypervigilance 
towards environmental stimuli and some advantages in cognitive functioning (see Homberg and 
Lesch review (Homberg and Lesch, 2011)).  While this behavioral adaptation could be 
advantageous in some aspects, it may also pre-dispose S-carriers to mood disorders (Hariri et al., 
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2002; Homberg and Lesch, 2011; Risch et al., 2009). Recently, Ho et al. showed that SERT 
availability was reduced in subjects with major depression but that this was not associated with 
SLC6A4 genotype (Ho et al., n.d.). Similarly, Kobiella and colleagues showed recently that 5-HTT 
binding potential did not mediate the relationship between 5-HTTLPR and amygdala reactivity, 
suggesting that 5-HTTLPR may not have a direct effect on 5-HTT availability (Kobiella et al., 
2011). Kobiella et al suggest that 5-HTTLPR effects on neurodevelopment, and not 5-HT levels, 
may confer genotype differences in adult cognition and MDD risk.  
The effects of 5-HTTLPR, either through its impact on 5-HT levels, 5-HTT functionality, 
or relationships with cognition and emotionality, are likely to interplay with TBI pathology to 
influence PTD development. In a highly stressed system like the injured brain, it is possible 5-
HTTLPR may more greatly impact cortical 5-HT levels or 5-HTT availability. TBI induces a 
global hypo-neurotransmission state (this is especially evident in the dopaminergic system, for 
review see Bales et al (James W Bales et al., 2009)) and in experimental TBI, there is evidence of 
a chronic hypo-serotonergic state (Busto et al., 1997).  Thus, a protective S-allele, with possibly 
lower 5-HT reuptake, may indicate a less severe hypo-serotonergic state post-TBI in S-carriers 
compared to L-homozygotes.  However, it is also important to note that 5-HTTLPR can be 
influenced by epigenetic regulation, particularly since TBI induces a global hypo-methylation state 
(Gao et al., 2006). Interestingly, the human 5-HTTLPR S-allele is associated with increased 
methylation compared to the L-allele (Philibert et al., 2007); methylation at 5-HTTLPR has also 
been associated with increased depressive effects of a stressor (van IJzendoorn et al., 2010).  
The effect of 5-HTTLPR on morphology of the fronto-limbic system may aid in 
understanding unique PTD associations, and these circuits show dysfunction in both TBI and 
depression (Maller et al., 2010). In the neurodegenerative state of TBI (Bendlin et al., 2008), 
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hippocampal atrophy frequently occurs (David F. Tate and Bigler, 2000). Hippocampal atrophy is 
also a common finding in MDD that is reportedly more severe in depressed L-homozygotes (Frodl 
et al., 2004)(Frodl et al., 2008), suggesting a potential ‘advantage’ for S-carriers, especially in 
reference to PTD. Morphological differences in the fronto-limbic system may also explain 
increased emotionality (increased amygdala reactivity) and cognition (better decision making, risk 
aversion) of S-carriers. As depression influences cognitive recovery post-TBI (Fann et al., 2001), 
genetic influences on cognitive recovery may impact PTD development.  As attentional deficits 
are a hallmark of TBI, an increased hypervigilant state pre-injury (attention to 
emotional/environmental stimuli) in S-carriers could be beneficial post-injury; similarly, studies 
show persons with ADHD tend to be L-carriers (Faraone et al., 2005). Better cognitive function at 
early time-points (6 months) post-injury may be protective against depressive symptomology. 
Future studies examining the effect of 5-HTTLPR on post-TBI cognitive recovery in relation to 
fronto-limbic function may aid in understanding how this polymorphism influences PTD risk. 
Increased PTD incidence among subjects with pre-morbid mood disorders, regardless of 
5-HTTLPR status, is consistent with other studies that have reported pre-morbid status a 
significant predictor in PTD development (Malec et al., 2010).  Our study also found that pre-
morbid mood disorder history was significantly associated with a persistent PTD subtype.  Other 
studies have shown that subjects with pre-morbid mood disorders were more likely to develop 
PTD at earlier time points compared to subjects with no history of mood disorders (Gould et al., 
2011). As our study did not investigate depression status specifically at the time of injury, it is 
possible PTD at early time-points could be a continuation of depression at injury.  However, 
Bombardier et al (Bombardier et al., 2010a)  reported similar rates and onset of depression in 
subjects with depression at injury compared to subjects with a pre-injury history for depression 
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that were not depressed at the time of the injury. Neuropathology associated with pre-morbid mood 
disorders [decreased neurogenesis in the hippocampus (Warner‐ Schmidt and Duman, 2006), 
altered neuroplasticity and functionality in fronto-limbic circuits, etc.] may overlap and/or interfere 
with normal recovery post-TBI, resulting in increased risk for PTD.  Furthermore, S-carriers with 
pre-morbid mood disorders were at greater risk for PTD compared to S-carriers with no history of 
mood disorders. It is possible that some of the suggested advantages of the S-allele in protection 
against PTD may be ameliorated by pre-injury neuropathology associated with pre-morbid mood 
disorders. Though there were no significant genetic predictors of pre-morbid status, subjects with 
pre-morbid mood disorders did tend to be S-carriers (Table 2), consistent with MDD literature. 
In this study, the LG- and S- alleles, believed to result in similar 5HTT expression levels 
based on other studies, have different temporal associations with PTD risk, particularly for those 
without premorbid mood disorders. It is possible that the LG-allele’s protective association has 
similar possible mechanisms as previously mentioned for the S-allele. Yet, it is not clear why these 
associations are temporally specific. While the LG association needs to be replicated in a larger 
sample, a temporal difference might be explained in several ways. One possibility may be due to 
the regulation of the LG allele by the transcription factor AP-2, as the LG allele has an additional 
AP-2 binding site compared to the LA allele (also, the S-allele does not have this site) (Damberg, 
2005).  Importantly, there is evidence to suggest that AP-2 function might highly impact injury x 
gene interactions (Garcı́a et al., 1996). It is also not clear how allele-specific methylation might 
affect these associations.  
While this study contains several novel and neurobiologically relevant findings, there are 
some caveats to consider.  This study was limited by population size, and future analyses will need 
to include larger samples.  Also, this study did not exclude subjects that were on antidepressant 
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treatment.  Patients with TBI are given SSRIs and other antidepressants frequently for a range of 
issues common to TBI, including problems associated with sleep, agitation, and behavior, in 
addition to treatment for a depressive episode (Zafonte et al., 2002).  Subjects taking 
antidepressants were more likely to be depressed in our study, suggesting that although subjects 
were taking these medications, they were still experiencing significant depressive symptoms, a 
finding similar to previous reports of reduced effectiveness of SSRIs in populations with TBI 
(Lanctôt et al., 2010).  Also, serotonergic genes may modulate antidepressant efficacy in 
individuals with TBI as well as rates of adverse events, as one study of a population with PTD 
showed S-homozygotes (compared to L-carriers) experienced less adverse effects of 
antidepressants (Lanctôt et al., 2010). As the effect of 5-HTTLPR on pharmacotherapy has also 
been suggest in non-injured populations (Kenna et al., 2012), future studies are needed to examine 
pharmacogenetic effects of antidepressant treatment in PTD. Another caveat to consider is how 
gender effects may moderate 5-HTTLPR risk profiles in PTD. Here we do not report significant 
gender differences in PTD development nor in genetic risk profiles, but our study is likely 
underpowered for this analysis. Women are more at risk for MDD (Kessler et al., 2005), yet TBI 
is more prevalent in men (Faul et al., 2010). Thus, sex will be an important factor to consider in 
future and larger studies of genetic risk associations with PTD.  
As serotonin signaling influences many mechanisms that impact TBI recovery (e.g. 
neurogenesis, regeneration, and synaptic plasticity) (Mattson et al., 2004), this study also 
highlights the need to understand serotonergic functioning post-TBI.  While genetic associations 
and interactions in a specialized population like PTD are highly intriguing, understanding how 
these mechanisms function across the spectrum of depression and cognitive recovery post-TBI 
may also aid in understanding brain repair mechanisms in general.   
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With the increased risk for depression following TBI and the paucity of effective 
treatments, there is an immense need for a better understanding of underlying pathology of PTD. 
The results of this study, with 5-HTTLPR genotype PTD risk associations that differ from MDD 
and interact with pre-morbid mood disorder status, suggest that depressive symptomology in TBI 
likely arises from a TBI-specific pathology. This study also serves as evidence of important gene 
x injury interactions that may differ from previously reported associations in non-injured 
populations and may significantly impact recovery and treatment course for those with TBI. 
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4.0  POST-TBI COGNITIVE PERFORMANCE IS MODERATED BY VARIATION 
WITHIN ANKK1 AND DRD2 GENES 
In Submission 
Michelle D. Failla, BS, John M. Myrga, Joseph H. Ricker, PhD, C. Edward Dixon, PhD, 
Yvette P. Conley, PhD, Amy K. Wagner, MD 
4.1 ABSTRACT 
Objective: As dopamine neurotransmission impacts cognition, we hypothesized functional 
variants in the linked dopamine D2 receptor (DRD2) and ankyrin repeat and kinase domain 
(ANKK1) genes might account for some individual variability in cognitive recovery post-TBI. 
Participants: Prospective cohort of 108 survivors of severe TBI, recruited consecutively from a 
level 1 trauma center. 
Design: We examined relationships between targeted dopamine genetic variation and functional 
recovery at 6 and 12 months post-TBI. 
Main Measures: Cognitive performance was evaluated using 8 neuropsychological tests targeting 
different cognitive domains. An overall cognitive composite was developed based on normative 
data. We also assessed functional cognition, depression status, and global outcome. Subjects were 
genotyped for 6 DRD2 tagging single nucleotide polymorphisms and Taq1A within ANKK1.  
Results: ANKK1 Taq1A heterozygotes performed better than homozygotes across several 
cognitive domains at both time-points post-injury. When adjusting for age, GCS, and education, 
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the Taq1A (ANKK1) and rs6279 (DRD2) variants were associated with overall composite scores 
at 6 months post-TBI (p=0.0494, 0.0371, respectively). At 12 months, only Taq1A remained a 
significant genetic predictor of cognition (p=0.0081).   
Conclusion: These data suggest genetic variation related to dopamine signaling mediates cognitive 
recovery post-TBI. Understanding genetic influences on dopamine systems post-TBI may impact 
current treatment paradigms. 
4.2 INTRODUCTION 
Among the approximately 1.7 million people treated for a traumatic brain injury (TBI) in the 
United States each year (“CDC - Injury - TBI - TBI in the US Report,” n.d.), the majority of those 
individuals will experience persistent cognitive deficits following their TBI. Cognitive impairment 
post-TBI can impact return to work and community reintegration for patients (Jennifer Fleming, 
Leigh Tooth, Mary, 1999). While the resultant cognitive impairments have been well-studied 
(Levin et al., 1982), identifying individual patterns in recovery is still difficult. In fact, the recent 
international guidelines for cognitive rehabilitation post-TBI (Bayley et al., 2014), emphasize the 
need for individualized cognitive rehabilitation paradigms. Genetic variation in targeted systems 
known to affect cognition in healthy individuals may explain some variance across recovery 
trajectories. This study approaches the issue of poor cognitive outcomes and prognostication 
following TBI from a Rehabilomics (A K Wagner, 2010; Wagner and Zitelli, 2012) perspective, 
assessing genetic variation, in addition to other common individual factors that contribute to 
cognitive performance, to enhance our understanding of individual variation in cognitive recovery. 
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In healthy populations, dopamine (DA) neurotransmission in the brain modulates attention, 
processing speed, executive functioning, and working memory (Braver and Cohen, 2000). Frontal 
lobe regions associated with these functions have dense projections to the DA-rich striatum. In 
fact, positron emission tomography (PET) studies characterizing striatal D2 receptor binding 
demonstrate D2 binding is correlated to several aspects of cognition, such as working memory in 
healthy populations (Aalto et al., 2005). Dysfunctional DAergic signaling may explain many of 
the persistent cognitive deficits observed with TBI (see (James W Bales et al., 2009) for review). 
Decreased DA transporter (DAT) levels in the prefrontal cortex and striatum (Shimada et al., 
2014a) have been confirmed in a rat model after TBI (H.Q. Yan et al., 2002), suggesting 
compensatory action by DA neurons to increase DA signaling post-TBI. In severe to very severe 
levels of injury associated with the controlled cortical impact (CCI) model of experimental TBI, 
tyrosine hydroxylase (TH), a rate-limiting enzyme in the synthesis of DA is upregulated in 
presynaptic terminals in the frontal cortex (Yan et al., 2001) and in the striatum (James W Bales 
et al., 2009; Wagner et al., 2009). These changes in DA synthesis proteins also suggest 
compensatory mechanisms in presynaptic DA neurons to increase DA neurotransmission post-
TBI. Interestingly, real time neurotransmission studies using fast scan voltammetry with 
stimulated DA release in the striatum demonstrate reductions in evoked DA overflow and altered 
DA clearance kinetics (Wagner et al., 2005) that can be restored with daily treatment with the 
neurostimulant methylphenidate (Wagner et al., 2009). In clinical TBI populations, both positron 
emission tomography (PET) (Amy K Wagner et al., 2014) and single photon emission tomography 
(Donnemiller et al., 2000) studies show reduced striatal binding of the (DAT). Similarly, DAergic 
pharmacological treatments have shown promise in cognitive restoration post-TBI (Bleiberg et al., 
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1993; Whyte et al., 2004). Together, these studies suggest that a highly dysfunctional 
dopaminergic state post-TBI could influence individual cognitive recovery.  
Genetic variation that may affect dopaminergic signaling may elucidate some of the 
individual variation in cognitive recovery post-TBI. Our previous work provides mounting 
evidence of genetic variation on DAergic signaling post-TBI. Variation in the DAT gene (DAT1) 
moderates cerebrospinal fluid (CSF) levels of DA (Amy K Wagner et al., 2007). We have also 
explored DAT1 and genetic variation associated with D2 function via the Taq1A variant in the 
ankyrin repeat and kinase domain (ANKK1) gene, just upstream from the DRD2 gene, with PET 
striatal binding using DA-associated ligands for D2 and DAT (Amy K Wagner et al., 2014). In 
this study, the data provided evidence that DAT1 genotype modulates DAT binding post-TBI and 
that both DAT1 and Taq1A genotype interact with injury status to influence DAT binding (Amy 
K Wagner et al., 2014). Another study in mild TBI demonstrated that Taq1A genotype moderates 
performance on a measure of memory recognition at 1 month post-injury (McAllister et al., 2008). 
Genetic variation within the enzyme that breaks down DA in the prefrontal cortex, catechol-O-
methyltransferase (COMT), also can moderate cognitive recovery post-TBI (Lipsky et al., 2005a; 
Willmott et al., 2014a), as can pharmacological interventions (Willmott et al., 2013). Thus, there 
are several lines of evidence to support our hypothesis that genetic variation in DAergic signaling 
may influence cognitive recovery post-TBI. 
Genetic variability related to the D2 receptor has been investigated by assessing both 
variation within the DRD2 gene itself and in evaluating the ANNK1 gene immediately upstream of 
DRD2. The DRD2 associated polymorphism rs1800497 Taq1A within the ANNK1 gene has been 
studied extensively in psychiatric disorders and DA-related endophenotypes, especially addictive 
behaviors (Ponce et al., 2009). Also, rs1800497 has been studied in response latency and memory 
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recovery following mild TBI (McAllister et al., 2008, 2005). The Taq1A genotype influences 
striatal D2 receptor density (Thompson et al., 1997) and may impact autoreceptor mediated 
inhibition of DA synthesis (Laakso et al., 2005). We examined 6 SNPs within the DRD2 gene, 
including rs6279. Rs6279 is in linkage disequilibrium (LD) with rs6277, a synonymous mutation 
of C957T, which reportedly affects mRNA stability and regulation of DA-induced D2 expression 
(Duan et al., 2003), making this locus a likely target for associations with cognitive function.  
The aim of this study was to investigate variation involved in DA function as it modulates 
cognitive recovery post-TBI, specifically utilizing a cognitive composite score to assess multiple 
cognitive performance domains. We hypothesized that genetic variation within the ANKK1 and 
DRD2 genes might influence individual cognitive recovery. In this study, we report that DRD2 
associated variation modulates cognitive recovery following TBI. Specifically, ANKK1 Taq1A 
rs1800497 heterozygotes and DRD2 rs6279C-homozygotes demonstrate better cognitive recovery 
across the first year following their injury. This study further supports the hypothesis that 
individual variation in dopamine signaling modulates cognitive recovery post-TBI. 
4.3 METHODS 
4.3.1 Participants 
This study was approved by the University of Pittsburgh’s Institutional Review Board and 
consisted of 108 consecutively recruited participants receiving care at inpatient and/or outpatient 
clinics within the University of Pittsburgh Medical Center (UPMC). Enrollment criteria included 
a non-penetrating TBI, with evidence of intracranial injury on Computed Tomography (CT), an 
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admission GCS score ≤8 indicating severe TBI, and age, ≥16 and <75 years. All subjects included 
for analysis survived at least 1 year post-injury were cognitively able to perform the 
neuropsychological battery.  Subjects were excluded for documented prolonged hypoxia prior to 
admission. Participants were a subset of a larger study investigating possible genetic factors related 
to individual recovery following TBI.  
While an admission GCS ≤8 was taken as evidence of severe TBI, we used the best GCS 
obtained within 24 hours post-injury for analysis, as the best GCS in 24hrs shows better sensitivity 
in discriminating cognitive outcomes (Cifu et al., 1997a; Udekwu et al., 2004a). Best GCS in 24hrs 
scores ranged from 3-15 (mean GCS, 8.02 ± 3.083, median=7). Demographic information, 
including age, sex, and education, was collected by chart review and subject or caregiver 
interviews. Subjects were aged 17-71 (mean age 34.19 ± 13.75 years) and 18.5% (n=20) of 
participants were women.  
4.3.2 Sample Collection and Genotyping 
Subjects were genotyped for the dopamine receptor D2 (DRD2) associated polymorphism Taq1A 
in the ANNK1 gene (rs1800497) and 6 tagging SNPs in the DRD2 gene (rs6279, rs2734838, 
rs17529477, rs4245147, rs7131056, rs4630328). Haploview(Barrett et al., 2005) (version 4.2) was 
used to determine the degree of linkage disequilibrium between these 7 SNPs within this 
population (see Figure 7).  
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Figure 7. Targeted single nucleotide polymorphisms (SNPs) within ANKK1 and DRD2.  
These SNPs lie within their respective genes as marked in the gray rectangles, and consecutively along the 
genome as mapped on the white rectangle. Linkage disequilibrium (LD) between the 7 SNPs examined (calculated 
LDs using Haploview v.4.2) is represented as the numbers in each square between each pair of SNPs (D’). Red squares 
indicate high LD and white squares indicate low LD based on algorithms calculated within Haploview. The bold black 
line around Block 1 indicates a haploblock that contains rs7131056 and rs4630328. In our sample, there is relatively 
low LD between rs1800497 and SNPs in DRD2. 
 
DNA was isolated from blood, using a simple salting out procedure, or from cerebrospinal fluid, 
using the Qiamp protocol from Qiagen (Valencia, CA, USA).  For Taq1A (rs1800497) genotyping, 
amplified DNA underwent 30 cycles of denaturation at 95oC for 1min., annealing at 58oC for 30s, 
and extension at 72oC for 1min., to amplify the 459bp product, which was then exposed to TaqI 
restriction endonuclease to perform restriction fragment length polymorphism (RFLP) analysis. 
Digested products were electrophoresed on a 3% agarose gel, stained with ethidium bromide for 
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DNA band detection, and assigned a genotype based on presence/absence of original or cut DNA 
fragments. Primers used were 5’-CCGTCGACCCTTCCTGAGTGTCATCA-3’ and 5’-
CCGTCGACGGCTGGCCAAGTTGTCTA-3’. Tagging SNPs (tSNPs) covering DRD2, and 1kb 
flanking DNA 5’ and 3’, were selected using HapMap (Release 28); tSNP selection criteria was 
set at r2=0.80 and minor allele frequency (MAF) ≥0.20 to allow for robust evaluation of 
heterozygote status (Comings and MacMurray, 2000) and potential associations with the outcomes 
of interest. rs2734838 was genotyped using Taqman allele discrimination and an ABI7000 
(Applied Biosystems, Carlsbad, CA, USA), and the remainder were genotyped using  iPLEX 
MassArray (Sequenom, San Diego, CA).  Technical replicates were used across plates, and 
genotypes were double blind called for quality control. 
Some participants were not successfully genotyped for each SNP (rs1800497, 1; rs6279, 
2; rs2734838, 2; rs17529477, 2; rs4245147, 4; rs7131056, 1; rs4630328, 2).  As this was a genetic 
association study, there were concerns about potential stratification effects(Freedman et al., 2004). 
In addition, previous studies indicate different rs1800497 allelic distributions by race that could 
confound association studies (Goldman et al., 1993). Thus, all reported associations were analyzed 
in a Caucasian sub-population (n=99). Of note, all results were also conducted in the full 
population showing consistent findings (data not shown). Among Caucasians, allele frequencies 
were in Hardy-Weinberg equilibrium. Genetic variant frequencies did not differ by demographics 
or clinical variables, except for associations with race (data not shown).  
4.3.3 Outcome Measurements 
General outcome was assessed with the Glasgow Outcome Scale (GOS) (3=severe disability, 
4=moderate disability, 5=good recovery) at 6 and 12 months (Jennett and Bond, 1975). Research-
  82 
trained neuropsychometrists, blinded to genetic information, collected information used to 
generate GOS scores. Additionally, subjects in this cohort were evaluated, using the Functional 
Independent Measure subscale for Cognitive Function (FIM-Cog) (Dodds et al., 1993), at both 6 
and 12 months. FIM-Cog is comprised of five component scales expression, comprehension, social 
interaction, problem solving, and memory.  Each scale is rated from one to seven, and the sum of 
these five components was considered the FIM-Cog Score. 
4.3.4 Cognitive Composite Score 
Cognitive performance was measured at both 6 and 12 months post-injury using a battery of 8 
neuropsychological tests targeting 4 domains of cognition (attention, language fluency, memory, 
and executive function). Trail Making Tests A and B, a test where participants draw lines between 
consecutive numbers (Part A) and then between alternating letters and numbers (Part B), was used 
to measure psychomotor processing speed and cognitive flexibility/task-switching, respectively 
(RM Reitan and Wolfson, 1985). Digit span, a sub-test from the Wechsler Adult Intelligence Scale-
R, measures attention and memory by asking participants to repeat a sequence of numbers forward 
and backwards (Glenn J. Larrabee and Curtiss, 1995). Rey-Osterreith Complex Figure Test 
assesses visuo-spatial episodic memory by asking participants to copy an abstract line drawing 
from memory (PA Osterrieth, 1944). The California Verbal Learning Test-II (CVLT-II (Delis and 
et al., 2000)) is a list learning paradigm, with subtests measuring learning, immediate recall, 
interference, and recognition. Different forms of the CVLT were used at 6 and 12 months to 
minimize practice effects from repeated administration. The Controlled Oral Word Association 
(JG Borkowski et al., 1967) and Delis-Kaplan Executive Function Systems (DKEFS) Verbal 
Fluency assess verbal fluency. In both, participants are asked to name words beginning with a 
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letter (phonemic) or within a subject category (semantic); a third condition in the DKEFS assesses 
ability to switch between two semantic categories. The Stroop Task(J. R. Stroop, 1935) examines 
selective attention and cognitive flexibility by asking an individual to name the color of ink a word 
is printed in, suppressing a habitual response (reading the word) to produce a more effortful 
response (naming the color of ink).   
A cognitive composite score was developed based on normed t-scores for each test 
(considering age, gender, race, and education where applicable) to determine a measure of overall 
cognitive recovery. Attention was measured using the Trails Making Test A, and the combined 
score of the forward and backward digit span tests. Memory was evaluated using the Rey-
Osterreith Complex Figure Test and the Long Delay Free Recall Subsection of the California 
Verbal Learning Test.  Language Fluency domain scores were calculated using Controlled Oral 
Word Association Animals Subsection and the Delis-Kaplan Executive Function Systems Verbal 
Fluency Letter Fluency subsection.  Lastly, executive function was measured using the Trials 
Making Test B and the Stroop Task Interference Subscore. These tests were selected as the most 
representative measures for their associated domains. Raw scores from each test were converted 
into T scores using appropriate metrics (i.e education, age, gender, race) based on norms indicated 
by the test manufacturer. T scores were averaged within each domain to create a domain subscore. 
To calculate a cognitive composite score, subjects had to complete at least one test in each domain. 
Mean values across domain subscores were calculated, and this mean was considered the overall 
cognitive composite score.   
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4.3.5 Depression 
Depression symptoms were evaluated at 6 and 12 months post-injury using the Patient Health 
Questionnaire-9 (PHQ9), a brief self-report inventory of depressive symptoms based on DSM-IV 
diagnostic criteria for Major Depressive Disorder (MDD). The PHQ-9 has been validated for 
assessing depression following TBI (Cook et al., 2011a; Fann et al., 2005). The PHQ-9 requires 
subjects to rate, on a scale between 0 (None) and 3 (Nearly Every Day), how often they experience 
each symptom over a two week period. A higher total score reflects a greater number of and/or 
greater severity of depressive symptoms, with a maximum score of 27. Individuals with TBI were 
grouped as “depressed” vs. “non-depressed” using the DSM diagnostic criteria as they map to 
specific PHQ-9 questions (Fann et al., 2005). Current DSM criteria require individuals to report at 
least 5 symptoms, with at least one being a cardinal symptom (anhedonia or depressive mood).  In 
our study, individuals were categorized as depressed if they endorsed at least five questions on the 
PHQ-9, with endorsement of either anhedonia, depressed mood, or both. This method is validated 
in populations with TBI (sensitivity, 93%; specificity, 89%) compared to the Structured Clinical 
Interview for DSM Diagnosis (SCID), a measure modeled after DSM diagnostic criteria (Fann et 
al., 2005).  
4.3.6 Statistical Analysis 
Statistical analyses were completed using SAS (Cary, NC; version 9.3). Descriptive analyses 
included mean (with standard deviation or standard error of the mean) and/or median for 
continuous and ordinal variables including age, GCS, and education. Frequencies were calculated 
for categorical variables. Demographic and relevant clinical information was compared between 
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genotype groups using Student’s t-tests or Mann-Whitney U to compare means and Chi-Square or 
Fisher’s Exact to compare frequencies.  
Each SNP was screened for associations with each outcome (GOS, PTD, FIM-Cog, and 
overall cognitive composite) at each time-point based on genotype, allele carrier status, or by 
heterozygote vs homozygote status, correcting for multiple comparisons using false discovery rate 
(FDR) (Benjamini and Hochberg, 1995). Several studies have suggested a heterozygote advantage 
for DRD2 (Comings and MacMurray, 2000), warranting specific investigation of heterozygote 
status. Of the SNPs screened for associations with outcomes, each significant association (p<0.05 
following FDR) with a specific outcome was further evaluated for effects on subcomponents of 
the associated outcome scale. Similarly, those same SNPs were then included in multivariate 
models examining the associated outcome in order to control for demographic/clinical or injury 
severity characteristics, and potential confounders. If a SNP association with an outcome was 
significant following FDR at only 1 time-point, it was explored in multivariate models at both 
time-points in order to understand the clinical implications of that SNP across recovery. A 
backward selection method was used to systematically remove non-significant variables from the 
model. The final regression model included variables that had a final p-value less than 0.2. 
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4.4 RESULTS 
4.4.1 Genotype associations with demographics, disability, functional cognition, and 
global outcome 
Table 11. Demographic and clinical variables by genotype. 
Variant Genotype Age Gender GCS Education 
rs1800497 CC (n=55) 35.4 ± 13.8 85.5% (47) 7 12.9 ± 1.9 
CT (n=40) 34.0 ± 14.8 75.0% (30) 7 12.8 ± 2.0 
TT (n=4) 25.5 ± 7.3 75.0% (3) 8 13.8 ± 2.1 
p value 0.315 0.425 0.714 0.519 
rs6279 CC (n=61) 34.4 ± 14.5 83.6% (51) 7 13.1 ± 2.0 
CG (n=30) 33.5 ± 14.0 76.7% (23) 7 12.6 ± 1.3 
GG (n=6) 37.8 ± 12.1 83.3% (5) 6 13.2 ± 3.1 
p value 0.659 0.758 0.368 0.417 
rs2734838 AA (n=9) 31.4 ± 14.0 66.7% (6) 7 12.1 ± 0.8 
AG (n=45) 34.3 ± 13.1 73.3% (33) 7 12.7 ± 1.9 
GG (n=43) 34.6 ± 14.5 90.7% (39) 7 13.3 ± 2.1 
p value 0.707 0.058 0.935 0.162 
rs17529477 AA (n=10) 32.6 ± 15.2 80.0% (8) 7.5 13.2 ± 2.9 
AG (n=47) 34.6 ± 15.1 80.9% (38) 7 12.9 ± 1.7 
GG (n=40) 34.5 ± 13.1 80.0% (32) 7 12.6 ± 1.9 
p value 0.815 0.994 0.945 0.804 
rs4245147 CC (n=21) 34.9 ± 15.2 85.7% (18) 8 12.6 ± 1.8 
CT (n=49) 32.9 ± 13.4 77.6% (38) 7 13.2 ± 1.9 
TT (n=25) 37.4 ± 15.2 80.0% (20) 7 12.6 ± 1.9 
p value 0.485 0.725 0.380 0.436 
rs7131056 AA (n=14) 38.5 ± 13.2 92.9% (13) 7 12.1 ± 1.6 
AC (n=55) 32.2 ± 13.8 80.0% (44) 7 12.9 ± 1.7 
CC (n=29) 36.4 ± 14.8 75.9% (22) 8 13.0 ± 2.4 
p value 0.186 0.352 0.975 0.532 
rs4630328 AA (n=11) 34.2 ± 15.9 81.8% (9) 9 13.1 ± 2.7 
AG (n=52) 34.0 ± 14.3 78.9% (41) 7 13.1 ± 1.9 
GG (n=34) 35.2 ± 13.6 85.3% (29) 7 12.3 ± 1.7 
p value 0.872 0.748 0.368 0.244 
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Demographic information by genotype is presented in Table 11. There was a trend for significantly 
different distributions based on sex within DRD2 rs2734838 genotypes (χ2=5.6940; p=0.058). 
None of the other examined demographic variables were significantly different by any of the 
genotypes examined. Table 12 shows a summary of associations between each SNP and outcomes 
measured.  
 
Table 12. SNP Associations with measured outcomes at 6 months and 12 months post-TBI. 
 GOS PTD FIM-Cog 
Cognitive 
Composite 
Variant Raw Corrected Raw Corrected Raw Corrected Raw Corrected 
       6 Months 
rs1800497 0.02441 0.2807 0.1369 0.9231 0.0278 0.1946 0.0080 0.0427 
rs6279 0.1486 0.5201 0.7087 0.9670 0.0207 0.1946 0.0008 0.0128 
rs2734838 0.9109 0.9928 0.1837 0.9231 0.2390 0.3718 0.0547 0.1250 
rs17529477 0.8104 0.9928 0.6635 0.9670 0.2314 0.3718 0.1288 0.2290 
rs4245147 0.8906 0.9928 0.6695 0.9670 0.2236 0.3718 0.0673 0.1346 
rs7131056 0.8312 0.9928 0.8979 0.9670 0.1570 0.3663 0.4483 0.7086 
rs4630328 0.6704 0.9928 0.7497 0.9670 0.5629 0.6970 0.1624 0.2362 
     12 Months 
rs1800497 0.7892 0.9359 0.3290 0.9746 0.4218 0.6327 0.0294 0.2464 
rs6279 0.1088 0.5698 0.3220 0.9746 0.1772 0.5697 0.0308 0.2464 
rs2734838 0.1311 0.5698 0.0225 0.3375 0.0395 0.5697 0.1654 0.3828 
rs17529477 0.2255 0.5698 0.4696 0.9746 0.3426 0.6172 0.3577 0.5723 
rs4245147 0.3139 0.5886 0.9316 0.9746 0.0908 0.5697 0.2122 0.3828 
rs7131056 0.2659 0.5698 0.8967 0.9746 0.2472 0.6172 0.2100 0.3828 
rs4630328 0.2587 0.5698 0.6384 0.9746 0.3703 0.6172 0.2153 0.3828 
 
 
The lowest p-value for each SNP grouping (genotype, allele carrier status, or heterozygote vs 
homozygote) is reported. There was a significant difference in PTD incidence by DRD2 rs2734838 
genotype at 12 months post-TBI (χ2= 7.589; p=0.023), but it did not survive correction for multiple 
comparisons (p=0.338). There were significant associations between ANKK1 rs1800497 and GOS 
at 6 months, where a larger percentage of rs1800497 heterozygotes were categorized as a GOS=5 
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(45.0% compared to 20.3% for homozygotes, χ2=7.428, p=0.024, uncorrected) but this did not 
survive correction (p=0.281, FDR corrected). There was no difference between GOS score and 
rs1800497 genotype/allele-carrier status at 12 months. FIM-Cog scores significantly differed by 
both rs1800497 and rs6279 at 6 months post-TBI. Both rs1800497 heterozygotes (p=0.028, 
uncorrected) and rs6279 C-homozygotes (p=0.021, uncorrected) had higher FIM-Cog scores at 6 
months, but neither of these findings survived FDR correction (p=0.195 and p=0.194, 
respectively). At 12 months, rs2734838 A-carriers had lower FIM-Cog scores (p=0.040) but this 
comparison did not survive FDR correction (p=0.593). There were no other significant 
associations between genotype and FIM-Cog at 12 months. 
4.4.2 Genotype associations with cognitive deficits 
The two polymorphisms had significant associations with overall cognitive composite 
performance that survived correction for at least one time-point (see Table 12), and these 
polymorphisms were then evaluated further for effects on subcomponents of the cognitive 
composite. The ANKK1 rs1800497 polymorphism had the strongest relationship to overall 
cognitive composite scores when comparing homozygotes vs heterozygotes (see Table 12). In 
further evaluation, Rs1800497 heterozygotes performed better than homozygotes across several 
cognitive domains at both 6 and 12 months post-injury (Figure 8).  
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Figure 8. Overall and domain specific cognitive composite scores at 6 and 12 months post-injury show 
rs1800497 (Taq1A) heterozygotes exhibit better cognitive recovery compared to homozygotes.  
Error bars represent SEM.  *p<0.05, #p<0.10. 
 
Rs1800497 heterozygotes performed better in attention (p=0.0086) at 6 months post-injury and 
with language fluency (p=0.032) at 12 months, with trends on other domains noted.  
In Table 13, individual neuropsychological tests were examined by rs1800497 group. At 
6 months, rs1800497 heterozygotes performed significantly better on Trails A, Trails B, and the 
CVLT Long Delay Free Recall. At 12 months, rs1800497 heterozygotes performed significantly 
better on Trails B and the COWA Animals category.  
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Table 13. T scores on neuropsychological tests utilized at 6 and 12 months post-injury. 
Cognitive Test 6 Months 12 Months 
rs1800497 CC, TT 
(n=59) 
CT (n=40) p 
value* 
CC, TT 
(n=37) 
CT (n=26) p 
value 
Rey 41.31±11.60 43.78±10.57 0.140 43.72±9.47 44.23±11.78 0.368 
Digit Span 41.38±6.98 42.12±7.43 0.221 40.58±7.27 42.38±8.02 0.182 
DKEFS 40.71±10.30 42.57±10.54 0.156 40.97±8.99 44.83±11.12 0.067 
Trails A 33.12±13.18 39.21±11.94 0.003 34.89±13.30 40.71±12.37 0.077 
Trails B 36.98±13.23 43.28±14.14 0.006 37.43±13.83 44.23±12.41 0.045 
CVLT Long Delay 
Free Recall 
32.94±16.55 39.74±14.80 0.036 37.05±16.30 41.96±16.79 0.210 
Stroop 54.11±8.13 52.93±7.93 0.182 54.38±7.06 53.68±7.70 0.293 
COWA Animals 32.82±12.93 34.69±12.71 0.291 30.86±12.25 37.04±12.35 0.035 
            rs6279 CC (n=61) CG, GG 
(n=36) 
p 
value 
CC (n=39) CG, GG 
(n=25) 
p 
value 
Rey 43.03±10.91 41.06±11.98 0.167 44.73±9.52 42.76±11.71 0.283 
Digit Span 43.27±6.66 39.34±7.16 0.008 42.54±7.86 39.56±6.91 0.072 
DKEFS 43.41±10.84 38.33±9.01 0.009 44.33±10.33 39.57±8.80 0.037 
Trails A 38.51±12.14 30.91±13.30 0.002 39.51±12.01 33.17±14.18 0.045 
Trails B 42.12±12.80 34.79±15.05 0.001 42.19±12.68 36.48±14.58 0.045 
CVLT Long Delay 
Free Recall 
37.85±16.43 32.63±14.96 0.074 41.03±17.23 35.83±15.16 0.137 
Stroop 54.41±7.42 52.56±9.01 0.317 55.03±7.22 52.72±7.26 0.082 
COWA Animals 36.07±12.69 29.79±12.20 0.017 34.12±12.49 32.36±12.92 0.362 
*Bolded p values, p<0.1. Bolded and italic p values, p<0.05. 
 
The DRD2 rs6279 polymorphism was also significantly related to cognitive performance. 
At 6 months post-injury, rs6279 C-homozygotes had higher overall composite scores (Table 12); 
at 12 months, rs6279 C-homozygotes performed significantly better overall (p=0.031) but this 
association did not survive correction for multiple comparison (p=0.246). Figure 9 shows that 
rs6279 C-homozygotes performed better in executive function (p=0.013), attention (p=0.001), and 
language fluency (p=0.003) domains at 6 months post-injury, and subjects this group performed 
better with executive function (p=0.022) and attention (p=0.039) domains at 12 months.  
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Figure 9. Overall and domain specific cognitive composite scores at 6 and 12 months post-injury show 
rs6279 C-homozygotes exhibit better cognitive recovery compared to G-carriers.  
Error bars represent SEM.  *p<0.05, #p<0.10. 
 
In Table 13, individual tests were examined by rs6279 G-carrier status. At 6 months, 
rs6279 C-homozygotes performed significantly better on Digit Span, DKEFS, Trails A, Trails B, 
and COWA Animals. At 12 months, rs6279 C-homozygotes performed significantly better on 
DKEFS, Trails A and Trails B. 
To evaluate these polymorphisms in overall cognitive performance, both SNPs were tested 
in backwards step-wise multivariate linear regression models predicting overall cognitive 
composite scores at 6 and 12 months. At 6 months, both rs1800497 and rs6279 contributed 
significantly to overall cognitive composite score prediction, even after adjusting for age, GCS, 
and education (Table 14). At 12 months, only rs1800497 remained in the final model.  
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Table 14. Multivariate model of overall cognitive composite scores at 6 and 12 Months. 
Variable 
Parameter 
Estimate 
Standard 
Error 
t value p value* 
95% Confidence 
Interval 
6 Months – Overall Composite (n=99) 
Age -0.12879 0.05196 -2.48 0.0151 (-0.23204 -  -0.02553) 
GCS 0.84796 0.24580 3.45 0.0009 (0.35955 - 1.33636) 
Education 1.19127 0.39517 3.01 0.0034 (0.40608 - 1.97646) 
rs1800497 Heterozygotes 2.97878 1.49539 1.99 0.0494 (0.00747 – 5.95010) 
rs6279 G-carriers -3.20962 1.51691 -2.12 0.0371 (-6.22369 - -0.19554) 
12 Months – Overall Composite (n=64) 
Age -0.12435 0.06068 -2.05 0.0450 (-0.24586 - -0.00284) 
GCS 0.92104 0.30755 2.99 0.0041 (0.30518 - 1.53690) 
Education 1.59569 0.50538 3.16 0.0025 (0.58368 - 2.60770) 
rs1800497 Heterozygotes 4.70872 1.71488 2.75 0.0081 (1.27474 - 8.14271) 
*Bolded p values, p<0.1. Bolded and italic p values, p<0.05. 
 
4.5 DISCUSSION 
While cognitive function restoration is one of the most important aspects in recovery post-TBI, 
there is considerable heterogeneity in cognitive recovery patterns. In this study, we utilize a 
Rehabilomics framework (A K Wagner, 2010; Wagner and Zitelli, 2012) to examine individual 
recovery patterns using genetic, clinical, and demographic factors that influence cognitive 
recovery, with the notion that genetics may influence other downstream outcomes like 
participation and quality of life.  In this study, we showed that genetic polymorphisms in the 
ANKK1 and DRD2 gene were associated with cognitive recovery post-TBI. This report is one of 
the first studies to utilize cognitive composite scores to evaluate genetic modulators of TBI 
cognitive recovery (Wagner et al., 2012). By using normative data adjustments prior to analysis of 
neuropsychological test performance, we showed injury specific effects of age and education 
effects beyond that observed in uninjured populations.  Furthermore, this work suggests a need for 
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personalized approaches to treatments like cognitive rehabilitation strategies and neurostimulant 
use.   
While the DRD2 gene codes for D2 receptor expression, most studies have focused on the 
Taq1A polymorphism in ANKK1 as a potential functional moderator of D2 expression/function. 
Previously, it was believed that the relationship between rs1800497 and D2 receptors was due to 
high LD with variation in DRD2. rs1800497 is in high LD with SNPs within DRD2 that are linked 
to alternative splice variants capable of moderating neuronal activity during a working memory 
task (Y. Zhang et al., 2007). Now, it is accepted that rs1800497 lies within the ANKK1 gene 
(Neville et al., 2004), calling into question the direct genetic link to D2 function. ANKK1 appears 
to code for a serine/threonine kinase that may interact with D2 receptor signal transduction. Also, 
rs1800497 induces an amino acid change (Glu713Lys) within a substrate binding domain, thus it 
is possible ANKK1 interacts with D2 or other DAergic signaling to impact cognitive recovery 
post-TBI, but more basic research into ANKK1 is needed to elucidate this mechanism.   
Even with this superficial understanding of ANKK1’s potential function, several studies 
have identified differences in DAergic function based on rs1800497 genotype. As D2 
autoreceptors are important for regulation of striatal DA synthesis, PET studies utilizing 
[18F]fluorodopa as a measure of DA synthesis suggest T-carriers have increased DA levels and 
reduced D2 receptor expression (Laakso et al., 2005). Increased DA synthesis capacity, and/or 
basal DA levels, could be beneficial to recovery given the functional hypo-dopaminergic state 
post-TBI that is postulated based on our experimental (Wagner et al., 2009) and clinical (Amy K 
Wagner et al., 2014) work. Similarly, if ANKK1 affects DAergic signaling, heterozygotes may 
express both kinase structures, exhibiting dopamine levels in an optimal range for recovery, 
consistent with the ‘inverted U’ hypothesis for DAergic function (Cools and D’Esposito, 2011a). 
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Many studies have examined rs1800497 Taq1A genotypes in ANKK1 grouped by T-carrier 
status. We grouped rs1800497 Taq1A based on genotype, allelic carrier status, and heterozygotes 
vs homozygotes. Using this approach, heterozygotes for rs1800487 had the best cognitive 
performance post-TBI. Consistent with this finding, multiple studies have evaluated 
heterozygosity for rs1800497 and found that heterozygote status is a biologically relevant 
comparison to explore, revealing a possible heterozygote advantage (Comings and MacMurray, 
2000). Consistent with much of the literature (Munafò et al., 2007), T-homozygotes are less 
frequent in our population (n=4). Thus, the comparison of rs1800497 heterozygotes vs 
homozygotes is similar to a T-carrier approach. With mean cognitive composite comparisons, T-
homozygotes were more similar to C-homozygotes than C/T heterozygotes, supporting a 
homozygotes/heterozygote approach. However, utilizing a T-carrier approach showed similar 
findings; T-carriers (91.6% of which are heterozygotes) had better cognitive composite scores at 
6 and 12 months (data not shown).  Our study was designed a priori with a MAF criteria of >0.2 
to provide robust heterozygosity within our sample size, maximizing our ability to evaluate 
heterozygosity with outcome prediction post-TBI. Examining heterozygosity across functional and 
tagging SNPs was an important study goal, given the dimerization patterns associated with the D2 
receptor(Zawarynski et al., 1998). Depending on SNP function, a mixture of different translated 
peptides, due to genetic heterozygosity associated with this receptor, could alter dimerization 
characteristics and affect DA signaling.  
ANKK1 rs1800497 heterozygotes (T/C) exhibited better cognitive performance in this 
study. Clinically relevant, in some domains, homozygotes would be considered impaired with T 
scores <40, where heterozygotes would not be significantly impaired. Previous work from our lab 
utilizing PET imaging indicates that T-carriers (A1-carriers, with the majority being 
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heterozygotes) have higher striatal dopamine transporter (DAT) binding following TBI.  Yet, in 
this same study, there were no significant differences in D2 binding by rs1800497 genotype. This 
lack of association between rs1800497 and D2 binding post-TBI, combined with another report of 
higher striatal DAT binding in A1-carriers, (Laine et al., 2001) suggests there may be important 
distinctions in trafficking striatal DAT based on rs1800497 genotype. It is also possible protein-
protein interactions between DAT and D2 (Lee et al., 2007) may significantly differ by rs1800497 
genotype.  
Previous studies in mild TBI show that T-carriers performed worse on the CVLT 
recognition measure at 1 month post-injury (McAllister et al., 2008). Our data demonstrate 
heterozygotes (C/T) perform better on other neuropsychological measures in our severe TBI 
population. These apparent differences in gene x cognition associations may be due to several 
factors. In mild TBI, McAllister et al (McAllister et al., 2008, 2005) demonstrated gene-risk 
relationships that mirror findings in healthy populations. Importantly, our study examines a larger, 
more severely injured population, and cognition was examined farther out from injury. Thus 
rs1800497 Taq1A may have a stratified injury severity interaction with cognitive recovery. Also, 
several factors (socioeconomic, access to care, spontaneous recovery) can influence cognitive 
recovery trajectories (Hoofien et al., 2002; León-Carrión et al., 2013). Outcome measures 
instruments also differed across these studies, suggesting this polymorphism may have domain-
specific relationships to cognition. However, our study examines multiple cognitive domains, 
demonstrating that variation within ANKK1 and DRD2 influences multiple areas of cognition.  
This study also examined 6 SNPs covering variation in the DRD2 gene. Rs6279 was 
significantly associated, across domains, with cognitive recovery at 6 months post-TBI; the 
association was less strong with cognition at 12 months. McAllister and colleagues(McAllister et 
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al., 2008) found a relationship between rs6279 and CVLT recognition task performance in subjects 
with TBI, but no relationship in healthy controls. Rs6279 has not been well studied, but it is in 
high linkage disequilibrium with rs6277, a synonymous mutation C957T, that results in impaired 
stabilization of DRD2 mRNA (Duan et al., 2003).  This mutation may impair the ability of DA to 
stabilize DRD2 mRNA, which then leads to reduced translation and D2 expression in response to 
increased DA concentrations. Rs6277 is implicated in risk for schizophrenia (Monakhov et al., 
2008) and posttraumatic stress disorder (Voisey et al., 2009). As there is no known functional 
impact of rs6279, our findings with rs6279 may actually be reflective of its high LD with rs6277. 
Interestingly, multivariate analysis including rs6279 and rs1800497 showed that both SNPs 
have independent effects at 6 months post-injury. While only rs1800497 was significantly 
associated with overall composites in our 12 month multivariate model, it is possible that in a 
larger sample size, there may be a significant influence of rs6279, in addition to rs1800497, on 
cognition. However, it is also possible the mechanism of rs6279’s impact on cognition post-TBI 
may be diminished at 12 months. The temporal dynamics of these DRD2 associations is consistent 
with other studies from our group that demonstrate transient genetic outcome associations across 
recovery post-TBI (Failla et al., 2014, 2013). Domain specific analysis supports slightly different 
roles for each SNP in overall cognitive recovery. For example, at 6 months post-TBI, rs6279 shows 
stronger associations to executive function and language fluency compared to rs1800497.  
Our multivariate data also suggests there are specific injury-age interactions following TBI 
that differ from control populations. Our cognitive composites accounted for age, gender, and 
education, based on standardized norms for each neuropsychological measure. Yet age and 
education were still significant predictors of cognitive composite score in our multivariate models, 
suggesting these demographic variables have an amplified injury-specific effect on cognitive 
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performance. Education may be a correlate for post-TBI cognitive reserve that could likely impact 
an individual’s cognitive recovery trajectory post-TBI (Green et al., 2008; Schneider et al., 2014). 
Given the detrimental effects of age on other TBI pathology/recovery domains (Kumar et al., 2013; 
Onyszchuk et al., 2008; Susman et al., 2002; Wagner et al., 2004), age enhanced vulnerability to 
cognitive dysfunction post-TBI likely also occurs. Additionally, our inclusion of the best GCS in 
first 24 hours post-injury confirms other studies findings where best GCS in 24 hours predicts 
long-term outcome (Cifu et al., 1997a; Udekwu et al., 2004a). 
This study also examined ANKK1 and DRD2 variation in post-TBI depression (PTD), FIM-
Cog, and GOS. Despite some associative trends, there were no relationships between any of the 
variants examined and PTD following FDR correction. While there is emerging evidence of 
DAergic signaling involvement in depressive symptoms (Dunlop and Nemeroff, 2007), this study 
may be underpowered to examine DAergic relationships to PTD. Rs1800497 and rs6279 were 
associated with GOS and FIM-Cog, though none survived correction for multiple corrections. 
However, consistent with the Rehabilomics Model (A K Wagner, 2010; Wagner and Zitelli, 2012), 
the data suggest a need for larger studies to examine how genetic relationships associated cognitive 
performance and may moderate modest effects on other outcomes like GOS and FIM-Cog.  
One important caveat in this study is the reported findings were conducted in a population 
of Caucasians-only. DRD2 SNP distributions were significantly different by race (data not shown), 
highlighting the need to limit our analysis to Caucasians to avoid any potential stratification 
effects. This study was not powered to examine genotypic associations by race in post-TBI 
cognitive outcomes, and future studies are needed to examine more racially-diverse populations. 
While this study is limited by its overall sample size, it is one of the larger studies examining 
genetic factors in cognitive recovery post-TBI, similar to our previous studies (Wagner et al., 
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2012). Investigating DA signaling effects of these gene variants post-TBI may inform relationships 
to cognitive recovery. Similarly, understanding how these genetic variants impacts DAergic 
pharmacological intervention (Mi et al., 2011) post-TBI may improve and personalize our current 
treatment paradigms. 
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5.0  BRAIN-DERIVED NEUROTROPHIC FACTOR IN TBI-RELATED 
MORTALITY: INTERRELATIONSHIPS BETWEEN GENETICS AND ACUTE 
SYSTEMIC AND CNS BDNF PROFILES 
In Submission 
Michelle D. Failla, BS, Yvette P. Conley, PhD, Amy K. Wagner, MD 
5.1 ABSTRACT 
While brain derived neurotrophic factor (BDNF) is relevant to traumatic brain injury pathology 
due to its role in neuronal survival, neurogenesis, and plasticity, BDNF also has strong effects on 
hypothalamic metabolic regulation and brainstem control of the cardiovascular system. Reduced 
BDNF production occurs immediately following experimental models of traumatic brain injury 
(TBI), with transient upregulation of BDNF’s pro-apoptotic receptors. Our recent work shows 
variation in the BDNF gene (expressed as a gene risk score including rs6265 and rs7124442) 
interacts with age to influence mortality. Evidence supporting dynamic, temporal balances of pro-
survival/pro-apoptotic target receptors may explain injury-specific and age-related gene 
associations. Thus, we investigated BDNF as a genetically-modulated biomarker of mortality 
following severe TBI. BDNF levels were examined in CSF and serum for 203 prospectively 
recruited subjects during the first week following severe TBI. Interrelationships between BDNF 
gene risk score and BDNF levels were assessed as mortality predictors, and compared to levels in 
a cohort of healthy controls (n=10). Average CSF BDNF levels tended to be higher following 
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injury compared to healthy controls (0.20±0.01ng/mL versus 0.14±0.02ng/mL, p=0.061), with 
similar trends noted for d1-5 (p<0.10). Average serum BDNF levels (150.05±4.90ng/mL) were 
reduced compared to healthy controls (277.86±28.11ng/mL, p<0.0001) beginning d0 (p=0.007) 
and remained low for all time-points (p<0.0001 for remaining comparisons). Following injury, 
CSF and serum BDNF levels tended to be negatively correlated (r=-0.209, p=0.070, n=76), but 
importantly, this correlation was likely modulated by age (age<45yrs: r=-0.307, p=0.029, n=51; 
age>45yrs: r=-0.113, p=0.590, n=25). Serum BDNF levels interacted with the BDNF gene risk 
score to influence mortality beyond that predicted by previously reported gene*age interactions 
alone. CSF BDNF levels directly impacted mortality predictions, where CSF BDNF levels 
predicted time until death (p=0.042, hazard ratio=10.973). BDNF is likely a genetically-
modulated, physiologically relevant prognostic biomarker for mortality following TBI. Compared 
to positive correlations in controls, the negative correlation between CSF and serum BDNF suggest 
blood-brain barrier transit alterations following injury. Yet, this work suggests a role for BDNF 
pathophysiology in contributing to mortality following TBI that may encompass neuronal survival 
as well as modulation of autonomic function. BDNF pathology is likely an important new target 
in relationship to individual variation in mortality predictions post-TBI, and understanding BDNF 
signaling in relation to other secondary injury cascades, age, and receptor regulation following 
TBI may inform new treatment paradigms. 
5.2 INTRODUCTION 
The World Health Organization suggests that traumatic brain injury (TBI) will be one of 
the major leading causes of death and disability by 2020, with about 10 million people affected 
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each year (Hyder et al., 2007). Advanced age is a consistent determinant of TBI survival (Brooks 
et al., 2013). Older adults comprise a large segment of the population sustaining TBI with 
comparatively worse outcomes and higher mortality rates despite similar injury parameters 
(Susman et al., 2002).  Beyond the acute mortality associated with moderate/severe TBI, recent 
literature also indicates that individuals initially surviving their TBI go on to have an increased 
risk for mortality during the post-acute phases of recovery and, on average, have a shorter life-
span (Brooks et al., 2013; Harrison-Felix et al., 2006). Several systemic and CNS biomarkers can 
inform acute mortality predictions after moderate/severe TBI (Goyal et al., 2013; Wagner et al., 
2011b). Biomarkers associated with acute mortality may also elucidate TBI-specific pathology 
relevant to the molecular pathways they represent, identifying new avenues to target for 
neuroprotective therapeutics or indicating important injury-specific phenomena in well-studied 
pathways. While some studies have evaluated early biomarker patterns when predicting later 
mortality and/or global outcomes (Goyal et al., 2013; Santarsieri et al., 2013; Wagner et al., 2011a, 
2011b), less is known about how innate biological factors, like genetics, interact with acute 
biomarkers to influence mortality. 
While current studies suggest demographic and clinical variables like age, injury severity, 
and pupillary reactivity influence mortality prediction (Roozenbeek et al., 2012), our previous 
work demonstrates that genetic variation within the brain derived neurotrophic factor (BDNF) 
gene improves mortality prognostication(Failla et al., 2014). BDNF is a neurotrophin involved in 
neuronal survival and synaptic plasticity in hippocampus and cortex (Martinowich and Lu, 2008). 
While BDNF is relevant to TBI pathology with neuronal survival, neurogenesis, and plasticity(Z.-
Y. Chen et al., 2004), BDNF also has strong effects on hypothalamic metabolic regulation (Kernie 
et al., 2000; Pelleymounter et al., 1995) and brainstem control of the cardiovascular system (Brady 
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et al., 1999; Wang and Zhou, 2002; Wan et al., 2014). Similarly, variation within the BDNF gene 
has been associated with hypothalamus-pituitary-adrenal (HPA) axis reactivity (Alexander et al., 
2010; Shalev et al., 2009) and autonomic regulation of heart rate (A. C. Yang et al., 2010). Given 
the role of BDNF in autonomic function and neuronal survival, BDNF likely has multiple actions 
that could impact TBI mortality, making BDNF an attractive biomarker to explore, across the 
recovery spectrum, where these actions may have dynamic influences.  
We have previously shown associations between TBI mortality and two single nucleotide 
polymorphisms (SNP) within the BDNF gene (Failla et al., 2014) that may affect BDNF secretion, 
thus influencing BDNF levels in serum and CSF. The current study targets a functional SNP, 
Val66Met (rs6265), which alters activity-dependent BDNF secretion BDNF in vitro (Egan et al., 
2003), as well as rs7124442, which is in linkage disequilibrium (LD) with rs6265, and affects 
neuronal BDNF mRNA trafficking (Orefice et al., 2013). The relationship between Val66Met and 
BDNF serum levels is controversial (Terracciano et al., 2013), but some studies suggest lower 
serum BDNF levels in Met allele-carriers. Thus, BDNF post-TBI may be a physiologically 
relevant, genetically-influenced biomarker. 
The relationship between BDNF and TBI-related mortality is also moderated by age. 
Advanced age likely adversely effects secondary injury cascades. Older age can lead to greater 
susceptibility during glutamate-mediated oxidative stress and damage (Wagner et al., 2004). In 
experimental models of injury, older animals show decreased neuronal survival (Onyszchuk et al., 
2008) and altered immune states (Kumar et al., 2013). Previous work from our lab demonstrates 
that age interacts with BDNF associations to predict mortality risk up to one year post-injury. We 
suggest that this interaction between age and BDNF variation in TBI-related mortality may be due 
to age-related changes in BDNF target receptor milieu (Romanczyk et al., 2002; Webster et al., 
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2006). Understanding associations between BDNF levels, aging, and mortality will aid our 
understanding of this complex association.  
BDNF has been extensively evaluated as a biomarker in affective disorders, where lower 
serum levels are associated with active depressive episodes (Brunoni et al., 2008). One TBI study 
by Kalish and Phillips (Kalish and Phillips, 2010) reported that serum BDNF levels are acutely 
decreased, correlating with injury severity. While BDNF levels have not been examined in 
connection with TBI-related mortality, studies show that decreases in serum BDNF levels are 
associated with mortality in uninjured populations (Halldén et al., 2013; Krabbe et al., 2009; Ritter 
et al., 2012). Based on previous studies involving uninjured humans and rodent models, serum 
BDNF levels may correlate with CSF and brain BDNF (Pan et al., 1998; Pillai et al., 2010). 
In this study, we measured BDNF levels in serum and CSF across the first seven days after 
severe TBI in 203 subjects. We evaluated BDNF levels for associations with mortality across the 
first year post-TBI, in relation to BDNF genetic mortality risk. Both CSF and serum demonstrated 
significant capacity for predicting mortality across a 1-year recovery period, in addition to genetic 
risk, suggesting BDNF is a novel and informative TBI biomarker. Additionally, this work supports 
further study into BDNF pathophysiology as a contributing factor in recovery and mortality 
following TBI. 
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5.3 METHODS 
5.3.1 Participants 
This prospective cohort study was approved by the University of Pittsburgh Institutional Review 
Board. Enrollment criteria for this study included age, ≥16 and <75 years, and an admission 
Glasgow Coma Scale (GCS) score ≤8 indicating severe TBI.  Exclusion criteria included 
documented prolonged hypoxia prior to admission or penetrating head injury. Participants were 
consecutively recruited while receiving inpatient care within the University of Pittsburgh Medical 
Center (UPMC). Consent was obtained from next-of-kin. All subjects sustained a non-penetrating 
TBI, and had evidence of intracranial injury on Computed Tomography (CT). Participants 
included had at least one sample measurement (serum or CSF, at any time-point). These 
participants were a subset of a larger study investigating possible biomarkers and genetic factors 
related to individual recovery following TBI.  
Injury severity was described by the best GCS obtained for each subject within the first 24 
hours post-injury. Demographics, including age, sex, and education, were collected by chart 
review and subject or caregiver interviews.  
5.3.2 Sample Collection and Processing 
BDNF levels were measured in both CSF and serum samples collected over the first week post-
injury. When possible, CSF samples were collected passively up to twice daily via an external 
ventricular drain placed for clinical care. Serum was collected daily. BDNF values derived from 
CSF and serum samples were binned by day, and an average was determined for each day post-
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injury for each subject. Of 203 participants, 149 had CSF samples (n=583), and 141 had serum 
samples (n=406). A subset had both CSF and serum samples (n=87). For biomarker comparisons, 
healthy adult control subjects were separately recruited to establish reference BDNF levels. 
Control participants providing samples [CSF (n=10) and serum (n=7)] for BDNF measurements 
were 18-70 years old, had no current/past history of brain injury, neurological disease, bleeding 
disorder or endocrine disorder. Women were excluded if pregnant, taking oral contraceptives or 
hormone replacement therapy, or had history of reproductive disorder. 
CSF and serum samples were stored at -80ºC before BDNF analysis using an ELISA kit 
(RayBiotech). Briefly, standards and samples were pipetted onto a 96-well plate pre-coated with 
human BDNF antibody. Following shaking for 2.5hrs at room-temperature, plates were washed 
and incubated with biotinylated BDNF antibody for 1hr.  HRP-conjugated streptavidin was then 
added for an incubation of 45 minutes. The addition of a tetramethylbenzidine substrate allowed 
for a color reaction. Concentrations were calculated using mean absorbance of each sample at 460 
nm to correlate with sample BDNF concentrations present. Samples were diluted within the range 
of the ELISA kit (no dilution for CSF, 1:250 for serum samples), with a kit sensitivity of 80pg/ml, 
an intra-assay variation of <10%, and an inter-assay variation of <12%. 
5.3.3 Mortality and Outcome 
Time until death (TUD) was recorded in days post-injury, up to 1yr post-injury, using the Social 
Security Death Index (“Social Security Death Index,” n.d.). For consistency with previous work 
(Failla et al., 2014), mortality was evaluated over two time-epochs, 0-7d post-injury (acute) and 
8d-365d post-injury (post-acute), and then across the entire recovery span of 0-365. For 0-7d, 
survivorship was right censored at 7d post-injury. For 8-365d, participants were included if they 
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survived >7d, and survivorship was right censored at 365d. Mortality was also examined as a 
binary outcome at 365d post-injury. Acutely, 11.62% of participants died (TUD: median=3d, 
min=0d, max=7d, Q1=2d, Q3=6d). An additional 14.16% died post-acutely (TUD: median=19d, 
min=8d, max=301d, Q1=11.5d, Q3=31d). 
We evaluated whether BDNF levels are indicative of mortality or graded across a range of 
outcomes using the Glasgow Outcome Scale (GOS) (1= dead, 2= vegetative state, 3=severe 
disability, 4=moderate disability, 5=good recovery) at 6 and 12 months (Jennett and Bond, 1975). 
Research-trained neuropsychometrists, blinded to genetic and biomarker information, obtained 
GOS scores. 
5.3.4 Genotyping and SNP Selection 
DNA was isolated from blood using a simple salting out procedure (S.A. Miller et al., 1988) or 
from CSF using the Qiamp protocol from Qiagen. BDNF rs6269 and rs7124442 were genotyped 
by TaqMan allele discrimination assay using Assay on Demand reagents (Applied Biosystems). 
This assay utilized fluorescent labeled probes to detect allele(s) present for DNA sample.  
Selected SNPs (rs6265, rs7124442) had a minor allele frequency >20%.  Each SNP 
represents a different haplotype block of BDNF covering variation corresponding to “isoform a”. 
A cumulative BDNF GRS was used as previously published(Failla et al., 2014), where rs6265 Met 
(Val/Met or Met/Met) and rs7124442 C (T/C or C/C) carrier status hypothesized as hypothesized 
risk alleles due to reduced BDNF secretion reported in the literature(Egan et al., 2003; Orefice et 
al., 2013). Thus, a GRS=0 was the hypothesized no risk group (Val/Val, T/T); GRS=1 included 
carriers for 1 risk allele (Val/Val, C-carriers or Met-carriers, T/T); GRS=2 included carriers of 
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both risk alleles (Met-carriers, C-carriers).  Due to possible genetic stratification effects (Freedman 
et al., 2004), genetic associations are reported in Caucasians only (n=181). 
5.3.5 Statistical Analysis 
Data analysis was conducted using Statistical Analysis Software (SAS) 9.3. Descriptive analyses 
included mean and standard deviation and/or median for continuous and ordinal variables, and 
analyses included frequencies for categorical variables.  Demographic and clinical information 
was examined for variation with BDNF levels using Mann-Whitney and Kruskal-Wallis tests, due 
to skewedness of BDNF level data. Genetic analysis utilized categorizations based on allele carrier 
status using Chi-square or Fishers Exact test where appropriate, and the BDNF GRS was used to 
examine cumulative genetic risk associations with mortality as previously described (Failla et al., 
2014). Age was dichotomized at 45yrs to emulate previous TBI mortality analyses (Failla et al., 
2014). 
Mortality was examined across two time-frames for consistency with previous work (Failla 
et al., 2014), 0-7d post-injury (acute) and 8d-365d post-injury (post-acute), and then across the 
entire recovery span of 0-365d. BDNF levels were examined for mortality associations post-TBI 
using TUD in Cox proportional hazards models (Cox, 1972). The proportionality of hazards 
assumption was tested and confirmed for all final Cox model variables. Interaction terms were 
identified by previous studies (in the case of age*GRS) or existing hypotheses (in the case of 
GRS*serum BDNF) and tested in Cox models. All models were developed using a backwards-
stepwise approach, with variables remaining in the final models if p≤0.2.  Final models were then 
tested to determine the effect of removal of the BDNF levels variable on the remaining associations 
in the model. A p-value<0.05 was considered statistically significant. 
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5.4 RESULTS 
5.4.1 Description of CSF and serum BDNF levels 0-6d post-TBI 
 
Figure 10. Daily brain derived neurotrophic factor (BDNF) levels over the first 7 days post-injury, 
compared to healthy controls. 
(A) Daily mean CSF BDNF levels tend to be higher than control levels (trending at days 1 and 5, p<0.1 for both). 
Average CSF levels across the first week post-injury are show trends elevated from control levels (p=0.061). (B) Daily 
mean serum BDNF levels fall below control levels immediately following injury (day 0, p=0.007) and remain reduced 
through day 6 (p<0.0001 for all comparisons). (# p<0.1; *p<0.05, **p<0.001) (mean represented by gray horizontal 
line, ±standard error in dashed gray horizontal lines) 
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As depicted in Figure 10A, average CSF BDNF levels tended to be higher for participants with 
TBI compared to healthy controls (0.20±0.01ng/mL versus 0.14±0.02ng/mL, p=0.061), with 
similar trends noted for d1-5 (p<0.10). Average serum BDNF levels in TBI participants 
(150.05±4.90ng/mL) were reduced versus healthy controls (277.86±28.11ng/mL, p<0.0001) 
beginning d0 (p=0.007) and remained below healthy controls for all time-points (p<0.0001 for 
remaining comparisons, Figure 10B). For participants with TBI, average CSF and serum BDNF 
levels tended to be negatively correlated (r=-0.209, p=0.070, n=76). In healthy controls, BDNF 
levels suggested a positive correlation between CSF and serum but this was not significant likely 
due to sample size (r=0.67, p=0.219, n=5). 
5.4.2 Associations of CSF & serum BDNF levels with demographic and clinical variables 
Average levels (d0-6) for both CSF and serum were examined for associations with demographic 
and clinical variables. Table 15 reports relationships between serum BDNF levels, CSF BDNF 
levels, and demographics, clinical variables, and BDNF genetic variants (rs6265 and rs7124442). 
All allele/genotype frequencies were in Hardy-Weinberg equilibrium. There were no significant 
associations between genetic variants and BDNF levels. Average CSF levels positively correlated 
with age (r=0.17, p=0.045), while serum levels did not correlate with age. Correlations between 
serum and CSF BDNF levels were examined by age.  There was a negative correlation in 
participants <45 yrs. (r=-0.307, p=0.029, n=51), but this was not significant for participants 
>45yrs. (r=-0.113, p=0.590, n=25). 
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Table 15. Demographic associations with BDNF CSF and serum levels. 
Demographic Variable 
CSF Weekly 
Average, ng/mL 
(n=149) 
Serum Weekly 
Average, ng/mL,  
(n=141) 
rs6265 
Val/Val (n=96) 0.20±0.11 159.05 ±106.59 
Met-carrier (n=61) 0.19±0.13 159.47±60.57 
p value 0.145 0.155 
rs7124442 
T/T (n=84) 0.19±0.10 163.13 ±113.62 
C-carrier (n=54) 0.19±0.14 153.35 ±65.49 
p value 0.238 0.311 
Age 
R, Mean 0.17 -0.11 
p value 0.045 0.244 
Sex  
Males 0.20±0.13 147.28±51.81 
Females 0.19±0.10 162.09±64.25 
p value 0.438 0.099 
GCS 
R, Mean -0.08 -0.01 
p value 0.343 0.927 
 
5.4.3 CSF and serum BDNF Associations with Mortality 
Consistent with previous work (Failla et al., 2014), CSF and serum BDNF were examined for 
associations within two mortality time-epochs. Associations with mortality outcomes are 
presented in Table 16. Age and GCS were associated with mortality during both time epochs and 
across the total survival period. Average CSF BDNF levels were higher in those participants who 
died within the post-acute time epoch. Serum BDNF levels tended to be associated with acute 
mortality; participants who died 0-7d post-injury had lower serum levels (130.75±17.26ng/mL) 
versus survivors (159.47±60.57ng/mL).  
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Table 16. Demographic associations with mortality time epochs. 
 
Acute Mortality 
(0-7 days) 
Post-Acute Mortality 
(8-365 days) 
Total Mortality 
(0-365 days) 
  
Died 
(n=23) 
Survived 
(n=157) 
p 
value 
Died 
(n=32) 
Survived 
(n=125) 
p 
value 
Died 
(n=55) 
Survived 
(n=125) 
p 
value 
Age, 
mean±STD 
45.3 
±17.2 
36.4 
±15.6 
0.010 
49.8 
±16.1 
32.9 
±13.6 
<0.001 
47 
±16.6 
32.9 
±13.6 
<0.001 
GCS, median 6 7 0.004 6 7 0.007 6 7 <0.001 
Male, # (%) 
15 
(65.2) 
129  
(82.2) 
0.073 
26 
(81.3) 
103 
(82.4) 
0.880 
41 
(74.6) 
103 
(82.4) 
0.232 
CSF Weekly 
Average,  
ng/mL (n=133) 
0.25 
±0.17 
0.19 
±0.12 
0.214 
0.26 
±0.17 
0.18 
±0.10 
0.013 
0.25 
±0.17 
0.18 
±0.10 
0.012 
Serum Weekly 
Average,  
ng/mL (n=124) 
130.75 
±17.26 
159.47 
±60.57 
0.054 
147.04 
±44.46 
155.23 
±51.84 
0.353 
140.06 
±58.30 
155.23 
±51.84 
0.107 
STD=standard deviation; GCS=Glasgow Coma Scale; CSF=cerebrospinal fluid 
 
Associations between CSF BDNF levels and TUD within each mortality epoch were 
examined (Supplementary Tables 17A/B). Given that CSF BDNF levels warranted inclusion into 
mortality models in both acute and post-acute models (p<0.2), a final model of TUD across the 
first year (0-365) was evaluated (Table 18A). In this model, average CSF BDNF levels predicted 
TUD (p=0.042, HR=10.973) with an age*GRS interaction (p=0.0561, HR=0.968) and GCS 
(p=0.004, HR=0.728) as covariates. Importantly, when CSF BDNF levels were excluded from this 
model, age*GRS was significant (p=0.034, HR=0.971), where similar to our previous report, older 
individuals were at higher risk for mortality if they carried fewer of the hypothesized risk (i.e. low 
BDNF secretion) alleles.  
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Table 17. Associations between BDNF levels and TUD within each mortality epoch. 
Parameter 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p value 
Hazard 
Ratio 
95% Hazard Ratio 
Confidence 
Limits 
A. Acute CSF Model, (0-7 days) 
Age 0.38433 0.16365 5.5155 0.0188 1.469 (1.066-2.024) 
GCS -0.33281 0.18838 3.1212 0.0773 0.717 (0.496-1.037) 
GRS=1* 12.22476 5.60575 4.7557 0.0292 203772.6 (3.448-1.20x1010) 
GRS=2 17.51545 7.74785 5.1107 0.0238 40445053 (10.277-1.59x10
14) 
Weekly average 
CSF (ng/mL) 
3.90419 2.50418 2.4307 0.1190 49.610 (0.366-6716.365) 
GRS x Age -0.16442 0.07791 4.4533 0.0348 0.848 (0.728-0.988) 
B. Post-acute CSF Model, (8-365 days) 
Age 0.07337 0.01516 23.4196 <.0001 1.076 (1.045-1.109) 
GCS -0.37071 0.13638 7.3889 0.0066 0.690 (0.528-0.902) 
Weekly average 
CSF (ng/mL) 
3.06877 1.37887 4.9532 0.0260 21.515 (1.442-320.955) 
C. Acute Serum Model, (0-7 days) 
Age 0.21986 0.10383 4.4838 0.0342 1.246 (1.016 - 1.527) 
GCS -0.31092 0.18350 2.8711 0.0902 0.733 (0.511 - 1.050) 
GRS=1* 7.21823 3.38859 4.5376 0.0332 1364.075 (1.780 – 1045232) 
GRS=2 10.62033 4.79042 4.9151 0.0266 40959.26 (3.426 – 4.8974x10
8) 
Weekly average 
Serum (ng/mL) 
-0.01039 0.00591 3.0906 0.0787 0.990 (0.978 – 1.001) 
GRS x Age -0.08914 0.04739 3.5376 0.0600 0.915 (0.834 – 1.004) 
D. Post-acute Serum Model, (8-365 days) 
Age 0.16839 0.05939 8.0396 0.0046 1.183 (1.053 – 1.329) 
GCS -0.25839 0.11724 4.8574 0.0275 0.772 (0.614 – 0.972) 
GRS=1* 5.63009 2.35580 5.7116 0.0169 278.686 (2.753 – 28207.98) 
GRS=2 11.50550 4.36513 6.9473 0.0084 99259.92 (19.106 – 5.1568x10
8) 
Weekly average 
Serum (ng/mL) 
0.03425 0.01797 3.6307 0.0567 1.035 (0.999 – 1.072) 
GRS x Age -0.05337 0.02728 3.8283 0.0504 0.948 (0.899 – 1.000) 
GRS x Weekly 
average Serum 
-0.01918 0.00875 4.8026 0.0284 0.981 (0.964 – 0.998) 
*Reference Group, GCS=0; GCS=Glasgow Coma Score, GRS=Gene Risk Score 
 
  113 
Associations between average serum BDNF and TUD were examined in each mortality 
epoch. Given similarities of acute and post-acute models (Supplementary Table 17C/D), a final 
model of TUD across the first year (d0-365) was evaluated. There was a serum BDNF*GRS 
interaction (p=0.047, HR=0.987), with an age*GRS interaction (p=0.007, HR=0.943) and GCS 
(p=0.010, HR=0.780) as covariates (Table 18B).  
Table 18. Modeling time until death across recovery (0-365 days). 
Parameter 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p value 
Hazard 
Ratio 
95% Hazard Ratio 
Confidence 
Limits 
A. CSF Model 
Age 0.11680 0.03343 12.2106 0.0005 1.124 (1.053 - 1.200) 
GCS -0.31807 0.11010 8.3462 0.0039 0.728 (0.586 - 0.903) 
GRS=1* 1.69271 1.04421 2.6278 0.1050 5.434 (0.702 - 42.069) 
GRS=2 3.29990 1.74153 3.5904 0.0581 27.110 (0.893 - 823.231) 
Weekly average 
CSF (ng/mL) 
2.39545 1.17526 4.1544 0.0415 10.973 (1.096 - 109.828) 
GRS x Age -0.03228 0.01690 3.6485 0.0561 0.968 (0.937 - 1.001) 
B. Serum Model 
Age 0.16690 0.04778 12.2032 0.0005 1.182 (1.076-1.298) 
GCS -0.24855 0.09676 6.5977 0.0102 0.780 (0.645-0.943) 
GRS=1 5.38067 1.74053 9.5567 0.0020 217.168 (7.166-6581.739) 
GRS=2 9.97054 3.06393 10.5896 0.0011 21387.04 (52.739-8673014) 
Weekly Average 
Serum (ng/mL) 
0.02089 0.01435 2.1189 0.1455 1.021 (0.993-1.050) 
GRS x Age -0.05840 0.02180 7.1755 0.0074 0.943 (0.904-0.984) 
GRS x Weekly 
Average Serum 
(ng/mL) 
-0.01261 0.00634 3.9496 0.0469 0.987 (0.975-1.000) 
*Reference Group, GRS=0; GCS=Glasgow Coma Score, GRS=Gene Risk Score 
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Figure 11. BDNF serum levels and BDNF gene variation show relationships to mortality at 1 year post-
TBI.  
The cohort is separated by BDNF GRS and age (below and above 45 yrs.). (A) CSF averaged serum levels 
by 0-365 day survival. Within the age <45 group who died by day 365, subjects with a GRS=0 had significantly higher 
CSF levels compared to GRS=2 (p=0.024), a similar trend existed compared to GRS=1 (p=0.076). Within survivors 
under the age of 45, there was a trend such that subjects with a GRS=0 showed higher levels compared to GRS=3 
(p=0.092). (B) Weekly averaged serum levels by 0-365 day survival. Within survivors under the age of 45, subjects 
with a GRS=0 had significantly lower serum levels compared to GRS=1 (p=0.037) and GRS=2 (p=0.018).  In subjects 
over the age of 45 who died by day 365, GRS=1 levels were significantly higher compared to GRS=0 (p=0.041) and 
GRS=2 (p=0.025). 
 
To interpret interactions between BDNF levels and GRS in the context of age in mortality 
predictions, Figure 11 shows averaged CSF and serum levels by 0-365 day survival. Participants 
were separated by GRS and age (split at 45 yrs.). While there were no significant interactions 
between CSF BDNF and GRS, BDNF CSF levels graphed by age, mortality, and GRS, are shown 
in Figure 11A. Within participants <45yrs who died, subjects with a GRS=0 (Val/Val, T/T) had 
higher CSF levels compared to GRS=2 (Met-carriers and C-carriers, p=0.024); a similar trend 
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existed versus GRS=1 (Met-carrier or C-carriers, p=0.076). Within survivors <45yrs, there were 
no associations with GRS, though similar trends were observed for the hypothesized high secretion 
and neuroprotection GRS (Val/Val, T/T, GRS=0) to have more CSF BDNF. For participants 
>45yrs. there were no differences in CSF BDNF levels by GRS, regardless of mortality. Figure 
11B shows averaged serum BDNF by age, GRS, and mortality. Among survivors <45yrs, 
participants with a GRS=0 (Val/Val, T/T) had lower serum levels compared to GRS=1 (Met-
carrier or C-carriers, p=0.037) and GRS=2 (Met-carriers and C-carriers, p=0.018).  There was no 
relationship of GRS to serum levels in participants <45yrs. who died by d365. Similarly, within 
survivors >45yrs., there was no relationship between GRS and serum BDNF. Yet, for subjects 
>45yrs. who died, GRS=1 levels were higher versus GRS=0 (p=0.041) and GRS=2 (p=0.025).  
5.4.4 CSF and serum BDNF Associations with GOS 
In a secondary analysis, we evaluated CSF and serum BDNF level associations with global 
outcome (GOS) to determine if BDNF levels are indicative of mortality or graded across a range 
of outcomes. Average CSF BDNF levels differed at 6 months between individuals who died versus 
survived (with both favorable and unfavorable outcome groups, Figure 12A). At 12 months, 
individuals with unfavorable outcome had CSF levels between those with favorable outcomes and 
those that died, but were not significantly different from either group. However, CSF BDNF levels 
were higher in those who died by 12 months vs. those with favorable outcome.  Serum BDNF was 
not associated with 6-month GOS scores, though qualitatively higher serum BDNF occurred in 
those with favorable outcomes. Serum BDNF levels tended to be lower in participants who died 
by 12 months (140.06±8.99 ng/mL) versus those with favorable outcomes (167.97±8.23 ng/mL, 
p=0.051, Figure 12B). 
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Figure 12. BDNF levels associations with Glasgow Outcome Scale.  
(A) At 6 months, weekly averages of CSF were significantly higher in subjects who died compared to subjects 
who survived (both favorable and unfavorable outcomes, p<0.05). At 12 months, GOS levels were significantly 
different between subjects who died and subjects with favorable outcomes (p<0.05). (B) Weekly serum levels tended 
to be lower in subjects who died by 12 months compared to subjects who had favorable outcomes (p=0.051), but there 
was no significant association at 6 months. 
5.5 DISCUSSION 
The work presented here suggests unique relationships between neurotrophic signaling, injury, 
genetics, and age. Importantly, this work furthers experimental studies that indicate BDNF 
signaling may be highly dependent on age and injury specific alterations in target receptor milieu, 
allowing for the possibility of both beneficial and detrimental effects following neurological 
injury. Additionally, this work suggests that BDNF profiles immediately following injury may 
impact both neuronal survival/apoptotic signaling as well as interplay with the autonomic nervous 
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system to affect outcome. With the growing elderly population globally, the implications of altered 
BDNF signaling in the context of advanced age could inform geriatric care. Similarly, this work 
may also have applications in acquired brain injuries like stroke, where BDNF signaling may be 
altered under ischemic conditions (Gomes et al., 2012; Vidaurre et al., 2012). Understanding 
BDNF signaling in relation to other secondary injury cascades, age, and receptor regulation in 
neurological injury may inform new and more tailored treatment paradigms. 
This study reports reduced serum BDNF levels immediately following TBI versus controls, 
and modestly higher CSF BDNF in individuals with TBI versus controls. Importantly, results show 
that serum and CSF BDNF levels aid mortality predictions post-TBI, in concert with BDNF genetic 
variation, age, and injury severity. Contrary to hypothesized relationships, elevated CSF BDNF 
may not be neuroprotective as it was associated with higher mortality risk. This finding is 
consistent with previous experimental work showing elevated pro-apoptotic CNS BDNF target 
receptors in the context of injury (Rostami et al., 2013) and our clinical work suggesting that 
age*GRS interactions for BDNF may represent age and injury specific increases in pro-apoptotic 
BDNF target receptors (Failla et al., 2014).  Also, serum BDNF, when considered in an interaction 
with BDNF genotypes, was associated with mortality.  The data also suggest that serum BDNF 
contributes, at least in part, to CSF BDNF levels via BBB disruption.  However, reduced serum 
BDNF may also have other relationships (e.g. autonomic function) that could contribute to 
mortality. 
Clinical TBI biomarker studies that focus on BDNF are limited, and to our knowledge, 
have not investigated BDNF levels and TBI outcome, especially in the context of genetic variation. 
One study in pediatric TBI showed rapid increases in CSF BDNF levels immediately following 
the injury (at 2hrs post-injury) that remained higher than controls throughout the first 24hrs 
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(Chiaretti et al., 2003). Kalish and Phillips (Kalish and Phillips, 2010) found serum BDNF levels 
were correlated with injury severity post-TBI, such that subjects with mild injuries had high serum 
BDNF levels. Yet, BDNF levels have never been examined as a marker for TBI-related mortality. 
Our previous research showed that BDNF variation interacts with age to influence 
mortality predictions post-TBI(Failla et al., 2014). In this study, we utilized our previous BDNF 
GRS to account for genetic variation at both loci within the BDNF gene. Previously, BDNF GRS 
was associated with acute mortality, regardless of age. Contrary to expectations, participants in the 
hypothesized “no-risk” (higher proposed BDNF secretion) group had the lowest survival 
probability. Post-acutely, BDNF-GRS interacted with age to support the neuroprotection 
hypothesis such that younger participants in the “no-risk” group had the highest survival 
probabilities, but older participants in the “no-risk” group had the lowest survival probabilities.  
Previously, we suggested that age-specific risk profiles are due to a balance shift in BDNF 
receptor ratios with aging, from pro-survival to pro-apoptotic, diminishing recovery post-TBI 
(Croll et al., 1998; Romanczyk et al., 2002; Tapia-Arancibia et al., 2008; Webster et al., 2006). 
BDNF’s signaling capabilities depend on a balance of tissue receptor milieu. In brain, BDNF is 
synthesized as pro-BDNF then cleaved to mature BDNF (Barker, 2009). Mature BDNF has pro-
survival signaling capabilities via the full length TrkB receptor (TrkB.FL), while pro-BDNF can 
be pro-apoptotic via the p75NTR receptor (Barrett, 2000). There are two truncated TrkB isoforms 
lacking intracellular tyrosine signaling capacity, with physiological implications in other pathways 
(Gomes et al., 2012; Vidaurre et al., 2012). Experimental TBI induces transient increases in 
hippocampal TrkB.FL followed by delayed increases in TrkB.T with regionally-specific p75NTR 
increases up to 8 weeks post-TBI (Rostami et al., 2013). Relevant to acute TBI mortality, the ratio 
of TrkB.FL/Trk.T expression may support cell survival during excitotoxic injury(Gomes et al., 
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2012; Vidaurre et al., 2012). With a shift in BDNF receptor ratios occurring in both injury and 
aging, understanding the effects of both is likely necessary for TBI-related mortality predictions.  
To build on our previous hypothesis, we examined how serum and CSF BDNF levels 
influenced mortality after adjusting for age*GRS interaction. Given our strategy examining 
age*GRS mortality effects with/without adjusting for CSF BDNF levels, the age*GRS interaction 
likely captures elements of aging effects on BDNF secretion in addition to aging influences on 
target receptor milieu in the context of TBI. Notably, BDNF serum levels are reduced in older 
individuals in studies without TBI (Erickson et al., 2010; Gunstad et al., 2008; Lommatzsch et al., 
2005), although age*BDNF levels interaction with mortality were not observed. 
BDNF biomarker profiles suggest an important TBI-specific neurotrophic pathology. 
Previously, evidence of BDNF upregulation immediately following experimental TBI (Hicks et 
al., 1997; Rostami et al., 2013) was thought to aid neuroprotection (Almeida et al., 2005; Lindvall 
et al., 1994). However, in our study, elevated CSF levels are associated with mortality. This may 
be due to age or injury related changes in BDNF target receptor expression that favor apoptotic 
(p75) pathways, effectively making BDNF exposure detrimental. Yet, there tended to be a negative 
correlation between CSF and serum in our study that differs from studies in healthy populations 
(Pillai et al., 2010) and rodent models (Pan et al., 1998). The negative correlation between CSF 
and serum following TBI suggests BBB disruption with serum BDNF transit into the CNS acutely 
after TBI and may also reflect platelet dumping BDNF near vascular injury sites. Thus, higher 
CSF BDNF levels associations with mortality may represent both receptor expression profiles and 
BBB disruption.  
Serum BDNF levels are thought to reflect brain BDNF levels in uninjured populations 
where BDNF is release into the blood stream from brain (Dawood et al., 2007; Rasmussen et al., 
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2009). However, in addition to a possible negative correlation between CSF and serum, there are 
also additional BDNF sources. BDNF is also synthesized and secreted from vascular endothelial 
cells and may have a peripheral action (see review, Caporali et al (Caporali and Emanueli, 2009)). 
In blood, BDNF is sequestered in platelets, and is synthesized in the periphery (Nakahashi et al., 
2000). Some reports suggest that platelets can release BDNF near injured tissue (Fujimura et al., 
2002), but it is unclear if platelet release is altered in TBI.  Similarly, serum BDNF could also be 
attributed to increased autonomic function, as HPA axis activation can diminish BDNF levels 
(Rothman et al., 2012). Thus, lower serum BDNF association with mortality may reflect platelets 
dumping BDNF into the CNS in the case of BBB disruption and/or reflect autonomic changes in 
BDNF levels related to HPA axis reactivity.  
In uninjured populations, studies are mixed on the relationship between the BDNF gene 
and serum BDNF levels. While some studies show a relationship between rs6265 and serum BDNF 
levels such that Met-carriers have reduced serum BDNF, a meta-analysis did not support this 
relationship (Terracciano et al., 2013). Some have examined relationships between rs7124442 and 
serum BDNF levels, with mixed results (Hohenadel et al., 2014; Mercader et al., 2007).  Yet, in 
our work post-TBI, relationships between genetic variation and serum BDNF levels are integral in 
mortality predictions, possibly reflecting injury-specific genetic effects on BDNF secretion and/or 
transit into the CNS.  
Given the relationships between age, BDNF gene, and BDNF levels in our mortality 
predictions post-TBI, we examined these relationships descriptively for interpretation purposes. 
Our final model includes age*GRS and GRS*serum BDNF interactions that may actually be 
reflective of dual BDNF actions in both autonomic function and neuronal support; alternatively 
there may also be a three-variable interaction for which this study is likely under-powered (Figure 
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11). Given the hypothesized effects on secretion associated with the BDNF variants examinede, 
we expected subjects with a GRS=0 would have the highest serum BDNF levels, yet Figure 11A 
shows this is not the case when considering age. Age related increases in BBB permeability 
(Cernak et al., 2010; Lee et al., 2012; Oakley and Tharakan, 2014) may contribute to a possible 3 
factor interaction. For example, among survivors where age<45, the hypothesized low secretion 
GRS=2 had significantly higher serum BDNF versus the ‘high secretion’ genotypes (GRS=0). This 
finding may be indicative of a compensatory BDNF response among younger individuals with 
GRS=2 but could also be due to less BBB disruption and transit into CSF as CSF levels are also 
lower in this group.  CSF BDNF levels did not interact with GRS in mortality predictions. 
Regardless of GRS, CSF BDNF levels were higher among those who died, suggesting that other 
factors like BBB transport and neuronal production contribute to the CSF levels observed and their 
associations with mortality. Among participants >45yrs, there was no difference between serum 
or CSF levels by GRS in subjects who survive. Among participants in this older group who died, 
those with the low secretion genotype (GRS=2) not only had the lowest serum levels but also the 
highest CSF levels, again possibly suggestive of greater age-related BBB disruption and transport 
affecting serum levels in addition to genotype.  
In evaluating BDNF utility as a biomarker, we examined CSF and serum relationships to 
6 and 12 month GOS. As GOS includes mortality as an outcome, CSF relationships were driven 
by higher CSF levels predicting mortality. Serum levels showed no relationship to 6 month GOS, 
but there was some capacity for mortality prediction with 12 month GOS. However the primary 
significant comparison at 12 months was between those who died versus those with favorable 
outcomes. This finding suggests acute serum BDNF levels are more reflective of mortality status, 
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lacking discrimination for outcome among survivors. Future BDNF evaluation in the context of 
other survivor-specific outcome measures should be explored.  
There are some limitations to consider. Our BDNF ELISA assay does not differentiate 
between proBDNF and mature BDNF. Future studies may investigate differences in pro versus 
mature BDNF. Serum BDNF levels can be affected by circadian rhythms (Piccinni et al., 2008b). 
However, it is not clear if/how BDNF levels vary daily in the context of acute TBI as studies report 
a loss of normal circadian rhythms acutely after TBI (Wagner et al., 2011b). As BDNF levels are 
associated with depression, participants depressed at the time of injury may have lower serum 
BDNF initially. Examining pre-injury function and pre-morbidity may help delineate more about 
these issues. One study suggests plasma BDNF levels predict mortality in ICU patients without 
TBI. While associated mechanisms are unclear (Ritter et al., 2012), with altered metabolic 
homeostasis and autonomic dysfunction immediately following TBI, there may be vascular BDNF 
actions that influence systemic contributors to mortality. This study suggests that BDNF pathology 
is likely an important new target in relationship to individual variation in mortality predictions 
post-TBI.  
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6.0  INTERRELATIONSHIPS BETWEEN MEMORY DEFICITS, FUNCTIONAL 
COGNITION, AND DEPRESSIVE SYMPTOMS FOLLOWING SEVERE TBI: 
TOWARD A BDNF HYPOTHESIS. 
Michelle D. Failla, BS, Shannon B. Juengst, PhD, Patricia Arenth, PhD, Amy K. Wagner, MD 
6.1 ABSTRACT 
Background: Traumatic brain injury (TBI) results in mood and cognitive complications that impact 
functional recovery. Understanding common signaling pathways between post-TBI depression 
(PTD) and cognition may elucidate underlying neuropathology. Brain-derived neurotrophic factor 
(BDNF) is a likely target as BDNF reductions occur in both experimental TBI and depression 
models.  
Objective: To evaluate BDNF as a biomarker for PTD, cognitive impairment, and 
functional cognition in a prospective cohort with severe TBI. 
Methods:  Participants with TBI (n=170) were evaluated for PTD (Patient Health 
Questionnaire-9), cognitive deficits (cognitive composite score) and functional cognition 
(Functional Independence Measure–Cognition, FIM-Cog). BDNF levels were measured in 
cerebrospinal fluid (CSF) and serum 0-6 days post-injury. Serum was also measured at 6 and 12 
months post-injury. 
Results: Serum BDNF was reduced compared to controls at all time-points. Acute serum 
BDNF were positively associated with Memory composite and FIM-Memory component scores 
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at 6 and 12 months. Chronic BDNF serum tended to be lower in participants with PTD, however, 
chronic BDNF serum levels correlated with depressive symptom severity at 12 months post-TBI 
Conclusions: PTD is associated with functional cognitive deficits, but not cognitive 
performance, with apathy/motivation as likely etiological factors. Acute BDNF associations with 
memory performance may implicate hippocampal damage/degeneration, though acute and chronic 
BDNF associations with PTD were not as strong. Further investigation may delineate longitudinal 
BDNF profiles, and BDNF responsive treatments, as they reflect mood and cognitive recovery 
following TBI. 
6.2 INTRODUCTION 
In recent years, traumatic brain injury (TBI) has been recognized as a chronic medical condition 
with accompanying mood and cognitive complications. Alterations in cognition and mood can 
negatively affect quality of life and influence return to work or school following TBI (Cifu et al., 
1997a; Fleming et al., 1999; Juengst et al., 2013; Yasuda et al., 2001).  Identifying sensitive TBI 
biomarkers may be useful to manage these two major clinical issues and to measure responses to 
pharmacological and/or behavioral interventions. In fact, post-traumatic depression (PTD) is the 
most common neurobehavioral complication following TBI. Individuals with TBI are 10 times 
more likely than the general population to experience a depressive episode during their first year 
of recovery (53% (Bombardier et al., 2010a) compared to 6% (Kessler et al., 2005) per 12 months 
in the general population). The identification of an early biomarker for PTD development would 
aid in screening and early intervention, by identifying those at greatest risk and in need of close 
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tracking and frequent follow-up. Additionally, a biomarker that is reflective of PTD symptoms 
may be useful in improving treatment effectiveness, by informing dose or timing of interventions.  
In non-brain injured populations, individuals with depression often have comorbid 
cognitive deficits, likely due to common pathology (Levin et al., 2007). While individuals with 
depression report a number of cognitive difficulties (Gotlib and Joormann, 2010), memory deficits 
are consistently problematic (Burt et al., 1995). Similar to individuals with depression, individuals 
with TBI commonly exhibit significant memory, executive function, and attentional difficulties 
after their injury (Brooks et al., 1999; Sumit N. Niogi et al., 2008; Perlstein et al., 2006; Vakil, 
2005).  We have recently shown individuals with PTD have no significant cognitive performance 
deficits compared to individuals with no PTD, even after correcting for a number of demographic 
and clinical variables. However, individuals with PTD still have significant functional cognition 
impairment (Chapter 2). Yet, some studies suggest that, for individuals with TBI, remittance of 
depressive symptoms often leads to increases in cognitive performance (Fann et al., 2001), 
suggesting overlapping biological pathways or interacting symptomology.  
One promising biomarker for common pathology in mood and cognitive complications 
post-TBI is brain-derived neurotrophic factor (BDNF). BDNF, a neurotrophin involved in 
neuronal survival and synaptic plasticity, has been implicated in depression (Martinowich et al., 
2007), memory and learning (Alonso et al., 2002), and TBI pathology (Chen et al., 2005; Failla et 
al., 2014; Griesbach et al., 2009). In the hippocampus, BDNF affects synaptogenesis and 
maintenance, particularly through long-term potentiation associated with activity-dependent 
secretion of BDNF (Kovalchuk et al., 2002). BDNF is also reportedly an underlying substrate for 
persistent long-term memory storage (Bekinschtein et al., 2008a, 2008b).  
  126 
Reduced BDNF is known to be associated with depression, and serum BDNF levels are a 
consistent marker for depressive symptomology (Sen et al., 2008). Serum BDNF levels are 
decreased in untreated depression but increase with antidepressant treatment, indicating the 
viability for BDNF serum levels as a biomarker of depression (Hashimoto, 2010; Karege et al., 
2002; Sen et al., 2008). In TBI, serum BDNF is acutely decreased, correlating with injury severity 
(Kalish and Phillips, 2010). Hippocampal BDNF is chronically decreased in experimental TBI 
(Chen et al., 2005). Importantly, therapies that increase brain BDNF expression, like 
environmental enrichment (Chen et al., 2005) and exercise (Griesbach et al., 2009; Hoffman et al., 
2010; Wise et al., 2012), are promising therapies for mood and cognitive recovery post-TBI. 
Similarly, hippocampal BDNF expression has been linked to spatial memory in experimental TBI 
studies (Griesbach et al., 2009).  These studies suggest that BDNF may be a viable biomarker for 
long-term complications like depression and memory deficits that impact TBI recovery.  
In this study, we assessed BDNF as a viable biomarker for interrelationships between 
cognitive deficits, functional cognitive impairments, and PTD in the first year following TBI, with 
specific attention to memory domains. As BDNF serum levels have never been examined in TBI 
beyond the first 24hrs or in relation to PTD or cognition, BDNF serum levels may be a novel 
biomarker for these complications and may help elucidate convergent pathways in cognitive and 
depressive symptomology post-TBI.  
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6.3 METHODS 
6.3.1 Participants 
Participants in this study, approved by the University of Pittsburgh’s Institutional Review Board, 
were recruited while receiving care at inpatient and/or outpatient clinics within the University of 
Pittsburgh Medical Center (UPMC). All participants sustained a non-penetrating traumatic brain 
injury (TBI), with evidence of intracranial injury on Computed Tomography (CT).  Exclusion 
criteria included: cardiac arrest prior to admission, documented prolonged hypoxia or hypotension 
prior to admission, or penetrating TBI. All participants survived for at least one year post-injury 
and were a subset of a larger study investigating possible biomarkers and genetic factors related to 
individual recovery following TBI.   
Healthy adult controls were also recruited for comparison in biomarker analysis (n=9).  
Control CSF was obtained via lumbar puncture for research purposes, and was not a part of a 
clinical work-up. Criteria for enrollment of controls included: (i) 18-70 years old; and (ii) no 
current or past history of brain injury, neurological disease, or bleeding disorder. Women were 
excluded if they were pregnant, were taking oral contraceptives or hormone replacement therapy, 
or had any history of reproductive or endocrine disorder. 
Injury severity was described using the best GCS obtained within the first 24 hours post-
injury.  Demographic information, including age, sex, and education, was collected by chart review 
as well as through participant or caregiver interviews. Similarly, anti-depressant use at 6 and 12 
months was extracted from both participant interview and chart review. A pre-injury history of 
mood disorders, including depression, bipolar disorder, and anxiety, was established by self-report 
and chart review.  
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6.3.2 Cognitive Assessment 
Participants’ functional cognitive impairment was assessed with the FIM-Cog(Dodds et al., 1993) 
at both 6 and 12 months. FIM-Cog has five component scales: expression, comprehension, social 
interaction, problem solving, and memory. Each scale is rated from one to seven, with a 5 or lower 
indicative of need for caregiver assistance.  The sum of these five components was considered the 
FIM-Cog Score. 
Similar to previous studies (Chapter 4), cognitive deficits were measured at both 6 and 12 
months post-injury using a cognitive composite score developed with a battery of 8 
neuropsychological tests targeting 4 domains of cognition (attention, language fluency, memory, 
and executive function). Attention was measured using the Trails Making Test A (RM Reitan and 
Wolfson, 1985), and the combined score of the forward and backward digit span tests from the 
Wechsler Adult Intelligence Scale-R (Glenn J. Larrabee and Curtiss, 1995). Memory was 
evaluated using the Rey-Osterreith Complex Figure Test (PA Osterrieth, 1944) and the Long Delay 
Free Recall Subsection of the California Verbal Learning Test (Delis and et al., 2000) (CVLT-II). 
Language Fluency domain scores were calculated using Controlled Oral Word Association (JG 
Borkowski et al., 1967) Animals Subsection and the Delis-Kaplan Executive Function Systems 
Verbal Fluency Letter Fluency subsection.  Lastly, executive function was measured using the 
Trails Making Test B (RM Reitan and Wolfson, 1985) and the Stroop Task (J. R. Stroop, 1935) 
Interference Sub-score. These tests were selected as representative measures for their associated 
domains. Raw scores from each test were converted into T-scores using appropriate metrics (i.e 
education, age, sex, race) based on norms indicated by the test manufacturer. T-scores were 
averaged within each domain to create a domain sub-score. To calculate a cognitive composite 
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score, participants had to complete at least one test in each domain. Mean values across domain 
sub-scores were calculated for the overall cognitive composite score. 
6.3.3 Depressive Symptom Assessment 
At 6 and 12 months, depressive symptoms were evaluated using the Patient Health Questionnaire-
9 (PHQ-9), a brief self-report symptom inventory based on the 9 DSM-IV diagnostic criteria for 
Major Depressive Disorder (MDD). The PHQ-9 asks participants to rate how often they have 
experienced symptoms of depression, on a scale between 0 (None) and 3 (Nearly Every Day), over 
a two-week period. Higher total scores (PHQ-9 Total) reflect greater number of and/or greater 
severity of depressive symptoms, with the maximum score being 27.  Participants were grouped 
as “depressed” vs. “non-depressed” using the PHQ-9 questions as they map to DSM diagnostic 
criteria (previously described) (Fann et al., 2005). For a categorization of depression (PTD), 
individuals responded positively to at least five symptom questions on the PHQ-9, with at least 
one pertaining to a cardinal symptom (anhedonia or depression).  Compared to the Structured 
Clinical Interview for DSM Diagnosis (SCID) (Fann et al., 2005), this method has been validated 
in populations with TBI showing a sensitivity of 93% and a specificity of 89%. Importantly, the 
PHQ-9 is reliably able to discriminate between chronic TBI and depression symptoms (Cook et 
al., 2011a). 
6.3.4 BDNF Sample Cohort, Collection, and Processing 
BDNF levels were measured in both CSF and serum. When possible, CSF samples were collected 
via passive drainage up to twice daily for six days post-injury by an external ventricular drain 
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(EVD) placed for clinical care.  Serum was collected acutely, daily for the first six days and 
chronically, at 6 months and 12 months post-injury, via venipuncture.  Acute CSF and serum 
samples were binned by day, and an average was calculated for each day post-injury for each 
participant.  
CSF and serum samples were stored at -80ºC before measuring BDNF levels with an 
enzyme-linked immunosorbent assay (ELISA) kit (RayBiotech, Georgia, USA). Briefly, standards 
(of varying BDNF concentrations) and samples were pipetted onto a 96-well plate pre-coated with 
human BDNF antibody. Following shaking for 2.5 hours at room-temp, the plate was washed and 
then incubated with biotinylated BDNF antibody for 1 hour.  HRP-conjugated streptavidin was 
then added for an incubation of 45 minutes. The addition of a tetramethylbenzidine substrate 
allows for a color reaction. Concentrations were calculated using mean absorbance of each sample 
at 460 nm, as it correlates to amount of BDNF present in the sample, as plotted on a per-assay 
standard curve. Samples were diluted within the range of the ELISA kit (no dilution for CSF, 1:250 
for serum samples), with a sensitivity of 80 pg/ml, a kit supplied intra-assay variation of <10%, 
and an inter-assay variation of <12%.  
For biomarker analysis, participants were assayed for BDNF levels in CSF or serum 
samples (n=170). As BDNF levels have been shown to be moderated by racial background 
(Nettiksimmons et al., 2014), our BDNF levels cohort associations were limited to Caucasians 
only. As the study population was 91.9% Caucasians, there was not enough power to detect racial 
differences between BDNF level associations and outcome. There were 117 participants with CSF 
samples (n=446) and 98 with acute serum samples (n=335). One acute serum sample measurement 
and 4 CSF sample measurements were removed as outliers (based on ±1.5*interquartile range). 
Chronic serum samples were collected at 6 and 12 months (±1 month) post-injury and averaged 
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for each time-point for each participant. At 6 months, 54 participants had at least 1 serum sample 
(n=112 samples); at 12 month, 36 participants had at least 1 serum sample (n=36 samples). A 
subset of participants had both acute and chronic samples (n=44).  
6.3.5 Statistical Analysis 
Data analysis was conducted using Statistical Analysis Software (version 9.4; SAS Institute). 
Descriptive analysis included mean and standard deviation and/or median for continuous and 
ordinal variables such as age, GCS, and education. Frequencies were calculated for categorical 
variables such as sex and antidepressant use. Demographic and relevant clinical information was 
assessed for relationships with BDNF levels using Student’s t-tests or ANOVA to compare means. 
Non-parametric tests (Mann-Whitney and Kruskal-Wallis) were used when appropriate. Outliers 
were assessed using ±1.5 * interquartile range. Pearson’s or Spearman’s rho (r) correlations were 
used to assess relationships between two continuous variables.  
6.4 RESULTS 
Specific cohort demographics are shown in Table 19. Overall, participants had a GCS (best in 
24hrs) of 3-15 (mean GCS, 7.7 ± 2.8, median=7). Participants were aged 16-72 (mean age 
33.2±13.8 years) and 16.1% of participants were women. At 6 months post-injury, 36.5% of 
participants with TBI had PTD, while 28.6% had PTD at 12 months. Participants with PTD tended 
to have a higher mean age compared to those without PTD. There was a higher percentage of 
women in the group with PTD at 6 months (32.3% compared to 11.1%, p=0.018). Participants 
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with PTD at both 6 (22.6 versus 5.6%, p=0.022) and 12 months (33.4 versus 8.3%, p=0.007) were 
more likely to have had premorbid mood disorders. Importantly, there was no difference in 
antidepressant use between PTD groups at 6 or 12 months.  
 
Table 19. Demographic description of study population. 
  Total 
Populatio
n 
(n=170) 
6 Months  12 Months 
None 
(n=54) 
PTD 
(n=31) 
p 
value 
None 
(n=60) 
PTD 
(n=24) 
p 
value 
Age, mean±STD 33.2±13.8 31.5±12.9 36.1±14.1 0.094 32.7±13.2 35.9±13.5 0.098 
GCS, median 7 7 7.5 0.431 7 7.5 0.426 
Sex, # (%) Males 141 (83.9) 48 (88.9) 21 (67.7) 0.018 50 (83.3) 16 (66.7) 0.102 
Race, # (%) 
Caucasian 
154 (91.7) 51 (94.4) 29 (93.6) 0.867 56 (93.3) 21 (87.5) 0.398 
Education, 
mean±STD 
12.8±1.7 12.9±1.9 12.4±1.5 0.261 12.9±1.7 12.1±1.5 0.137 
Premorbid Mood 
Disorders, # (%) 
 3 (5.6) 7 (22.6) 0.022 5 (8.3) 8 (33.4) 0.007 
Antidepressant  
Use, # (%) 
 18 (34.0) 16 (51.6) 0.113 19 (32.2) 10 (41.6) 0.416 
STD, Standard Deviation; PTD, Post-TBI Depression; GCS, Glasgow Coma Scale 
 
As shown in Figure 13A, daily mean CSF BDNF levels among TBI participants did not 
differ from healthy control levels. Conversely, daily mean serum BDNF levels in participants with 
TBI were consistently reduced compared to healthy control levels starting at day 0 
(206.27±16.4ng/mL compared to 277.86±28.1ng/mL for healthy controls, p=0.024) and remained 
below healthy controls for all days (all comparisons p<0.01, n=49, Figure 13B). Serum BDNF 
levels at 6 (205.57±10.2ng/mL, p=0.011) and 12 (188.67±13.5ng/mL, p=0.008) months were also 
below healthy control levels.  
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Figure 13. Daily brain derived neurotrophic factor (BDNF) levels over the first 7 days post-injury, 
compared to healthy controls. 
Means in black line, standard error in light gray dashed lines. (A) Daily mean CSF BDNF levels do not differ 
significantly from control levels. (B) Daily mean serum BDNF levels fall below control levels at day 0 post-injury 
and remain reduced through day 6 (day 0, p<0.05, day 1-6, p<0.001).   
 
 
BDNF levels were examined for associations to PTD. CSF BDNF levels were higher in 
participants with PTD at 6 months, though this was not significant (p=0.089). Acute serum BDNF 
levels in participants with PTD tended to be reduced compared to those with no PTD at 6 months 
(p=0.074) and were negatively correlated with PHQ-9 Total at 6 months (r=-0.38, p=0.044, n=29, 
Table 20).  
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Table 20. Bivariate Correlations between BDNF Levels and Mood and Cognitive Outcome. 
 
Acute Serum Acute CSF Chronic 
 r* 
p 
value 
n r 
p 
value 
n r 
p 
value 
n 
6 Months 
PHQ-9 Total -0.13 0.490 30 0.16 0.334 39 -0.20 0.242 37 
Cognitive Composites 
Overall 0.14 0.474 30 0.13 0.424 41 0.09 0.625 35 
Memory 0.43 0.019 30 0.11 0.490 42 0.04 0.803 35 
Executive Function -0.18 0.332 31 0.01 0.964 42 0.13 0.448 36 
Attention -0.11 0.532 32 -0.02 0.900 43 -0.08 0.626 37 
Language Fluency 0.10 0.599 30 -0.09 0.589 42 -0.01 0.953 35 
Functional Independence Measure 
Cognitive Total 0.31 0.041 45 -0.24 0.090 53 0.16 0.271 47 
Memory 0.35 0.019 45 -0.24 0.080 53 0.13 0.369 47 
Problem Solving 0.33 0.029 45 -0.33 0.015 53 0.11 0.463 47 
Social Interaction 0.30 0.044 45 -0.22 0.116 53 0.05 0.738 47 
Expression 0.34 0.024 45 -0.12 0.390 53 0.19 0.190 47 
Comprehension 0.20 0.186 45 -0.06 0.648 53 0.27 0.068 47 
12 Months 
PHQ-9 Total -0.38 0.044 29 0.10 0.551 37 -0.41 0.019 32 
Cognitive Composites 
Overall 0.39 0.101 19 0.06 0.746 32 -0.04 0.856 28 
Memory 0.53 0.005 26 0.17 0.339 34 0.11 0.580 28 
Executive Function -0.15 0.502 22 0.01 0.962 33 -0.14 0.478 29 
Attention -0.08 0.756 19 0.04 0.840 32 0.09 0.641 29 
Language Fluency 0.18 0.372 26 0.10 0.584 34 0.00 0.984 29 
Functional Independence Measure 
Cognitive Total 0.31 0.063 38 0.00 0.991 47 0.19 0.271 35 
Memory 0.38 0.018 38 -0.15 0.327 47 0.20 0.251 34 
Problem Solving 0.30 0.068 38 -0.05 0.762 47 0.04 0.805 34 
Social Interaction 0.25 0.133 38 -0.02 0.893 47 0.08 0.672 34 
Expression 0.27 0.098 38 0.03 0.817 47 0.07 0.692 34 
Comprehension 0.18 0.282 38 0.24 0.101 47 0.32 0.062 34 
*Spearman’s r; PHQ-9, Patient Health Questionnaire-9. 
 
 
Figure 2 shows chronic serum BDNF levels by PTD status. At 6 months, there were no 
significant differences in chronic serum BDNF by PTD status (p=0.174). Yet, participants with 
PTD had significantly lower serum BDNF compared to controls (p=0.012), while those without 
PTD did not differ significantly from controls (p=0.070). At 12 months, participants with PTD 
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tended to have lower serum BDNF levels than those without PTD (p=0.066).  Participants with 
and without PTD showed lower chronic serum BDNF levels compared to controls (p=0.037, 0.004, 
respectively). At 12 months, chronic BDNF serum levels negatively correlated with PHQ-9 Total 
(r=-0.41, p=0.019, n=32, Table 20).  
 
 
Figure 14. Serum BDNF levels during chronic recovery at 6 and 12 months by PTD status.  
At 6 months (A), there were no significant differences in serum BDNF by PTD status (p=0.174). At 12 
months (B), participants with PTD had lower serum BDNF levels compared to participants with no PTD, though this 
was not significant (p=0.066).  Levels in participants with PTD were reduced compared to control levels at 6 months 
and 12 months, similarly levels of participants with no PTD were reduced compared to controls (p<0.05 for all 
comparisons). 
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BDNF levels were examined for associations to cognitive deficits and functional 
impairments (Table 20). Acute serum BDNF levels were positively correlated with memory 
composite scores at 6 (r=0.43, p=0.019, n=30) and 12 months (r=0.53, p=0.005, n=26). CSF BDNF 
and chronic serum BDNF levels were not associated with any cognitive composite components. 
Acute serum BDNF levels were positively correlated with FIM-Cog at 6 months (r=0.31, p=0.041, 
n=45). CSF BDNF levels tended to show a negative correlation with FIM-Cog at 6 months (r=-
0.24, p=0.090, n=53), with a significant association with FIM-Problem Solving (r=-0.33, 
p=0.015). At 12 months, acute serum BDNF levels were positively correlated to FIM-Memory 
(p=0.018); CSF BDNF did not show any significant correlations to 12 month FIM-Cog or FIM-
Cog components. There were no significant relationships between chronic BDNF and functional 
cognition at either 6 or 12 months. 
6.5 DISCUSSION 
This study aimed to investigate the relationship between mood and cognitive complications post-
TBI by identifying a biomarker (BDNF) that may elucidate common mechanisms of PTD and 
cognitive deficits and functional cognitive impairment. In our previous study (Chapter 2) there 
was no significant evidence that cognitive deficits were associated with PTD, yet individuals with 
PTD had significantly more functional impairments. In this current study, we examined BDNF 
acute and chronic associations with PTD, cognitive deficits, and functional cognition. Acute serum 
BDNF levels were associated with chronic memory deficits, global functional cognitive 
impairment, and depressive symptom severity. Chronic serum BDNF levels were not associated 
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with any cognitive outcomes, but did tend be lower in individuals with PTD. This work suggests 
a common underlying BDNF-related pathology in both mood and cognitive recovery post-TBI.   
This study supports BDNF as a biomarker for cognitive and mood complications post-TBI. 
Serum BDNF levels were low immediately after injury, consistent with previous work (Kalish and 
Phillips, 2010). However, inconsistent with previous studies (Kalish and Phillips, 2010), there was 
no association between GCS (best in 24hrs) and serum BDNF. This may be due to differences in 
severity measures or specific timing of measurements between studies. We also show serum 
BDNF levels remain reduced chronically, adding evidence to the chronicity of TBI pathology. We 
show a trend for a negative correlation between CSF and serum BDNF (consistent with previous 
work, Chapter 4). While it has been suggested that BDNF can cross the blood brain barrier (BBB) 
in both directions under normal conditions (Pan et al., 1998; Poduslo and Curran, 1996), periods 
of BBB disruption following TBI could allow for increased movement of BDNF into the brain, 
especially acutely (Başkaya et al., 1997; Pan et al., 1998). This increased movement into the CSF 
from the blood could reflect a possible restorative process, as platelets dump BDNF in response to 
vascular injury (Nakahashi et al., 2000). Therefore, lower BDNF levels in serum acutely could be 
suggestive of more extensive injury that could correlate with later chronic complications.  
In uninjured populations, BDNF serum levels have been shown to be consistently reduced 
in individuals experiencing depressive symptoms (Karege et al., 2005). Under normal 
circumstances, serum BDNF levels likely reflect CNS functioning, as BDNF is primarily 
synthesized in the brain and secreted in an activity dependent manner (Z.-Y. Chen et al., 2004). A 
number of studies suggest serum increases in BDNF are due to brain level changes (Dawood et 
al., 2007; Rasmussen et al., 2009). It is suggested that serum BDNF is likely reflective of BDNF 
function in the hippocampus. In the hippocampus, BDNF expression levels are decreased in 
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correlation with stress and depression (Pittenger and Duman, 2007). BDNF signaling in the 
hippocampus is also implicated in mechanisms of antidepressant treatment (D’Sa and Duman, 
2002). In rat models, intracerebral BDNF infusions have antidepressant effects, while decreased 
BDNF signaling results in decreased hippocampal neurogenesis (Siuciak et al., 1997).  
There is evidence that BDNF could be indicative of a depressive state following 
neurological insult. Following stroke, BDNF serum levels were increased during periods of no 
depressive symptoms, but decreased when individuals presented with depression (L. Yang et al., 
2010). However, our study did not show concrete evidence for associations between PTD and 
BDNF levels at the time of the depressive state. However, acute serum BDNF levels did correlate 
with depressive symptom severity (PHQ-9 Total) at 12 months. Similarly, chronic BDNF levels 
at 12 months correlated with depressive symptom severity. These data suggest BDNF may be more 
reflective of depressive symptomology later in recovery. In our previous studies (Failla et al., 
2013), we have shown transient risk factors for depression across the first year, thus, BDNF may 
be more representative of stable risk factors and/or depressive state once other risk factors have 
resolved. It is also possible that this study was underpowered to detect reductions in chronic serum 
BDNF associated with current depressive state given the possible effects of demographics like age 
and gender on BDNF levels (Lommatzsch et al., 2005). 
 The data from this study suggest acute serum levels of BDNF are highly associated 
with memory deficits post-TBI. Other studies have demonstrated similar relationships between 
serum BDNF levels and cognitive function (Griffin et al., 2011). Specifically, in patient 
populations (schizophrenia, bipolar disorder, mild cognitive impairment) and healthy controls 
(Gunstad et al., 2008), there are relationships between BDNF levels and memory performance 
(Dias et al., 2009).  Animal studies with conditional BDNF knock-out mice show impairment in 
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hippocampal-dependent cognition and behavior (Bath and Lee, 2006). Thus, in injury, reduced 
serum BDNF acutely may be indicative of more damage to the hippocampus. Similarly, it may 
also be indicative of an acute injury state that is conducive to neuronal death and atrophy that 
would predict later memory performance. Low BDNF signaling in the hippocampus may diminish 
synaptic plasticity and neurogenesis, negatively affecting these chronic recovery endpoints. Future 
studies are needed to examine the relationship between acute BDNF levels and chronic 
hippocampal volume, as this may aid interpretation of these findings. As experimental models of 
TBI show that BDNF expression in the hippocampus is correlated with cognitive recovery 
(Griesbach et al., 2009), it will be critical to understand if this could be relevant to early 
interventions to improve chronic memory problems. Participants with lower BDNF levels acutely 
do tend to have lower levels chronically, thus, understanding the trajectory of these profiles, and 
their relationship to memory performance, could impact treatment and intervention strategies.  
Acute BDNF serum levels did not correlate with any other measures of cognitive 
performance, but were significantly associated with multiple components of the FIM-Cog. This 
may be due to the role of memory deficits in other aspects of functional cognition (Lewis and 
Horn, 2013). Similarly, BDNF CSF levels did not show consistent associations with any aspects 
of mood or cognitive recovery. For CSF BDNF levels, higher CSF levels tended to be associated 
with worse outcomes on the FIM-Cog subcomponents. This is consistent with our previous work 
(Chapter 4) showing high levels of CSF were associated with greater mortality post-TBI. CSF 
levels may not be as indicative of functional outcome post-TBI as there are competing sources of 
BDNF (brain versus platelets in blood) and the relationship between brain levels, CSF, and serum 
is unclear immediately following TBI. 
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Importantly, BDNF levels may be influenced by BDNF genetic variation (Terracciano et 
al., 2013). Future studies in larger cohorts are needed to determine the effect BDNF variation on 
post-TBI BDNF levels, especially chronically. It will also be important to evaluate BDNF serum 
post-TBI in relation to therapies that stimulate BDNF signaling (e.g. exercise, SSRIs). In uninjured 
populations, serum BDNF levels are decreased in untreated depression but increase with 
antidepressant treatment, indicating the viability for BDNF serum levels as a biomarker of 
depression (Hashimoto, 2010; Karege et al., 2002; Sen et al., 2008). Unfortunately, this study was 
not designed to evaluate the usefulness of BDNF as a biomarker of PTD remittance following 
antidepressant use. A limitation in this study is the inclusion of individuals on antidepressants, 
however, BDNF levels are thought to be more indicative of depressive symptomology and 
remittance than antidepressant use (Piccinni et al., 2008a), thus, future studies in PTD will need to 
examine these relationships carefully.  
There are some important limitations to consider in this study. In consideration of BDNF 
levels, larger sample sizes are needed to address covariates that may affect CSF and serum levels, 
namely genetic variants and other demographics (age, sex, race). Another limitation is the 
assumption that serum BDNF levels represent brain levels, as there is a substantial peripheral 
production of BDNF in vascular endothelial cells (Nakahashi et al., 2000) and stored in platelets 
(Gass and Hellweg, 2010). Literature suggests platelet release is not altered in depression (Karege 
et al., 2005), but it is unclear if platelet release could be altered in PTD or TBI or how this store of 
BDNF might influence our findings. This study suggests that, while functional cognition is 
impacted by PTD (Chapter 2), BDNF’s usefulness as a biomarker may be more linked to cognitive 
deficits post-TBI. Importantly, overlapping symptoms can also make identification of PTD 
difficult, though the PHQ-9 has been shown to differentiate between cognitive symptoms and PTD 
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(Fann et al., 2005). Identifying biomarkers like BDNF for mood and cognitive difficulties may 
also help to delineate risk for PTD with or without cognitive deficits. Future studies may examine 
BDNF levels across recovery as PTD develops and/or resolves for a better understanding of its 
relationship to mood post-TBI. Similarly, it will be important to understand the relationship 
between BDNF levels in participants with PTD, with and without cognitive deficits.  
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7.0  POST-TBI ALTERATIONS IN FRONTO-LIMBIC MORPHOMETRY ARE 
ASSOCIATED WITH DEPRESSION 
Michelle D. Failla, BS, Anne C. Ritter, MPH, John M. Myrga, Patricia M. Arenth, PhD, 
Joseph H. Ricker, PhD, Amy K. Wagner, MD 
 
7.1 ABSTRACT 
Post-traumatic depression (PTD) is a common neurobehavioral complication following traumatic 
brain injury (TBI). Studies shows volumetric alterations in fronto-limbic brain regions are 
associated with depressive symptomology. This study examined fronto-limbic brain morphometry 
in TBI as a possible biomarker of PTD susceptibility, implicating regional reductions post-TBI. 
Structural MRI scans were acquired 1-3 years post-TBI in 40 adults with moderate/severe TBI and 
33 age-matched controls. Regional brain volumes were calculated using automatic segmentation 
software (FreeSurfer). A subset of individuals with TBI (cases, n=21) were assessed for depressive 
symptomology using the Patient Health Questionnaire (PHQ-9). Mann-Whitney and Spearman 
correlations were used as appropriate. Data were corrected for multiple comparisons. Within cases, 
amygdala volume (right, p=0.002) and hippocampus (bilaterally, p<0.005) were reduced versus 
controls. Correlations between regional volumes also differed among cases versus controls. 
Among cases, left amygdala volume was positively correlated with left hippocampus (r=0.428, 
p=0.023) and left caudal anterior cingulate volume (r=0.461, p=0.014), while these correlations 
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were non-significant among controls. However, bilateral amygdala volumes were more correlated 
with medial orbitomedial cortex volumes in controls versus cases.  Interestingly, cases with PTD 
had larger left amygdala volumes compared to cases with no depression (p=0.0003). We suggest 
relative regional atrophy within fronto-limbic circuits following TBI may result in altered volume 
correlations. This relative TBI-related fronto-limbic regional atrophy may contribute to PTD 
susceptibility following TBI. Larger amygdala volumes in individuals with PTD could indicate 
increased emotional reactivity. Future studies need to validate these findings in larger populations, 
examining how fronto-limbic regional volumes may reflect fronto-limbic circuit function and 
relate to PTD susceptibility. 
 
7.2 INTRODUCTION 
Approximately 1.7 million individuals sustain a TBI in the United States every year (“CDC - Injury 
- TBI - TBI in the US Report,” n.d.). The most common neurobehavioral complication is post-TBI 
depression (PTD), with the prevalence reported at 53% over the first year post-injury (Bombardier 
et al., 2010b). PTD is associated with poorer psychosocial function (Hibbard et al., 2004), 
functional outcome (Hudak et al., 2012), and especially functional cognition (Chapter 2). Recent 
studies report that treatment with selective serotonin reuptake inhibitors (SSRI) in PTD have both 
limited effectiveness and increased incidence of adverse events (Fann et al., 2009a; Lanctôt et al., 
2010; Lee et al., 2005), emphasizing the need for a greater understanding of the underlying 
mechanisms of PTD in order to refine treatment and intervention. 
  144 
In uninjured populations, significant alterations in fronto-limbic circuit function are 
hypothesized to contribute to depression pathology (Mayberg, 2003). Consistent with this 
hypothesis, individuals with major depressive disorder have reduced fronto-limbic volumes in 
structures like the hippocampus (Sheline et al., 2003), amygdala, anterior cingulate, and 
orbitomedial frontal cortex (Koolschijn et al., 2009). Recent reviews show overlapping regions of 
vulnerability between depression and TBI, including frontal-limbic regions, with decreased white 
matter integrity implicated in the uncinate fasciculus, cingulum gyrus, and fimbria-fornix (Maller 
et al., 2010). These tracts are also implicated in fronto-limbic circuits associated with depression 
(Hamani et al., 2011; Mayberg, 2003; Mettenburg et al., 2012) due to their connectivity with the 
hippocampus, amygdala, and anterior cingulate.  
As TBI is a clinically heterogeneous disorder, making personalized and early treatment 
interventions difficult, we have proposed a Rehabilomics approach to understanding how 
demographic and clinical variables interact with risk for complications (like PTD) to impact 
functional recovery and rehabilitation post-TBI (Wagner, 2011; A K Wagner, 2010). In the field 
of brain injury, neuroimaging has the potential to inform clinical decisions and rehabilitation as 
well as to serve as a biomarker for successful treatment paradigms (Irimia et al., 2014). While the 
potential ability of imaging to identify patients at risk for complications like PTD remains to be 
seen, the susceptibility of patients with TBI to mood regulation deficits suggests a common 
pathology that may be more nuanced than would be currently available on clinical MRI. As such, 
there has not been conclusive evidence to suggest location of injury predicts PTD development. In 
experimental TBI models, there is evidence of depressive-like behavior following frontal lobe 
damage (Moritz et al., 2014). Some clinical studies support the notion that injury foci in left 
frontal/medial regions (as well as regional brain volume relationships in chronic TBI) are relevant 
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to PTD development (Chan et al., 2008; Jorge et al., 2004); though this susceptibility pattern does 
not explain pathology mechanisms for a large portion of PTD sufferers (Maller et al., 2010).  
One common pathology that may impact PTD susceptibility is diffuse axonal injury (DAI). 
Angular rotation occurs even during linear blows to the head as basilar brain structures, including 
the pituitary stalk) are tethered to the base of the skull (Bayly et al., 2005). This rotational force 
around the brain’s fulcrum regions often results in shearing of long axonal tracts that connect 
fronto-limbic areas (Sabet et al., 2008). Compared to penetrating TBI, closed head injuries often 
result in wide-spread DAI. DAI is an inherent biomechanical component of the TBI complex, and 
DAI relationships to PTD have been suggested (Maller et al., 2010). DAI is due to microstructural 
axonal damage resulting in axonal disruptions and disconnections that, when severe enough, result 
in diaschisis (Carrera and Tononi, 2014; Hernández, 2006). While DAI cannot always be imaged 
using standard magnetic resonance imaging (MRI) techniques, there is evidence that white matter 
integrity measures associated with techniques like diffusion tensor imaging (DTI) are highly 
related to gray matter volume of fronto-limbic regions in PTD(Warner et al., 2010), suggesting 
overall reductions in fronto-limbic structural integrity. In fact, atrophy is a widespread 
radiographic feature characterizing TBI (MacKenzie et al., 2002). Previous PTD studies provide 
evidence of atrophy in the hippocampus (D. F Tate and Bigler, 2000) and anterior cingulate (Chen 
et al., 2008b; Maller et al., 2014). Recent work involving populations with moderate-severe TBI 
suggests that the degree of fronto-limbic structure atrophy in the hippocampus and other regions, 
was associated with PTD severity (Hudak et al., 2011).  
Based on this literature, we hypothesized that reduced structural integrity in fronto-limbic 
regions post-TBI may underlie alterations in functional connectivity of these circuits, leading to 
PTD susceptibility. Importantly, we suggest there are consistent patterns of fronto-limbic atrophy 
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that are not uniform across all areas, and thus, investigated volumetric associations between fronto-
limbic regions in healthy controls and subjects with TBI. We report non-uniform atrophy post-TBI 
and propose that these regional volumetric patterns that occur within fronto-limbic circuits after 
TBI, may be a neural correlate of PTD susceptibility and development. Similarly, for cases with 
TBI, we show relatively higher amygdala volumes in subjects with PTD that correlate with 
depressive severity. 
7.3 MATERIALS AND METHODS 
7.3.1 Participants 
This study consisted of 40 subjects recruited consecutively while receiving care at inpatient and/or 
outpatient clinics within the University of Pittsburgh Medical Center (UPMC) and this study was 
approved by the University of Pittsburgh’s Institutional Review Board. Enrollment criteria for this 
study included age (≥16 and <75 years), right-hand dominance, and a non-penetrating TBI. This 
study included severe (≤8), moderate (9-12), and complicated mild (≥13) injures as defined by an 
admission GCS (Teasdale and Jennett, 1974b) score. Complicated mild injuries were defined by 
both GCS and positive neuroradiological findings attributable to TBI. Subjects were excluded for 
documented prolonged hypoxia prior to admission or for metal in body preventing research MRI 
scans.  We also examined the best GCS obtained within 24 hours post-injury. Participants had a 
best GCS in 24hrs score of 3-15, mean GCS of 9.9 ± 3.6 with a median of 10. Demographic 
information including age, sex, and education was collected by chart review as well as through 
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subject or caregiver interviews. Subjects were aged 18-54 (mean age 29.0 ± 10.3 yrs) and 9 
participants were female.  
Healthy adult control subjects were separately recruited as age and sex matched to subjects 
with TBI to minimize effects of age and sex on brain volumes. Control subjects included 29 men 
and 8 women, with a mean age of 28.2±10.0yrs and education 15.3±2.7yrs. Control subjects self-
reported no current or past history of brain injury or neurological disease, and had no contradictions 
to MRI (ie. no metallic implants), and were all right-hand dominant. 
7.3.2 PTD Symptom Assessment 
PTD symptom assessment was done at 6, 12, and 24 months. Depressive symptoms were evaluated 
using the Patient Health Questionnaire-9 (PHQ9), a brief self-report symptom inventory based on 
the nine DSM-IV diagnostic criteria for Major Depressive Disorder (MDD). The PHQ-9 asks 
participants to rate how often they have experienced symptoms of depression, on a scale between 
0 (None) and 3 (Nearly Every Day), over a two-week period. Higher total scores reflect greater 
number of and/or greater severity of depressive symptoms, with the maximum score being 27.  
Participants were grouped as “depressed” vs. “non-depressed” using the PHQ-9 questions as they 
map to DSM diagnostic criteria (previously described (Fann et al., 2005)). For a categorization of 
depression (PTD), individuals responded positively to at least five symptom questions on the PHQ-
9, with at least one pertaining to a cardinal symptom (anhedonia or depression). Depressive 
symptoms were examined as a continuous variable using PHQ-9 total score to represent depressive 
symptom severity. The PHQ-9 has been validated in populations with TBI showing a sensitivity 
of 93% and a specificity of 89% when compared to the Structured Clinical Interview for DSM 
Diagnosis (SCID) (Fann et al., 2005),. Importantly, the use of the PHQ-9 in this manner is reliably 
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able to discriminate between chronic TBI and depression symptoms(Cook et al., 2011a). Pre-
morbid history of mood disorders (depression, bipolar disorder, and anxiety) was extracted from 
subject interview or chart review for those subjects with depressive symptomology assessments. 
Only one individual had a history of premorbid mood disorders. For each individual, depression 
assessment for association with imaging was taken at the closest time-point to imaging acquisition. 
7.3.3 Magnetic Resonance Imaging (MRI) Acquisition and Analysis 
MRI scans were acquired between 6 months and 3 years post-TBI (mean: 1.6±0.1yrs; min: 0.7; 
max: 3.1). For all participants, T1-weighted images were acquired on either a 1.5 or 3T GE Signa 
or a 3T Siemens Trio system, similar to published protocols(Arenth et al., 2012; Amy K Wagner 
et al., 2014). For the GE Signa, SPGR sequences were collected with slice thickness=1.5 mm/0mm 
interslice, TR=25ms, TE=5, 256x192 matrix, FOV=240mm and a flip angle=40°. For the 3T 
Siemens Trio, sagittal 3D MPRAGE sequences were collects with 224 contiguous 0.78mm slices, 
TR = 1680ms, TE = 2.48ms, 256x256 matrix, FOV = 200mm, flip angle = 8°.  
Fronto-limbic volumes were obtained using FreeSurfer (v5.3.0, Martinos Center for 
Biomedical Imaging, Laboratory for Computational Neuroimaging) whole-brain automatic 
segmentation (Fischl et al., 2004, 2002). This automatic segmentation method uses probabilistic 
estimations of 40 anatomical regions of interest based on a manually labeled dataset from 40 
individuals. Several comparative studies have shown subcortical and cortical segmentation with 
FreeSurfer is comparable to manual labeling (Morey et al., 2009; Pardoe et al., 2009; Sánchez-
Benavides et al., 2010). FreeSurfer provides automatic segmentation of cortical regions and is 
highly adept at parcellation of particularly heterogeneous structures (Fischl, 2012).   
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We examined the right and left of the following regions: amygdala, hippocampus, caudal 
anterior cingulate cortex (ACC), rostral ACC, and medial orbitofrontal cortex (mOFC). After 
visual inspection, two subjects with TBI had one region each (right hippocampus and left rostral 
ACC) that could not be measured due to errors within the FreeSurfer process. To control for 
individual brain size, regional volumes were examined as ratios to total intracranial volume (ICV, 
estimated with FreeSurfer). Because published work shows minimal differences across different 
scanners in regard to volumetric measurements (Nugent et al., 2013), volumes were collapsed 
across scanners.  
7.3.4 Statistical Analysis 
Data management and analysis was performed using Statistical Analysis Software (SAS) version 
9.4 (Cary, NC). Descriptive analyses included mean (with standard deviation or standard error of 
the mean) and/or median for continuous and ordinal variables including age, best in 24hr GCS, 
and education. Frequencies were calculated for categorical variables. Demographic information 
was compared between healthy controls and cases with TBI using Student’s t-tests or Mann-
Whitney U to compare means and Chi-Square or Fisher’s Exact to compare frequencies. 
Spearman’s r correlations were calculated to examine relative brain atrophy across regions (region 
to region correlations among healthy controls and subjects with TBI) and relationships between 
continuous demographic or outcome variables with regional volumes. Multiple comparison 
correction was performed using false discovery rate (FDR) (Benjamini and Hochberg, 1995). 
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7.4 RESULTS 
Table 21. Population Descriptions. 
A. Description of overall population. 
Demographic  
Variable 
TBI  
(n=40) 
Controls  
(n=37) 
p  
value 
Age (mean±STD) 29.01±10.32 28.15±10.01 0.395 
Sex (Male, n (%)) 31 (77.5) 29 (78.4) 0.926 
Race (Caucasian, n (%)) 38 (95.0) 30 (81.1) 0.080 
Education (mean±STD) 14.30±2.17 15.30±2.72 0.096 
GCS (median) 10 - - 
    
B. Subpopulation of participants with TBI and PTD assessment. 
Demographic  
Variable 
No Depressed  
(n=14) 
Depressed  
(n=8) 
p  
value 
Age (mean±STD) 29.95±12.55 32.64±8.23 0.103 
Sex (Male, n (%)) 13 (92.9) 7 (87.5) 0.485 
Race (Caucasian, n (%)) 14 (100.0) 8 (100.0) - 
Education (mean±STD) 14.29±1.82 14.13±2.95 0.999 
GCS (median) 7 9.5 0.198 
 
 
Table 21 describes demographic information for the total population (A) and for the population 
assessed for depressive symptomology (B). Within healthy controls, there were no significant 
associations between any regional volumes with age or education. For cases with TBI, there were 
no significant associations between any of the regions and age, education, GCS, or time from 
injury. GCS tended to have a positive association between left hippocampus (r=0.28135, 
p=0.0786) and left caudal ACC, (r=0.27414, p=0.0869). Education tended to have a positive 
correlation with left hippocampus (r=0.29056, p=0.0689). Out of the 22 subjects with TBI 
screened for depressive symptomology, 8 (36.3%) were depressed on the PHQ-9 at the time of 
MR acquisition.   
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Figure 15. Fronto-limbic gray matter volumes show relative reductions following TBI (dark gray 
boxes), compared to healthy controls (light gray boxes).  
Significant reductions are observed in the right and left amygdala, right and left hippocampus, and the left 
rostral anterior cingulate (ACC).  There were trends for similar associations in the right caudal ACC, right rostral 
ACC, and right medial orbitofrontal cortex (OFC). All volumes expressed as a ratio to estimated total intracranial 
volume (ICV). (**p<0.01, *p<0.05, #p<0.1) 
 
 
In Figure 15, fronto-limbic gray matter volumes were compared in subjects with TBI 
versus healthy controls. Overall, there were relative reductions in multiple regions following TBI. 
Significantly reduced volumes were observed in the right (p=0.005; FDR corrected, p=0.016) and 
left hippocampus (p<0.0001; FDR corrected, p=0.001) and the right amygdala (p=0.0002; FDR 
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corrected, p=0.001). There were similar reductions in the left amygdala (p=0.039) and the left 
rostral ACC (p=0.035) that did not remain significant following FDR correction (p=0.077, 0.077 
respectively).  Table 22 shows correlations between fronto-limbic regional volumes within healthy 
controls and cases with TBI. Several regional volumes are correlated in healthy controls, including 
bilateral medial OFC with bilateral amygdala volume. However, in cases with TBI, only right 
medial OFC correlated with left amygdala volume. Multiple region-to-region volumes are more 
correlated in TBI cases compared to healthy controls. Both rostral and caudal ACC volumes are 
more positively correlated with medial OFC and amygdala in subjects with TBI compared to 
control subjects.  
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Table 22. Region to region correlations in healthy controls and subjects with TBI.  
Controls 
R 
Hipp 
L Hipp 
R 
Amyg-
dala 
L 
Amyg-
dala 
R  
caudal 
ACC 
L caudal 
ACC 
R  
rostral 
ACC 
L 
rostral 
ACC 
R medial 
OFC 
L 
 medial 
OFC 
R Hipp - 
0.803* 
(0.001) 
0.479 
(0.014) 
0.448 
(0.017) 
0.280 
(0.223) 
0.018 
(0.980) 
0.075 
(0.875) 
-0.049 
(0.941) 
0.425 
(0.029) 
0.307 
(0.172) 
L Hipp  - 
0.352 
(0.099) 
0.318 
(0.155) 
0.135 
(0.661) 
0.007 
(0.991) 
-0.005 
(0.991) 
-0.069 
(0.881) 
0.125 
(0.679) 
0.201 
(0.475) 
R 
Amygdala 
   0.789 0.112 0.049 0.148 -0.002 0.528 0.554 
  - (0.001) (0.719) (0.941) (0.614) (0.991) (0.005) (<0.001) 
L 
Amygdala 
    0.299 -0.031 0.237 0.103 0.571 0.557 
   - (0.180) (0.941) (0.341) (0.742) (<0.001) (<0.001) 
R caudal 
ACC 
     -0.169 0.597 0.031 0.464 0.188 
    - (0.550) (0.001) (0.941) (0.016) (0.495) 
L caudal 
ACC 
      -0.044 0.537 0.123 0.157 
     - (0.941) (0.005) (0.679) (0.587) 
R rostral 
ACC 
       -0.031 0.271 0.184 
      - (0.941) (0.236) (0.495) 
L rostral 
ACC 
        0.452 0.197 
       - (0.017) (0.475) 
R medial 
OFC 
         0.596 
        - (0.001) 
L medial 
OFC 
         - 
TBI 
R 
Hipp 
L Hipp 
R 
Amyg
dala 
L 
Amygdal
a 
R  
caudal 
ACC 
L caudal 
ACC 
R  
rostral 
ACC 
L 
rostral 
ACC 
R medial 
OFC 
L  
medial 
OFC 
R Hipp - 
0.766 
(0.001) 
0.516 
(0.006) 
0.373 
(0.047) 
0.113 
(0.611) 
0.356 
(0.059) 
-0.069 
(0.706) 
-0.106 
(0.611) 
0.173# 
(0.412) 
0.101 
(0.611) 
L Hipp 
  0.194 0.428 -0.063 0.184 -0.259 -0.080 0.099 0.030 
 - (0.357) (0.023) (0.716) (0.377) (0.207) (0.675) (0.611) (0.854) 
R 
Amygdala 
   0.530 0.232 0.547 0.085 0.213 0.211 0.322 
  - (<0.001) (0.268) (<.0001) (0.661) (0.310) (0.310) (0.092) 
L 
Amygdala 
    0.314 0.461 0.104 0.378 0.410 0.145 
   - (0.098) (0.014) (0.611) (0.047) (0.027) (0.480) 
R caudal 
ACC 
     0.149 0.552 0.163 0.424 0.213 
    - (0.474) (<0.001) (0.436) (0.024) (0.310) 
L caudal 
ACC 
      0.182 0.527 0.243 0.459 
     - (0.377) (0.006) (0.248) (0.014) 
R rostral 
ACC 
       0.436 0.369 0.487 
      - (0.023) (0.047) (0.006) 
L rostral 
ACC 
        0.404 0.418 
       - (0.031) (0.026) 
R medial 
OFC 
         0.559 
        - (0.001) 
L medial 
OFC 
         - 
*Correlations are reported as Spearman’s r (p value). All p values are FDR corrected.  
#Correlations in subjects with TBI are highlighted if the correlation is stronger (dark gray) or weaker (light gray) 
compared to the corresponding correlation in healthy controls.  
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Fronto-limbic gray matter volumes were then examined for differences by depressive 
symptomology within cases with TBI (Figure 16). Cases with depression had significantly higher 
left amygdala volumes compared to those with no depression (p=0.0003; FDR corrected, p=0.003). 
Several other regions had significantly higher volumes in cases with depression versus those with 
no depression (right hippocampus, p=0.029; right amygdala, p=0.026; left caudal ACC, p=0.022; 
and right medial OFC p=0.022) but did not survive FDR correction (p=0.057 for all comparisons). 
When compared to healthy controls, cases with PTD showed comparatively reduced left 
hippocampal volumes (p=0.009) and increased left amygdala (p=0.003) and caudal ACC volumes 
(p=0.047).  
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Figure 16. Fronto-limbic gray matter volumes show relative sparing in subjects with PTD (dark gray 
boxes), compared to subjects with TBI and no depressive symptoms (light gray boxes).  
Subjects with PTD show higher right hippocampus, right and left amygdala, left caudal anterior cingulate 
(ACC), and right medial orbitofrontal cortex (OFC) volumes compared to subjects with no depressive symptoms 
(**p<0.01, *p<0.05, #p<0.1).  All volumes expressed as a ratio to estimated total intracranial volume (ICV). 
 
All regional volumes were examined for significant correlations to PHQ-9 total values. 
Left amygdala volume correlated with PHQ-9 total (r=0.645, p=0.0012; FDR corrected, p=0.012, 
Figure 17) regardless of PTD status. Similarly, right amygdala volume correlated with PHQ-9 
total score regardless of PTD status (r=0.424, p=0.049) regardless of PTD status, but this did not 
survive FDR correction. However, sensitivity analysis showed that with removal of a visual outlier 
(empty circle data point in Figure 17), right amygdala volumes correlated significantly with PHQ-
9 total scores (r=0.613, p=0.003, FDR corrected, p=0.016). There were no other significant 
correlations between PHQ-9 total and fronto-limbic regional volumes. 
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Figure 17. Amygdala gray matter volumes are correlated with PHQ-9 total scores.  
(A) Left amygdala volumes show a strong correlation (r=0.645, p=0.0012; FDR corrected, p=0.012) with 
PHQ-9 total scores. Dashed line is representative of best-fit. (B) Right amygdala volumes (filled circles) were 
correlated with PHQ-9 total score with removal of a visual outlier (empty circle) (r=0.613, p=0.003, FDR corrected, 
p=0.016). Dashed line is representative of best-fit line when outlier (empty circle) is removed. All volumes corrected 
by estimated total intracranial volume (ICV). 
7.5 DISCUSSION 
The study examined fronto-limbic brain regional volumes following TBI, showing atrophy 
in multiple regions compared to healthy controls. These findings are consistent with similar studies 
showing reduced hippocampal and ACC volumes post-TBI (Chen et al., 2008b; D. F Tate and 
Bigler, 2000). This study applies a unique approach to regional volume analysis by examining 
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correlations between regions. Multiple region-to-region correlations are altered post-TBI 
suggesting specific regional atrophy that is not uniform across regions. 
Overall, cases with TBI had reduced gray matter volumes in several fronto-limbic regions 
when compared to healthy controls. This is consistent with previous studies showing atrophy 
across a number of cortical and subcortical regions (Fujiwara et al., 2008; Gale et al., 2005; Hudak 
et al., 2011; Kim et al., 2008; Salmond et al., 2005). In this study, we show the most significant 
reductions in the hippocampus and amygdala volumes. Previous studies have shown reduced 
hippocampal volumes post-TBI (Arciniegas et al., 2001; D. F Tate and Bigler, 2000; Tomaiuolo 
et al., 2004) and one study has suggested reduced amygdala volumes in mild blast TBI(Depue et 
al., 2014). The unique patterns of reduced atrophy post-TBI, as illustrated by altered region-to-
region correlations, may be related to reduced white matter tract integrity between regions due to 
DAI. The work here showing altered volumetric patterns in PTD and evidence for structural 
connectivity alterations in PTD as seen with DTI (Hudak et al., 2011) suggest structural 
susceptibility of fronto-limbic circuits in PTD. These structural changes may underlie 
hypothesized alterations in functional connectivity of limbic circuits, leading to PTD.  
In both healthy controls and cases with TBI, right and left hemispheres correlate well across 
fronto-limbic regions, with the exception of ACC regions. In healthy controls, mOFC volumes 
were well correlated with amygdala volumes, but this pattern was not evident in cases with TBI. 
If these volumetric changes led to altered circuit function, the findings could be indicative of 
susceptibility of reduced top-down control (higher-order regions modulation of lower-order, 
subcortical regions (Pessoa et al., 2003)) from the mOFC over the amygdala as theorized in 
uninjured populations with depression (Disner et al., 2011).  Overall, cases with TBI show more 
significant correlations between fronto-limbic regions compared to healthy controls. Specifically, 
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the left caudal ACC was more correlated with the amygdala and the right rostral ACC was more 
correlated with mOFC. These patterns suggests atrophy within these three regions is not uniform 
and may be functionally altering fronto-limbic circuit function. Computational modeling studies 
of TBI (Bayly et al., 2005; Kim et al., 2008), and studies of axonal force during angular rotation 
of the head in humans (Sabet et al., 2008), demonstrate that fronto-limbic regions may be at greater 
risk for TBI-related shearing, suggesting there may be a common pattern of non-uniform fronto-
limbic degeneration/atrophy post-TBI. 
Overall, cases with PTD showed higher fronto-limbic volumes in a number of regions 
when compared to subjects with TBI and no depressive symptoms. Cases with PTD show larger 
amygdala volumes compared to cases with no PTD. In uninjured populations, individuals with 
depression have greater amygdala reactivity in response to negative stimuli(Bylsma et al., 2008). 
Less relative amygdala atrophy may be a susceptibility marker for greater amygdala reactivity and 
PTD. Importantly, amygdala volumes in subjects with PTD were actually higher than healthy 
controls. Thus, this finding could be indicative of pre-injury susceptibility to mood disorders or 
maladaptive compensatory mechanisms post-injury. Yet, a meta-analyses of studies involving 
amygdala volumes in uninjured populations with depression found inconsistent results, perhaps 
due to modulation of amygdala volume by medication (Hamilton et al., 2008). In fact, larger 
amygdala volumes are reported following antidepressant treatment in individuals with depression 
(Hamilton et al., 2008), which could be due to increased neurogenesis following antidepressant 
treatment (Jiang et al., 2014). As subjects with TBI tend to be less responsive to antidepressant 
treatment (Fann et al., 2009a), larger amygdala volumes could reflect a treatment-resistant 
depression phenotype post-TBI. Future studies will need to examine this effect in medicated 
subjects with PTD. Amygdala volume positively correlated with total PHQ-9, suggesting it may 
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also be a biomarker for PTD severity. Interestingly, following TBI, smaller amygdala volumes are 
associated with post-traumatic stress disorder and a loss of inhibitory cognitive control following 
TBI (Depue et al., 2014). Animal TBI studies show evidence of increased excitation within the 
basolateral amygdala following injury, with an increase in fear conditioning and generalization 
(Reger et al., 2012). Studies show that the mOFC and ACC may influence emotional regulation, 
particularly in a top-down fashion, modulating amygdalar responses (Etkin et al., 2011). If these 
regulatory regions are comparatively more susceptible to injury or atrophy, the result could 
functionally alter the circuit.  
Our PTD rates in this study (36.3% depressed) were similar to our previous reports (Failla 
et al., 2013) and within published ranges (Bombardier et al., 2010b). Multiple studies suggest an 
even greater susceptibility to depression following TBI with rates of ~53% within the first year 
post-TBI (Bombardier et al., 2010b), though this finding was reflective of depression over the first 
year post-injury. There were no significant demographic characteristics associated with PTD 
development in this study. Many studies do suggest associations with injury severity and PTD, 
though this finding has not been noted consistently (Maller et al., 2010). Importantly, in this study 
there was only one individual with a reported history of mood disorders, which likely did impact 
our findings significantly. It will be important in future studies to understand how pre-injury mood 
disorders impact fronto-limbic volumes. Similarly, understanding treatment effects on these 
measures following TBI will be important for use of morphometry as a neural correlate of PTD. 
There are several important caveats to morphometric studies to consider. Regional volume 
may not always reflect function within healthy populations, yet, following TBI, where there is 
potential for considerable atrophy, volumetric analysis may be more closely related to 
functionality. However, atrophy may still serve as a susceptibility marker, and thus, fronto-limbic 
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circuit function may be able to compensate for injury-related volumetric reductions. Recent work 
following TBI showed regional grey matter atrophy is closely linked to damaged white matter 
tracts post-TBI (Warner et al., 2010), indicating that volumetric loss following TBI may also 
reflect structural connectivity changes, possibly reducing the ability for circuit-level functional 
compensation. Another limitation with morphometric studies is reliance on manual-tracing versus 
automatic segmentation software. While manual tracing of regions can be more reliable, expert 
raters are not always available, and for large scale studies, reliable metrics obtained using 
automatic segmentation paradigms are practical. Several studies have suggested FreeSurfer 
automatic segmentations correlate reliably with manually-labeled segmentation. On average, 
errors from automatic segmentation are likely to result in false negatives (Pardoe et al., 2009), 
finding that then support the robustness of our findings, given the small sample size for this study. 
While this study, and others (Hudak et al., 2011), demonstrate the utility of automatic segmentation 
tools in cases with TBI, there have not been definitive comparative studies.  
Future studies are needed to validate these findings in larger populations, understanding 
what injury parameters might lead to these specific volumetric alterations. It will be important to 
investigate why specific fronto-limbic regions may be more susceptible to TBI-related atrophy, 
possibly providing insight into mechanisms of PTD. Similarly, understanding exactly what 
volumetric measurements reflect with regard to neuronal loss, neural pill, or glial support changes 
will inform treatment paradigms. However, this study suggests that structural changes in fronto-
limbic regions is related to depressive symptomology. Similarly, this study suggests underlying 
structural patterns of fronto-limbic atrophy that emerge after TBI and are related to PTD but, it 
will be imperative to examine how fronto-limbic regional volumes may reflect functional changes, 
in the areas of both depression and cognition. 
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8.0  DISCUSSION   
8.1 REHABILOMICS: TAKING ON THE COMPLEXITY OF POST-TBI 
DEPRESSION 
When studying depression in a population with another primary disease or disorder, like traumatic 
brain injury, a natural approach is to evaluate the etiology of idiopathic depression to identify 
similarities. In some diseases or disorders, where the central nervous system is not directly 
impacted, the research into increased incidence of depression may center on psychological impacts 
of the diagnosis, such as employment status, increased care burden on family, loss of 
independence, or changes in life roles. However, depression involving systemic disorders may also 
have a biologically induced component such as sickness behavior (Dantzer et al., 2008). Sickness 
behavior is a concerted strategy of the immune, endocrine, and nervous systems to work in concert 
to fight an infection. In many chronic disorders like TBI, with associated chronic inflammation 
(Kumar et al., 2014), this physiological interplay may lead to a pathological cytokine induced 
depression, with accompanying neuroendocrine dysfunction. In the context of brain injury, where 
there is the possibility of direct neurological injury to the brain circuits involved in emotional 
regulation, there is an additional layer of complexity in understanding the depressive 
symptomology that often accompanies TBI. In post-TBI depression (PTD), it is likely that 
psychogenic reactions to injury effects interact heavily with neurological damage to brain regions 
involved in emotional regulation and sickness behavior (due to increased inflammation and 
neuroendocrine dysregulation), as well as pre-injury predispositions to depression, either in the 
form of pre-morbid mood disorders, environmental risk factors, or genetic risk. In severe TBI, 
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understanding survival from the injury and resultant cognitive deficits can add another layer to 
investigation of post-TBI depression. Given this level of complexity, we utilized a Rehabilomics 
(A K Wagner, 2010) approach to understanding how monoaminergic and neurotrophic signaling 
may impact survival, depression, and cognition following TBI. Figure 18 highlights the findings 
described here in a comprehensive model. 
 
Figure 18. Summary of investigation into monoaminergic-neurotrophic signaling in mortality, 
depression and cognition following TBI. 
 
 
In survival studies, we have discovered that BDNF genetic variation interacts with age 
(Appendix A), in concert with BDNF levels (Chapter 5), to influence mortality predictions. This 
work is discussed in greater detail in section 8.3.1. Briefly, we suggest these findings may be due 
to injury- and age-induced alterations in receptor milieu, altering the signaling capacity of BDNF 
immediately following injury. However, in Chapter 6, we also highlight relationships between 
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acute BDNF levels that predict chronic cognitive deficits and depression risk after TBI. In 
survivors, acute BDNF levels maybe reflective of early neurotrophic support, such that reduced 
neurotrophic support may result in less neuroplasticity, synaptogenesis, or neuronal survival. We 
suggest reduced neurotrophic support in survivors, early in recovery, may lead to non-uniform 
fronto-limbic atrophy (Chapter 7) and susceptibility to depression and cognitive deficits at 
chronic time-points. Future studies are needed to examine the relationship between acute BDNF 
levels and chronic fronto-limbic atrophy. Similarly, we aim to understand the relationship between 
fronto-limbic atrophy and specific cognitive deficits. While we demonstrated no depression effects 
on cognitive deficits within our sample, there may be nuanced differences in individuals with PTD 
in how fronto-limbic atrophy correlates with cognitive functioning.   
In Chapter 2, we demonstrated that while there was no predictable pattern of cognitive 
deficits in individuals with PTD, both cognitive performance and PTD contribute to functional 
cognition. Antidepressant use, of which was more common in individuals with PTD, was also a 
contributing negative factor on cognitive performance and functional cognition. This was 
surprising, as antidepressants are thought to improve cognition (in uninjured populations). 
However, the literature following brain injury suggests antidepressants have no real effect on 
cognition post-TBI (Wang et al., 2011; Wilson and Hamm, 2002). Future studies may examine the 
relationship between serotonin and BDNF during treatment with to determine if variable SSRI 
efficacy may, in part, be due to neurotrophic mechanisms post-TBI. 
In studying genetic risk for depression post-TBI, we show in Chapter 3 important dynamic 
risk relationships for SLC6A4 in PTD that differ from the literature reporting on uninjured 
populations with depression. We suggest this risk may be exhibited through the developmental 
effects of the serotonin transporter on fronto-limbic circuitry, particularly for those with a pre-
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injury history of depression, in addition to a possible role of SLC6A4 in serotonergic signaling 
post-injury where there may be a hypo-monoaminergric state.  We also demonstrate important 
relationships between dopaminergic genetic variation in DRD2 (Chapter 4) and COMT 
(interacting with sex, Appendix B) on cognitive function. We suggest that variation in these genes 
have such impactful relationships on cognitive function post-TBI due to a hypodopaminergic state 
post-TBI.   
In the remaining sections of this Chapter, we discuss a number of caveats to this work, both 
inherent to studying clinical populations, as well as limitations specific to studying individuals 
with traumatic brain injury. We also present comments on future studies that would support and 
increase the weight of the work presented thus far.  
8.2 MONOAMINERGIC-NEUROTROPHIC GENETIC RISK IN SURVIVAL, 
DEPRESSION, AND COGNITION POST-TBI 
In the work presented here, one of our main tools in understanding implications of monoaminergic-
neurotrophic signaling in survival, depression, and cognition is studying functional genetic 
variants as proxies for individual differences in signaling within these pathways. Several human 
studies have begun to study the impact of genetic variation in TBI recovery and biosusceptibility 
to complications, both in the acute care (Failla et al., 2014; Wagner et al., 2010; Amy K Wagner 
et al., 2007) and chronic rehabilitation phases (Darrah et al., 2012; Failla et al., 2013; Hoh et al., 
2010; Krueger et al., 2011; Wagner et al., 2012, 2010). Many of these studies have focused on 
genetic variation within our targeted pathways in addition to studies in inflammatory pathways. 
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Table 23 highlights to findings from the work presented here in monoaminergic and neurotrophic 
gene variation.  
Table 23. Summary of observed monoaminergic and neurotrophic genetic risk in mortality, PTD, and 
cognition post-TBI. 
 
8.2.1 Development of a gene risk score 
As shown in Table 23, we have observed genetic risk factors in a number of our targeted genes in 
PTD and cognitive deficits post-TBI. Given the overlapping nature of these genes, in both 
interactive signaling and effects on similar outcomes, we aim to develop a comprehensive 
monoaminergic-neurotrophic gene risk score as a future direction arising from our work. We are 
Gene Variation 
Function; 
Implications
  
Mortality PTD 
Cognition 
SLC6A4 5-HTTLPR 
5-HTT expression, 
fronto-limbic circuitry; 
depression risk, TBI 
Not examined 
 S-carriers show 
reduced PTD risk at 6 
months post-injury 
(Chapter 3) 
Trend interaction 
with sex (data not 
shown) 
DAT1 
10/9 
VNTR 
Reduced DAT 
expression(VanNess et 
al., 2005); TBI 
Not examined No significant effect No significant effect 
COMT Val158Met 
Reduced COMT 
activity(Lotta et al., 
1995); 
depression(Baune et al., 
2007), TBI(Lipsky et al., 
2005a) 
Not examined 
Interacts with 
behavioral disinhibition 
to influence PTD (in 
preparation) 
Interacts with sex to 
impact cognition 
(Appendix 2) 
DRD2 TaqIA1 
Related to D2 binding; 
depression(Opmeer et 
al., 2010), 
TBI(McAllister et al., 
2008) 
Not examined No significant effect 
A1/A2 show better 
overall cognitive 
performance 
(Chapter 4) 
BDNF Val66Met 
Reduced 
BDNFsecretion(Egan et 
al., 2003); 
depression(Martinowich 
et al., 2007), 
TBI(Krueger et al., 
2011)  
Acutely, Met-
alleles have 
increased survival; 
Chronically, 
interacts with age 
in mortality. 
(Chapter 5)  
BDNF interacts with 5-
HTTLPR to modulate 
PTD risk* 
(data not shown) 
Trend interaction 
with DRD2 (data 
not shown) 
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especially interested in this as many genetic risk effects can be quite small, perhaps even 
undetectable alone, but may contribute to risk associations in an incremental way. In this 
mechanism, we may be able to understand genetic risk within genes that we are not powered to 
observe in individual candidate gene studies. There is also evidence our targeted genes may 
interact in an epistatic fashion, where having both risk alleles may result in a greater than additive 
effect. Thus, understanding how a battery of genetic risk influences depression or cognition post-
TBI may provide greater benefit than individual candidate gene studies.  
Future work will develop a gene risk score, encompassing all of our tagerted genes. In these 
score, there is an incorporated genetic “load” assumption, suggesting there is a positive 
relationship between increased risk allelic load risk for the targeted disorder or disease. The recent 
guidelines published in the GRIPS (Genetic RIsk Prediction Studies) statement do not recommend 
methodological approaches, but note the lack of discrimination between count (unweighted) and 
weighted GRS approaches (H. Chen et al., 2011). Weighted approaches draw from individual 
candidate gene studies, utilizing effect sizes as weighting mechanisms. In our preliminary data, we 
have noted no significant differences between unweighted and weighted approaches.  However, as 
we have noted a number of interactions in our outcomes (ie. COMT x sex on cognitive outcomes), 
our genetic risk scores must embody the Rehabilomics approach and incorporate effect size 
differences among different demographic groups. We believe gene risk scores are a promising 
strategy for post-TBI rehabilitation studies in assessing complication risk, with the caveat of 
understanding important relationships to demographic variables within each proposed candidate 
gene that would be considered in a GRS. 
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8.2.2 Considerations for candidate gene studies in TBI 
8.2.2.1 Divergent Risk Relationships from Uninjured Populations  
Unsurprisingly, many studies in clinical TBI set out to identify candidate genes that may influence 
recovery by examining gene risk associations in the uninjured literature. For example, when 
considering genetic risk factors for PTD, understanding candidate genes from literature on major 
depressive disorder (MDD) is invaluable of the previous literature available outlining possible 
genetic risk factors. However, as evidenced by our work described in Chapter 3 (Failla et al., 
2013), there can be risk relationships following TBI that are opposite in direction (risk versus 
protective) when compared to uninjured populations, even when studying similar outcomes like 
depressive symptomology.  A number of studies within our lab (Wagner et al., 2012) (and see 
Chapters 3, 4, 5) and others (Krueger et al., 2011) have begun to demonstrate gene risk 
relationships following TBI that differ substantially from risk relationships in uninjured 
populations, which may be logical genetic predictions when understanding the pathology 
accompanying TBI within these pathways. Similarly, it is important to understand evolving genetic 
risk relationships following TBI where there is a specific temporal recovery within many aspects 
of recovery (secondary cascades, evolving neurodegeneration) that may impact genetic risk 
relationships of TBI recovery.  
There are likely a few reasons for divergent genetic risk profiles post-TBI. While not well-
understood, TBI induces a number of epigenetic alterations(Z.-Y. Zhang et al., 2007) that may 
differ wildly from patterns in uninjured populations, making interpretation of gene-candidate 
studies difficult. Another layer of complexity stems from a lack of or rudimentary understanding 
of TBI-induced signaling or receptor changes with certain pathways. A prime example of this 
phenomenon is apparent in our work with the BDNF gene in mortality predictions (Appendix A 
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and Chapter 5). Still further, candidate gene studies (as well as genome wide association studies) 
in uninjured populations may differ from relationships observed with TBI because of a lack of 
well-defined outcomes or endophenotypes. As we show in Chapter 2, the expected relationships 
between cognitive deficits and depression differ following TBI compared to idiopathic depression, 
thus, the outcome of PTD may be inherently, biologically different from MDD. With the distinct 
possibility of a unique pathology profile for PTD, it is then unsurprising that we find ‘divergent’ 
or ‘opposite’ risk profiles in PTD (Chapter 3) when compared to idiopathic depression. 
8.2.2.2 Impact of Mortality Associations on Candidate Gene Associations with Recovery 
When studies aim to identify candidate genes for recovery post-TBI, one important caveat within 
these studies in disease populations, and especially TBI, is to be cognizant of mortality effects. If 
the gene under evaluation is associated with mortality, this association can result in a 
disproportionate amount of individuals with a particular allele, altering observed frequencies of 
alleles among survivors. Even aside from maintaining Hardy-Weinberg equilibrium, this issue can 
have effects on how powered studies are for genetic variants with lower minor-allele frequencies. 
Additionally, understanding how variants seemingly unrelated to the cause of mortality under 
investigation (e.g. BDNF and TBI) may interact in other body systems outside of the CNS to 
influence mortality, may add insight in to work with chronic outcome endpoints like depression 
and cognition. 
8.2.2.3 Limitations of candidate gene studies 
There are a number of limitations in candidate gene studies that are inherent to the approach. 
Importantly, there is the risk of stratification effects, where unintentionally, variation in racial 
background can be contributing to candidate gene associations. To combat this, we have used self-
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reported race categorizations and examined all genetic findings in Caucasians-only as well as the 
total population. Using self-reported race categorization is not ideal, yet genotyping racial 
background using commercially available microchips with upwards of 10,000 markers carries its 
own complexities. Importantly, our studies tend to draw from a fairly racially homogenous 
population. While this abates some concerns about possible stratification effects, the issue also 
results in a lack of generalizability of our candidate gene studies to racially diverse TBI population 
that exists nationally (“CDC - Injury - TBI - TBI in the US Report,” n.d.). Future studies will need 
to examine these associations in larger, more diverse populations with TBI to aid in the 
generalizability of our findings. 
8.3 BIOMARKERS FOR DEPRESSION AND COGNITION POST-TBI 
8.3.1 BDNF Serum and CSF as a biomarker in TBI 
The work presented here suggests BDNF signaling post-TBI may have a number of different 
effects based on age, time from injury, and the outcome of interest. For example, in Chapter 5, 
we demonstrate acute BDNF levels are associated with mortality when BDNF genetic variation is 
taken into account. Yet, acute serum BDNF levels predicted chronic memory problems 
independent of genetic risk among survivors. These complex relationships between genetics and 
BDNF levels in CSF and serum, across recovery, may be due to the diverse actions of BDNF. 
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Figure 19. Schematic of BDNF’s actions relevant to mortality, depression or cognition following TBI. 
 
 
Figure 19 summarizes a several areas of BDNF action that may be relevant to survival, 
depression, and cognition post-TBI. Traditionally, BDNF has been studied due to its role in 
synaptic plasticity, neurogenesis and neuronal survival (Z.-Y. Chen et al., 2004), making it an 
interesting target for chronic TBI. Yet, newer lines of investigation show BDNF can regulate 
energy metabolism and autonomic function. Evidence suggests that BDNF may be involved in 
brainstem regulation of cardiovascular function (Brady et al., 1999; Wang and Zhou, 2002; Wan 
et al., 2014).  Similarly, BDNF modulates the sympathetic/parasympathetic balance in 
cardiovascular function (Yang et al., 2002).  Interestingly, rs6265 is associated with innate 
differences in heart rate variability (A. C. Yang et al., 2010) and acute stress heart rate reactivity 
in healthy populations (Alexander et al., 2010). In fact, one study showed that local BDNF 
administration following surgical sympathectomy induced hippocampal vascular changes and 
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edema (Kasselman et al., 2006). This study suggests BDNF effects during a state of compromised 
autonomic function (e.g. immediately following TBI (Goldstein et al., 1998)) could impact TBI 
pathology, particularly with regard to acute survival. There is a dearth of research about BDNF 
function outside of cognition or plasticity post-TBI, limiting speculation about how BDNF and 
CNS-peripheral modulation of autonomic function post-TBI might occur. Thus, BDNF may affect 
autonomic regulation and reflect the current energy state (Rothman et al., 2012), suggesting 
multiple mechanisms through which BDNF signaling could influence TBI mortality and, later, 
recovery. 
 As far as a biomarker for mortality, Figure 20 depicts our overall model of BDNF as an 
acute biomarker following TBI based on our findings in Chapter 5 and Appendix A.  
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Figure 20. Schematic of relationships affecting serum and CSF BDNF levels following TBI. 
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Under normal conditions, BDNF serum levels are thought to reflect CSF and brain tissue levels. 
BDNF moves from the interstitial space to CSF and then into the serum, where it is stored in 
platelets. After brain injury, permeability of the BBB increases, allowing serum BDNF to leak into 
the CSF, resulting in a negative correlation between CSF and serum. BDNF rs6265 Val allele 
results in reduced efficiency of BDNF into synaptic vesicles for release. BDNF rs7124442 C-allele 
results in reduced trafficking of BDNF to dendrites, reducing spine density and formation. Both 
rs6265 and rs7124442 may result in reduced BDNF in the intracellular space, thus less signaling 
on target receptors. While under normal conditions, TrkB receptors are the most ubiquitous 
receptor, both age and injury (Rostami et al., 2013) upregulate truncated TrkB receptors and pro-
apoptotic p75 receptors, altering the balance of pro-survival to pro-apoptotic signaling. In injury, 
understanding the underlying receptor milieu in tissue immediately following injury, and in 
association with aging, can support interpretation of BDNF CSF and serum as a biomarker for 
mortality following brain injury. Serum BDNF levels may be related to secretion of BDNF as 
understood by BDNF gene risk score (GRS, rs6265 and rs7124442) as well as an understanding 
of GRS to age-altered balance of receptors. CSF BDNF may be most heavily related to BBB 
permeability.  
In chronic time-points, BDNF levels may be more reflective of a “carryover effect” of 
neurotrophic support in acute recovery, rather than depressive symptomology, as were not able to 
show a clear relationship between BDNF levels and current depressive symptoms. While in non-
injured populations with depression it is not wholly clear whether decreases in BDNF levels occur 
prior to the depressive symptomology or are due to the depression. Yet in injury, we have the 
advantage of tracking BDNF levels prior to PTD development and may better be able to delineate 
the time-course of BDNF levels that lead to depressive symptomology.  
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8.4 INTERACTIONS BETWEEN OBSERVED EFFECTS: CONVERGING LINES 
OF EVIDENCE 
Much of the work presented here borrows from the extensive literature on monoaminerigic and 
neurotrophic signaling in normal conditions or in idiopathic depression.  Yet, understanding this 
literature in the context of TBI is difficult as TBI likely disrupts many signaling pathways 
important for long term function and recovery. For example, there is a paucity of literature on 
serotonergic function post-TBI, thus it is unclear how serotonergic signaling capacity may be 
altered post-TBI, and how that dysfunction contributes to our findings in genetic studies. While 
better characterized after TBI than the serotonergic system, contemporary understanding of 
dopaminergic function post-TBI (reviewed (Bales et al., 2009)) is still in a formative state of 
development. Thus, understanding monoaminergic and neurotrophic signaling in PTD risk is 
limited by our lack of fundamental understanding of TBI-induced alterations in these pathways. 
The work presented here speaks to interacting pathways among serotonin, dopamine, and 
BDNF signaling. Future work will examine interacting effects as many of these lines of evidence 
converge on similar mechanisms involving a functional hypomonoaminergic state. As eluded to 
in Figure 18 many of the findings we report may converge on functional connectivity of fronto-
limbic circuits. We show that acute BDNF levels are associated with depression and cognition at 
chronic time-points (Chapter 6). We hypothesize these findings may be due to neurotrophic 
signaling during acute recovery that results in fronto-limbic atrophy, and thus, impaired functional 
connectivity of fronto-limbic circuits. Future studies can examine if acute BDNF levels predict 
hippocampal volume, for example, and if therapies like exercise, which may improve BDNF 
signaling, may rescue this effect. As all of our targeted genes have been shown to be relevant to 
either fronto-limbic atrophy (in gray or white matter) and function (5-HTTLPR (Pezawas et al., 
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2005), BDNF (Kim et al., 2013), DAT (Bertolino et al., 2009), DRD2 (Bartrés-Faz et al., 2002), 
and COMT (Honea et al., 2009)), we also plan to develop a  gene risk score, accounting for 
variation in multiple targeted genes, known to influence fronto-limbic volumes. Additionally, it 
will be important to understand how the non-uniform atrophy identified in Chapter 7 may relate 
to functional alterations. It is possible that monoaminergic or neurotrophic signaling may explain 
some of the non-uniform atrophy pattern observed.  
However, the lack of association between cognition and depression in TBI complicates the 
hypothesis of fronto-limbic dysfunction in PTD. Further work is needed to address the possibility 
of more nuanced effects of depression on cognition post-TBI (like emotional regulation, 
motivation). As we demonstrate strong associations for dopaminergic functioning in cognition, we 
hypothesized overlapping relationships with depression. A role for dopamine in depression has 
been proposed in idiopathic depression, but we observed no clear relationship to depression after 
TBI among the DA genes evaluated thus far. However, future work in development now suggests 
a role for dopamine in behavioral complications that may moderate depressive symptoms. 
Similarly, future work will investigate the functional recovery of individuals with depression and 
DRD2-related cognitive deficits to elucidate the effects of the dopaminergic system on PTD-
Cognition interactions.  
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8.5 CONSIDERATION OF OTHER RELATED SIGNALING PATHWAYS IN PTD 
AND COGNITION POST-TBI 
8.5.1 Stress and HPA Axis 
Stress is likely an important factor in recovery following TBI. The psychosocial adjustments and 
enduring cognitive/physical impairments after injury can create a chronically stressful 
environment for those with TBI. The hypothalamus-pituitary-adrenal (HPA) axis modulates the 
body’s reaction to both physical and emotional stress. Cortisol (in humans) or corticosterone 
(rodents), or CORT, is a known stress hormone and an end product of the HPA axis that binds to 
brain glucocorticoid receptors (Joëls, 2008). The stress of major trauma results in increase 
adrenocorticotropin and CORT (Woolf, 1992).  Our published work suggests that serum CORT is 
elevated for many subjects after clinical TBI and linked to other adrenal/peripheral hormone 
production (estradiol) that is associated with outcome (Wagner et al., 2011c). CSF increases in 
CORT early after TBI are even more striking after TBI and associated with poor outcomes 
(Santarsieri et al., 2013). Elevated cortisol is a known biological characteristic of depression. 
While there is limited data on cortisol levels and cognitive function in depressed subjects, several 
lines of evidence suggest cortisol has effects on cognition, including performance on memory 
testing (Hinkelmann et al., 2009; Newcomer et al., 1994).  
Experimental TBI studies show important relationships to stress response following TBI. 
One study showed that stressed and injured rats showed increased levels of CORT up to 2 months 
following blast TBI that was related to altered anxiety-like behaviors (Kwon et al., 2011). Forced 
exercise therapies increase CORT in rodents and result in reduced benefits of exercise following 
experimental TBI (Griesbach et al., 2012).  Importantly, the benefits of exercise in experimental 
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TBI also seem to be dependent on recovery of the stress response prior to induction of exercise 
(Griesbach et al., 2013).  
Given our work with BDNF and survival, and the likelihood of our survival associations 
being related to modulation of stress circuitry, examining the role of BDNF in relationship to stress 
and neuroendocrine function in PTD and cognition will likely provide additional insight. In 
addition, understanding the stress response in relationship to PTD and cognitive outcomes post-
TBI, will greatly impact neurorehabilitation research design and study interpretation.  
8.5.2 Inflammation 
A growing line of research in the field indicates chronic, maladaptive inflammation may play a 
role in PTD. Inflammatory processes associated with chronic disease, including cardiovascular 
disease, multiple sclerosis, and others, have been associated with increased propensity for 
depressive symptoms and depression (Miller et al., 2009). Causative studies show that immune-
stressors (e.g. lipopolysaccharide) can induce depressed mood(Frenois et al., 2007). We have 
shown acute inflammation can predict chronic depressive-like symptoms in clinical populations 
TBI (Juengst et al., 2014). Studies in experimental TBI have demonstrated a link between chronic 
inflammation and depressive symptoms as well (Fenn et al., 2013). Given that neuroinflammation 
is a hallmark of acute TBI, and there is evidence of long-term inflammation even several years 
post-injury (Nagamoto-Combs et al., 2007), inflammation is an intriguing line of research in PTD. 
Many of the cytokines that might be biomarkers for PTD have relationships with 
monoaminergic neurotransmission. For example, IL-6 and TNF-alpha activate the HPA axis, and, 
in turn, can affect levels of tryptophan (precursor for 5-HT). Cytokines also impact neurotrophic 
support. One study of acute inflammation suggested that TNF-alpha is protective through its 
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transcriptional facilitation of BDNF via stimulation of nf-kappa-b and CCAAT-enhancer-binding 
proteins (or C/EBPs) (Saha et al., 2006). However, in chronic stress, pro-inflammatory cytokine 
expression in the hippocampus decreases mRNA BDNF levels (You et al., 2011). These studies 
suggest that chronic inflammation could impact depressive symptomology dependent on the 
timing and duration of inflammation.  
 
8.6 REHABILOMICS: A ROLE FOR MONOAMINERGIC AND NEUROTROPHIC 
SIGNALING IN SURVIVAL, DEPRESSION AND COGNITION POST-TBI  
Within our proposed framework of Rehabilomics (A K Wagner, 2010; Wagner and Zitelli, 2012), 
we sought to understand how a wide-range of individual factors (like genetics, age, and sex) that 
interact with injury parameters that could influence response to rehabilitation and alter outcomes 
following TBI. It is imperative for clinical studies, in addition to experimental paradigms, to 
rigorously evaluate important factors in rehabilitation like timing, chronicity of treatment, 
maintenance of treatment effects and influences of acute management on chronic care. Much of 
the work presented here, supports these important caveats. With an integrative approach, the 
Rehabilomics-framework combined with rigorous experimental models of neurorehabilitation will 
likely yield rapid improvements in the current state of neurorehabilitation research and clinical 
care for individuals dealing with the chronic effects of TBI. 
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8.6.1 Injury parameters and chronicity in PTD and Cognition post-TBI 
TBI is an inherently heterogenous disorder with varying mechanisms of injury, a wide range of 
injury severities, and a chronic, evolving symptom profile. These are all important considerations 
in the studies described here. For example, in understanding genetic studies post-TBI, the context 
of injury severity may interact with findings. In Chapter 4, we suggest that some of the 
discrepancies in the literature regarding DRD2 may be related to differences in injury severity 
between study populations. Genetic effects in more mild TBI cohorts may be more reflective of 
non-injury genetic risk relationships as the associated injury pathology burden may be relatively 
less. It is also possible these studies examining more mild injuries have greater potential to be 
reflective of pre-injury functioning or environmental effects. It is also important to use a wide 
range of clinical studies and experimental models to examine important issues like how acute care 
can influence response to chronic rehabilitation, focusing on any unintended consequences of acute 
management of injuries. One example of this effect is evidenced by how acute BDNF levels map 
to chronic outcomes better than chronic BDNF levels (Chapter 6). 
8.6.2 Influence on treatment paradigms 
The studies presented here demonstrate a number of considerations in development of new 
treatments for depression and cognition post-TBI. Importantly, cognitive difficulties can impede 
treatment for depression when utilizing cognitive-behavioral interventions, yet, in Chapter 2, we 
suggest the addition of PTD may not increase cognitive deficits per se on individuals. Future work 
is needed to evaluate how cognitive functioning, in concert with PTD, may impact efficacy of and 
participation in cognitive-based therapies.  Along this line, our work suggests antidepressant use 
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may negatively impact cognitive performance. Comprehensive studies are needed to understand 
how antidepressants affect cognition post-TBI, and whether this potential “side-effect” out-weighs 
any benefit of depression remittance, thus, aiding clinical decision making.  
Similarly, the biomarker and genetic work presented here has not been validated in the 
context of treatment or rehabilitation. Examining the biomarkers we presented here (i.e. BDNF) 
for relationships to treatment effects is also important when considering how to improve 
prognostication or personalize treatments. It is not known if BDNF levels return to healthy control 
levels following remittance of depression and cognitive rehabilitation, which may suggest BDNF 
as a required substrate for TBI-related recovery. How our observed genetic effects would interact 
with depression treatment may provide a greater understanding about the signaling pathways that 
underlie symptomology. Studying genetic risk relationships could also inform clinical 
pharmacological interventions. Importantly, work in transgenic animals will likely lead to 
important pharmacogenetic studies elucidating individual responses to targeted pharmacological 
interventions post-TBI. 
Preclinical testing of rehabilitation focused treatments are far less common compared to 
early intervention studies, and for the field of translational TBI research to continue to evolve and 
progress, rehabilitation relevant treatment designs are an important contribution to the field.  
However, one of the major challenges of translational rehabilitation research is the ability to model 
complex, higher order behaviors and deficits following TBI. Modeling depression in experimental 
TBI research is important for understanding treatment effects and mechanisms. Yet, language or 
cultural barriers, social support, and participation in rehabilitation are important factors in the 
clinic that cannot be addressed using experimental models.   
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In the future, it will be important to determine therapeutic windows. For example, are there 
treatments that can be administered for a limited time period that will have lasting effects, or will 
chronic treatments require long-term exposure to address ongoing symptom profiles? Similarly, 
the understanding of how multiple treatments interact with each other to affect recovery, and 
susceptibility to overlapping complications like depression, apathy, and cognition, will be 
important to evaluate. It may be that treatment timing and order are necessary to maximize patient 
benefits. Further, it will be important to assess pharmacological interventions in combination with 
non-pharmacological interventions in neurorehabilitation. 
8.6.3 Conclusions and Summary 
As monoaminergic and neurotrophic signaling have been heavily studied in idiopathic depression 
and cognition, we sought to understand how these interactive signaling pathways may influence 
survival, depression, and cognition post-TBI. By employing the Rehabilomics framework, we 
were able to identifying risk for complications in an individual’s recovery from TBI that are likely 
relevant for treatment and early intervention. The studies presented here were both 
multidisciplinary and multimodal to discern relevant biological mechanisms contributing to PTD 
and cognitive deficits post-TBI, in order to aid in identifying and treating an “at-risk” and highly 
complex, population. The results of this work will advance both clinical investigation into the 
monoaminergic and neurotrophin pathology of TBI as well as basic research into fronto-limbic 
system vulnerabilities and their involvement in depressive symptomology and cognitive 
impairments post-TBI.  
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8.6.4 Limitations and Future Directions 
One of the major limitations of the work presented here is the lack of causal studies. The findings 
suggests highly intriguing correlative evidence for a contribution of monoaminerigic and 
neurotrophic associations with post-TBI survival, depression, and cognition. While this does not 
reduce the caliber of the work, these studies will need support from experimental work in rodent 
models and interventional studies in humans. Mapping portions of our holistic Rehabilomics 
approach to an experimental rehabilitation paradigm will likely accelerate the pace in which 
rehabilitation research can translate the work presented here into individualized treatment plans 
while yielding important insights into rehabilitation-relevant mechanisms. 
We suggest future studies should focus on four major lines of research. First, there is an 
important need to elucidate the mechanisms of our genetic association studies in experimental 
models of TBI. While we have proposed likely mechanisms for each of our findings, there is a 
need for evidentiary support from animal models. Secondly, the work in Chapter 2 suggests a 
major gap in our understanding of PTD regarding its relationship to cognitive deficits. As this 
assumption borrowed from extensive MDD literature that demonstrates this relationship, it is 
imperative to rigorously examine aspects of cognitive dysfunction vs. functional cognition 
impairment in the context of PTD. Thirdly, we suggest that several of these findings implicate 
fronto-limbic circuit function in PTD. Critical evaluation of this pathology in clinical studies, using 
task-based and resting state fMRI studies, are likely to inform the role of fronto-limbic function in 
PTD development. Lastly, all of these findings suggest new lines scientific inquiry about multiple 
potential therapeutic targets that have yet to be explored.   
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APPENDIX A 
A.1 VARIATION IN THE BDNF GENE INTERACTS WITH AGE TO PREDICT 
MORTALITY IN A PROSPECTIVE, LONGITUDINAL COHORT WITH SEVERE  
Published in Neurorehabilitation and Neural Repair (2014) 
Michelle D. Failla, BS1,2; Raj Kumar, MPH2; Andrew Peitzman, MD3; Yvette P. Conley, 
PhD4,5; Robert E. Ferrell, PhD5; Amy K. Wagner, MD1,2 
A.1.1 Abstract 
Background: Mortality predictions following traumatic brain injury (TBI) may be improved by 
including genetic risk in addition to traditional prognostic variables.  One promising target is the 
gene coding for brain-derived neurotrophic factor (BDNF), a ubiquitous neurotrophin important 
for neuronal survival and neurogenesis.  
Objective:  We hypothesized the addition of BDNF genetic variation would improve mortality 
prediction models and that BDNF Met-carriers (rs6265) and C-carriers (rs7124442) would have 
the highest mortality rates post-TBI.  
Methods: This study examined BDNF functional single nucleotide polymorphisms (SNPs) 
rs6265r (val66met) and rs7124442 (T>C) in relation to mortality in a prospective, longitudinal 
cohort with severe TBI.  We examined 315 individuals receiving care for a closed head injury 
within the University of Pittsburgh Medical Center, aged 16–79. Mortality was examined acutely 
(0-7 days post-injury) and post-acutely (8-365 days post-injury). A gene risk score (GRS) was 
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developed to examine both BDNF loci.  Cox proportional hazards models were used to calculate 
hazard ratios for survivability post-TBI while controlling for covariates.  
Results: BDNF GRS was significantly associated with acute mortality, regardless of age. 
Interestingly, subjects in the hypothesized no-risk allele group had the lowest survival probability. 
Post-acutely, BDNF-GRS interacted with age such that younger participants in the no-risk group 
had the highest survival probability, while older participants in the hypothesized no-risk group had 
the lowest probability of survival.  
Conclusions: These data suggest complex relationships between BDNF and TBI mortality that 
interact with age to influence survival predictions beyond clinical variables alone. Evidence 
supporting dynamic, temporal balances of pro-survival/pro-apoptotic target receptors may explain 
injury and age-related gene associations.  
A.1.2 Introduction 
In the US, ~52,000 deaths are attributed to traumatic brain injury (TBI) yearly (“CDC - Injury - 
TBI - TBI in the US Report,” n.d.). As TBI is a highly heterogeneous disease, it is difficult to 
predict immediate and long-term outcomes. Understanding factors that predict mortality post-TBI 
may improve treatment. With the recent focus on personalized medicine, this study utilizes a 
Rehabilomics (Wagner and Zitelli, 2012) approach, examining genetic factors that capture innate 
heterogeneity across recovery to improve mortality predictions beyond traditional prognostic 
factors.  
The International Mission on Prognosis and Analysis of randomized Controlled Trials in 
TBI (IMPACT) has demonstrated high predictability of post-TBI mortality/outcome using a core 
model of age, injury severity (motor subscale of the Glasgow Coma Scale, GCS (Teasdale and 
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Jennett, 1974a)), and pupillary reactivity (Maas et al., 2013). Further studies support extending 
this model by adding neurological findings (evidence of midline shift or presence of subarachnoid 
hemorrhage (Roozenbeek et al., 2012)). However, these studies have not examined genetic factors, 
nor have they addressed the possibility of evolving or dynamic predictors of mortality. As 
influences on mortality likely change across recovery, it is important to examine mortality 
predictors over time. 
Age is a consistent determinant of TBI survival. Older adults comprise a large segment of 
the population sustaining TBI with comparatively worse outcomes and higher mortality rates 
despite similar injury parameters (Susman et al., 2002).  This phenomenon may be due to adverse 
age effects on secondary injury cascades.  Older age leads to greater susceptibility to glutamate-
mediated oxidative stress and damage (Wagner et al., 2004). In experimental models, older animals 
show decreased neuronal survival post-injury (Onyszchuk et al., 2008).   
A ubiquitous neurotrophin in the brain, brain-derived neurotrophic factor (BDNF), may 
interact with age to influence TBI pathology. BDNF is important for synaptic plasticity, 
neurogenesis and neuronal survival (Z.-Y. Chen et al., 2004).  Yet in areas like the hypothalamus, 
BDNF can regulate metabolism (Kernie et al., 2000; Pelleymounter et al., 1995). Evidence 
suggests BDNF may also affect brainstem control of cardiovascular function (Brady et al., 1999; 
Wang and Zhou, 2002; Wan et al., 2014). Thus, BDNF may affect autonomic regulation and reflect 
the current energy state (Rothman et al., 2012), suggesting multiple mechanisms through which 
BDNF signaling could influence TBI mortality and recovery. While BDNF may affect mortality 
in other populations (Halldén et al., 2013; Krabbe et al., 2009; Ritter et al., 2012), no study has 
examined BDNF in mortality post-TBI.  
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BDNF signals through the tyrosine-related kinase-B (TrkB) receptor, full length (TrkB.FL) 
and truncated (TrkB.T), as well as the p75NTR receptor, activating antagonistic signaling cascades 
that are dependent on receptor milieu. Studies suggest TrkB.FL/TrkB.T/p75NTR expression ratios 
may vary across the lifespan (Croll et al., 1998) and following ischemia (Gomes et al., 2012).  
Similarly, there are dynamic receptor expression changes following experimental TBI (Rostami et 
al., 2013).  Thus, BDNF’s role in TBI recovery may be dependent on the relative balance of these 
target receptors.   
The BDNF gene has a common, functional, single nucleotide polymorphism (SNP), 
Val66Met (rs6265) that alters activity-dependent secretion of BDNF in vitro (Egan et al., 2003) 
and shows an age-dependent relationship in cognition (Erickson et al., 2012). Importantly, rs6265 
is in linkage disequilibrium (LD) with another BDNF SNP, rs7124442. The rs7124442 variant  
reportedly affects neuronal BDNF mRNA trafficking (Orefice et al., 2013). While rs6265 (Krueger 
et al., 2011) and rs7124442 (Rostami et al., 2011) have been associated with TBI recovery, no 
studies have examined how these variants influence other aspects of TBI recovery, specifically 
mortality. As rs6265 can influence hypothalamus-pituitary-adrenal (HPA) axis reactivity 
(Alexander et al., 2010; Shalev et al., 2009) and autonomic control of heart rate (A. C. Yang et al., 
2010), there may be important contributions for BDNF variants in TBI recovery outside of 
cognitive outcomes.  
We examined BDNF variation in survivorship post-TBI. We hypothesized that the Met-
allele (rs6265), with its decreased activity-dependent BDNF secretion, and the C-allele 
(rs7124442), with its impaired BDNF mRNA trafficking, would be risk alleles in mortality 
predictions. We chose to examine a cumulative gene risk score (GRS) incorporating variation at 
both loci when developing mortality prediction models. In this report, we demonstrate a dynamic, 
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temporal relationship between BDNF GRS and post-TBI survivorship. Our data show a BDNF 
gene risk relationship with survivorship 0-7d post-injury that is contrary to hypothesized 
relationships. Yet, when evaluating mortality models 8-365d post-injury, we show a BDNF 
age*GRS interaction in survivorship. These findings underscore the importance of understanding 
age and BDNF signaling relationships following TBI. 
Demographics 
This prospective cohort study was approved by the University of Pittsburgh Institutional 
Review Board. Enrollment criteria for this study included age, ≥16 and <75 years, and an 
admission GCS score ≤8 indicating severe TBI. Exclusion criteria included documented prolonged 
hypoxia prior to admission or a history of seizures. Subjects were consecutively recruited and 
consent obtained from a next of kin. To minimize genetic stratification effects,(Freedman et al., 
2004) associations are reported in Caucasians only (n=284, reported findings). Important for 
generalizability of findings, reported analyses in Caucasians-only were similar to results in the 
total population (n=315, data not shown). 
The analyzed cohort (284 participants) was aged 16–74 yrs. (mean: 35.96±15.46; 
median=33) with closed head injury receiving care within the University of Pittsburgh Medical 
Center (UPMC).  GCS scores (Teasdale and Jennett, 1974a) ranged from 3-15 (mean GCS: 
6.20±2.54; median=6) when using the best GCS obtained within 24 hours post-injury.  
Demographic information (age, race, sex, and mechanism of injury) was collected through clinical 
chart review and subject/caregiver interviews.  Age was treated as a continuous and categorical 
variable, split at the 75% quartile (Q3) of our population (above and below, Q3=45 yrs). By 365d 
post-injury, 25.8% of subjects had died and distribution of Glasgow Outcome Scale (GOS)(Wilson 
et al., 1998) scores for survivors was as follows: 2, n=13; 3, n=66; 4, n=49; 5, n=22. 
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Table 1. Complications categories. 
Category Complications Listed in Trauma Registry 
Pulmonary Acute Respiratory Distress Syndrome (ARDS) 
Acute Respiratory Failure 
Aspiration/ Pneumonia Atelectasis  
Pleural Effusion 
Pneumonia 
Pulmonary Embolus 
Bronchial Mainstem Intubation 
Acute Sinusitis 
Empyema 
Infection CNS Infection 
Sepsis/Septicemia 
Cardiovascular  Acute Arterial Occlusion 
Cardiopulmonary Arrest (not cause of death) 
Major Arrhythmia 
Myocardial Infarction  
Musculoskeletal Extremity Compartment Syndrome 
Hematological Coagulopathy 
Post-Operative Hemorrhage 
Renal Acute Renal Failure 
Renal Failure 
Urinary Tract Infection  
Wounds Wound Infection 
Decubitis Ulcer 
Wound Dehiscence 
Gastrointestinal C Difficile Colitis 
Esophageal Intubation 
GI Bleed 
Bowel Obstruction 
Pancreatitis 
Small Bowel Obstruction 
Neurological CNS Infection 
Diabetes Insipidus 
Neuro-sequelae  
Progression of Neurologic Insult 
Seizures 
 
The University of Pittsburgh Trauma Registry provided abstracted information from the 
acute care medical record regarding post-injury complications. These complications were 
categorized as: pulmonary, infection, cardiovascular, musculoskeletal, hematological, renal, 
wound, gastrointestinal, and neurological complications (Table 1).   
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Neurological injury assessments were abstracted from admission head CT reports and were 
categorized by the following injury subtypes: contusion, subdural hematoma, subarachnoid 
hemorrhage (SAH), intraventricular hemorrhage (IVH), intracranial hemorrhage (ICH), epidural 
hematoma (EDH), and diffuse axonal injury (DAI).  A neurological burden score (NBS) was 
calculated by summing injury types that significantly impacted survival for a given mortality 
group. NBS was only utilized in the acute mortality analysis and consisted of SDH, EDH, and 
contusion. For the post-acute mortality group, only the ICH category survived correction for age 
and GCS in Cox model predictions of survivorship. 
Seizure information was abstracted from available medical records and coded as time to 
first post-traumatic seizure (PTS), up to 365d post-injury.  Time to first seizure was divided into 
two groups, consistent with mortality cohorts and standard PTS nomenclature: acute (0-7d) and 
post-acute PTS (8-365d) (Temkin et al., 1990). Notation in medical records referring to 
convulsions, seizures, status epilepticus, or seizure disorder was documented as a PTS episode. 
Mortality 
Time until death was recorded in days post-injury, up to 1 year post-injury, using the Social 
Security Death Index.(“Social Security Death Index,” n.d.)  Mortality was evaluated over two 
time-epochs, 0-7d post-injury (acute) and 8d-365d post-injury (post-acute). For 0-7d, survivorship 
was right censored at 7d post-injury. For 8-365d, subjects were only included if they survived 
greater than 7d, and survivorship was right censored at 365d. For logistic regression and receiver 
operating curve (ROC) analysis, mortality was examined as a binary outcome at 7d post-injury 
(acute) and 365d post-injury (post-acute, excluding subjects who died before 7d). Acutely, 11.62% 
of subjects died (time until death: median=3d, min=0d, max=7d, Q1=2d, Q3=6d). An additional 
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14.16% died post-acutely (time until death: median=19d, min=8d, max=301d, Q1=11.5d, 
Q3=31d). 
Genotyping and SNP Selection 
DNA was isolated from blood using a simple salting out procedure(S.A. Miller et al., 1988) 
or from cerebrospinal fluid using the Qiamp protocol from Qiagen. BDNF rs6269 and rs7124442 
were genotyped by TaqMan allele discrimination assay using Assay on Demand reagents (Applied 
Biosystems). This assay utilized fluorescent labeled probes to detect allele(s) present for DNA 
sample.  All allele frequencies were in Hardy-Weinberg equilibrium.  
Selected SNPs (rs6265, rs7124442) have been reported as functional. Both SNPs have a 
minor allele frequency >20%. Each SNP represents a different haplotype block of BDNF covering 
variation corresponding to isoform a. A cumulative BDNF GRS was developed using rs6265 Met 
(Val/Met or Met/Met) and rs7124442 C (T/C or C/C) carrier status as hypothesized risk alleles 
based on the literature (Egan et al., 2003; Orefice et al., 2013). Thus, a GRS of 0 was the 
hypothesized no risk group (Val/Val, T/T); a GRS of 1 included carriers for 1 risk allele (Val/Val, 
C-carriers or Met-carriers, T/T); and a GRS of 2 included carriers of both risk alleles (Met-carriers, 
C-carriers).   
Statistical Analysis 
Analysis was conducted using Statistical Analysis Software (version 9.2; SAS Institute) 
and the Statistical Package for Social Sciences (version 21.0; SPSS).  Descriptive analysis included 
mean+standard deviation (STD) for continuous variables. Frequencies were calculated for 
categorical variables.  Genetic analysis utilized categorizations based on allele carrier status, and 
the BDNF GRS was used to examine cumulative genetic risk associations with mortality. 
Demographic and clinical information was compared with mortality status and genotype using 
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Student’s t-tests and ANOVA (Mann-Whitney or Kruskal-Wallis where appropriate) to compare 
means, and Chi-Square or Fisher’s Exact test to compare frequencies.   
Demographic, clinical, and genotype information was examined for survivorship 
associations using either a Kaplan-Meier or Cox proportional hazards model (Cox, 1972).  The 
Log-rank test was used to determine significant differences between two survival curves 
(significant if p<0.05). To control for covariates, we used multivariate Cox proportional hazards 
regression.  Demographic and clinical variables remained in the final Cox models if they survived 
correction for age and GCS (p≤0.2). The proportionality of hazards assumption was tested and 
confirmed for relevant variables.   
Mortality status was examined using multivariate receiver operating curve (ROC) analysis 
to quantify model prediction capacity and to relate to published studies (Roozenbeek et al., 2012). 
Mortality was assessed at 7d and 365d post-injury. Using area under the curve (AUC), ROCs 
estimated incremental increases in model sensitivity and specificity gained when including GRS 
and/or GRS interactions, compared to base models of relevant clinical variables. Base models were 
compared to final models using a chi-square test for significant differences in AUC (p<0.05 
considered significant).   
A.1.3 Results 
Genetic Associations with Demographics 
 
Table 2. Demographic variables by genotypes. 
 
Rs6265 Rs7124442 
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Val/Val 
(n=170) 
Val/Met, 
Met/Met 
(n=114) 
p 
value 
C/C, C/T 
(n=126) 
T/T 
 (n=158) 
p value 
Age 35.55±15.48 36.57±15.46 0.962 33.38±14.02 38.01±16.25 0.011 
Gender 
(% Male)  134 (78.8%) 96 (84.2%) 0.283 102 (80.9%) 128 (81.0%) 0.989 
Mechanism of Injury  0.779  0.776 
Automobile/ 
Motorcycle 128 (75.3%) 85 (75.2%)  97 (77.0%) 116 (73.9%)  
Fall/Jump 25 (14.7%) 19 (16.8%)  19 (15.1%) 25 (15.9%)  
Other 17 (10.0%) 9 (8.0%)  10 (7.9%) 16 (10.2%)  
GCS 6 6 0.678 6 6 0.368 
Length of 
Hospital Stay 
(days) 19.72 ± 11.38 21.02 ± 12.32 0.517 19.32 ± 11.69 20.99 ± 11.80 0.306 
ISS 35.17 ± 10.01 34.69 ± 8.91 0.625 35.04 ± 9.26 34.92 ± 9.83 0.925 
Seizures 25 (14.8%) 15 (13.8%) 0.697 14 (11.2%) 26 (16.5%) 0.208 
Complication Type (% Present) 
Pulmonary 108 (63.5%) 63 (55.3%) 0.175 75 (59.5%) 96 (60.8%) 0.833 
Infection 32 (15.3%) 29 (25.4%) 0.471 31 (24.6%) 34 (21.5%) 0.538 
Cardio-
vascular 6 (3.5%) 7 (6.1%) 0.387 4 (3.2%) 9 (5.7%) 0.312 
MSK 3 (1.80%) 0 (0%) 0.227 2 (1.6%) 1 (0.6%) 0.434 
Heme 27 (15.9%) 12 (10.5%) 0.222 13 (10.3%) 26 (16.5%) 0.135 
Renal 23 (13.5%) 16 (14.0%) 0.999 19 (15.1%) 20 (12.7%) 0.556 
Wounds 8 (4.7%) 11 (9.6%) 0.145 10 (7.9%) 9 (5.7%) 0.453 
GI 18 (10.6%) 9 (7.9%) 0.538 14 (11.1%) 13 (8.2%) 0.411 
Neuro 29 (17.9%) 22 (19.3%) 0.639 22 (17.5%) 29 (18.4%) 0.845 
Neurological Injury Type (% Present) 
SDH 107 (62.9%) 73 (64.0%) 0.900 82 (65.1%) 98 (62.0%) 0.596 
DAI 51 (30.0%) 33 (28.9%) 0.895 45 (35.7%) 39 (24.7%) 0.043 
EDH 22 (12.9%) 23 (20.2%) 0.135 21 (16.7%) 24 (15.2%) 0.735 
Contusion 76 (44.7%) 60 (52.6%) 0.226 62 (49.2%) 74 (46.8%) 0.691 
IVH 44 (25.9%) 36 (31.6%) 0.346 35 (27.8%) 45 (28.5%) 0.896 
ICH 67 (39.4%) 37 (32.5%) 0.259 44 (34.9%) 60 (38.0%) 0.596 
SAH 116 (68.2%) 74 (64.9%) 0.608 87 (69.0%) 103 (65.2%) 0.493 
 
 
 
Demographic distributions were examined for both BDNF loci (Table 2). The mean age 
for T/T homozygotes (rs7124442) was higher versus C-carriers (38.0±16.3 versus 33.4±14.0, 
  193 
p=0.011). DAI was less common among T/T homozygotes versus C-carriers (24.7% vs. 35.7%, 
p=0.043).  However, subjects with DAI were significantly younger compared to subjects without 
DAI (28.7±11.9 vs. 39.0±15.8, p=0.038).  There were no demographic variable differences by 
rs6265 Met-carrier status. 
Mortality Associations with Demographics 
Demographic associations with acute/post-acute mortality and survivorship were examined 
(Table 3).  Survivors had lower mean age (all group, p<0.001) and higher GCS scores (all group, 
p=0.002) compared to non-survivors. In Cox proportional hazards regression, age and GCS 
predicted survival probability for both 0-7d and 8-365d models (p<0.03, all comparisons). 
Pulmonary (adjusted for age, GCS: p<0.001, HR=0.156) and cardiac (adjusted for age, GCS: 
p=0.196, HR=2.065) complications survived correction for age and GCS (p<0.2) and were added 
to the overall models for acute survival. Pulmonary complications were less frequent in subjects 
who died acutely (Table 3), but subjects with pulmonary complications were significantly younger 
than those without pulmonary complications (34.1±15.1 versus 38.8±15.6, p=0.009). Cardiac 
complications were more frequent in subjects who died acutely compared to survivors (12.1% vs. 
2.8%, all group, p=0.026).  For the 8-365d model, a wound complication (adjusted for age, GCS: 
p=0.020, HR=2.857) was the only complication to significantly predict survival probability. 
While there were no differences in frequency of radiological findings between acute and 
post-acute mortality groups, there were significant associations with survivorship. For the 0-7d 
model, the NBS (including SAH, epidural hematoma, and contusion; range of 0-3), tended to 
predict survivorship (corrected for age, GCS: p=0.046, HR=1.379). SAH and contusions were 
more frequent in subjects who died (0-7d or 8-365d) versus survivors (Table 3). For the 8-365d 
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model, those with ICH tended to have higher survival frequencies (age and GCS corrected, 
p=0.079, HR=0.541).  
 
Table 3: Demographic information across mortality groups (acute, post-acute, and 
survivor).(Kruskal-Wallis, Fischer’s Exact, significance at p<0.05) 
Variable 
Acute  
Mortality  
(0-7d, n=33) 
Post-Acute 
Mortality  
(8-365d, n=40) 
Survivors  
(at 365d, 
n=211) 
All 
Groups 
(p value) 
Age, years (mean±STD) 42.69±17.30 47.5±16.39 32.72±13.54 <0.001 
Gender (n, % Male)  23 (69.7%) 31 (77.5%) 176 (83.4%) 0.141 
Mechanism of Injury (n, %)  0.004 
Automobile/Motorcycle 17 (51.5%) 27 (67.5%) 169 (80.5%)   
Fall/Jump 13 (39.4%) 9 (22.5%) 22 (10.5%)   
Other 3 (9.1%) 4 (10.0%) 19 (9.0%)   
GCS, median 5 6 6 0.002 
ISS, mean ± STD 35.61±10.86 36.58 ± 9.89 34.57±9.29 0.589 
Length of Hospital Stay,  
days, mean±STD 
3.82±2.42 18.62±8.63 23.24±10.92     <0.001 
Seizures 1 (3.0%) 4 (10.0%) 35 (16.5%) 0.081 
Complication Type (% Present)  
Pulmonary 8 (24.2%) 28 (70.0%) 135 (64.0%) <0.001 
Infection 4 (12.1%) 10 (25.0%) 51 (24.2%) 0.293 
Cardiovascular 4 (12.1%) 3 (7.5%) 6 (2.8%) 0.026 
Heme 4 (12.1%) 4 (10.0%) 31 (14.7%) 0.844 
Renal 3 (9.1%) 6 (15.0%) 30 (14.2%) 0.746 
Wounds 0 (0%) 6 (15.0%) 13 (6.2%) 0.037 
GI 0 (0%) 3 (7.5%) 24 (11.4%) 0.093 
Neuro 6 (18.2%) 10 (25.0%) 35 (16.6%) 0.440 
Neurological Injury Type (% Present)  
SDH 23 (69.7%) 28 (70.0%) 129 (61.1%) 0.254 
DAI 5 (15.2%) 7 (17.5%) 72 (34.1%) 0.074 
EDH 2 (6.1%) 6 (15.0%) 37 (17.5%) 0.291 
Contusion 21 (63.6%) 24 (60.0%) 91 (43.1%) 0.004 
IVH 7 (21.2%) 14 (35.0%) 59 (28.0%) 0.338 
ICH 12 (36.4%) 14 (35.0%) 78 (37.5%) 0.947 
SAH 29 (87.9%) 30 (75.0%) 131 (62.1%) 0.005 
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Figure 1. Kaplan-Meier curves show survivorship probabilities stratified by BDNF GRS. 
Kaplan-Meier curves stratified by BDNF GRS at (A) 0-7d (GRS, p=0.144) and (B) 8-365d (GRS, 
p=0.134). GRS was significant in the Cox model for acute mortality, correcting for covariates. The 
post-acute (8-365d) is further examined in age cohorts split at age 45, (C) <45 (GRS, p=0.006) 
and (D) ≥45 (GRS, p=0.106).  The GRS*age interaction was significant in the Cox model for post-
acute mortality, correcting for covariates (Gene risk score, GRS: GRS=0, Val/Val, T/T; GRS=1, 
Val/Val, C-carriers or Met-carriers, T/T; GRS=2, Met-carriers, C-carriers).   
Genetic Associations with Mortality 
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Kaplan-Meier curves reflecting mortality 0-7d post-injury tended to have different 
survivorship probabilities based on BDNF GRS (p=0.144, Figure 1A). Those with a GRS=0 
hypothesized risk alleles had the lowest probability of survival.  Multivariate Cox regression 
predicting survivorship 0-7d post-injury showed BDNF GRS became significant after adjusting 
for age, GCS, NBS, pulmonary complications, and cardiac complications (Table 4A).  Those with 
a GRS of 1 or 2 had a higher probability of survival compared to those with a GRS of 0 (GRS=1, 
p=0.0107, HR=0.351, 95% CI: 0.157-0.784; GRS=2, p=0.0286, HR=0.349, 95% CI: 0.136-0.895). 
For 8-365d post-injury, there was a trend for different survivorship probabilities based on BDNF 
GRS (p=0.134, Figure 1B), where those with a GRS=0 had the highest survival probability. In 
this case, multivariate Cox regression demonstrated that this trend for BDNF GRS did not survive 
covariate adjustment (Table 4B).  
Next, age*GRS interactions with survival probability were examined. There was no 
significant age*GRS interaction in 0-7d survivorship probability (data not shown). However, 
Table 4C shows a significant age*GRS interaction for 8-365d survivorship (Age*GRS interaction, 
p=0.0003, HR=0.933, 95% CI: 0.898-0.968).  To increase the interpretability of this interaction, 
we tested the relationship of GRS with survivorship prediction in 8-365d post-injury across 
different age cut-points. The population was stratified, below and above Q3 (age=45), and GRS 
was examined in Kaplan-Meier curves for the two age strata. Among participants <45 years, GRS 
associations with survivorship demonstrated that those with a GRS=0 had the highest probability 
of survival (p=0.006), while participants >45 with a GRS=0 had the lowest survivorship 
probability (p=0.106) (Figure 1C-D).  
 
Table 4: Cox Model of BDNF Gene Risk Score (GRS 
  197 
Variable 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p value 
Hazard 
Ratio 
95% Hazard Ratio 
CI# 
A. BDNF GRS predicting time until death, 0-7d post-injury (n=279, with 33 events) 
Age 0.02419 0.01118 4.6814 0.0305 1.024 (1.002 - 1.047) 
GCS* -0.35982 0.08939 16.2041 <0.0001 0.698 (0.586-0.831) 
NBS¥ 0.47135 0.23476 4.0312 0.0447 1.602 (1.011-2.538) 
Pulmonary 
Complication 
-2.16656 0.43392 24.9300 <0.0001 0.115 (0.049-0.268) 
Cardiac 
Complication 
1.69773 0.59712 8.0839 0.0045 5.462 (1.695-17.603) 
GRS (1 risk 
SNP)** 
-1.04771 0.41069 6.5081 0.0107 0.351 (0.157-0.784) 
GRS (2 risk 
SNP)** 
-1.05395 0.48134 4.7944 0.0286 0.349 (0.136-0.895) 
B. BDNF GRS predicting time until death, 8-365d post-injury (n=246, with 39 events) 
Age 0.07138 0.01113 41.1539 <0.0001 1.074 (1.051-1.098) 
GCS* -0.29592 0.07565 15.3018 <0.0001 0.744 (0.641-0.863) 
Intracranial 
Hemorrhage 
-0.65714 0.35339 3.4578 0.0630 0.518 (0.259-1.036) 
Wound 
Complication 
1.08121 0.45695 5.5986 0.0180 2.948 (1.204-7.220) 
GRS (1 risk 
SNP)** 
0.35669 0.48177 0.5482 0.4591 1.429 (0.556-3.673) 
GRS (2 risk 
SNP)** 
0.36536 0.51130 0.5106 0.4749 1.441 (0.529-3.925) 
C. BDNF GRS x Age interaction predicting time until death, 8-365d post-injury (n=246, with 39 
events) 
Age 0.13921 0.02388 33.9730 <0.0001 1.149 (1.149-1.204) 
GCS* -0.27425 0.07230 14.3896 0.0001 0.760 (0.660-0.876) 
Intracranial 
Hemorrhage 
-0.53117 0.35590 2.2274 0.1356 0.588 (0.293-1.181) 
Wound 
Complication 
1.22736 0.46444 6.9838 0.0082 3.412 (1.373-8.479) 
GRS (1 risk 
SNP)** 
2.90541 1.00668 8.3298 0.0039 18.273 (2.540-131.428) 
GRS (2 risk 
SNP)** 
5.46647 1.68218 10.5601 0.0012 236.62 (8.754-6396.365) 
GRS x Age 
Interaction 
-0.05889 0.01791 10.8113 0.0010 0.943 (0.910-0.976) 
 * GCS (Glasgow Coma Scale, Best in 24 hours) 
 ¥ Neurological Burden Score 
 **GRS (0 risk SNP) was the reference category 
 # CI: Confidence Interval 
 
 
We further validated these models in multivariate ROC examining post-TBI mortality 
status.  Using a similar censorship strategy and covariate selection as with our Cox models, we 
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examined mortality status for acute (0-7d) and post-acute (8-365d) mortality. The 0-7d base model 
had an AUC=0.8412. The addition of BDNF GRS and a GRS*age interaction did not significantly 
improve this model. The 8-365d base model (excluding subjects who died in the acute phase) had 
an AUC=0.836. The addition of the GRS*age interaction increased the AUC above the base model 
(from 0.836 to 0.876, p=0.021, Figure 2). 
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Figure 2. Receiver operating curves of GRS models in acute (0-7d) and post-acute (8-365d) 
mortality.  
 (A) Mortality at 7d. The base model of age, GCS, pulmonary complications, cardiac 
complications, and neurological burden score did not differ from the base model+GRS 
(AUC=0.8412, 0.8532; p=0.501) or base model+GRS*age (AUC=0.8412, 0.8571; p=0.664). (B) 
Mortality at 365d (excluding subjects who died <7d). The AUC of the base model of age, GCS, 
wound complications and ICH plus the GRS*age interaction (base model+GRS*age, AUC=0.876) 
was increased from the base model (AUC=0.836, p=0.021) and the base model+GRS 
(AUC=0.844, p=0.248). (AUC, area under the curve; GCS, Glasgow Coma Score; Gene risk score, 
GRS: GRS=0, Val/Val, T/T; GRS=1, Val/Val, C-carriers or Met-carriers, T/T; GRS=2, Met-
carriers, C-carriers). 
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A.1.4 Discussion 
This study demonstrates important gene and gene*age interactions with BDNF in post-TBI 
mortality.  First, we identified a dynamic temporal relationship between BDNF and survival. 
Second, we showed the hypothesized BDNF gene risk relationship to mortality is not supported 
acutely (0-7d post-injury), as the hypothesized no risk group had the lowest survival probability.  
Third, we demonstrated BDNF genetics interacts with age to inform survivorship predictions 8-
365d post-injury. Here, the hypothesized risk relationship was supported in younger individuals, 
while older individuals maintained a similar risk pattern to that observed acutely. We speculate 
dynamic relationships between BDNF and mortality risk post-TBI may be attributable to age and 
injury effects on BDNF target receptors. Other actions of BDNF in autonomic function and other 
body systems may also impact its role in TBI-related mortality.  
These unique relationships between BDNF and TBI mortality may be related to specific 
alterations in target receptor milieu with regard to TBI and age. BDNF, first synthesized as 
proBDNF, is processed either in the soma, extracellular space (after release), or dendrites (after 
endocytosis) (Barker, 2009).  If not cleaved, proBDNF targets the pro-apoptotic p75NTR receptor, 
(Barrett, 2000) while mature BDNF initiates pro-survival signaling through the full length TrkB 
receptor (TrkB.FL). Following experimental TBI, tissue plasminogen activator (tPA), an enzyme 
that cleaves proBDNF, shows increased activity ipsilateral to the injury (Sashindranath et al., 
2011) and mice lacking tPA show reduced edema and cortical lesion volume (Mori et al., 2001).  
Additionally, there are two truncated isoforms of TrkB, TrkB.T1 and TrkB.T2, which lack 
intracellular tyrosine signaling, but are implicated in other pathways (Gomes et al., 2012; Vidaurre 
et al., 2012). In experimental TBI, there are transient increases in hippocampal TrkB.FL; this study 
also showed regionally-specific p75NTR increases up to 8 weeks post-TBI (Rostami et al., 2013).  
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Although controversial, the ratio of TrkB.FL/Trk.T expressed has been suggested to influence cell 
survival during excitotoxic injury (Gomes et al., 2012),(Vidaurre et al., 2012). Other studies report 
pre-incubation with BDNF prior to excitotoxic conditions/insults may be neuroprotective 
(Almeida et al., 2005; Lindvall et al., 1994), but this effect is likely receptor-dependent. As studies 
demonstrate transient increases in hippocampal BDNF transcription immediately following 
experimental TBI (Hicks et al., 1997; Rostami et al., 2013), followed by chronically decreased 
levels,31 understanding temporal receptor expression changes may be critical in TBI.   
Under the assumption that mature BDNF-TrkB.FL signaling is the primary action in 
adults,(Matsumoto et al., 2008) our risk allele assignment was based on the hypothesis that lower 
BDNF signaling would result in reduced pro-survival signaling and negatively impact survival.  
Thus, it would be reasonable to suggest lower BDNF signaling prior to/during an injury would 
exacerbate neuronal death post-TBI via reduced pro-survival signaling. However, the genetic 
variant hypothesized to increase BDNF activity-dependent secretion (Val/Val, rs6265) was 
associated with increased acute (0-7d) mortality risk. Consistent with animal literature (Rostami 
et al., 2013), this relationship may be the result of an injury-specific balance of BDNF’s target 
receptors, with relative increases in TrkB.T or p75NTR compared to uninjured adults. 
We show an important age*gene interaction with the BDNF GRS in post-acute mortality 
prediction. One explanation for age-specific risk profiles is differential expression patterns of 
target receptors across aging (Croll et al., 1998; Tapia-Arancibia et al., 2008),  Romanczyk et al 
reports dynamic prefrontal cortex TrkB expression across the lifespan, with a peak in young to 
middle adulthood that decreases with age (Romanczyk et al., 2002). Webster et al reported similar 
TrkB expression patterns in the hippocampus and temporal lobe (Webster et al., 2006).  Compared 
to young adult rats, aged rats have reduced TrkB.FL, but not TrkB.T,(Silhol et al., 2005) altering 
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receptor ratios.  Post-TBI, an age-specific shift in the balance of BDNF receptor ratios, from pro-
survival to pro-apoptotic, could diminish recovery. Thus, older individuals with BDNF genotypes 
associated with higher baseline BDNF signaling may have a disadvantage.  
This study focuses on two variants, rs6265 and rs7124442.  While the rs6265 Met-allele 
impairs secretion and intracellular processing of mature BDNF in hippocampal neurons,(Egan et 
al., 2003) there is currently no evidence that it alters proBDNF/BDNF ratios. The rs7124442 C-
allele reduces BDNF mRNA trafficking from the soma to dendrites in hippocampal cultures.20  
Given that studies suggest BDNF mRNA translated in dendrites are more likely to be secreted in 
the proBDNF form (An et al., 2008), it is possible rs7124442 alters proBDNF/BDNF ratios. While 
these variants are hypothesized to affect BDNF signaling, it is unclear if this remains true with age 
or injury. We suggest these variants are indicative of variability in neurotrophic support post-
injury, and thus, may interact with receptor expression to produce TBI-specific dynamic risk 
profiles.   
Previous studies with the BDNF gene suggest it interacts with age and environment to 
affect cognitive function (Kaplan et al., 2010). One study showed Met-carriers, despite 
theoretically lower activity-dependent BDNF secretion, have greater cognitive recovery following 
penetrating TBI decades after injury (Krueger et al., 2011). These data are part of a growing 
literature demonstrating TBI-specific risk genetic relationships in TBI outcomes (Failla et al., 
2013; Graham et al., 2013; Wagner et al., 2012).  However, in contrast to our findings, BDNF 
variation has also been examined in stroke, where the Met-allele was linked to poor recovery, 
regardless of age (Siironen et al., 2007), though it is unclear if age interactions were explored in 
this relatively older population compared to our cohort.  However, a preclinical study examining 
Val66Met in a rodent stroke model showed the Met-allele enhanced motor recovery chronically, 
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further supporting the concept of injury-specific associations for this variant.(Qin et al., 2014) Yet 
these studies focused on cognitive/plasticity effects of BDNF. It will be important to understand 
regional and temporal roles for BDNF in recovery or rehabilitation-based interventions compared 
to mortality risk.  
In addition, BDNF can regulate energy metabolism and autonomic function. Evidence 
suggests that BDNF may be involved in brainstem regulation of cardiovascular function.(Brady et 
al., 1999; Wang and Zhou, 2002; Wan et al., 2014)  Similarly, BDNF modulates the 
sympathetic/parasympathetic balance in cardiovascular function (Yang et al., 2002).   
Interestingly, rs6265 is associated with differences in heart rate variability(A. C. Yang et al., 2010) 
and acute stress heart rate reactivity in healthy populations (Alexander et al., 2010). In fact, one 
study showed that local BDNF administration following surgical sympathectomy induced 
hippocampal vascular changes and edema (Kasselman et al., 2006). This study suggests BDNF 
effects during a state of compromised autonomic function (e.g. immediately following TBI 
(Goldstein et al., 1998)) could impact TBI pathology, particularly at early time-points when 
mortality rates are highest. There is a dearth of research about BDNF function outside of cognition 
or plasticity post-TBI, limiting speculation about how BDNF and CNS-peripheral modulation of 
autonomic function post-TBI might occur. It is also not clear how age may interact with BDNF in 
autonomic regulation.   
Our data also suggest temporally specific prognostic factors for mortality across recovery. 
Many TBI survival studies use a cross-sectional approach to mortality.  Our results suggest there 
are different factors contributing to mortality predictions over time that are not captured within the 
current literature.  Acutely, a higher NBS significantly reduced survivorship probability, consistent 
with published studies showing the addition of neuroradiological findings improves mortality 
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prediction (Roozenbeek et al., 2012). While pulmonary complications occur less frequently in 
survivors, subjects with pulmonary complications also were significantly younger, consistent with 
published studies in TBI (Rincon et al., 2012). However, pulmonary complication effects were 
independent of age. One consideration for this finding is the possibility that there is a delayed onset 
for pulmonary complications, such as acute respiratory distress syndrome (ARDS), that may be 
secondary to TBI-specific ICP management, and thus, may not be a large negative factor within 
acute mortality models (Contant et al., 2001).  Also, cardiac complications were a negative 
predictor of survival acutely. GCS was a significant factor in mortality predictions, consistent with 
previous studies on the relationship of injury severity to mortality post-TBI (Roozenbeek et al., 
2012). 
Subjects in the post-acute survival model had a median time until death of 19d, suggesting 
that in this early post-acute time frame there are unique factors in mortality prediction. Early post-
traumatic seizures were not related to mortality predictions in acute cohort. Yet, acute seizure 
occurrence negatively impacted survivorship post-acutely, consistent with epidemiological studies 
linking seizures to higher mortality risk after TBI (Harrison-Felix et al., 2006), suggesting the 
pathology associated with early seizures is also relevant to post-acute mortality. Subjects with 
wound complications had reduced survival probability, likely reflecting other important 
health/recovery factors, such as mobility, as contributing post-acute mortality risk (Zhan C and 
Miller MR, 2003). Wounds may also be a surrogate measure for infections or sepsis that could 
impact mortality post-TBI. Subjects with ICH had a higher probability of survival post-acutely 
compared to those without ICH. As these subjects survived acutely, they were likely monitored 
closely for surgical intervention, standard care that may have increased survival probability post-
acutely.   
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This study also shows that, in our post-acute model, our GRS significantly added 
prognostic capacity to the base mortality model. While different cohorts, assessed over different 
time-frames, our AUC displays better mortality discrimination ability compared to previously 
published prediction models that include age, GCS, and pupil dilation only (AUC=0.787 
(Roozenbeek et al., 2012)). Further, the use of Cox models strengthens our survivorship 
predictions. These data suggest that, while clinical variables (eg. GCS) inform outcome, genetic 
factors can influence mortality predictions beyond what standard clinical variables are able to 
accomplish, particularly for the post-acute period when most primary neurological injury effects 
on mortality outcomes have already occurred. While novel and promising prognostic models, these 
findings need validation in independent studies with larger populations. 
There are some limitations in interpretation and generalizability to consider. While BDNF 
is primarily expressed in the brain,33 BDNF is also synthesized and secreted from vascular 
endothelial cells and may have a peripheral action (see review, Caporali et al (Caporali and 
Emanueli, 2009)). Also, there is a substantial peripheral store of BDNF in platelets,51 yet it is 
unclear if platelet release is altered in TBI. One study suggests plasma BDNF levels predict 
mortality in ICU patients without direct brain injury, but the mechanism of this association is 
unclear(Ritter et al., 2012). Plasma BDNF levels were also related to all-cause mortality in a cohort 
of older women (Krabbe et al., 2009). With altered metabolic homeostasis immediately following 
TBI, there may be a vascular action of BDNF that could influence mortality.  
There are some additional considerations in this study as it uses a candidate gene approach. 
The study findings are specific to a racially homogenous population, though models incorporating 
our small population with other racial backgrounds were stable with similar results as reported 
(data not shown).  Future studies should evaluate BDNF risk in populations with diverse racial 
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backgrounds to increase generalizability to the TBI population. The variants studied also had 
relatively low frequency for some genotypes, warranting a carrier approach, similar to published 
Val66Met studies (Krueger et al., 2011; Shalev et al., 2009).  Similarly, these variants only cover 
the most well-studied isoform of BDNF, yet emerging research indicates that there are multiple 
isoforms for BDNF (Pruunsild et al., 2007). Future research may require additional genotyping to 
assess the relevance of these isoforms on TBI pathology and outcome prognostication.  
Future studies may examine how these findings relate to other genetic variants such as 
apolipoprotein E(APOE) that have shown associations to TBI mortality.(Teasdale et al., 2005) It 
was also difficult to examine genetic relationships to injury type given the severity of injury in this 
cohort, as many subjects showed multiple injury sub-types.  As we do not have specific cause of 
deaths for this study, future studies may examine specific cause of death relationships to genetic 
risk. 
Importantly, this study implicates BDNF signaling in TBI mortality prediction, supporting 
the need for validation studies and a better understanding of BDNF signaling post-TBI across body 
systems. This work supports the need for examination of specific regional 
TrkB.FL/TrkB.T/p75NTR receptor ratios in experimental TBI models and post-mortem tissue.  As 
serum BDNF is decreased acutely in clinical TBI (Kalish and Phillips, 2010), future studies may 
investigate BDNF as a biomarker, with age/gene variation as possible BDNF modifiers post-TBI. 
Future studies focusing on the dynamic roles of BDNF in mortality compared to rehabilitation and 
recovery following TBI are needed and may yield different associations reflective of unique 
pathology and/or recovery mechanisms.  
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A.2 COMT VAL158MET GENOTYPE AND SEX INTERACT TO AFFECT 
COGNITIVE DYSFUNCTION AFTER TBI  
John M. Myrga1, Michelle D. Failla, BS1,2, Joseph H. Ricker, PhD3, C., Yvette P. Conley, PhD4,5, 
Patricia M. Arenth, PhD1, Amy K. Wagner, MD1,2,6 
A.2.1 Introduction 
With over 1.7 million traumatic brain injuries (TBI) each year, 17-23% of which are 
moderate-severe, it is important to understand how these injuries impact patient outcomes(“CDC 
- TBI in the US Report - Traumatic Brain Injury - Injury Center,” n.d.). A major area of concern 
for individuals with TBI is cognitive dysfunction(Arciniegas, 2002). Those with moderate-severe 
TBI often exhibit cognitive dysfunction lasting 6 months or longer, which can significantly impact 
functional recovery, supervision needs, and caregiver burden of individuals post-TBI(Levin et al., 
1979). Another important issue when attempting to discern prognosis for recovery and cognitive 
dysfunction is the variability observed in individuals who have similar injury complexes and 
clinical care factors.  Variation in personal biology as it relates to overall recovery, 
biosusceptibility to complications, and individual prognosis is a relatively contemporary concept 
in TBI research, and this variability can be examined through a Rehabilomics framework to 
determine the role of biomarkers, as surrogate markers of personal biology, in categorizing these 
diverse outcomes.  A growing body of work suggests that analyzing how genetic heterogeneity 
affects biological systems of interest is an important application of the Rehabilomics model and 
may elucidate genetic contributions to cognitive dysfunction following TBI(A. K. Wagner, 
2010),(Wagner and Zitelli, 2013). 
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One important neurotransmitter system that modulates cognition is the dopamine (DA) 
system. DA systems, particularly those involving the prefrontal cortex (PFC), influences executive 
function, memory consolidation, verbal language skills, and attention.  PFC DA release is 
regulated primarily by the mesocortical pathway, which contains DA neurons that project from the 
ventral tegmental area (VTA) to the dorsolateral pre-frontal cortex (PFC) (Seamans and Robbins, 
2010). Recent studies in healthy and diseased populations have suggested an important role for 
DA in cognitive outcomes (Seamans and Robbins, 2010). The “inverted U” hypothesis further 
states that too much or too little DA can negatively impact cognition via D1 receptors, particularly 
in the context of ADHD and other pathological conditions (Cools and D’Esposito, 2011b). 
Mounting evidence within animal models of TBI suggests that functional hypodopaminergia can 
occur after TBI (James W. Bales et al., 2009) and we hypothesize that DA dysfunction post-injury 
may be further affected by genetic variation.  Currently published work implicates genetic 
variation within the DA transporter (DAT) as influencing both acute (Shimada et al., 2014b),(Hong 
Qu Yan et al., 2002),(Amy K. Wagner et al., 2007b) and chronic DA relevant pathology (Amy K. 
Wagner et al., 2014).  In addition, genetic variation within the ANKK1 Taq1a polymorphism has 
been implicated as affecting both striatal DA physiology and cognition during the first year after 
moderate to severe TBI(Failla et al., n.d.) 
In TBI-specific studies, Bales et al summarizes clinical and experimental data showing 
efficacy with DA treatments in addressing cognitive dysfunction and in further supporting a DA 
hypothesis for providing clinical treatments that address cognitive dysfunction (James W. Bales et 
al., 2009). This knowledge has translated to clinical care, with multiple DA agonists considered as 
potentially effective agents in treating cognitive dysfunction after TBI (Neurobehavioral 
Guidelines Working Group et al., 2006). However, it is unknown which patients would most 
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benefit from such treatments; additional knowledge about DA system genetic heterogeneity and 
its effects on endogenous DA function may further refine our understanding of which individuals 
might benefit the most from specific DA therapies.  
In addition to controlled DA release from VTA projection neurons, the brain has other 
mechanisms that modulate DA levels. Most brain regions use DAT as the primary method of DA 
removal from the synapse (Ciliax et al., 1995). In the PFC, DAT expression is lower than structures 
like the striatum (Sesack et al., 1998) so DA clearance is primarily mediated by the enzyme 
catechol-o-methyltransferase (COMT) encoded by the COMT gene(Jingshan Chen et al., 2004). 
COMT inactivates catecholamines through the addition of a methyl group. Within COMT, there 
exists a well-characterized functional single-nucleotide polymorphism, which causes a substitution 
from valine to methionine at position 158. Studies have shown that Val158Met (rs4680) 
substitution leads to instability of the enzyme and up to a 40% decrease in enzyme activity, 
resulting in higher levels of DA available at PFC synapses for those carrying either one or two Met 
alleles (Männistö and Kaakkola, 1999).  In addition to the importance of COMT to PFC DA levels, 
studies have suggested COMT may play a role in altering tonic DA levels that impact subcortical 
regions of the brain such as the hippocampus and striatum (Robert M Bilder et al., 2004). 
In healthy populations, the Val158Met variation can modulate behavioral and cognitive 
functioning (Malhotra et al., 2002).  Val-carriers have increased enzyme activity, leading to lower 
DA levels, and often perform worse on memory tasks (Egan et al., 2001). However, Val-carriers 
have greater levels of cognitive flexibility and less anxiety (Bellander et al., 2014). The Met allele, 
with greater synaptic DA levels, has been associated with greater baseline cognitive scores on 
memory but lower levels of cognitive flexibility (Mattay et al., 2003). Few studies have studied 
the relationship between Val158Met and cognition in a TBI population. Lipsky et al showed that 
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Met/Met homozygotes performed better than Val/Val homozygotes on perseverative responses in 
a 113 participant, predominantly male military population (Lipsky et al., 2005b).  However, 
Willmott and colleagues did not find significant differences between genotype status and various 
cognitive outcomes measures in a 223 participant study that included women and men evaluated 
at an early time point following TBI (Willmott et al., 2014b). 
Since studies have indicated a sex based dimorphism within the DA system (Munro et al., 
2006),(Becker, 1999), recent work has considered the possibility of a Val158Met interaction with 
sex affecting outcomes. Significant sex and Val158Met genotype interactions have been 
demonstrated when investigating sensation seeking personality traits(Lang et al., 2007a) and risk-
taking propensity in youth (Amstadter et al., 2012). Various studies have also shown the potential 
of a DAergic gene – sex interaction in cognition in both healthy and diseased populations (Harrison 
and Tunbridge, 2007),(Soeiro-De-Souza et al., 2013),(Amy K. Wagner et al., 2007a). Jacobs and 
Esposito have further reported that Val158Met status has an important role in understanding the 
observed impact of estradiol on cognition(Jacobs and D’Esposito, 2011). We investigated a 
potential gene x sex interaction in a TBI specific population to further elucidate the role of the 
Val158Met mutation on multiple domains of cognitive performance as well as functional cognitive 
impairment. 
A.2.2 Methods 
Participants 
106 participants were recruited from both inpatient and outpatient clinics located at the 
University of Pittsburgh Medical Center (UPMC) as part of a larger genetic TBI study approved 
by the University of Pittsburgh Institutional Review Board. Enrollment criteria for this study 
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included a non-penetrating TBI, admission Glasgow Coma Scale (GCS)≤8 indicating severe TBI, 
a CT scan with evidence of intracranial injury, and age ≥16 and <75 years.  Subjects with evidence 
of extended hypoxia prior to admission were excluded. Other studies have suggested racial 
differences in rs4680 allelic frequencies(Cross et al., 2010). Therefore, this study was restricted to 
Caucasians only (n=98). Of note, findings in Caucasian-only analyses were similar to results in 
the entire population (n=106).  
For these 98 participants, demographic information was obtained from medical record 
review, and/or participant/caregiver interview. The best GCS within 24 hrs post-injury was used 
for analysis, as this injury severity index has greater accuracy when considering cognitive 
outcomes (Udekwu et al., 2004b),(Cifu et al., 1997b).  At both 6 and 12-month post-injury, trained 
staff members administered a battery of neuropsychological tests. 94 participants had sufficient 
neuropsychological data recorded at the 6-month time point, and 64 participants at the 12-month 
time point had sufficient neuropsychological data to be included in this analysis.  
Sample Collection and Genotyping 
All subjects were genotyped for the Val158Met, a missense mutation in the COMT gene 
(rs4680). DNA was obtained from whole blood, using a simple salting out procedure(S. A. Miller 
et al., 1988).  Genotyping was completed using TaqMan allele discrimination technology and 
available 5′ exonuclease Assay-on-Demand TaqMan assays (Applied Biosystems). 
Cognitive Outcome Measures 
A brief overview of the cognitive composite score methods are outlined here but for a more 
thorough explanation, refer to Failla et al(Failla et al., n.d.) for more detailed description about 
creating the composite score.  The cognitive composite score for this population was formulated 
using eight neuropsychological tests organized into four domain-specific groupings. The verbal 
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fluency domain includes the Delis-Kaplan Executive Function Systems (DKEFS) Verbal Fluency 
section(Delis et al., 2001) and the Controlled Oral Word Association (COWA)(John Borkowski et 
al., 1967), both designed to target verbal fluency.  The attention domain includes Trail Making 
Test A(Ralph Reitan and Wolfson, 1985) and the Digit span subsection from the Wechsler Adult 
Intelligence Scale-R(G. J. Larrabee and Curtiss, 1995) designed to focus on attention deficits.  The 
memory domain includes The California Verbal Learning Test-Long Delay Free Recall 
section(Delis, 2000) and the Rey-Osterrieth Complex Figure Test(P Osterrieth, 1944), and the 
executive function domain used the Trail Making Test B(Ralph Reitan and Wolfson, 1985) and 
Stroop Interference Score(J. Stroop, 1935). 
Raw scores for these tests were converted into T-scores using provider recommended 
normative data; correcting for age, race, sex, and education level when indicated.  To obtain a 
domain score, participants needed to complete at least one of the two tests for each domain.  If the 
results from both tests were present, the individual T-scores were averaged to create the reported 
T-score. The overall composite score consisted of an equally weighted average of the four domains 
specified above. In order to be included into our analysis, individuals were required to have valid 
cognitive composite scores. 
Functional cognition was evaluated by the Cognitive Function subscale of the Functional 
Independence Measures (FIM-Cog) at 6 and 12 months after TBI. The FIM-Cog is numerically 
scored from 1-7 with a greater number indicating fewer functional cognitive impairments across 
five questions involving - expression, comprehension, social interaction, problem solving, and 
memory.  
Depression  
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Self-reported depressive symptoms were obtained from participants at 6 and 12 months 
post-injury using the Patient Health Questionnaire-9 (PHQ9), a measurement tool that is derived 
from the DSM-IV criteria for Major Depressive Disorder (MDD).  This instrument requires 
participants to rate their depressive symptoms over a two-week period on a scale from 0-3, with 3 
indicating the more severe or frequent appearance of symptoms. Categorization as depressed 
required the self-selection of a minimum of five symptoms, with at least one of which was cardinal 
symptom (i.e anhedonia, or depressive mood). This metric has been successfully used previously 
to identify and assess depressive symptoms in TBI populations(Cook et al., 2011b),(Fann et al., 
2009b). 
Statistical Analysis 
 Statistical analyses were completed using SPSS (Version 22).  Mean, median, 
standard deviation, and standard error of the mean were calculated when appropriate for GCS, age, 
and education levels.  Categorical variables, such as MDD and sex, are presented as frequencies. 
Comparison of individual neuropsychological tests and demographic variables were grouped by 
variable and compared using Mann-Whitney, ANOVA, Kruskall-Wallis, T-Tests, or Chi-Square 
tests as appropriate. 
 Since a “dose dependent” effect has been observed in other studies, analyses were 
first completed comparing the Val/Val, Val/Met, and Met/Met genotypes. If warranted, carrier 
analysis was then performed grouping carriers with non-significant differences in post-hoc 
analysis and comparing them to the remaining variant of interest.  To control for confounding 
variables and injury specific events, a multivariate model was created for each overall cognitive 
composite score using covariates that were either associated with COMT Met158Val genotype or 
cognitive composite scores or both. A backwards linear regression was conducted where any 
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variables with a p>0.2 were removed from the final model. Associated variables with a p≤0.05 
were considered statistically significant. 
A.2.3 Results 
The average age of the population was 34.37±13.80 with a range of 17-71. The best GCS 
within 24hr averaged 7.93±3.08 for the population, with a range of 3-15. Demographic data by 
genotype is shown in Table 1.  There were no significant differences in age, sex, GCS, education, 
or depression status between carrier groups.   
 
Table 1. Demographics of Caucasian only populations with composite scores at 6 & 12 
month time points. 
 
 
 
 
 
Figure 1. Genotypic breakdown of sex x genotype interaction (6 month given only as a reference). Some 
evidence for the possibility of a “dose dependent” effect for the Met allele.  Using post-hoc analysis no difference was 
seen between the Val/Met and Val/Val groups.  Data presented as overall composite average with SEM.   
  6 Month n=94  12 Month n=64 
  
  
 
Met/Met 
n Val Carriers n 
p 
value 
 
Met/Met 
n Val Carriers n 
p 
value 
Age 36.03 ± 
15.270 
2
9 
33.42 ± 
13.435 
65 
0.58
9 
32.86 ± 
13.752 
2
1 
33.72 ± 
14.158 
4
3 
0.753 
Sex 
3 (10.34%) 
2
9 
13 (20.0%) 65 
0.25
3 
3 (14.28%) 
2
1 
14 
(32.55%) 
4
3 
0.225 
GCS 
7 
2
9 
8 65 
0.42
8 
7 
2
1 
7 
4
3 
0.212 
Education 12.48 ± 
1.765 
2
9 
12.95 ± 
1.988 
65 
0.59
3 
12.95 ± 
1.717 
2
1 
12.74 ± 
1.787 
4
3 
0.659 
Depressed 10 
(37.04%) 
2
7 
23 
(37.09%) 
62 1.00 6 (28.6%) 
2
1 
11 
(26.83%) 
4
1 
1.00 
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Figure 1 shows the overall composite scores by each genotype as a function of sex.  There 
was no significant difference in cognitive performance between women who were Val-
homozygotes and women Val-carriers, while significant differences were observed at both 6 and 
12 months when comparing cognitive performance for Met-homozygotes to their Val/Val and 
Val/Met counterparts. Therefore, in further analysis, Met-homozygotes were compared to Val-
carriers as consistent with the literature (Willmott et al., 2014b).  PTD status (data not shown), sex, 
and carrier status alone had no significant impact on any individual neuropsychological test, 
cognitive composite domain score, or the overall composite score at 6 or 12-month time-points as 
shown in Table 2.  There were no differences in overall FIM-Cog score by sex or genotype. At 6 
months, PTD negatively impacted overall FIM-Cog (p=0.011). 
 
Table 2. Bivariate analysis of gender and carrier impact on cognitive outcomes alone. A) 6 
Month and B) 12 Months. Presented scores are T-scores with standard deviation. 
 
A. 
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B. 
 
We then examined sex*gene interactions with cognitive composites.  As shown in Figure 
2 there was a significant gene*sex interaction in the Language Fluency domain (p=0.046) at 6 
6 Month Sex Analysis 
Sex 
Sig Carrier Analysis 
Carrier 
Sig 
 Female Male   Val-Carrier Met/Met  
Attention 35.7 ±7.80 38.2 ± 10.35 0.352 38.04 ± 9.65 37.08 ± 10.74 0.668 
Trails A 31.11 ± 12.71 36.44 ± 13.23 0.134 35.43 ± 13.44 35.57 ± 12.95 0.963 
Digit Span 42.30 ± 7.9622 41.87 ± 6.84 0.841 42.29 ± 6.83 41.06 ± 7.59 0.528 
Memory 37.76 ± 14.46 39.21± 10.97 0.701 38.46 ± 11.48 40.05 ± 11.99 0.542 
CVLT: LDFR 38.00 ± 20.12 35.00 ± 14.69 0.591 35.42 ± 15.92 35.71 ± 15.39 0.936 
Rey Complex Figure 38.88 ± 12.33 42.92 ± 11.01 0.184 41.23 ± 10.77 44.34 ± 12.33 0.219 
Language Fluency 38.21 ± 15.03 38.43 ± 10.20 0.954 39.05 ± 10.92 36.91 ± 11.65 0.394 
COWA: Animals 31.69 ± 16.39 34.32 ± 12.09 0.510 34.00 ± 12.51 33.42 ± 14.28 0.870 
DKEFS: Verbal Fluency 45.71 ± 9.98 40.73 ± 10.37 0.104 42.57 ± 9.64 39.46 ± 11.86 0.211 
Executive Function 44.74 ± 7.82 46.16 ± 9.68 0.572 45.94 ± 8.53 45.83 ± 11.14 0.958 
Trails Making Test B 36.47 ± 16.41 40.23 ± 13.45 0.322 39.83 ± 12.61 38.85 ± 17.07 0.762 
Stroop Task Interference 53.38 ± 8.26 53.58 ± 8.10 0.928 53.67 ± 7.08 53.22 ± 10.26 0.822 
Overall 39.10 ± 9.85 40.50 ± 7.65 0.520 40.37 ± 7.60 39.96 ± 9.13 0.824 
FIM Cog 29.94 4.56 31.16 ± 3.79 0.308 31.084 ± 4.05 30.52 ± 3.64 0.386 
12 Month Sex Analysis 
SEX 
Sig Carrier Analysis 
Carrier 
Sig 
 Female Males  Val Carrier Met/Met  
Attention 38.19 ± 11.96 39.74 ± 6.47 0.626 38.49 ± 7.70 41.12 ± 8.82 0.226 
Trails A 36.47 ± 20.41 37.66 ± 11.61 0.832 36.17 ± 13.02 40.06 ± 16.57 0.336 
Digit Span 40.67 ±  8.56 42.04 ± 7.04 0.536 41.30 ± 7.48 42.38 ± 7.37 0.609 
Memory 40.31 ± 13.73 41.31 ± 11.15 0.771 41.02 ± 11.08 41.14 ± 13.29 0.970 
CVLT: LDFR 38.71 ± 19.45 38.48 ± 16.06 0.964 39.66 ± 16.02 36.11 ± 18.39 0.449 
Rey Complex Figure 41.13 ± 11.30 44.48 ± 10.12 0.272 42.19 ± 10.12 46.60 ± 10.75 0.121 
Language Fluency 40.00 ± 11.41 38.02 ± 10.03 0.511 38.46 ± 10.14 38.62 ± 10.97 0.956 
COWA: Animals 33.64 ± 12.31 34.15 ± 12.83 0.896 33.15 ± 11.85 35.67 ± 14.07 0.466 
DKEFS: Verbal Fluency 47.00 ± 9.69 41.07 ± 10.36 0.063 43.20 ± 10.26 41.05 ± 10.92 0.466 
Executive Function 44.88 ± 12.44 47.48 ± 8.56 0.353 46.21 ± 9.47 48.09 ± 10.06 0.466 
Trails Making Test B 36.60 ± 20.76 40.89 ± 11.12 0.455 38.80 ± 13.74 42.00 ± 14.91 0.418 
Stroop Task Interference 51.75 ± 7.51 54.28 ±  7.62 0.255 53.07 ± 8.28 54.8 ± 5.98 0.408 
Overall 40.84 ± 10.19 41.64 ± 6.75 0.723 41.05 ± 7.36 42.24 ± 8.39 0.562 
FIM Cog 30.125 ± 4.09 31.68 ± 3.31 0.127 31.38 ± 3.66 31.00 ± 3.25 0.583 
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months. There were similar trends in terms of memory domain scores (p=0.075) and the overall 
composite (p=0.067). Met homozygote women performed significantly better than Met 
homozygote men at 6 months in the language fluency domain (p=0.001). At 12 months, a 
significant sex*carrier interaction was observed in the attention domain (p=0.003), memory 
domain (p=0.021), and the overall composite score (p=0.008). Met Homozygote women 
performed better than their male counterparts in the attention (p=0.029) and overall (p=0.025) 
subscales while there was a trend towards significance observed with the language fluency 
(p=0.081) and memory (p=0.091) domains. Figure 3 shows the average cognitive composite T-
scores for the sex*carrier interaction, with women who were Met/Met homozygotes performing 
~8 points better on their t-score than their Val-Carriers counterparts and also better than both the 
Met/Met and Val-Carrier men at 6 months post-injury.  At 12 months, women Met-Homozygotes 
performed ~12 points higher on their cognitive composite t-score, and these women performed 
even better than Val-Carrier men (p=0.045), Met-Homozygote men (p=0.025), and Val-Carrier 
women (p=0.008). As reported in Figure 4, genetic comparisons with functional cognition 
followed the same pattern with Met-Homozygote women performing ~2-4 points higher than Val-
carrier women as well as both Val-Carrier and Met-Homozygote men.  Post-hoc analysis showed 
a significant difference between Val-Carrier men and Val-Carrier women at both 6 (p=0.046) and 
12 (p=0.027) months. There was also a trend towards significance observed between Met-
Homozygote women and Val carrier women at 6 (p=0.099) and 12 (p=0.053) months.  
 
Figure 2. Domain and overall average T-scores scores by sex*gene groups at A) 6 months 
and B) 12 months. Error bars presented as SEM. A star above signifies a significant 
sex*gene interaction in the associated domain.  An ampersand signifies a significant 
difference between Women Met Homozygotes and Men Met Homozygotes. 
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Figure 3. Overall cognitive composite T-scores A) 6 months B) 12 months.  Error bars 
presented as SEM. A star indicates the group is significantly different from all three other 
groups. 
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Figure 4. FIM-Cog scores by sex*gene grouping A) 6 months and B) 12 months after TBI. 
Data presented as average of the group with SEM.   
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To adjust for potential demographic, clinical, and injury specific factors, a backwards step-
wise multivariate linear regression model was used to predict overall cognitive composite scores 
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at 6 and 12 months.  The sex*gene interaction was significant at 6 months (p=0.024) and at 12 
months (p=0.002) even after adjusting for age, education, and GCS as shown in Table 3. Met-
Homozygote women performed significantly better than their Val-carrier counterparts as well as 
men who were Met-homozygotes.  The addition of the sex*gene interaction term to the cognitive 
composite model resulted in a significant increase in incremental variance as measured by change 
in R-square at both 6 (F=5.24, p<0.05) and 12 (F=10.09, p<0.01) months. Using the same model, 
functional cognition as measured by FIM-Cog was also had a significant sex*gene interaction at 
6 months (p=0.038) and tended to be significant at 12 months (p=0.058). The addition of the 
sex*gene interaction term to the FIM-Cog model resulted in a significant in incremental variance 
as measured by change in R-square at 6 (F=4.45, p<0.05) but was not significant at 12 months 
(F=3.735, p>0.05).  While depression was added to the FIM-Cog model, it did not meet the 
significance threshold and was removed from the model at both 6 and 12 months. 
 
 
 
 
 
 
 
 
Table 3. Parameters used to model functional cognition and overall composite scores at 
both 6 and 12 months. 
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Variable Parameter 
Estimate 
Standard 
Error 
t value p value 95% Confidence 
Interval 
A. 6 months – Cognitive Composite, R Squared = .258 (Adjusted R Squared = .207) 
Age -0.099 0.056 -1.763 0.081 (-0.211- 0.013) 
GCS 0.924 0.266 3.48 0.001 (0.396 – 1.452) 
Education 1.272 0.393 3.237 0.002 (0.491 – 2.053) 
Sex 9.184 4.540 2.023 0.046 (.160– 18.208) 
Rs4680 0.667 1.755 0.380 0.705 (-2.822 – 4.156) 
Sex*Rs4680 -11.400 4.980 -2.289 0.024 (-21.297 – -1.502) 
B. 12 months – Cognitive Composite, R Squared = .374 (Adjusted R Squared = .308) 
Age -0.066 0.062 -1.073 0.288 (0.191- 1.443) 
GCS 0.817 0.313 2.613 0.011 (0.396 – 1.452) 
Education 1.685 0.479 3.520 0.001 (0.726 – 2.643) 
Sex 11.219 4.566 2.709 0.113 (2.927– 19.511) 
Rs4680 1.316 1.937 0.679 0.013 (-2.563 – 5.195) 
Sex*Rs4680 -14.506 4.980 -3.177 0.002 (-21.297 – -1.502) 
C. 6 months – Functional Cognition, R Squared = .176 (Adjusted R Squared = .120 ) 
Age -.056 0.029 -1.915 0.059 (-0.113 - 0.002) 
GCS 0.326 0.137 2.377 0.020 (0.053 - 0.598) 
Education 0.404 0.203 1.990 0.050 (0.000 - 0.807) 
Sex 3.509 2.343 1.497 0.138 (-1.149 – 8.166) 
Rs4680 0.754 0.906 0.832 0.408 (-1.047 – 2.555) 
Sex*Rs4680 -5.423 2.570 -2.110 0.038 (-10.532 - -0.315) 
D. 12 months – Functional Cognition, R Squared = .325 (Adjusted R Squared = .254) 
Age -0.096 0.030 -3.232 0.002 (-0.155 - -0.036) 
GCS 0.476 0.150 3.168 0.002 (0.175 - 0.777) 
Education 0.302 0.230 1.310 0.195 (-0.159 - -0.763) 
Sex 2.689 1.992 1.350 0.182 (-1.299 – 6.678) 
Rs4680 0.163 0.932 0.175 0.862 (-1.703 – 2.029) 
Sex*Rs4680 -4.244 2.196 -1.933 0.058 (-8.642 - 0.154) 
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A.2.4 Discussion 
Following a TBI, cognitive recovery is often difficult to predict, and current methodologies 
provide little insight into reasons for observed heterogeneity.  This study investigated the 
functional polymorphism Val158Met in COMT with cognitive outcomes, aiming to identify 
genetic influences on cognition post-TBI.  The current study is the first to establish a gene*sex 
interaction with COMT on cognitive outcomes in a severe TBI population. We show that women 
who were Met-homozygotes performed significantly better than women Val-carriers with both 
functional and cognitive performance measures.  We did not observe this relationship among men. 
Furthermore, the addition of the sex*gene interaction term to our model resulted in significant 
improvements in its predictive power. Although this work requires validation in an independent 
cohort, the work suggests a possible role for considering sex based genetics in a clinical setting 
when considering pharmacological and cognitive therapies to use for individuals following TBI.  
In the literature, there is evidence of a sex*Val158Met interaction on cognitive and 
behavioral measures, but often with inconsistent results.  Some studies show significant sex based 
relationships between COMT and behavioral traits like sensation seeking (Lang et al., 2007a), risk 
taking (Amstadter et al., 2012), and general emotionality (C. Chen et al., 2011). When considering 
gene*sex interactions, the literature is quite variable without a consistent relationship between 
Val158Met status and outcomes (Soeiro-De-Souza et al., 2013),(O’Hara et al., 2006),(Barnett et 
al., 2007),(Harrison and Tunbridge, 2007). Lipsky et al showed that the Met-Homozygote 
genotype was associated with higher outcomes on the Wisconsin Card Sorting Test (WCST) 
following TBI (Lipsky et al., 2005b), while Willmott and colleagues reported no difference in 
measures of executive function based on Val158Met status following TBI (Willmott et al., 2014c).  
  224 
However, Lipsky et al studied a primarily male population, and Willmott’s neuropsychological 
data was taken at an acute time point and did not examine a gene*sex interaction.    
COMT in an important regulator of DA, which is critical for attention, memory, and 
planning, and DA deficiencies have often been associated with cognitive deficits in schizophrenia 
and bipolar disorder (Harrison and Tunbridge, 2007),(Egan et al., 2001),(Seamans and Yang, 
2004). One way to interpret these results is using the “inverted U” curve of the DA hypothesis 
observed in other conditions (Mattay et al., 2003), which suggests there is an optimal level of DA; 
levels above or below this optimal level lead to suboptimal outcomes via D1 receptor stimulation 
(Vijayraghavan et al., 2007). This point was further corroborated in control populations by 
pharmacological studies using methylphenidate and bromocriptine where excessive dosages led to 
negative cognitive outcomes and where increasing DA did not have a linear relationship with 
cognitive improvements (Cools and D’Esposito, 2011b). In this framework, understanding control 
mechanisms for basal DA levels is critical to determining their role in cognitive outcomes (Cools 
and D’Esposito, 2011b).                                                                                                                                                        
Prefrontal COMT activity and DA levels are highly dependent on Val158Met status 
(Tunbridge et al., 2006). Studies have shown that the Met allele leads to lower enzyme activity 
and higher levels of prefrontal DA (Tunbridge et al., 2006).  This genetic state results in higher 
prefrontal DA levels which may be why healthy Met-carriers often perform better on working 
memory tasks (Tunbridge et al., 2006). Greater synaptic DA levels can increase D1 receptor 
activation associated with efficient memory and attentional processes (Sawaguchi and Goldman-
Rakic, 1991). Val/Val individuals have greater enzyme activity and lower PFC DA levels(Egan et 
al., 2001). One hypothesis put forth by Bilder and Volkva suggests that since COMT is still 
expressed in subcortical regions, COMT may play a role in altering tonic and phasic DA levels 
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subcortically in addition to DA regulation under control by the PFC (Robert M. Bilder et al., 2004). 
Therefore, COMT may still influence subcortical DA levels, even though it is COMT effects on 
PFC DA transmission that are better characterized.  The literature reported here may help explain 
why there were significant associations with COMT status with memory and attention, domains 
that are not solely PFC focused. In addition, studies have suggested a “dose-dependent” effect for 
the Met allele, with the heterozygote having an intermediate outcome(Egan et al., 2001).  While 
not statistically significant, our data does suggest this possibility in women as shown in Figure 1. 
Estradiol can enhance DA activity by increasing DA synthesis and altering tonic firing 
rates of DA neurons (Becker, 1999),(Xiao and Becker, 1994). Kritzer and Creutz have even shown 
that mesocortical pathways in female rats consist of 50% DA neurons where male rats only have 
30% (Kritzer and Creutz, 2008). A post-mortem study has shown that independent of Val158Met 
status, men have a 17% greater activity in PFC COMT than women(Jingshan Chen et al., 2004). 
Estradiol also specifically regulates COMT activity and expression (ref).  Further, studies have 
reported two estrogen response elements (EREs) on the COMT promoter region, and physiological 
estradiol levels inhibit COMT expression in rat livers (Xie et al., 1999).  However, for similar 
levels of transcription, men still have higher COMT activity than women (Harrison and Tunbridge, 
2007). Recently, Jacobs and D’Esposito have shown baseline DA levels are controlled by 
Val158Met interactions with estradiol levels that vary during the female menstrual cycle to impact 
PFC DA levels and functioning (Jacobs and D’Esposito, 2011).  Met/Met women perform better 
under low estradiol conditions, with Val/Val women having opposite relationships. Although the 
precise mechanism is unclear, an estradiol related component to DAergic control over cognition is 
present. Those with TBI can also exhibit hypopituitarism (Tanriverdi et al., 2006) and altered 
gonadotropin levels as far as 12 months post injury (Bondanelli et al., 2005), for which outcomes 
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are impaired in men with persistent hypogonadism. This work suggests a role for an interaction 
between TBI and systemic estradiol levels suggesting the importance of this hormone when 
considering sex and Val158Met status in context of DA dysfunction. 
TBI causes a functional hypodopaminergic state (James W. Bales et al., 2009), leaving 
many individuals with TBI with low basal DA levels. In the case of the inverted U hypothesis, TBI 
likely shifts individuals toward the low DA left portion of the curve.  Since women have lower 
COMT enzyme activity, even prior to TBI, they would be expected to have a rightward shift on 
the curve compared to men. All Met/Met carriers would exhibit a rightward shift relative to Val-
carriers. Since we hypothesize that a TBI induced hypodopaminergic state shifts DA levels to the 
left of the U-shaped curve, reasonable rightward DA increases at baseline would be beneficial to 
cognition. We observed this as our Met/Met women had the best cognitive outcomes.  However, 
this framework would also suggest that male Val-carriers would have the worst cognitive 
outcomes, which we did not observe.  This finding suggests that these there may be more factors 
that interact to impact baseline DA levels other just the observed Val158Met*sex interaction when 
considering the inverted U framework for interpreting DA system pathophysiology. 
    While COMT is typically associated with the PFC, the mesolimbic DAergic pathway 
also innervates the hippocampus. Since we included a memory component in the cognitive score, 
it is important to consider the role of COMT and DA in the hippocampus. Studies using tolcapone 
to block COMT activity in rats have shown increases in DA levels in the hippocampus and better 
performance on hippocampal dependent cognitive activities (Laatikainen et al., 2012). There are 
also numerous areas of the literature suggesting that Val158Met status impacts functional 
connectivity, which shows synchronous activation of biologically relevant connections between 
brain regions. Liu and colleagues have shown that Val homozygotes have decreased connectivity 
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between cingulate cortices and PFC regions compared to Val/Met heterozygotes, providing 
complementary imaging evidence that Val-carrier participants with lower levels of connectivity 
had lower cognitive outcomes that Met homozygotes. Similarly, evidence from Bertolino and 
colleagues shows that Val158Met status impacts coupling between the PFC and the hippocampal 
formation during memory processing. In this study, the Val allele led to reduced hippocampal 
activation at encoding and retrieval, uncoupled from the PFC (Bertolino et al., 2006). Thus, while 
memory is not PFC centered, Val-alleles may have reduced ability to modulate hippocampal 
function.  FIM-Cog score analysis helps to illustrate that these genetic associations are not limited 
to neuropsychiatric tests, but also play a role in functional cognitive impairments that can limit 
daily activity.   
The literature also provides evidence of other potential Val158Met interactions, of which 
the age and Val158Met interaction received the most focus (Dumontheil et al., 2011),(Frias et al., 
2005). However, we were unable to find such an association with cognitive outcomes in our study, 
perhaps due to the fact the standardized scores account for age in their calculations.  One limitation 
of this study is our relatively small sample size for a genetics study, so our outcomes may not be 
large enough to delineate more subtle differences that might be present in the population. Also, 
since estrogen may play an important role in Val158Met transcription and activity, estrogen levels 
at time of cognitive testing would be useful.  We also limited our analysis to Caucasians only since 
allelic distributions were significantly different by race, limiting our generalizability. Future 
studies in a larger and more diverse population that focus on additional factors that impact baseline 
DA levels are warranted.  While this study looked at only cognitive outcomes, future studies should 
also look at more in depth behavioral measures also important in TBI populations since they have 
also been shown to be relevant to Val158Met status. Combined knowledge of how multiple DA 
  228 
genetic factors impact cognition following TBI are important to determine which patients may 
benefit the most from DA targeted therapies post-TBI. 
 
 
 
  229 
BIBLIOGRAPHY 
Aalto, S., Brück, A., Laine, M., Någren, K., Rinne, J.O., 2005. Frontal and Temporal Dopamine 
Release during Working Memory and Attention Tasks in Healthy Humans: a Positron 
Emission Tomography Study Using the High-Affinity Dopamine D2 Receptor Ligand 
[11C]FLB 457. J. Neurosci. 25, 2471–2477. doi:10.1523/JNEUROSCI.2097-04.2005 
Åberg, E., Fandiño-Losada, A., Sjöholm, L.K., Forsell, Y., Lavebratt, C., 2011. The functional 
Val158Met polymorphism in catechol-O-methyltransferase (COMT) is associated with 
depression and motivation in men from a Swedish population-based study. J. Affect. 
Disord. 129, 158–166. doi:10.1016/j.jad.2010.08.009 
Alexander, N., Osinsky, R., Schmitz, A., Mueller, E., Kuepper, Y., Hennig, J., 2010. The BDNF 
Val66Met polymorphism affects HPA-axis reactivity to acute stress. 
Psychoneuroendocrinology 35, 949–953. doi:10.1016/j.psyneuen.2009.12.008 
Almeida, R.D., Manadas, B.J., Melo, C.V., Gomes, J.R., Mendes, C.S., Grãos, M.M., Carvalho, 
R.F., Carvalho, A.P., Duarte, C.B., 2005. Neuroprotection by BDNF against glutamate-
induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death 
Differ. 12, 1329–1343. doi:10.1038/sj.cdd.4401662 
Alonso, M., Vianna, M.R.M., Depino, A.M., Mello e Souza, T., Pereira, P., Szapiro, G., Viola, H., 
Pitossi, F., Izquierdo, I., Medina, J.H., 2002. BDNF-triggered events in the rat 
hippocampus are required for both short- and long-term memory formation. Hippocampus 
12, 551–560. doi:10.1002/hipo.10035 
Amstadter, A.B., MacPherson, L., Wang, F., Banducci, A.N., Reynolds, E.K., Potenza, M.N., 
Gelernter, J., Lejuez, C.W., 2012. The relationship between risk-taking propensity and the 
COMT Val158Met polymorphism among early adolescents as a function of sex. J. 
Psychiatr. Res. 46, 940–945. doi:10.1016/j.jpsychires.2012.04.010 
Andersson, S., Bergedalen, A.-M., 2002. Cognitive correlates of apathy in traumatic brain injury. 
Cogn. Behav. Neurol. 15, 184–191. 
An, J.J., Gharami, K., Liao, G.-Y., Woo, N.H., Lau, A.G., Vanevski, F., Torre, E.R., Jones, K.R., 
Feng, Y., Lu, B., Xu, B., 2008. Distinct role of long 3’ UTR BDNF mRNA in spine 
morphology and synaptic plasticity in hippocampal neurons. Cell 134, 175–187. 
doi:10.1016/j.cell.2008.05.045 
Arciniegas, D.B., 2002. Cognitive impairment following traumatic brain injury. Curr. Treat. 
Options Neurol. 4, 43+. 
Arciniegas, D.B., Topkoff, J.L., Rojas, D.C., Sheeder, J., Teale, P., Young, D.A., Sandberg, E., 
Reite, M.L., Adler, L.E., 2001. Reduced Hippocampal Volume in Association With P50 
Nonsuppression Following Traumatic Brain Injury. J. Neuropsychiatry Clin. Neurosci. 13, 
213–221. doi:10.1176/appi.neuropsych.13.2.213 
Arenth, P.M., Russell, K.C., Scanlon, J.M., Kessler, L.J., Ricker, J.H., 2012. Encoding and 
recognition after traumatic brain injury: Neuropsychological and functional magnetic 
resonance imaging findings. J. Clin. Exp. Neuropsychol. 34, 333–344. 
doi:10.1080/13803395.2011.633896 
Ashman, T.A., Cantor, J.B., Gordon, W.A., Spielman, L., Flanagan, S., Ginsberg, A., Engmann, 
C., Egan, M., Ambrose, F., Greenwald, B., 2009. A randomized controlled trial of sertraline 
  230 
for the treatment of depression in persons with traumatic brain injury. Arch. Phys. Med. 
Rehabil. 90, 733–740. doi:10.1016/j.apmr.2008.11.005 
Bales, J.W., Wagner, A.K., Kline, A.E., Dixon, C.E., 2009. Persistent cognitive dysfunction after 
traumatic brain injury: A dopamine hypothesis. Neurosci. Biobehav. Rev. 33, 981–1003. 
doi:10.1016/j.neubiorev.2009.03.011 
Bales, J.W., Wagner, A.K., Kline, A.E., Dixon, C.E., 2009. Persistent cognitive dysfunction after 
traumatic brain injury: A dopamine hypothesis. Neurosci. Biobehav. Rev. 33, 981–1003. 
doi:10.1016/j.neubiorev.2009.03.011 
Baños, J.H., Novack, T.A., Brunner, R., Renfroe, S., Lin, H.-Y., Meythaler, J., 2010. Impact of 
early administration of sertraline on cognitive and behavioral recovery in the first year after 
moderate to severe traumatic brain injury. J. Head Trauma Rehabil. 25, 357–361. 
doi:10.1097/HTR.0b013e3181d6c715 
Barker, P.A., 2009. Whither proBDNF? Nat. Neurosci. 12, 105–106. doi:10.1038/nn0209-105 
Barnett, J.H., Heron, J., Ring, S.M., Golding, J., Goldman, D., Xu, K., Jones, P.B., 2007. Gender-
specific effects of the catechol-O-methyltransferase Val108/158Met polymorphism on 
cognitive function in children. Am. J. Psychiatry 164, 142–149. 
doi:10.1176/appi.ajp.164.1.142 
Barrett, G.L., 2000. The p75 neurotrophin receptor and neuronal apoptosis. Prog. Neurobiol. 61, 
205–229. 
Barrett, J.C., Fry, B., Maller, J., Daly, M.J., 2005. Haploview: analysis and visualization of LD 
and haplotype maps. Bioinformatics 21, 263–265. 
Bartrés-Faz, D., Junqué, C., Serra-Grabulosa, J.M., López-Alomar, A., Moya, A., Bargalló, N., 
Mercader, J.M., Moral, P., Clemente, I.C., 2002. Dopamine DRD2 Taq I polymorphism 
associates with caudate nucleus volume and cognitive performance in memory impaired 
subjects. Neuroreport 13, 1121–1125. 
Başkaya, M.K., Rao, A.M., Doğan, A., Donaldson, D., Dempsey, R.J., 1997. The biphasic opening 
of the blood-brain barrier in the cortex and hippocampus after traumatic brain injury in 
rats. Neurosci. Lett. 226, 33–36. 
Bath, K.G., Lee, F.S., 2006. Variant BDNF (Val66Met) impact on brain structure and function. 
Cogn. Affect. Behav. Neurosci. 6, 79–85. 
Baune, B.T., Hohoff, C., Berger, K., Neumann, A., Mortensen, S., Roehrs, T., Deckert, J., Arolt, 
V., Domschke, K., 2007. Association of the COMT val158met variant with antidepressant 
treatment response in major depression. Neuropsychopharmacology 33, 924–932. 
Bayley, M.T., Tate, R., Douglas, J.M., Turkstra, L.S., Ponsford, J., Stergiou-Kita, M., Kua, A., 
Bragge, P., 2014. INCOG Guidelines for Cognitive Rehabilitation Following Traumatic 
Brain Injury: Methods and Overview. J. Head Trauma Rehabil. 29, 290–306. 
doi:10.1097/HTR.0000000000000070 
Bayly, P.V., Cohen, T.S., Leister, E.P., Ajo, D., Leuthardt, E.C., Genin, G.M., 2005. Deformation 
of the Human Brain Induced by Mild Acceleration. J. Neurotrauma 22, 845–856. 
doi:10.1089/neu.2005.22.845 
Becker, J.B., 1999. Gender Differences in Dopaminergic Function in Striatum and Nucleus 
Accumbens. Pharmacol. Biochem. Behav. 64, 803–812. doi:10.1016/S0091-
3057(99)00168-9 
Bekinschtein, P., Cammarota, M., Izquierdo, I., Medina, J.H., 2008a. Reviews: BDNF and 
Memory Formation and Storage. The Neuroscientist 14, 147 –156. 
doi:10.1177/1073858407305850 
  231 
Bekinschtein, P., Cammarota, M., Katche, C., Slipczuk, L., Rossato, J.I., Goldin, A., Izquierdo, I., 
Medina, J.H., 2008b. BDNF is essential to promote persistence of long-term memory 
storage. Proc. Natl. Acad. Sci. 105, 2711–2716. doi:10.1073/pnas.0711863105 
Bellander, M., Bäckman, L., Liu, T., Schjeide, B.-M.M., Bertram, L., Schmiedek, F., 
Lindenberger, U., Lövdén, M., 2014. Lower baseline performance but greater plasticity of 
working memory for carriers of the val allele of the comt val158met polymorphism. 
Neuropsychology. doi:10.1037/neu0000088 
Bendlin, B.B., Ries, M.L., Lazar, M., Alexander, A.L., Dempsey, R.J., Rowley, H.A., Sherman, 
J.E., Johnson, S.C., 2008. Longitudinal changes in patients with traumatic brain injury 
assessed with diffusion-tensor and volumetric imaging. NeuroImage 42, 503–514. 
doi:10.1016/j.neuroimage.2008.04.254 
Benjamini, Y., Hochberg, Y., 1995. Controlling the False Discovery Rate: A Practical and 
Powerful Approach to Multiple Testing. J. R. Stat. Soc. Ser. B Methodol. 57, 289–300. 
Berridge, K.C., Kringelbach, M.L., 2008. Affective neuroscience of pleasure: reward in humans 
and animals. Psychopharmacology (Berl.) 199, 457–480. doi:10.1007/s00213-008-1099-6 
Bertolino, A., Fazio, L., Di Giorgio, A., Blasi, G., Romano, R., Taurisano, P., Caforio, G., 
Sinibaldi, L., Ursini, G., Popolizio, T., Tirotta, E., Papp, A., Dallapiccola, B., Borrelli, E., 
Sadee, W., 2009. Genetically determined interaction between the dopamine transporter and 
the D2 receptor on prefronto-striatal activity and volume in humans. J. Neurosci. Off. J. 
Soc. Neurosci. 29, 1224–1234. doi:10.1523/JNEUROSCI.4858-08.2009 
Bertolino, A., Rubino, V., Sambataro, F., Blasi, G., Latorre, V., Fazio, L., Caforio, G., Petruzzella, 
V., Kolachana, B., Hariri, A., Meyer-Lindenberg, A., Nardini, M., Weinberger, D.R., 
Scarabino, T., 2006. Prefrontal-hippocampal coupling during memory processing is 
modulated by COMT val158met genotype. Biol. Psychiatry 60, 1250–1258. 
doi:10.1016/j.biopsych.2006.03.078 
Bhang, S., Ahn, J.-H., Choi, S.-W., 2010. Brain-derived neurotrophic factor and serotonin 
transporter gene-linked promoter region genes alter serum levels of brain-derived 
neurotrophic factor in humans. J. Affect. Disord. doi:10.1016/j.jad.2010.07.008 
Bilder, R.M., Volavka, J., Lachman, H.M., Grace, A.A., 2004. The catechol-O-methyltransferase 
polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric 
phenotypes. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 29, 
1943–1961. doi:10.1038/sj.npp.1300542 
Bilder, R.M., Volavka, J., Lachman, H.M., Grace, A.A., 2004. The Catechol-O-Methyltransferase 
Polymorphism: Relations to the tonic-phasic dopamine hypothesis and neuropsychiatric 
phenotypes. Neuropsychopharmacology 29, 1943–1961. doi:10.1038/sj.npp.1300542 
Bleiberg, J., Garmoe, W., Cederquist, J., Reeves, D., 1993. Effect of dexedrine on performance 
consistency following brain injury: A double-blind placebo crossover case study. 
Neuropsychiatry. Neuropsychol. Behav. Neurol. 
Bombardier, C.H., Fann, J.R., Temkin, N.R., Esselman, P.C., Barber, J., Dikmen, S.S., 2010a. 
Rates of Major Depressive Disorder and Clinical Outcomes Following Traumatic Brain 
Injury. JAMA 303, 1938–1945. doi:10.1001/jama.2010.599 
Bombardier, C.H., Fann, J.R., Temkin, N.R., Esselman, P.C., Barber, J., Dikmen, S.S., 2010b. 
Rates of Major Depressive Disorder and Clinical Outcomes Following Traumatic Brain 
Injury. JAMA 303, 1938–1945. doi:10.1001/jama.2010.599 
  232 
Bondanelli, M., Ambrosio, M.R., Zatelli, M.C., Marinis, L.D., Uberti, E.C. degli, 2005. 
Hypopituitarism after traumatic brain injury. Eur. J. Endocrinol. 152, 679–691. 
doi:10.1530/eje.1.01895 
Borkowski, J., Benton, A., Spreen, O., 1967. Word fluency and brain damage. Neuropsychologia 
5, 135–140. 
Borkowski, J., Benton, A., Spreen, O., 1967. Word Fluency and Brain Damage. Neuropsychologia 
135–140. 
Bornstein, R.A., Miller, H.B., van Schoor, J.T., 1989. Neuropsychological deficit and emotional 
disturbance in head-injured patients. J. Neurosurg. 70, 509–513. 
doi:10.3171/jns.1989.70.4.0509 
Brady, R., Zaidi, S.I., Mayer, C., Katz, D.M., 1999. BDNF is a target-derived survival factor for 
arterial baroreceptor and chemoafferent primary sensory neurons. J. Neurosci. Off. J. Soc. 
Neurosci. 19, 2131–2142. 
Brandeis, R., Brandys, Y., Yehuda, S., 1989. The use of the Morris water maze in the study of 
memory and learning. Int. J. Neurosci. 48, 29–69. 
Braver, T.S., Cohen, J.D., 2000. On the control of control: The role of dopamine in regulating 
prefrontal function and working memory. Control Cogn. Process. Atten. Perform. XVIII 
713–737. 
Brooks, J.C., Strauss, D.J., Shavelle, R.M., Paculdo, D.R., Hammond, F.M., Harrison-Felix, C.L., 
2013. Long-Term Disability and Survival in Traumatic Brain Injury: Results From the 
National Institute on Disability and Rehabilitation Research Model Systems. Arch. Phys. 
Med. Rehabil. 94, 2203–2209. doi:10.1016/j.apmr.2013.07.005 
Brooks, J., Fos, L.A., Greve, K.W., Hammond, J.S., 1999. Assessment of executive function in 
patients with mild traumatic brain injury. J. Trauma 46, 159–163. 
Brunoni, A.R., Lopes, M., Fregni, F., 2008. A Systematic Review and Meta-Analysis of Clinical 
Studies on Major Depression and BDNF Levels: Implications for the Role of 
Neuroplasticity in Depression. Int. J. Neuropsychopharmacol. 11, 1169–1180. 
doi:10.1017/S1461145708009309 
Buckley, M.J., 2005. The role of the perirhinal cortex and hippocampus in learning, memory, and 
perception. Q. J. Exp. Psychol. B 58, 246–268. doi:10.1080/02724990444000186 
Burt, D.B., Zembar, M.J., Niederehe, G., 1995. Depression and memory impairment: a meta-
analysis of the association, its pattern, and specificity. Psychol. Bull. 117, 285–305. 
Bushnik, T., Englander, J., Wright, J., 2008. Patterns of fatigue and its correlates over the first 2 
years after traumatic brain injury. J. Head Trauma Rehabil. 23, 25–32. 
doi:10.1097/01.HTR.0000308718.88214.bb 
Busto, R., Dietrich, W.D., Globus, M.Y.-T., Alonso, O., Ginsberg, M.D., 1997. Extracellular 
Release of Serotonin following Fluid-Percussion Brain Injury in Rats. J. Neurotrauma 14, 
35–42. doi:10.1089/neu.1997.14.35 
Bylsma, L.M., Morris, B.H., Rottenberg, J., 2008. A meta-analysis of emotional reactivity in major 
depressive disorder. Clin. Psychol. Rev. 28, 676–691. 
Canli, T., Lesch, K.-P., 2007. Long story short: the serotonin transporter in emotion regulation and 
social cognition. Nat Neurosci 10, 1103–1109. doi:10.1038/nn1964 
Caporali, A., Emanueli, C., 2009. Cardiovascular actions of neurotrophins. Physiol. Rev. 89, 279–
308. doi:10.1152/physrev.00007.2008 
Carrera, E., Tononi, G., 2014. Diaschisis: past, present, future. Brain J. Neurol. 137, 2408–2422. 
doi:10.1093/brain/awu101 
  233 
CDC - Injury - TBI - TBI in the US Report [WWW Document], n.d. URL 
http://www.cdc.gov/traumaticbraininjury/tbi_ed.html (accessed 11.22.10a). 
CDC - Injury - TBI - TBI in the US Report [WWW Document], n.d. URL 
http://www.cdc.gov/traumaticbraininjury/tbi_ed.html (accessed 11.22.10b). 
CDC - TBI in the US Report - Traumatic Brain Injury - Injury Center [WWW Document], n.d. 
URL http://www.cdc.gov/traumaticbraininjury/tbi_ed.html (accessed 6.26.13). 
Cernak, I., Chang, T., Ahmed, F.A., Cruz, M.I., Vink, R., Stoica, B., Faden, A.I., 2010. 
Pathophysiological response to experimental diffuse brain trauma differs as a function of 
developmental age. Dev. Neurosci. 32, 442–453. doi:10.1159/000320085 
Chamelian, L., Feinstein, A., 2006. The effect of major depression on subjective and objective 
cognitive deficits in mild to moderate traumatic brain injury. J. Neuropsychiatry Clin. 
Neurosci. 18, 33–38. doi:10.1176/appi.neuropsych.18.1.33 
Chan, F., Lanctôt, K.L., Feinstein, A., Herrmann, N., Strauss, J., Sicard, T., Kennedy, J.L., 
McCullagh, S., Rapoport, M.J., 2008. The serotonin transporter polymorphisms and major 
depression following traumatic brain injury. Brain Inj. BI 22, 471–479. 
doi:10.1080/02699050802084886 
Chen, C., Chen, C., Moyzis, R., Dong, Q., He, Q., Zhu, B., Li, J., Li, H., Li, J., Lessard, J., 2011. 
Sex modulates the associations between the COMT gene and personality traits. 
Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 36, 1593–1598. 
doi:10.1038/npp.2011.39 
Chen, H., Poon, A., Yeung, C., Helms, C., Pons, J., Bowcock, A.M., Kwok, P.-Y., Liao, W., 2011. 
A genetic risk score combining ten psoriasis risk loci improves disease prediction. PloS 
One 6, e19454. doi:10.1371/journal.pone.0019454 
Chen, J.-K., Johnston, K.M., Petrides, M., Ptito, A., 2008a. Neural Substrates of Symptoms of 
Depression Following Concussion in Male Athletes With Persisting Postconcussion 
Symptoms. Arch Gen Psychiatry 65, 81–89. doi:10.1001/archgenpsychiatry.2007.8 
Chen, J.-K., Johnston, K.M., Petrides, M., Ptito, A., 2008b. Neural Substrates of Symptoms of 
Depression Following Concussion in Male Athletes With Persisting Postconcussion 
Symptoms. Arch Gen Psychiatry 65, 81–89. doi:10.1001/archgenpsychiatry.2007.8 
Chen, J., Lipska, B.K., Halim, N., Ma, Q.D., Matsumoto, M., Melhem, S., Kolachana, B.S., Hyde, 
T.M., Herman, M.M., Apud, J., Egan, M.F., Kleinman, J.E., Weinberger, D.R., 2004. 
Functional Analysis of Genetic Variation in Catechol-O-Methyltransferase (COMT): 
Effects on mRNA, Protein, and Enzyme Activity in Postmortem Human Brain. Am. J. 
Hum. Genet. 75, 807–821. doi:10.1086/425589 
Chen, J., Lipska, B.K., Halim, N., Ma, Q.D., Matsumoto, M., Melhem, S., Kolachana, B.S., Hyde, 
T.M., Herman, M.M., Apud, J., others, 2004. Functional Analysis of Genetic Variation in 
Catechol-O-Methyltransferase (< i> COMT</i>): Effects on mRNA, Protein, and Enzyme 
Activity in Postmortem Human Brain. Am. J. Hum. Genet. 75, 807–821. 
Chen, X., Li, Y., Kline, A.E., Dixon, C.E., Zafonte, R.D., Wagner, A.K., 2005. Gender and 
environmental effects on regional brain-derived neurotrophic factor expression after 
experimental traumatic brain injury. Neuroscience 135, 11–17. 
doi:10.1016/j.neuroscience.2005.05.041 
Chen, Z.-Y., Patel, P.D., Sant, G., Meng, C.-X., Teng, K.K., Hempstead, B.L., Lee, F.S., 2004. 
Variant Brain-Derived Neurotrophic Factor (BDNF) (Met66) Alters the Intracellular 
Trafficking and Activity-Dependent Secretion of Wild-Type BDNF in Neurosecretory 
  234 
Cells and Cortical Neurons. J Neurosci 24, 4401–4411. doi:10.1523/JNEUROSCI.0348-
04.2004 
Chiaretti, A., Piastra, M., Polidori, G., Di Rocco, C., Caresta, E., Antonelli, A., Amendola, T., 
Aloe, L., 2003. Correlation between neurotrophic factor expression and outcome of 
children with severe traumatic brain injury. Intensive Care Med. 29, 1329–1338. 
doi:10.1007/s00134-003-1852-6 
Cicerone, K.D., Langenbahn, D.M., Braden, C., Malec, J.F., Kalmar, K., Fraas, M., Felicetti, T., 
Laatsch, L., Harley, J.P., Bergquist, T., Azulay, J., Cantor, J., Ashman, T., 2011. Evidence-
based cognitive rehabilitation: updated review of the literature from 2003 through 2008. 
Arch. Phys. Med. Rehabil. 92, 519–530. doi:10.1016/j.apmr.2010.11.015 
Cifu, D.X., Keyser-Marcus, L., Lopez, E., Wehman, P., Kreutzer, J.S., Englander, J., High, W., 
1997a. Acute predictors of successful return to work 1 year after traumatic brain injury: a 
multicenter analysis. Arch. Phys. Med. Rehabil. 78, 125–131. 
Cifu, D.X., Keyser-Marcus, L., Lopez, E., Wehman, P., Kreutzer, J.S., Englander, J., High, W., 
1997b. Acute predictors of successful return to work 1 year after traumatic brain injury: a 
multicenter analysis. Arch. Phys. Med. Rehabil. 78, 125–131. 
Ciliax, B.J., Heilman, C., Demchyshyn, L.L., Pristupa, Z.B., Ince, E., Hersch, S.M., Niznik, H.B., 
Levey, A.I., 1995. The dopamine transporter: immunochemical characterization and 
localization in brain. J. Neurosci. 15, 1714–1723. 
Clarke, H.F., Walker, S.C., Dalley, J.W., Robbins, T.W., Roberts, A.C., 2007. Cognitive 
Inflexibility after Prefrontal Serotonin Depletion Is Behaviorally and Neurochemically 
Specific. Cereb. Cortex 17, 18–27. doi:10.1093/cercor/bhj120 
Comings, D.E., MacMurray, J.P., 2000. Molecular heterosis: a review. Mol. Genet. Metab. 71, 
19–31. doi:10.1006/mgme.2000.3015 
Contant, C.F., Valadka, A.B., Gopinath, S.P., Hannay, H.J., Robertson, C.S., 2001. Adult 
respiratory distress syndrome: a complication of induced hypertension after severe head 
injury. J. Neurosurg. 95, 560–568. doi:10.3171/jns.2001.95.4.0560 
Conti, A.C., Cryan, J.F., Dalvi, A., Lucki, I., Blendy, J.A., 2002. cAMP response element-binding 
protein is essential for the upregulation of brain-derived neurotrophic factor transcription, 
but not the behavioral or endocrine responses to antidepressant drugs. J. Neurosci. Off. J. 
Soc. Neurosci. 22, 3262–3268. doi:20026293 
Cook, K.F., Bombardier, C.H., Bamer, A.M., Choi, S.W., Kroenke, K., Fann, J.R., 2011a. Do 
Somatic and Cognitive Symptoms of Traumatic Brain Injury Confound Depression 
Screening? Arch. Phys. Med. Rehabil. 92, 818–823. doi:16/j.apmr.2010.12.008 
Cook, K.F., Bombardier, C.H., Bamer, A.M., Choi, S.W., Kroenke, K., Fann, J.R., 2011b. Do 
somatic and cognitive symptoms of traumatic brain injury confound depression screening? 
Arch. Phys. Med. Rehabil. 92, 818–823. doi:10.1016/j.apmr.2010.12.008 
Cools, R., D’Esposito, M., 2011a. Inverted-U-shaped dopamine actions on human working 
memory and cognitive control. Biol. Psychiatry 69, e113–125. 
doi:10.1016/j.biopsych.2011.03.028 
Cools, R., D’Esposito, M., 2011b. Inverted-U–Shaped Dopamine Actions on Human Working 
Memory and Cognitive Control. Biol. Psychiatry 69, e113–e125. 
doi:10.1016/j.biopsych.2011.03.028 
Cooper, B.R., Hester, T.J., Maxwell, R.A., 1980. Behavioral and biochemical effects of the 
antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine 
uptake in vivo. J. Pharmacol. Exp. Ther. 215, 127. 
  235 
Cope, E.C., Morris, D.R., Scrimgeour, A.G., VanLandingham, J.W., Levenson, C.W., 2011. Zinc 
supplementation provides behavioral resiliency in a rat model of traumatic brain injury. 
Physiol. Behav. 104, 942–947. doi:10.1016/j.physbeh.2011.06.007 
Cox, D.R., 1972. Regression models and life-tables. J. R. Stat. Soc. Ser. B Methodol. 187–220. 
Croll, S.D., Ip, N.Y., Lindsay, R.M., Wiegand, S.J., 1998. Expression of BDNF and trkB as a 
function of age and cognitive performance. Brain Res. 812, 200–208. 
Cross, D.S., Ivacic, L.C., Stefanski, E.L., McCarty, C.A., 2010. Population based allele 
frequencies of disease associated polymorphisms in the Personalized Medicine Research 
Project. BMC Genet. 11, 51. doi:10.1186/1471-2156-11-51 
Damberg, M., 2005. Transcription factor AP-2 and monoaminergic functions in the central 
nervous system. J. Neural Transm. 112, 1281–1296. doi:10.1007/s00702-005-0325-1 
Damsa, C., Bumb, A., Bianchi-Demicheli, F., Vidailhet, P., Sterck, R., Andreoli, A., Beyenburg, 
S., others, 2004. “ Dopamine-dependent” side effects of selective serotonin reuptake 
inhibitors: a clinical review. J. Clin. Psychiatry 65, 1064. 
Dantzer, R., O’Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., 2008. From 
inflammation to sickness and depression: when the immune system subjugates the brain. 
Nat. Rev. Neurosci. 9, 46–56. doi:10.1038/nrn2297 
Darrah, S.D., Miller, M.A., Ren, D., Hoh, N.Z., Scanlon, J.M., Conley, Y.P., Wagner, A.K., 2012. 
Genetic variability in glutamic acid decarboxylase genes: Associations with post-traumatic 
seizures after severe TBI. Epilepsy Res. doi:10.1016/j.eplepsyres.2012.07.006 
Dawood, T., Anderson, J., Barton, D., Lambert, E., Esler, M., Hotchkin, E., Haikerwal, D., Kaye, 
D., Lambert, G., 2007. Reduced overflow of BDNF from the brain is linked with suicide 
risk in depressive illness. Mol. Psychiatry 12, 981–983. doi:10.1038/sj.mp.4002059 
De Kloet, E.R., Joëls, M., Holsboer, F., 2005. Stress and the brain: from adaptation to disease. Nat. 
Rev. Neurosci. 6, 463–475. doi:10.1038/nrn1683 
Delis, D., 2000. The California Verbal Learning Test. The Psychological Corporation, San 
Antonio. 
Delis, D.C., et al., 2000. The California Verbal Learning Test. The Psychological Corporation, San 
Antonio. 
Delis, D., Kaplan, E., Kramer, J.H., 2001. D-KEFS: examiners manual. The Psychological 
Corporation, San Antonio. 
Depue, B.E., Olson-Madden, J.H., Smolker, H.R., Rajamani, M., Brenner, L.A., Banich, M.T., 
2014. Reduced Amygdala Volume Is Associated with Deficits in Inhibitory Control: A 
Voxel- and Surface-Based Morphometric Analysis of Comorbid PTSD/Mild TBI. BioMed 
Res. Int. 2014. doi:10.1155/2014/691505 
Dias, V.V., Brissos, S., Frey, B.N., Andreazza, A.C., Cardoso, C., Kapczinski, F., 2009. Cognitive 
function and serum levels of brain-derived neurotrophic factor in patients with bipolar 
disorder. Bipolar Disord. 11, 663–671. doi:10.1111/j.1399-5618.2009.00733.x 
Disner, S.G., Beevers, C.G., Haigh, E.A.P., Beck, A.T., 2011. Neural mechanisms of the cognitive 
model of depression. Nat. Rev. Neurosci. 12, 467–477. doi:10.1038/nrn3027 
Dixon, C., Kochanek, P.M., Yan, H.Q., Schiding, J.K., Griffith, R.G., Baum, E., Marion, D.W., 
DeKosky, S.T., 1999. One-year study of spatial memory performance, brain morphology, 
and cholinergic markers after moderate controlled cortical impact in rats. J. Neurotrauma 
16, 109–122. 
  236 
Dodds, T.A., Martin, D.P., Stolov, W.C., Deyo, R.A., 1993. A validation of the functional 
independence measurement and its performance among rehabilitation inpatients. Arch. 
Phys. Med. Rehabil. 74, 531–536. 
Donnemiller, E., Brenneis, C., Wissel, J., Scherfler, C., Poewe, W., Riccabona, G., Wenning, G.K., 
2000. Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a 
SPET study using 123 I-\ss-CIT and 123 I-IBZM. Eur. J. Nucl. Med. Mol. Imaging 27, 
1410–1414. 
Drueke, B., Schlaegel, S.M.A., Seifert, A., Moeller, O., Gründer, G., Gauggel, S., Boecker, M., 
2013. The role of 5-HT in response inhibition and re-engagement. Eur. 
Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 23, 830–841. 
doi:10.1016/j.euroneuro.2013.05.005 
D’Sa, C., Duman, R.S., 2002. Antidepressants and neuroplasticity. Bipolar Disord. 4, 183–194. 
doi:10.1034/j.1399-5618.2002.01203.x 
Duan, J., Wainwright, M.S., Comeron, J.M., Saitou, N., Sanders, A.R., Gelernter, J., Gejman, P.V., 
2003. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA 
stability and synthesis of the receptor. Hum. Mol. Genet. 12, 205–216. 
Dumontheil, I., Roggeman, C., Ziermans, T., Peyrard-Janvid, M., Matsson, H., Kere, J., Klingberg, 
T., 2011. Influence of the COMT Genotype on Working Memory and Brain Activity 
Changes During Development. Biol. Psychiatry 70, 222–229. 
doi:10.1016/j.biopsych.2011.02.027 
Dunlop, B.W., Nemeroff, C.B., 2007. The Role of Dopamine in the Pathophysiology of 
Depression. Arch Gen Psychiatry 64, 327–337. doi:10.1001/archpsyc.64.3.327 
Edenberg, H., Reynolds, J., 1998. Improved method for detecting the long and short promoter 
alleles of the serotonin transporter gene HTT (SLC6A4). Psychiatr. Genet. 8, 193. 
Egan, M.F., Goldberg, T.E., Kolachana, B.S., Callicott, J.H., Mazzanti, C.M., Straub, R.E., 
Goldman, D., Weinberger, D.R., 2001. Effect of COMT Val108/158 Met genotype on 
frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. 98, 6917–6922. 
doi:10.1073/pnas.111134598 
Egan, M.F., Kojima, M., Callicott, J.H., Goldberg, T.E., Kolachana, B.S., Bertolino, A., Zaitsev, 
E., Gold, B., Goldman, D., Dean, M., Lu, B., Weinberger, D.R., 2003. The BDNF val66met 
polymorphism affects activity-dependent secretion of BDNF and human memory and 
hippocampal function. Cell 112, 257–269. 
Eker, C., Kitis, O., Taneli, F., Eker, O.D., Ozan, E., Yucel, K., Coburn, K., Gonul, A.S., 2010. 
Correlation of serum BDNF levels with hippocampal volumes in first episode, medication-
free depressed patients. Eur. Arch. Psychiatry Clin. Neurosci. 260, 527–533. 
doi:10.1007/s00406-010-0110-5 
Elovic, E.P., Lansang, R., Li, Y., Ricker, J.H., 2003. The use of atypical antipsychotics in traumatic 
brain injury. J. Head Trauma Rehabil. 18, 177–195. 
Erickson, K.I., Miller, D.L., Roecklein, K.A., 2012. The aging hippocampus: interactions between 
exercise, depression, and BDNF. Neurosci. Rev. J. Bringing Neurobiol. Neurol. Psychiatry 
18, 82–97. doi:10.1177/1073858410397054 
Erickson, K.I., Prakash, R.S., Voss, M.W., Chaddock, L., Heo, S., McLaren, M., Pence, B.D., 
Martin, S.A., Vieira, V.J., Woods, J.A., McAuley, E., Kramer, A.F., 2010. Brain-derived 
neurotrophic factor is associated with age-related decline in hippocampal volume. J. 
Neurosci. Off. J. Soc. Neurosci. 30, 5368–5375. doi:10.1523/JNEUROSCI.6251-09.2010 
  237 
Erritzoe, D., Holst, K., Frokjaer, V.G., Licht, C.L., Kalbitzer, J., Nielsen, F.Å., Svarer, C., Madsen, 
J., Knudsen, G.M., 2010. A Nonlinear Relationship between Cerebral Serotonin 
Transporter and 5-HT2A Receptor Binding: An In Vivo Molecular Imaging Study in 
Humans. J. Neurosci. 30, 3391–3397. doi:10.1523/JNEUROSCI.2852-09.2010 
Etkin, A., Egner, T., Kalisch, R., 2011. Emotional processing in anterior cingulate and medial 
prefrontal cortex. Trends Cogn. Sci. 15, 85–93. doi:10.1016/j.tics.2010.11.004 
Failla, M.D., Burkhardt, J.N., Miller, M.A., Scanlon, J.M., Conley, Y.P., Ferrell, R.E., Wagner, 
A.K., 2013. Variants of SLC6A4 in depression risk following severe TBI. Brain Inj. BI 27, 
696–706. doi:10.3109/02699052.2013.775481 
Failla, M.D., John Myrga M., Ricker, J.H., Dixon, C.E., Conley, Y.P., Wagner, A.K., n.d. Post-
TBI Cognitive Performance is moderated by variation within ANKK1 and DRD2 genes. J. 
Head Trauma Rehabil. 
Failla, M.D., Kumar, R.G., Peitzman, A.B., Conley, Y.P., Ferrell, R.E., Wagner, A.K., 2014. 
Variation in the BDNF Gene Interacts With Age to Predict Mortality in a Prospective, 
Longitudinal Cohort with Severe TBI. Neurorehabil. Neural Repair. 
doi:10.1177/1545968314542617 
Fales, C.L., Barch, D.M., Rundle, M.M., Mintun, M.A., Snyder, A.Z., Cohen, J.D., Mathews, J., 
Sheline, Y.I., 2008. Altered emotional interference processing in affective and cognitive-
control brain circuitry in major depression. Biol. Psychiatry 63, 377–384. 
doi:10.1016/j.biopsych.2007.06.012 
Fann, J.R., Bombardier, C.H., Dikmen, S., Esselman, P., Warms, C.A., Pelzer, E., Rau, H., 
Temkin, N., 2005. Validity of the Patient Health Questionnaire-9 in assessing depression 
following traumatic brain injury. J. Head Trauma Rehabil. 20, 501–511. 
Fann, J.R., Hart, T., Schomer, K.G., 2009a. Treatment for Depression after Traumatic Brain Injury: 
A Systematic Review. J. Neurotrauma 26, 2383–2402. doi:10.1089/neu.2009.1091 
Fann, J.R., Hart, T., Schomer, K.G., 2009b. Treatment for Depression after Traumatic Brain 
Injury: A Systematic Review. J. Neurotrauma 26, 2383–2402. doi:10.1089/neu.2009.1091 
Fann, J.R., Uomoto, J.M., Katon, W.J., 2001. Cognitive Improvement With Treatment of 
Depression Following Mild Traumatic Brain Injury. Psychosomatics 42, 48–54. 
doi:10.1176/appi.psy.42.1.48 
Faraone, S.V., Perlis, R.H., Doyle, A.E., Smoller, J.W., Goralnick, J.J., Holmgren, M.A., Sklar, 
P., 2005. Molecular genetics of attention-deficit/hyperactivity disorder. Biol. Psychiatry 
57, 1313–1323. doi:10.1016/j.biopsych.2004.11.024 
Faul, M., Xu, L., Wald, M.M., Coronado, V.G., 2010. Traumatic Brain Injury in the United States: 
Emergency Department Visits, Hospitalizations and Deaths 2002–2006. Atlanta GA Cent. 
Dis. Control Prev. Natl. Cent. Inj. Prev. Control. 
Fenn, A.M., Gensel, J.C., Huang, Y., Popovich, P.G., Lifshitz, J., Godbout, J.P., 2013. Immune 
Activation Promotes Depression 1 Month After Diffuse Brain Injury: A Role for Primed 
Microglia. Biol. Psychiatry. doi:10.1016/j.biopsych.2013.10.014 
Fischl, B., 2012. FreeSurfer. NeuroImage. doi:10.1016/j.neuroimage.2012.01.021 
Fischl, B., Salat, D.H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., 
Killiany, R., Kennedy, D., Klaveness, S., Montillo, A., Makris, N., Rosen, B., Dale, A.M., 
2002. Whole brain segmentation: automated labeling of neuroanatomical structures in the 
human brain. Neuron 33, 341–355. 
Fischl, B., van der Kouwe, A., Destrieux, C., Halgren, E., Ségonne, F., Salat, D.H., Busa, E., 
Seidman, L.J., Goldstein, J., Kennedy, D., Caviness, V., Makris, N., Rosen, B., Dale, A.M., 
  238 
2004. Automatically parcellating the human cerebral cortex. Cereb. Cortex N. Y. N 1991 
14, 11–22. 
Fleming, J., Tooth, L., Hassell, M., Chan, W., 1999. Prediction of community integration and 
vocational outcome 2-5 years after traumatic brain injury rehabilitation in Australia. Brain 
Inj. BI 13, 417–431. 
Freedman, M.L., Reich, D., Penney, K.L., McDonald, G.J., Mignault, A.A., Patterson, N., Gabriel, 
S.B., Topol, E.J., Smoller, J.W., Pato, C.N., Pato, M.T., Petryshen, T.L., Kolonel, L.N., 
Lander, E.S., Sklar, P., Henderson, B., Hirschhorn, J.N., Altshuler, D., 2004. Assessing the 
impact of population stratification on genetic association studies. Nat. Genet. 36, 388–393. 
doi:10.1038/ng1333 
Frenette, A.J., Kanji, S., Rees, L., Williamson, D.R., Perreault, M.M., Turgeon, A.F., Bernard, F., 
Fergusson, D.A., 2012. Efficacy and safety of dopamine agonists in traumatic brain injury: 
a systematic review of randomized controlled trials. J. Neurotrauma 29, 1–18. 
doi:10.1089/neu.2011.1812 
Frenois, F., Moreau, M., O’Connor, J., Lawson, M., Micon, C., Lestage, J., Kelley, K.W., Dantzer, 
R., Castanon, N., 2007. Lipopolysaccharide induces delayed FosB/DeltaFosB 
immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, 
that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 32, 
516–531. doi:10.1016/j.psyneuen.2007.03.005 
Frias, C.M. de, Annerbrink, K., Westberg, L., Eriksson, E., Adolfsson, R., Nilsson, L.-G., 2005. 
Catechol O-Methyltransferase Val158Met Polymorphism is Associated with Cognitive 
Performance in Nondemented Adults. J. Cogn. Neurosci. 17, 1018–1025. 
doi:10.1162/0898929054475136 
Frodl, T., Koutsouleris, N., Bottlender, R., Born, C., Jager, M., Morgenthaler, M., Scheuerecker, 
J., Zill, P., Baghai, T., Schule, C., Rupprecht, R., Bondy, B., Reiser, M., Moller, H.-J., 
Meisenzahl, E.M., 2008. Reduced gray matter brain volumes are associated with variants 
of the serotonin transporter gene in major depression. Mol Psychiatry 13, 1093–1101. 
Frodl, T., Meisenzahl, E.M., Zill, P., Baghai, T., Rujescu, D., Leinsinger, G., Bottlender, R., 
Schule, C., Zwanzger, P., Engel, R.R., Rupprecht, R., Bondy, B., Reiser, M., Moller, H.-
J., 2004. Reduced Hippocampal Volumes Associated With the Long Variant of the 
Serotonin Transporter Polymorphism in Major Depression. Arch Gen Psychiatry 61, 177–
183. doi:10.1001/archpsyc.61.2.177 
Fujimura, H., Altar, C.A., Chen, R., Nakamura, T., Nakahashi, T., Kambayashi, J., Sun, B., 
Tandon, N.N., 2002. Brain-derived neurotrophic factor is stored in human platelets and 
released by agonist stimulation. Thromb. Haemost. 87, 728–734. 
Fujiwara, E., Schwartz, M.L., Gao, F., Black, S.E., Levine, B., 2008. Ventral frontal cortex 
functions and quantified MRI in traumatic brain injury. Neuropsychologia 46, 461–474. 
doi:10.1016/j.neuropsychologia.2007.08.027 
Gale, S.D., Baxter, L., Roundy, N., Johnson, S.C., 2005. Traumatic brain injury and grey matter 
concentration: a preliminary voxel based morphometry study. J. Neurol. Neurosurg. 
Psychiatry 76, 984–988. doi:10.1136/jnnp.2004.036210 
Gao, W.-M., Chadha, M.S., Kline, A.E., Clark, R.S.B., Kochanek, P.M., Dixon, C.E., Jenkins, 
L.W., 2006. Immunohistochemical analysis of histone H3 acetylation and methylation--
evidence for altered epigenetic signaling following traumatic brain injury in immature rats. 
Brain Res. 1070, 31–34. doi:10.1016/j.brainres.2005.11.038 
  239 
Garcı́a, M.A., Vázquez, J., Giménez, C., Valdivieso, F., Zafra, F., 1996. Transcription Factor AP-
2 Regulates Human Apolipoprotein E Gene Expression in Astrocytoma Cells. J. Neurosci. 
16, 7550–7556. 
Gass, P., Hellweg, R., 2010. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker 
for affective disorders? Int. J. Neuropsychopharmacol. Off. Sci. J. Coll. Int. 
Neuropsychopharmacol. CINP 13, 1–4. doi:10.1017/S1461145709991039 
Gelernter, J., Cubells, J.F., Kidd, J.R., Pakstis, A.J., Kidd, K.K., 1999. Population studies of 
polymorphisms of the serotonin transporter protein gene. Am. J. Med. Genet. 88, 61–66. 
doi:10.1002/(SICI)1096-8628(19990205)88:1<61::AID-AJMG11>3.0.CO;2-K 
Gfeller, J.D., Chibnall, J.T., Duckro, P.N., 1994. Postconcussion symptoms and cognitive 
functioning in posttraumatic headache patients. Headache 34, 503–507. 
Goldman, D., Brown, G.L., Albaugh, B., Robin, R., Goodson, S., Trunzo, M., Akhtar, L., Lucas-
Derse, S., Long, J., Linnoila, M., 1993. DRD2 dopamine receptor genotype, linkage 
disequilibrium, and alcoholism in American Indians and other populations. Alcohol. Clin. 
Exp. Res. 17, 199–204. 
Goldstein, B., Toweill, D., Lai, S., Sonnenthal, K., Kimberly, B., 1998. Uncoupling of the 
autonomic and cardiovascular systems in acute brain injury. Am. J. Physiol. 275, R1287–
1292. 
Gomes, J.R., Costa, J.T., Melo, C.V., Felizzi, F., Monteiro, P., Pinto, M.J., Inácio, A.R., Wieloch, 
T., Almeida, R.D., Grãos, M., Duarte, C.B., 2012. Excitotoxicity downregulates TrkB.FL 
signaling and upregulates the neuroprotective truncated TrkB receptors in cultured 
hippocampal and striatal neurons. J. Neurosci. Off. J. Soc. Neurosci. 32, 4610–4622. 
doi:10.1523/JNEUROSCI.0374-12.2012 
Gotlib, I.H., Joormann, J., 2010. Cognition and depression: current status and future directions. 
Annu. Rev. Clin. Psychol. 6, 285–312. doi:10.1146/annurev.clinpsy.121208.131305 
Gould, K.R., Ponsford, J.L., Johnston, L., Sch�nberger, M., 2011. The Nature, Frequency and 
Course of Psychiatric Disorders in the First Year After Traumatic Brain Injury: A 
Prospective Study. Psychol. Med. FirstView, 1–11. doi:10.1017/S003329171100033X 
Goyal, A., Failla, M.D., Niyonkuru, C., Amin, K., Fabio, A., Berger, R.P., Wagner, A.K., 2013. 
S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic 
brain injury. J. Neurotrauma 30, 946–957. doi:10.1089/neu.2012.2579 
Grade, C., Redford, B., Chrostowski, J., Toussaint, L., Blackwell, B., 1998. Methylphenidate in 
early poststroke recovery: a double-blind, placebo-controlled study. Arch. Phys. Med. 
Rehabil. 79, 1047–1050. 
Graham, D.P., Helmer, D.A., Harding, M.J., Kosten, T.R., Petersen, N.J., Nielsen, D.A., 2013. 
Serotonin transporter genotype and mild traumatic brain injury independently influence 
resilience and perception of limitations in Veterans. J. Psychiatr. Res. 47, 835–842. 
doi:10.1016/j.jpsychires.2013.02.006 
Graybiel, A.M., 2005. The basal ganglia: learning new tricks and loving it. Curr. Opin. Neurobiol. 
15, 638–644. doi:10.1016/j.conb.2005.10.006 
Green, R.E., Colella, B., Christensen, B., Johns, K., Frasca, D., Bayley, M., Monette, G., 2008. 
Examining moderators of cognitive recovery trajectories after moderate to severe traumatic 
brain injury. Arch. Phys. Med. Rehabil. 89, S16–24. doi:10.1016/j.apmr.2008.09.551 
Greicius, M.D., Supekar, K., Menon, V., Dougherty, R.F., 2009. Resting-state functional 
connectivity reflects structural connectivity in the default mode network. Cereb. Cortex 19, 
72–78. 
  240 
Griesbach, G.S., Hovda, D.A., Gomez-Pinilla, F., 2009. Exercise-induced improvement in 
cognitive performance after traumatic brain injury in rats is dependent on BDNF activation. 
Brain Res. 1288, 105–115. doi:10.1016/j.brainres.2009.06.045 
Griesbach, G.S., Tio, D.L., Nair, S., Hovda, D., 2013. Recovery of Stress Response Coincides with 
Responsiveness to Voluntary Exercise after Traumatic Brain Injury. J. Neurotrauma. 
doi:10.1089/neu.2013.3151 
Griesbach, G.S., Tio, D.L., Vincelli, J., McArthur, D.L., Taylor, A.N., 2012. Differential Effects 
of Voluntary and Forced Exercise on Stress Responses after Traumatic Brain Injury. J. 
Neurotrauma 29, 1426–1433. doi:10.1089/neu.2011.2229 
Griffin, É.W., Mullally, S., Foley, C., Warmington, S.A., O’Mara, S.M., Kelly, A.M., 2011. 
Aerobic exercise improves hippocampal function and increases BDNF in the serum of 
young adult males. Physiol. Behav. 104, 934–941. doi:10.1016/j.physbeh.2011.06.005 
Guillin, O., Diaz, J., Carroll, P., Griffon, N., Schwartz, J.-C., Sokoloff, P., 2001. BDNF controls 
dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411, 86–
89. doi:10.1038/35075076 
Gunstad, J., Benitez, A., Smith, J., Glickman, E., Spitznagel, M.B., Alexander, T., Juvancic-
Heltzel, J., Murray, L., 2008. Serum brain-derived neurotrophic factor is associated with 
cognitive function in healthy older adults. J. Geriatr. Psychiatry Neurol. 21, 166–170. 
doi:10.1177/0891988708316860 
Halldén, S., Sjögren, M., Hedblad, B., Engström, G., Narkiewicz, K., Hoffmann, M., Wahlstrand, 
B., Hedner, T., Melander, O., 2013. Smoking and obesity associated BDNF gene variance 
predicts total and cardiovascular mortality in smokers. Heart Br. Card. Soc. 99, 949–953. 
doi:10.1136/heartjnl-2013-303634 
Hamani, C., Mayberg, H., Stone, S., Laxton, A., Haber, S., Lozano, A.M., 2011. The subcallosal 
cingulate gyrus in the context of major depression. Biol. Psychiatry 69, 301–308. 
Hamilton, J.P., Siemer, M., Gotlib, I.H., 2008. Amygdala volume in major depressive disorder: a 
meta-analysis of magnetic resonance imaging studies. Mol. Psychiatry 13, 993–1000. 
doi:10.1038/mp.2008.57 
Hammond, F.M., Grattan, K.D., Sasser, H., Corrigan, J.D., Rosenthal, M., Bushnik, T., Shull, W., 
2004. Five years after traumatic brain injury: A study of individual outcomes and predictors 
of change in function. NeuroRehabilitation 19, 25–35. 
Hariri, A.R., Mattay, V.S., Tessitore, A., Kolachana, B., Fera, F., Goldman, D., Egan, M.F., 
Weinberger, D.R., 2002. Serotonin Transporter Genetic Variation and the Response of the 
Human Amygdala. Science 297, 400 –403. doi:10.1126/science.1071829 
Harrison-Felix, C., Whiteneck, G., Devivo, M.J., Hammond, F.M., Jha, A., 2006. Causes of death 
following 1 year postinjury among individuals with traumatic brain injury. J. Head Trauma 
Rehabil. 21, 22–33. 
Harrison, P.J., Tunbridge, E.M., 2007. Catechol-O-Methyltransferase (COMT): A Gene 
Contributing to Sex Differences in Brain Function, and to Sexual Dimorphism in the 
Predisposition to Psychiatric Disorders. Neuropsychopharmacology 33, 3037–3045. 
doi:10.1038/sj.npp.1301543 
Hashimoto, K., 2010. Brain-derived neurotrophic factor as a biomarker for mood disorders: an 
historical overview and future directions. Psychiatry Clin. Neurosci. 64, 341–357. 
doi:10.1111/j.1440-1819.2010.02113.x 
Heaton, R.K., 1981. Wisconsin Card Sorting Test Manual. Psychological Assesment Resources, 
Odessa, FL. 
  241 
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., Lesch, K.P., 2002. Allelic 
Variation of Human Serotonin Transporter Gene Expression. J. Neurochem. 66, 2621–
2624. doi:10.1046/j.1471-4159.1996.66062621.x 
Hernández, T.D., 2006. Post-traumatic neural depression and neurobehavioral recovery after brain 
injury. J. Neurotrauma 23, 1211–1221. doi:10.1089/neu.2006.23.1211 
Hertel, P.T., 1998. Relation between rumination and impaired memory in dysphoric moods. J. 
Abnorm. Psychol. 107, 166–172. 
Hertel, P.T., Rude, S.S., 1991. Depressive deficits in memory: focusing attention improves 
subsequent recall. J. Exp. Psychol. Gen. 120, 301–309. 
Hibbard, M.R., Ashman, T.A., Spielman, L.A., Chun, D., Charatz, H.J., Melvin, S., 2004. 
Relationship between depression and psychosocial functioning after traumatic brain injury. 
Arch. Phys. Med. Rehabil. 85, S43–53. 
Hicks, R.R., Numan, S., Dhillon, H.S., Prasad, M.R., Seroogy, K.B., 1997. Alterations in BDNF 
and NT-3 mRNAs in rat hippocampus after experimental brain trauma. Brain Res. Mol. 
Brain Res. 48, 401–406. 
Hinkelmann, K., Moritz, S., Botzenhardt, J., Riedesel, K., Wiedemann, K., Kellner, M., Otte, C., 
2009. Cognitive impairment in major depression: association with salivary cortisol. Biol. 
Psychiatry 66, 879–885. doi:10.1016/j.biopsych.2009.06.023 
Hoffman, J.M., Bell, K.R., Powell, J.M., Behr, J., Dunn, E.C., Dikmen, S., Bombardier, C.H., 
2010. A randomized controlled trial of exercise to improve mood after traumatic brain 
injury. PM R 2, 911–919. doi:10.1016/j.pmrj.2010.06.008 
Hohenadel, M.G., Thearle, M.S., Grice, B.A., Huang, H., Dai, M.-H., Tao, Y.-X., Hunter, L.A., 
Palaguachi, G.I., Mou, Z., Kim, R.C., Tsang, M.M., Haack, K., Voruganti, V.S., Cole, 
S.A., Butte, N.F., Comuzzie, A.G., Muller, Y.L., Baier, L.J., Krakoff, J., Knowler, W.C., 
Yanovski, J.A., Han, J.C., 2014. Brain-derived neurotrophic factor in human subjects with 
function-altering melanocortin-4 receptor variants. Int. J. Obes. 38, 1068–1074. 
doi:10.1038/ijo.2013.221 
Hoh, N.Z., Wagner, A.K., Alexander, S.A., Clark, R.B., Beers, S.R., Okonkwo, D.O., Ren, D., 
Conley, Y.P., 2010. BCL2 genotypes: functional and neurobehavioral outcomes after 
severe traumatic brain injury. J. Neurotrauma 27, 1413–1427. doi:10.1089/neu.2009.1256 
Homberg, J.R., Lesch, K.-P., 2011. Looking on the bright side of serotonin transporter gene 
variation. Biol. Psychiatry 69, 513–519. doi:10.1016/j.biopsych.2010.09.024 
Honea, R., Verchinski, B.A., Pezawas, L., Kolachana, B.S., Callicott, J.H., Mattay, V.S., 
Weinberger, D.R., Meyer-Lindenberg, A., 2009. Impact of interacting functional variants 
in COMT on regional gray matter volume in human brain. NeuroImage 45, 44–51. 
doi:10.1016/j.neuroimage.2008.10.064 
Hoofien, D., Gilboa, A., Vakil, E., Donovick, P.J., 2001. Traumatic brain injury (TBI) 10-20 years 
later: a comprehensive outcome study of psychiatric symptomatology, cognitive abilities 
and psychosocial functioning. Brain Inj. BI 15, 189–209. 
doi:10.1080/026990501300005659 
Hoofien, D., Vakil, E., Gilboa, A., Donovick, P.J., Barak, O., 2002. Comparison of the predictive 
power of socio-economic variables, severity of injury and age on long-term outcome of 
traumatic brain injury: sample-specific variables versus factors as predictors. Brain Inj. BI 
16, 9–27. doi:10.1080/02699050110088227 
Ho, P.-S., Ho, K.K.-J., Huang, W.-S., Yen, C.-H., Shih, M.-C., Shen, L.-H., Ma, K.-H., Huang, 
S.-Y., n.d. Association study of serotonin transporter availability and SLC6A4 gene 
  242 
polymorphisms in patients with major depression. Psychiatry Res. Neuroimaging. 
doi:10.1016/j.pscychresns.2012.04.005 
Horch, H.W., Katz, L.C., 2002. BDNF release from single cells elicits local dendritic growth in 
nearby neurons. Nat Neurosci 5, 1177–1184. doi:10.1038/nn927 
Horsfield, S.A., Rosse, R.B., Tomasino, V., Schwartz, B.L., Mastropaolo, J., Deutsch, S.I., 2002. 
Fluoxetine’s effects on cognitive performance in patients with traumatic brain injury. Int. 
J. Psychiatry Med. 32, 337–344. 
Hranilovic, D., Stefulj, J., Schwab, S., Borrmann-Hassenbach, M., Albus, M., Jernej, B., 
Wildenauer, D., 2004. Serotonin transporter promoter and intron 2 polymorphisms: 
relationship between allelic variants and gene expression. Biol. Psychiatry 55, 1090–1094. 
doi:10.1016/j.biopsych.2004.01.029 
Hudak, A.M., Hynan, L.S., Harper, C.R., Diaz-Arrastia, R., 2012. Association of depressive 
symptoms with functional outcome after traumatic brain injury. J. Head Trauma Rehabil. 
27, 87–98. doi:10.1097/HTR.0b013e3182114efd 
Hudak, A., Warner, M., Marquez de la Plata, C., Moore, C., Harper, C., Diaz-Arrastia, R., 2011. 
Brain morphometry changes and depressive symptoms after traumatic brain injury. 
Psychiatry Res. Neuroimaging 191, 160–165. 
Hyder, A.A., Wunderlich, C.A., Puvanachandra, P., Gururaj, G., Kobusingye, O.C., 2007. The 
impact of traumatic brain injuries: A global perspective. NeuroRehabilitation 22, 341–353. 
Ikonomidou, C., Turski, L., 2002. Why did NMDA receptor antagonists fail clinical trials for 
stroke and traumatic brain injury? Lancet Neurol. 1, 383–386. 
Irimia, A., Goh, S.-Y.M., Torgerson, C.M., Vespa, P.M., Van Horn, J.D., 2014. STRUCTURAL 
AND CONNECTOMIC NEUROIMAGING FOR THE PERSONALIZED STUDY OF 
LONGITUDINAL ALTERATIONS IN CORTICAL SHAPE, THICKNESS AND 
CONNECTIVITY AFTER TRAUMATIC BRAIN INJURY. J. Neurosurg. Sci. 58, 129–
144. 
Jacobs, E., D’Esposito, M., 2011. Estrogen shapes dopamine-dependent cognitive processes: 
implications for women’s health. J. Neurosci. Off. J. Soc. Neurosci. 31, 5286–5293. 
doi:10.1523/JNEUROSCI.6394-10.2011 
Jacobson, L., Sapolsky, R., 1991. The role of the hippocampus in feedback regulation of the 
hypothalamic-pituitary-adrenocortical axis. Endocr. Rev. 12, 118–134. 
Jennett, B., Bond, M., 1975. Assessment of outcome after severe brain damage. Lancet 1, 480–
484. 
Jennifer Fleming, Leigh Tooth, Mary, 1999. Prediction of community integration and vocational 
outcome 2-5 years after traumatic brain injury rehabilitation in Australia. Brain Inj. 13, 
417–431. doi:10.1080/026990599121476 
Jiang, L., Liu, C., Tong, J., Mao, R., Chen, D., Wang, H., Huang, J., Li, L., 2014. Fluoxetine 
Pretreatment Promotes Neuronal Survival and Maturation after Auditory Fear 
Conditioning in the Rat Amygdala. PLoS ONE 9, e89147. 
doi:10.1371/journal.pone.0089147 
Joëls, M., 2008. Functional actions of corticosteroids in the hippocampus. Eur. J. Pharmacol. 583, 
312–321. doi:10.1016/j.ejphar.2007.11.064 
Joormann, J., Dkane, M., Gotlib, I.H., 2006. Adaptive and maladaptive components of rumination? 
Diagnostic specificity and relation to depressive biases. Behav. Ther. 37, 269–280. 
Jorge, R.E., Arciniegas, D.B., 2014. Mood Disorders After TBI. Psychiatr. Clin. North Am., 
Neuropsychiatry of Traumatic Brain Injury 37, 13–29. doi:10.1016/j.psc.2013.11.005 
  243 
Jorge, R.E., Robinson, R.G., Arndt, S.V., Starkstein, S.E., Forrester, A.W., Geisler, F., 1993. 
Depression following traumatic brain injury: a 1 year longitudinal study. J. Affect. Disord. 
27, 233–243. doi:16/0165-0327(93)90047-N 
Jorge, R.E., Robinson, R.G., Moser, D., Tateno, A., Crespo-Facorro, B., Arndt, S., 2004. Major 
depression following traumatic brain injury. Arch. Gen. Psychiatry 61, 42–50. 
doi:10.1001/archpsyc.61.1.42 
Jorge, R.E., Robinson, R.G., Starkstein, S.E., Arndt, S.V., 1994. Influence of major depression on 
1-year outcome in patients with traumatic brain injury. J. Neurosurg. 81, 726–733. 
doi:10.3171/jns.1994.81.5.0726 
Juengst, S.B., Kumar, R.G., Failla, M.D., Goyal, A., Wagner, A.K., 2014. Acute Inflammatory 
Biomarker Profiles Predict Depression Risk Following Moderate to Severe Traumatic 
Brain Injury. J. Head Trauma Rehabil. doi:10.1097/HTR.0000000000000031 
Juengst, S., Skidmore, E., Arenth, P.M., Niyonkuru, C., Raina, K.D., 2013. Unique contribution 
of fatigue to disability in community-dwelling adults with traumatic brain injury. Arch. 
Phys. Med. Rehabil. 94, 74–79. doi:10.1016/j.apmr.2012.07.025 
Kalish, H., Phillips, T.M., 2010. Analysis of neurotrophins in human serum by immunoaffinity 
capillary electrophoresis (ICE) following traumatic head injury. J. Chromatogr. B Analyt. 
Technol. Biomed. Life. Sci. 878, 194–200. doi:10.1016/j.jchromb.2009.10.022 
Kaplan, G.B., Vasterling, J.J., Vedak, P.C., 2010. Brain-derived neurotrophic factor in traumatic 
brain injury, post-traumatic stress disorder, and their comorbid conditions: role in 
pathogenesis and treatment. Behav. Pharmacol. 21, 427–437. 
doi:10.1097/FBP.0b013e32833d8bc9 
Karege, F., Bondolfi, G., Gervasoni, N., Schwald, M., Aubry, J.-M., Bertschy, G., 2005. Low 
Brain-Derived Neurotrophic Factor (BDNF) levels in serum of depressed patients probably 
results from lowered platelet BDNF release unrelated to platelet reactivity. Biol. Psychiatry 
57, 1068–1072. doi:10.1016/j.biopsych.2005.01.008 
Karege, F., Perret, G., Bondolfi, G., Schwald, M., Bertschy, G., Aubry, J.-M., 2002. Decreased 
serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 
109, 143–148. 
Karg, K., Burmeister, M., Shedden, K., Sen, S., 2011. The Serotonin Transporter Promoter Variant 
(5-HTTLPR), Stress, and Depression Meta-analysis Revisited: Evidence of Genetic 
Moderation. Arch Gen Psychiatry 68, 444–454. doi:10.1001/archgenpsychiatry.2010.189 
Kasselman, L.J., Sideris, A., Bruno, C., Perez, W.R., Cai, N., Nicoletti, J.N., Wiegand, S.J., Croll, 
S.D., 2006. BDNF: A missing link between sympathetic dysfunction and inflammatory 
disease? J. Neuroimmunol. 175, 118–127. doi:10.1016/j.jneuroim.2006.03.008 
Katz, D.I., Alexander, M.P., 1994. Traumatic brain injury. Predicting course of recovery and 
outcome for patients admitted to rehabilitation. Arch. Neurol. 51, 661–670. 
Katz, D.I., Alexander, M.P., Klein, R.B., 1998. Recovery of arm function in patients with paresis 
after traumatic brain injury. Arch. Phys. Med. Rehabil. 79, 488–493. 
Kenna, G.A., Roder-Hanna, N., Leggio, L., Zywiak, W.H., Clifford, J., Edwards, S., Kenna, J.A., 
Shoaff, J., Swift, R.M., 2012. Association of the 5-HTT gene-linked promoter region (5-
HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and 
pharmacotherapy. Pharmacogenomics Pers. Med. 5, 19–35. doi:10.2147/PGPM.S23462 
Kennedy, K.M., Rodrigue, K.M., Land, S.J., Raz, N., 2009. BDNF Val66Met polymorphism 
influences age differences in microstructure of the Corpus Callosum. Front. Hum. 
Neurosci. 3, 19. doi:10.3389/neuro.09.019.2009 
  244 
Kernie, S.G., Liebl, D.J., Parada, L.F., 2000. BDNF regulates eating behavior and locomotor 
activity in mice. EMBO J. 19, 1290–1300. doi:10.1093/emboj/19.6.1290 
Kessler, R.C., Chiu, W.T., Demler, O., Walters, E.E., 2005. Prevalence, Severity, and Comorbidity 
of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication. Arch 
Gen Psychiatry 62, 617–627. doi:10.1001/archpsyc.62.6.617 
Kim, J., Avants, B., Patel, S., Whyte, J., Coslett, B.H., Pluta, J., Detre, J.A., Gee, J.C., 2008. 
Structural consequences of diffuse traumatic brain injury: a large deformation tensor-based 
morphometry study. NeuroImage 39, 1014–1026. doi:10.1016/j.neuroimage.2007.10.005 
Kim, J., Whyte, J., Patel, S., Europa, E., Wang, J., Coslett, H.B., Detre, J.A., 2011. 
Methylphenidate modulates sustained attention and cortical activation in survivors of 
traumatic brain injury: a perfusion fMRI study. Psychopharmacology (Berl.). 
doi:10.1007/s00213-011-2622-8 
Kim, S.N., Kang, D.-H., Yun, J.-Y., Lee, T.Y., Jung, W.H., Jang, J.H., Kwon, J.S., 2013. Impact 
of the BDNF Val66Met Polymorphism on Regional Brain Gray Matter Volumes: 
Relevance to the Stress Response. Psychiatry Investig. 10, 173–179. 
doi:10.4306/pi.2013.10.2.173 
Kline, A.E., Yu, J., Massucci, J.L., Zafonte, R.D., Dixon, C.E., 2002. Protective effects of the 5-
HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin against traumatic brain 
injury-induced cognitive deficits and neuropathology in adult male rats. Neurosci. Lett. 
333, 179–182. doi:10.1016/S0304-3940(02)01101-1 
Kline, A.., Yu, J., HorvÃ¡th, E., Marion, D.., Dixon, C.., 2001. The selective 5-HT1A receptor 
agonist repinotan HCl attenuates histopathology and spatial learning deficits following 
traumatic brain injury in rats. Neuroscience 106, 547–555. doi:10.1016/S0306-
4522(01)00300-1 
Kobiella, A., Reimold, M., Ulshofer, D.E., Ikonomidou, V.N., Vollmert, C., Vollstadt-Klein, S., 
Rietschel, M., Reischl, G., Heinz, A., Smolka, M.N., 2011. How the serotonin transporter 
5-HTTLPR polymorphism influences amygdala function: the roles of in vivo serotonin 
transporter expression and amygdala structure. Transl Psychiatry 1, e37. 
Koolschijn, P.C.M.P., van Haren, N.E.M., Lensvelt-Mulders, G.J.L.M., Hulshoff Pol, H.E., Kahn, 
R.S., 2009. Brain volume abnormalities in major depressive disorder: a meta-analysis of 
magnetic resonance imaging studies. Hum. Brain Mapp. 30, 3719–3735. 
doi:10.1002/hbm.20801 
Koponen, S., Taiminen, T., Portin, R., Himanen, L., Isoniemi, H., Heinonen, H., Hinkka, S., 
Tenovuo, O., 2002. Axis I and II psychiatric disorders after traumatic brain injury: a 30-
year follow-up study. Am. J. Psychiatry 159, 1315–1321. 
Kouneiher, F., Charron, S., Koechlin, E., 2009. Motivation and cognitive control in the human 
prefrontal cortex. Nat. Neurosci. 12, 939–945. doi:10.1038/nn.2321 
Kovalchuk, Y., Hanse, E., Kafitz, K.W., Konnerth, A., 2002. Postsynaptic Induction of BDNF-
Mediated Long-Term Potentiation. Science 295, 1729–1734. doi:10.1126/science.1067766 
Krabbe, K.S., Mortensen, E.L., Avlund, K., Pedersen, A.N., Pedersen, B.K., Jørgensen, T., 
Bruunsgaard, H., 2009. Brain-derived neurotrophic factor predicts mortality risk in older 
women. J. Am. Geriatr. Soc. 57, 1447–1452. doi:10.1111/j.1532-5415.2009.02345.x 
Kraus, M.F., Susmaras, T., Caughlin, B.P., Walker, C.J., Sweeney, J.A., Little, D.M., 2007. White 
matter integrity and cognition in chronic traumatic brain injury: a diffusion tensor imaging 
study. Brain 130, 2508 –2519. doi:10.1093/brain/awm216 
  245 
Krishnan, V., Nestler, E.J., 2008. The molecular neurobiology of depression. Nature 455, 894–
902. doi:10.1038/nature07455 
Kritzer, M.F., Creutz, L.M., 2008. Region and sex differences in constituent dopamine neurons 
and immunoreactivity for intracellular estrogen and androgen receptors in mesocortical 
projections in rats. J. Neurosci. Off. J. Soc. Neurosci. 28, 9525–9535. 
doi:10.1523/JNEUROSCI.2637-08.2008 
Krueger, F., Pardini, M., Huey, E.D., Raymont, V., Solomon, J., Lipsky, R.H., Hodgkinson, C.A., 
Goldman, D., Grafman, J., 2011. The role of the Met66 brain-derived neurotrophic factor 
allele in the recovery of executive functioning after combat-related traumatic brain injury. 
J. Neurosci. Off. J. Soc. Neurosci. 31, 598–606. doi:10.1523/JNEUROSCI.1399-10.2011 
Kumar, A., Stoica, B.A., Sabirzhanov, B., Burns, M.P., Faden, A.I., Loane, D.J., 2013. Traumatic 
brain injury in aged animals increases lesion size and chronically alters 
microglial/macrophage classical and alternative activation states. Neurobiol. Aging 34, 
1397–1411. doi:10.1016/j.neurobiolaging.2012.11.013 
Kumar, R.G., Boles, J.A., Wagner, A.K., 2014. Chronic Inflammation After Severe Traumatic 
Brain Injury: Characterization and Associations With Outcome at 6 and 12 Months 
Postinjury. J. Head Trauma Rehabil. doi:10.1097/HTR.0000000000000067 
Kwon, S.-K.C., Kovesdi, E., Gyorgy, A.B., Wingo, D., Kamnaksh, A., Walker, J., Long, J.B., 
Agoston, D.V., 2011. Stress and Traumatic Brain Injury: A Behavioral, Proteomics, and 
Histological Study. Front. Neurol. 2. doi:10.3389/fneur.2011.00012 
Laakso, A., Pohjalainen, T., Bergman, J., Kajander, J., Haaparanta, M., Solin, O., Syvälahti, E., 
Hietala, J., 2005. The A1 allele of the human D2 dopamine receptor gene is associated with 
increased activity of striatal L-amino acid decarboxylase in healthy subjects. 
Pharmacogenet. Genomics 15, 387–391. 
Laasonen-Balk, T., Kuikka, J., Viinamäki, H., Husso-Saastamoinen, M., Lehtonen, J., Tiihonen, 
J., 1999. Striatal dopamine transporter density in major depression. Psychopharmacology 
(Berl.) 144, 282–285. 
Laatikainen, L.M., Sharp, T., Bannerman, D.M., Harrison, P.J., Tunbridge, E.M., 2012. 
Modulation of hippocampal dopamine metabolism and hippocampal-dependent cognitive 
function by catechol-O-methyltransferase inhibition. J. Psychopharmacol. Oxf. Engl. 26, 
1561–1568. doi:10.1177/0269881112454228 
Laine, T.P., Ahonen, A., Räsänen, P., Pohjalainen, T., Tiihonen, J., Hietala, J., 2001. The A1 allele 
of the D2 dopamine receptor gene is associated with high dopamine transporter density in 
detoxified alcoholics. Alcohol Alcohol. Oxf. Oxfs. 36, 262–265. 
Lamar, M., Craig, M., Daly, E.M., Cutter, W.J., Tang, C., Brammer, M., Rubia, K., Murphy, 
D.G.M., 2012. Acute tryptophan depletion promotes an anterior-to-posterior fMRI 
activation shift during task switching in older adults. Hum. Brain Mapp. 
doi:10.1002/hbm.22187 
Lanctôt, K.L., Rapoport, M.J., Chan, F., Rajaram, R.D., Strauss, J., Sicard, T., McCullagh, S., 
Feinstein, A., Kiss, A., Kennedy, J.L., Bassett, A.S., Herrmann, N., 2010. Genetic 
predictors of response to treatment with citalopram in depression secondary to traumatic 
brain injury. Brain Inj. BI 24, 959–969. doi:10.3109/02699051003789229 
Lang, U.E., Bajbouj, M., Sander, T., Gallinat, J., 2007a. Gender-Dependent Association of the 
Functional Catechol-O-Methyltransferase Val158Met Genotype with Sensation Seeking 
Personality Trait. Neuropsychopharmacology 32, 1950–1955. doi:10.1038/sj.npp.1301335 
  246 
Lang, U.E., Hellweg, R., Sander, T., Gallinat, J., 2009. The Met allele of the BDNF Val66Met 
polymorphism is associated with increased BDNF serum concentrations. Mol Psychiatry 
14, 120–122. 
Lang, U.E., Hellweg, R., Seifert, F., Schubert, F., Gallinat, J., 2007b. Correlation Between Serum 
Brain-Derived Neurotrophic Factor Level and An In Vivo Marker of Cortical Integrity. 
Biol. Psychiatry 62, 530–535. doi:10.1016/j.biopsych.2007.01.002 
Larrabee, G.J., Curtiss, G., 1995. Construct validity of various verbal and visual memory tests. J. 
Clin. Exp. Neuropsychol. 17, 536–547. doi:10.1080/01688639508405144 
Larrabee, G.J., Curtiss, G., 1995. Construct validity of various verbal and visual memory tests. J. 
Clin. Exp. Neuropsychol. 17, 536–547. doi:10.1080/01688639508405144 
Larson, E.B., Zollman, F.S., 2010. The effect of sleep medications on cognitive recovery from 
traumatic brain injury. J. Head Trauma Rehabil. 25, 61–67. 
doi:10.1097/HTR.0b013e3181c1d1e1 
Lazarus, L.W., Winemiller, D.R., Lingam, V.R., Neyman, I., Hartman, C., Abassian, M., Kartan, 
U., Groves, L., Fawcett, J., 1992. Efficacy and side effects of methylphenidate for 
poststroke depression. J. Clin. Psychiatry 53, 447–449. 
Lee, F.J., Pei, L., Moszczynska, A., Vukusic, B., Fletcher, P.J., Liu, F., 2007. Dopamine 
transporter cell surface localization facilitated by a direct interaction with the dopamine D2 
receptor. EMBO J. 26, 2127–2136. doi:10.1038/sj.emboj.7601656 
Lee, H., Kim, S.-W., Kim, J.-M., Shin, I.-S., Yang, S.-J., Yoon, J.-S., 2005. Comparing effects of 
methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with 
traumatic brain injury. Hum. Psychopharmacol. 20, 97–104. doi:10.1002/hup.668 
Lee, P., Kim, J., Williams, R., Sandhir, R., Gregory, E., Brooks, W.M., Berman, N.E.J., 2012. 
Effects of aging on blood brain barrier and matrix metalloproteases following controlled 
cortical impact in mice. Exp. Neurol. 234, 50–61. doi:10.1016/j.expneurol.2011.12.016 
León-Carrión, J., De Serdio-Arias, M.L., Cabezas, F.M., Roldán, J.M., Domínguez-Morales, R., 
Martín, J.M., Sanchez, M.A., 2001. Neurobehavioural and cognitive profile of traumatic 
brain injury patients at risk for depression and suicide. Brain Inj. BI 15, 175–181. 
doi:10.1080/026990501458407 
León-Carrión, J., Machuca-Murga, F., Solís-Marcos, I., León-Domínguez, U., Domínguez-
Morales, M.D.R., 2013. The sooner patients begin neurorehabilitation, the better their 
functional outcome. Brain Inj. BI 27, 1119–1123. doi:10.3109/02699052.2013.804204 
Lesch, K.-P., 2011. When the serotonin transporter gene meets adversity: the contribution of 
animal models to understanding epigenetic mechanisms in affective disorders and 
resilience. Curr. Top. Behav. Neurosci. 7, 251–280. doi:10.1007/7854_2010_109 
Lesch, K.-P., Bengel, D., Heils, A., Sabol, S.Z., Greenberg, B.D., Petri, S., Benjamin, J., Müller, 
C.R., Hamer, D.H., Murphy, D.L., 1996. Association of Anxiety-Related Traits with a 
Polymorphism in the Serotonin Transporter Gene Regulatory Region. Science 274, 1527–
1531. doi:10.1126/science.274.5292.1527 
Levin, H., Benton, A., Grossman, R.G., 1982. Neurobehavioral Consequences of Closed Head 
Injury. Oxford University Press, New York. 
Levin, H.S., Grossman, R.G., Rose, J.E., Teasdale, G., 1979. Long-term neuropsychological 
outcome of closed head injury. J. Neurosurg. 50, 412–422. doi:10.3171/jns.1979.50.4.0412 
Levin, R.L., Heller, W., Mohanty, A., Herrington, J.D., Miller, G.A., 2007. Cognitive deficits in 
depression and functional specificity of regional brain activity. Cogn. Ther. Res. 31, 211–
233. 
  247 
Lewis, F.D., Horn, G.J., 2013. Traumatic brain injury: analysis of functional deficits and 
posthospital rehabilitation outcomes. J. Spec. Oper. Med. Peer Rev. J. SOF Med. Prof. 13, 
56–61. 
Lindvall, O., Kokaia, Z., Bengzon, J., Elme´r, E., Kokaia, M., 1994. Neurotrophins and brain 
insults. Trends Neurosci. 17, 490–496. doi:10.1016/0166-2236(94)90139-2 
Lipsky, R.H., Sparling, M.B., Ryan, L.M., Xu, K., Salazar, A.M., Goldman, D., Warden, D.L., 
2005a. Association of COMT Val158Met Genotype With Executive Functioning 
Following Traumatic Brain Injury. J. Neuropsychiatry Clin. Neurosci. 17, 465–471. 
doi:10.1176/appi.neuropsych.17.4.465 
Lipsky, R.H., Sparling, M.B., Ryan, L.M., Xu, K., Salazar, A.M., Goldman, D., Warden, D.L., 
2005b. Association of COMT Val158Met Genotype With Executive Functioning 
Following Traumatic Brain Injury. J. Neuropsychiatry Clin. Neurosci. 17, 465–471. 
doi:10.1176/appi.neuropsych.17.4.465 
Little, K.Y., McLaughlin, D.P., Zhang, L., Livermore, C.S., Dalack, G.W., McFinton, P.R., 
DelProposto, Z.S., Hill, E., Cassin, B.J., Watson, S.J., Cook, E.H., 1998. Cocaine, ethanol, 
and genotype effects on human midbrain serotonin transporter binding sites and mRNA 
levels. Am. J. Psychiatry 155, 207–213. 
Lommatzsch, M., Zingler, D., Schuhbaeck, K., Schloetcke, K., Zingler, C., Schuff-Werner, P., 
Virchow, J.C., 2005. The impact of age, weight and gender on BDNF levels in human 
platelets and plasma. Neurobiol. Aging 26, 115–123. 
doi:10.1016/j.neurobiolaging.2004.03.002 
Lopez-Leon, S., Janssens, A.C.J.W., Gonzalez-Zuloeta Ladd, A.M., Del-Favero, J., Claes, S.J., 
Oostra, B.A., van Duijn, C.M., 2007. Meta-analyses of genetic studies on major depressive 
disorder. Mol Psychiatry 13, 772–785. 
Lotrich, F.E., Pollock, B.G., Ferrell, R.E., 2003. Serotonin transporter promoter polymorphism in 
African Americans : allele frequencies and implications for treatment. Am. J. 
Pharmacogenomics Genomics-Relat. Res. Drug Dev. Clin. Pract. 3, 145–147. 
Lotta, T., Vidgren, J., Tilgmann, C., Ulmanen, I., Melén, K., Julkunen, I., Taskinen, J., 1995. 
Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised 
mechanism and description of the thermolabile variant of the enzyme. Biochemistry 
(Mosc.) 34, 4202–4210. 
Lu, L., Dempsey, J., Liu, S.Y., Bossert, J.M., Shaham, Y., 2004. A single infusion of brain-derived 
neurotrophic factor into the ventral tegmental area induces long-lasting potentiation of 
cocaine seeking after withdrawal. J. Neurosci. Off. J. Soc. Neurosci. 24, 1604–1611. 
doi:10.1523/JNEUROSCI.5124-03.2004 
Lupien, S.J., McEwen, B.S., Gunnar, M.R., Heim, C., 2009. Effects of stress throughout the 
lifespan on the brain, behaviour and cognition. Nat. Rev. Neurosci. 10, 434–445. 
Maas, A.I.R., Murray, G.D., Roozenbeek, B., Lingsma, H.F., Butcher, I., McHugh, G.S., Weir, J., 
Lu, J., Steyerberg, E.W., 2013. Advancing care for traumatic brain injury: findings from 
the IMPACT studies and perspectives on future research. Lancet Neurol. 12, 1200–1210. 
doi:10.1016/S1474-4422(13)70234-5 
MacKenzie, J.D., Siddiqi, F., Babb, J.S., Bagley, L.J., Mannon, L.J., Sinson, G.P., Grossman, R.I., 
2002. Brain atrophy in mild or moderate traumatic brain injury: a longitudinal quantitative 
analysis. Am. J. Neuroradiol. 23, 1509–1515. 
  248 
Mak, K.K., Kong, W.Y., Mak, A., Sharma, V.K., Ho, R.C.M., 2012. Polymorphisms of the 
serotonin transporter gene and post-stroke depression: a meta-analysis. J. Neurol. 
Neurosurg. Psychiatry. doi:10.1136/jnnp-2012-303791 
Malec, J.F., Brown, A.W., Moessner, A.M., Stump, T.E., Monahan, P., 2010. A preliminary model 
for posttraumatic brain injury depression. Arch. Phys. Med. Rehabil. 91, 1087–1097. 
doi:10.1016/j.apmr.2010.04.002 
Malhotra, A.K., Kestler, L.J., Mazzanti, C., Bates, J.A., Goldberg, T., Goldman, D., 2002. A 
Functional Polymorphism in the COMT Gene and Performance on a Test of Prefrontal 
Cognition. Am. J. Psychiatry 159, 652–654. doi:10.1176/appi.ajp.159.4.652 
Maller, J.J., Thomson, R.H.S., Lewis, P.M., Rose, S.E., Pannek, K., Fitzgerald, P.B., 2010. 
Traumatic brain injury, major depression, and diffusion tensor imaging: making 
connections. Brain Res. Rev. 64, 213–240. doi:10.1016/j.brainresrev.2010.04.003 
Maller, J.J., Thomson, R.H.S., Pannek, K., Bailey, N., Lewis, P.M., Fitzgerald, P.B., 2014. 
Volumetrics relate to the development of depression after traumatic brain injury. Behav. 
Brain Res. 271, 147–153. doi:10.1016/j.bbr.2014.05.047 
Mamounas, L.A., Altar, C.A., Blue, M.E., Kaplan, D.R., Tessarollo, L., Lyons, W.E., 2000. BDNF 
Promotes the Regenerative Sprouting, But Not Survival, of Injured Serotonergic Axons in 
the Adult Rat Brain. J Neurosci 20, 771–782. 
Männistö, P.T., Kaakkola, S., 1999. Catechol-O-methyltransferase (COMT): Biochemistry, 
Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT 
Inhibitors. Pharmacol. Rev. 51, 593–628. 
Martinowich, K., Lu, B., 2008. Interaction between BDNF and serotonin: role in mood disorders. 
Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 33, 73–83. 
doi:10.1038/sj.npp.1301571 
Martinowich, K., Manji, H., Lu, B., 2007. New insights into BDNF function in depression and 
anxiety. Nat. Neurosci. 10, 1089–1093. doi:10.1038/nn1971 
Matsumoto, T., Rauskolb, S., Polack, M., Klose, J., Kolbeck, R., Korte, M., Barde, Y.-A., 2008. 
Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, 
not pro-BDNF. Nat. Neurosci. 11, 131–133. doi:10.1038/nn2038 
Mattay, V.S., Goldberg, T.E., Fera, F., Hariri, A.R., Tessitore, A., Egan, M.F., Kolachana, B., 
Callicott, J.H., Weinberger, D.R., 2003. Catechol O-methyltransferase val158-met 
genotype and individual variation in the brain response to amphetamine. Proc. Natl. Acad. 
Sci. 100, 6186–6191. doi:10.1073/pnas.0931309100 
Mattson, M.P., Maudsley, S., Martin, B., 2004. BDNF and 5-HT: a dynamic duo in age-related 
neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 27, 589–594. 
doi:10.1016/j.tins.2004.08.001 
Mayberg, H.S., 2003. Modulating dysfunctional limbic-cortical circuits in depression: towards 
development of brain-based algorithms for diagnosis and optimised treatment. Br. Med. 
Bull. 65, 193–207. doi:10.1093/bmb/65.1.193 
McAllister, T.W., Flashman, L.A., Harker Rhodes, C., Tyler, A.L., Moore, J.H., Saykin, A.J., 
McDonald, B.C., Tosteson, T.D., Tsongalis, G.J., 2008. Single nucleotide polymorphisms 
in ANKK1 and the dopamine D2 receptor gene affect cognitive outcome shortly after 
traumatic brain injury: a replication and extension study. Brain Inj. BI 22, 705–714. 
doi:10.1080/02699050802263019 
  249 
McAllister, T.W., Rhodes, C.H., Flashman, L.A., McDonald, B.C., Belloni, D., Saykin, A.J., 2005. 
Effect of the dopamine D2 receptor T allele on response latency after mild traumatic brain 
injury. Am. J. Psychiatry 162, 1749–1751. doi:10.1176/appi.ajp.162.9.1749 
McCullagh, S., Feinstein, M., 2004. Cognitive impairment, in: Textbook of Traumatic Brain 
Injury. American Psychiatric Press, Washington, DC, p. 321—336. 
McNett, M., 2007. A review of the predictive ability of Glasgow Coma Scale scores in head-
injured patients. J. Neurosci. Nurs. J. Am. Assoc. Neurosci. Nurses 39, 68–75. 
Mercader, J.M., Ribasés, M., Gratacòs, M., González, J.R., Bayés, M., De Cid, R., Badía, A., 
Fernández-Aranda, F., Estivill, X., 2007. Altered brain-derived neurotrophic factor blood 
levels and gene variability are associated with anorexia and bulimia. Genes Brain Behav. 
6, 706–716. doi:10.1111/j.1601-183X.2007.00301.x 
Mettenburg, J.M., Benzinger, T.L., Shimony, J.S., Snyder, A.Z., Sheline, Y.I., 2012. Diminished 
performance on neuropsychological testing in late life depression is correlated with 
microstructural white matter abnormalities. Neuroimage 60, 2182–2190. 
Meyer, J.H., Krüger, S., Wilson, A.A., Christensen, B.K., Goulding, V.S., Schaffer, A., Minifie, 
C., Houle, S., Hussey, D., Kennedy, S.H., 2001. Lower dopamine transporter binding 
potential in striatum during depression. Neuroreport 12, 4121. 
Mi, H., Thomas, P.D., Ring, H.Z., Jiang, R., Sangkuhl, K., Klein, T.E., Altman, R.B., 2011. 
PharmGKB summary: dopamine receptor D2. Pharmacogenet. Genomics 21, 350–356. 
doi:10.1097/FPC.0b013e32833ee605 
Miller, A.H., Maletic, V., Raison, C.L., 2009. Inflammation and Its Discontents: The Role of 
Cytokines in the Pathophysiology of Major Depression. Biol. Psychiatry 65, 732–741. 
doi:10.1016/j.biopsych.2008.11.029 
Miller, G., Madras, B., others, 2002. Polymorphisms in the 3’-untranslated region of human and 
monkey dopamine transporter genes affect reporter gene expression. Mol. Psychiatry 7, 44. 
Miller, S.A., Dykes, D.D., Polesky, H.F., 1988. A simple salting out procedure for extracting DNA 
from human nucleated cells. Nucleic Acids Res. 16, 1215. doi:10.1093/nar/16.3.1215 
Miller, S.A., Dykes, D.D., Polesky, H.F., 1988. A simple salting out procedure for extracting DNA 
from human nucleated cells. Nucleic Acids Res. 16, 1215. 
Mill, J., Asherson, P., Browes, C., D’Souza, U., Craig, I., 2002. Expression of the dopamine 
transporter gene is regulated by the 3′ UTR VNTR: Evidence from brain and lymphocytes 
using quantitative RT-PCR. Am. J. Med. Genet. 114, 975–979. 
Monakhov, M., Golimbet, V., Abramova, L., Kaleda, V., Karpov, V., 2008. Association study of 
three polymorphisms in the dopamine D2 receptor gene and schizophrenia in the Russian 
population. Schizophr. Res. 100, 302–307. doi:10.1016/j.schres.2008.01.007 
Montag, C., Markett, S., Basten, U., Stelzel, C., Fiebach, C., Canli, T., Reuter, M., 2010. Epistasis 
of the DRD2/ANKK1 Taq Ia and the BDNF Val66Met polymorphism impacts novelty 
seeking and harm avoidance. Neuropsychopharmacology 35, 1860–1867. 
Morey, R.A., Petty, C.M., Xu, Y., Hayes, J.P., Wagner, H.R., Lewis, D.V., LaBar, K.S., Styner, 
M., McCarthy, G., 2009. A comparison of automated segmentation and manual tracing for 
quantifying hippocampal and amygdala volumes. NeuroImage 45, 855–866. 
doi:10.1016/j.neuroimage.2008.12.033 
Mori, T., Wang, X., Kline, A.E., Siao, C.J., Dixon, C.E., Tsirka, S.E., Lo, E.H., 2001. Reduced 
cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma. 
Neuroreport 12, 4117–4120. 
  250 
Moritz, K.E., Geeck, K., Underly, R.G., Searles, M., Smith, J.S., 2014. Post-operative 
environmental enrichment improves spatial and motor deficits but may not ameliorate 
anxiety- or depression-like symptoms in rats following traumatic brain injury. Restor. 
Neurol. Neurosci. 32, 701–716. doi:10.3233/RNN-140414 
Munafò, M.R., Matheson, I.J., Flint, J., 2007. Association of the DRD2 gene Taq1A polymorphism 
and alcoholism: a meta-analysis of case–control studies and evidence of publication bias. 
Mol. Psychiatry 12, 454–461. doi:10.1038/sj.mp.4001938 
Munro, C.A., McCaul, M.E., Wong, D.F., Oswald, L.M., Zhou, Y., Brasic, J., Kuwabara, H., 
Kumar, A., Alexander, M., Ye, W., Wand, G.S., 2006. Sex Differences in Striatal 
Dopamine Release in Healthy Adults. Biol. Psychiatry 59, 966–974. 
doi:10.1016/j.biopsych.2006.01.008 
Nagamoto-Combs, K., McNeal, D.W., Morecraft, R.J., Combs, C.K., 2007. Prolonged 
microgliosis in the rhesus monkey central nervous system after traumatic brain injury. J. 
Neurotrauma 24, 1719–1742. doi:10.1089/neu.2007.0377 
Nakahashi, T., Fujimura, H., Altar, C.A., Li, J., Kambayashi, J., Tandon, N.N., Sun, B., 2000. 
Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS 
Lett. 470, 113–117. doi:10.1016/S0014-5793(00)01302-8 
Narayan, R.K., Michel, M.E., Ansell, B., Baethmann, A., Biegon, A., Bracken, M.B., Bullock, 
M.R., Choi, S.C., Clifton, G.L., Contant, C.F., Coplin, W.M., Dietrich, W.D., Ghajar, J., 
Grady, S.M., Grossman, R.G., Hall, E.D., Heetderks, W., Hovda, D.A., Jallo, J., Katz, R.L., 
Knoller, N., Kochanek, P.M., Maas, A.I., Majde, J., Marion, D.W., Marmarou, A., 
Marshall, L.F., McIntosh, T.K., Miller, E., Mohberg, N., Muizelaar, J.P., Pitts, L.H., Quinn, 
P., Riesenfeld, G., Robertson, C.S., Strauss, K.I., Teasdale, G., Temkin, N., Tuma, R., 
Wade, C., Walker, M.D., Weinrich, M., Whyte, J., Wilberger, J., Young, A.B., Yurkewicz, 
L., 2002. Clinical trials in head injury. J. Neurotrauma 19, 503–557. 
doi:10.1089/089771502753754037 
Nettiksimmons, J., Simonsick, E.M., Harris, T., Satterfield, S., Rosano, C., Yaffe, K., for the 
Health ABC Study, 2014. The Associations between Serum Brain-Derived Neurotrophic 
Factor, Potential Confounders, and Cognitive Decline: A Longitudinal Study. PLoS ONE 
9, e91339. doi:10.1371/journal.pone.0091339 
Neurobehavioral Guidelines Working Group, Warden, D.L., Gordon, B., McAllister, T.W., Silver, 
J.M., Barth, J.T., Bruns, J., Drake, A., Gentry, T., Jagoda, A., Katz, D.I., Kraus, J., Labbate, 
L.A., Ryan, L.M., Sparling, M.B., Walters, B., Whyte, J., Zapata, A., Zitnay, G., 2006. 
Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain 
injury. J. Neurotrauma 23, 1468–1501. doi:10.1089/neu.2006.23.1468 
Neville, M.J., Johnstone, E.C., Walton, R.T., 2004. Identification and characterization of ANKK1: 
a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum. Mutat. 
23, 540–545. doi:10.1002/humu.20039 
Newcomer, J., Craft, S., Hershey, T., Askins, K., Bardgett, M., 1994. Glucocorticoid-induced 
impairment in declarative memory performance in adult humans. J. Neurosci. 14, 2047 –
2053. 
Nibuya, M., Nestler, E., Duman, R., 1996. Chronic antidepressant administration increases the 
expression of cAMP response element binding protein (CREB) in rat hippocampus. J 
Neurosci 16, 2365–2372. 
Niogi, S.N., Mukherjee, P., Ghajar, J., Johnson, C.E., Kolster, R., Lee, H., Suh, M., Zimmerman, 
R.D., Manley, G.T., McCandliss, B.D., 2008. Structural dissociation of attentional control 
  251 
and memory in adults with and without mild traumatic brain injury. Brain 131, 3209–3221. 
doi:10.1093/brain/awn247 
Niogi, S.N., Mukherjee, P., Ghajar, J., Johnson, C., Kolster, R.A., Sarkar, R., Lee, H., Meeker, M., 
Zimmerman, R.D., Manley, G.T., McCandliss, B.D., 2008. Extent of Microstructural 
White Matter Injury in Postconcussive Syndrome Correlates with Impaired Cognitive 
Reaction Time: A 3T Diffusion Tensor Imaging Study of Mild Traumatic Brain Injury. 
AJNR Am J Neuroradiol 29, 967–973. doi:10.3174/ajnr.A0970 
Nugent, A.C., Luckenbaugh, D.A., Wood, S.E., Bogers, W., Zarate, C.A., Jr, Drevets, W.C., 2013. 
Automated subcortical segmentation using FIRST: Test-retest reliability, interscanner 
reliability, and comparison to manual segmentation. Hum. Brain Mapp. 34, 2313–2329. 
doi:10.1002/hbm.22068 
Nutt, D.J., 2006. The role of dopamine and norepinephrine in depression and antidepressant 
treatment. J. Clin. Psychiatry 67 Suppl 6, 3–8. 
Oakley, R., Tharakan, B., 2014. Vascular hyperpermeability and aging. Aging Dis. 5, 114–125. 
doi:10.14336/AD.2014.0500114 
Ogilvie, A.D., Battersby, S., Bubb, V.J., Fink, G., Harmar, A.J., Goodwim, G.M., Smith, C.A., 
1996. Polymorphism in serotonin transporter gene associated with susceptibility to major 
depression. Lancet 347, 731–733. 
O’Hara, R., Miller, E., Liao, C.-P., Way, N., Lin, X., Hallmayer, J., 2006. COMT genotype, gender 
and cognition in community-dwelling, older adults. Neurosci. Lett. 409, 205–209. 
doi:10.1016/j.neulet.2006.09.047 
Olvera-Cortés, M.E., Anguiano-Rodríguez, P., López-Vázquez, M.A., Alfaro, J.M.C., 2008. 
Serotonin/dopamine interaction in learning. Prog. Brain Res. 172, 567–602. 
doi:10.1016/S0079-6123(08)00927-8 
Onyszchuk, G., He, Y.-Y., Berman, N.E.J., Brooks, W.M., 2008. Detrimental effects of aging on 
outcome from traumatic brain injury: a behavioral, magnetic resonance imaging, and 
histological study in mice. J. Neurotrauma 25, 153–171. doi:10.1089/neu.2007.0430 
Opmeer, E.M., Kortekaas, R., Aleman, A., 2010. Depression and the role of genes involved in 
dopamine metabolism and signalling. Prog. Neurobiol. 92, 112–133. 
Orefice, L.L., Waterhouse, E.G., Partridge, J.G., Lalchandani, R.R., Vicini, S., Xu, B., 2013. 
Distinct roles for somatically and dendritically synthesized brain-derived neurotrophic 
factor in morphogenesis of dendritic spines. J. Neurosci. Off. J. Soc. Neurosci. 33, 11618–
11632. doi:10.1523/JNEUROSCI.0012-13.2013 
Osterrieth, P., 1944. The Complex Figure Copy Test. Arch. Psychol. 30, 206–356. 
Osterrieth, P., 1944. The Complex Figure Copy Test. Arch Psychol 206–256. 
Owens, M.J., Nemeroff, C.B., 1994. Role of serotonin in the pathophysiology of depression: focus 
on the serotonin transporter. Clin. Chem. 40, 288–295. 
Pacheco, J., Beevers, C.G., Benavides, C., McGeary, J., Stice, E., Schnyer, D.M., 2009. Frontal-
limbic white matter pathway associations with the serotonin transporter gene promoter 
region (5-HTTLPR) polymorphism. J. Neurosci. Off. J. Soc. Neurosci. 29, 6229–6233. 
doi:10.1523/JNEUROSCI.0896-09.2009 
Palacios, E.M., Sala-Llonch, R., Junque, C., Fernandez-Espejo, D., Roig, T., Tormos, J.M., 
Bargallo, N., Vendrell, P., 2013. Long-term declarative memory deficits in diffuse TBI: 
correlations with cortical thickness, white matter integrity and hippocampal volume. 
Cortex J. Devoted Study Nerv. Syst. Behav. 49, 646–657. 
doi:10.1016/j.cortex.2012.02.011 
  252 
Palacios, E.M., Sala-Llonch, R., Junque, C., Roig, T., Tormos, J.M., Bargallo, N., Vendrell, P., 
2013. Resting-state functional magnetic resonance imaging activity and connectivity and 
cognitive outcome in traumatic brain injury. JAMA Neurol. 70, 845–851. 
doi:10.1001/jamaneurol.2013.38 
Pan, W., Banks, W.A., Fasold, M.B., Bluth, J., Kastin, A.J., 1998. Transport of brain-derived 
neurotrophic factor across the blood-brain barrier. Neuropharmacology 37, 1553–1561. 
Pardoe, H.R., Pell, G.S., Abbott, D.F., Jackson, G.D., 2009. Hippocampal volume assessment in 
temporal lobe epilepsy: How good is automated segmentation? Epilepsia 50, 2586–2592. 
doi:10.1111/j.1528-1167.2009.02243.x 
Pariante, C.M., Lightman, S.L., 2008. The HPA axis in major depression: classical theories and 
new developments. Trends Neurosci. 31, 464–468. doi:10.1016/j.tins.2008.06.006 
Park, E., Bell, J.D., Baker, A.J., 2008. Traumatic brain injury: Can the consequences be stopped? 
Can. Med. Assoc. J. 178, 1163–1170. 
Parsey, R.V., Hastings, R.S., Oquendo, M.A., Hu, X., Goldman, D., Huang, Y., Simpson, N., 
Arcement, J., Huang, Y., Ogden, R.T., Van Heertum, R.L., Arango, V., Mann, J.J., 2006. 
Effect of a Triallelic Functional Polymorphism of the Serotonin-Transporter-Linked 
Promoter Region on Expression of Serotonin Transporter in the Human Brain. Am J 
Psychiatry 163, 48–51. doi:10.1176/appi.ajp.163.1.48 
Peckham, A.D., McHugh, R.K., Otto, M.W., 2010. A meta‐analysis of the magnitude of biased 
attention in depression. Depress. Anxiety 27, 1135–1142. doi:10.1002/da.20755 
Pelleymounter, M.A., Cullen, M.J., Wellman, C.L., 1995. Characteristics of BDNF-induced 
weight loss. Exp. Neurol. 131, 229–238. 
Perlstein, W.M., Larson, M.J., Dotson, V.M., Kelly, K.G., 2006. Temporal dissociation of 
components of cognitive control dysfunction in severe TBI: ERPs and the cued-Stroop 
task. Neuropsychologia 44, 260–274. 
Perona, M.T.G., Waters, S., Hall, F.S., Sora, I., Lesch, K.P., Murphy, D.L., Caron, M., Uhl, G.R., 
2008. Animal models of depression in dopamine, serotonin and norepinephrine transporter 
knockout mice: prominent effects of dopamine transporter deletions. Behav. Pharmacol. 
19, 566. 
Pessoa, L., Kastner, S., Ungerleider, L.G., 2003. Neuroimaging studies of attention: from 
modulation of sensory processing to top-down control. J. Neurosci. Off. J. Soc. Neurosci. 
23, 3990–3998. 
Pezawas, L., Meyer-Lindenberg, A., Drabant, E.M., Verchinski, B.A., Munoz, K.E., Kolachana, 
B.S., Egan, M.F., Mattay, V.S., Hariri, A.R., Weinberger, D.R., 2005. 5-HTTLPR 
polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility 
mechanism for depression. Nat Neurosci 8, 828–834. doi:10.1038/nn1463 
Pezawas, L., Meyer-Lindenberg, A., Goldman, A.L., Verchinski, B.A., Chen, G., Kolachana, B.S., 
Egan, M.F., Mattay, V.S., Hariri, A.R., Weinberger, D.R., 2008. MET BDNF protects 
against morphological S allele effects of 5-HTTLPR. Mol Psychiatry 13, 654. 
Phelps, T.I., Bondi, C.O., Ahmed, R.H., Olugbade, Y.T., Kline, A.E., 2014. Divergent long-term 
consequences of chronic treatment with haloperidol, risperidone, and bromocriptine on 
traumatic brain injury-induced cognitive deficits. J. Neurotrauma. 
doi:10.1089/neu.2014.3711 
Philibert, R., Madan, A., Andersen, A., Cadoret, R., Packer, H., Sandhu, H., 2007. Serotonin 
transporter mRNA levels are associated with the methylation of an upstream CpG island. 
Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B, 101–105. doi:10.1002/ajmg.b.30414 
  253 
Piccinni, A., Marazziti, D., Catena, M., Domenici, L., Del Debbio, A., Bianchi, C., Mannari, C., 
Martini, C., Da Pozzo, E., Schiavi, E., others, 2008a. Plasma and serum brain-derived 
neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant 
treatments. J. Affect. Disord. 105, 279–283. 
Piccinni, A., Marazziti, D., Del Debbio, A., Bianchi, C., Roncaglia, I., Mannari, C., Origlia, N., 
Catena Dell’Osso, M., Massimetti, G., Domenici, L., others, 2008b. Diurnal variation of 
plasma brain-derived neurotrophic factor (BDNF) in humans: an analysis of sex 
differences. Chronobiol. Int. 25, 819–826. 
Pillai, A., Kale, A., Joshi, S., Naphade, N., Raju, M.S.V.K., Nasrallah, H., Mahadik, S.P., 2010. 
Decreased BDNF Levels in CSF of Drug-Naive First-Episode Psychotic Subjects: 
Correlation with Plasma BDNF and Psychopathology. Int. J. Neuropsychopharmacol. 13, 
535–539. doi:10.1017/S1461145709991015 
Pittenger, C., Duman, R.S., 2007. Stress, Depression, and Neuroplasticity: A Convergence of 
Mechanisms. Neuropsychopharmacology 33, 88–109. 
Poduslo, J.F., Curran, G.L., 1996. Permeability at the blood-brain and blood-nerve barriers of the 
neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res. Mol. Brain Res. 36, 280–286. 
Ponce, G., Pérez-González, R., Aragüés, M., Palomo, T., Rodríguez-Jiménez, R., Jiménez-Arriero, 
M.A., Hoenicka, J., 2009. The ANKK1 kinase gene and psychiatric disorders. Neurotox. 
Res. 16, 50–59. doi:10.1007/s12640-009-9046-9 
Praschak-Rieder, N., Kennedy, J., Wilson, A.A., Hussey, D., Boovariwala, A., Willeit, M., 
Ginovart, N., Tharmalingam, S., Masellis, M., Houle, S., Meyer, J.H., 2007. Novel 5-
HTTLPR Allele Associates with Higher Serotonin Transporter Binding in Putamen: A 
[11C] DASB Positron Emission Tomography Study. Biol. Psychiatry 62, 327–331. 
doi:10.1016/j.biopsych.2006.09.022 
Pruunsild, P., Kazantseva1, A., Aid, T., Palm, K., Timmusk, T., 2007. Dissecting the human 
BDNF locus: Bidirectional transcription, complex splicing, and multiple promoters. 
Genomics 90, 397–406. doi:10.1016/j.ygeno.2007.05.004 
Qin, L., Jing, D., Parauda, S., Carmel, J., Ratan, R.R., Lee, F.S., Cho, S., 2014. An Adaptive Role 
for BDNF Val66Met Polymorphism in Motor Recovery in Chronic Stroke. J. Neurosci. 34, 
2493–2502. doi:10.1523/JNEUROSCI.4140-13.2014 
Radua, J., El-Hage, W., Monté, G.C., Gohier, B., Tropeano, M., Phillips, M.L., Surguladze, S.A., 
2013. COMT Val158Met x SLC6A4 5-HTTLPR interaction impacts on gray matter 
volume of regions supporting emotion processing. Soc. Cogn. Affect. Neurosci. 
doi:10.1093/scan/nst089 
Rapoport, M.J., McCullagh, S., Shammi, P., Feinstein, A., 2005. Cognitive Impairment Associated 
With Major Depression Following Mild and Moderate Traumatic Brain Injury. J 
Neuropsychiatry Clin Neurosci 17, 61–65. doi:10.1176/appi.neuropsych.17.1.61 
Rapoport, M., McCauley, S., Levin, H., Song, J., Feinstein, A., 2002. The role of injury severity 
in neurobehavioral outcome 3 months after traumatic brain injury. Neuropsychiatry. 
Neuropsychol. Behav. Neurol. 15, 123–132. 
Rasmussen, P., Brassard, P., Adser, H., Pedersen, M.V., Leick, L., Hart, E., Secher, N.H., 
Pedersen, B.K., Pilegaard, H., 2009. Evidence for a release of brain-derived neurotrophic 
factor from the brain during exercise. Exp. Physiol. 94, 1062–1069. 
doi:10.1113/expphysiol.2009.048512 
Rees, M., Norton, N., Jones, I., McCandless, F., Scourfield, J., Holmans, P., Moorhead, S., 
Feldman, E., Sadler, S., Cole, T., Redman, K., Farmer, A., McGuffin, P., Owen, M.J., 
  254 
Craddock, N., 1997. Association studies of bipolar disorder at the human serotonin 
transporter gene (hSERT; 5HTT). Mol. Psychiatry 2, 398–402. 
Reger, M.L., Poulos, A.M., Buen, F., Giza, C.C., Hovda, D.A., Fanselow, M.S., 2012. Concussive 
brain injury enhances fear learning and excitatory processes in the amygdala. Biol. 
Psychiatry 71, 335–343. doi:10.1016/j.biopsych.2011.11.007 
Reimold, M., Smolka, M.N., Schumann, G., Zimmer, A., Wrase, J., Mann, K., Hu, X.-Z., 
Goldman, D., Reischl, G., Solbach, C., Machulla, H.-J., Bares, R., Heinz, A., 2007. 
Midbrain serotonin transporter binding potential measured with 
[&lt;sup&gt;11&lt;/sup&gt;C]DASB is affected by serotonin transporter genotype. J. 
Neural Transm. 114, 635–639. doi:10.1007/s00702-006-0609-0 
Reitan, R., Wolfson, D., 1985. The Halstead-Reitan Neuropsychological Test Battery: Theory and 
Clinical Interpretation. Neuropsychology Press, Tucson, AZ. 
Reitan, R., Wolfson, D., 1985. The Helstead-Reitan neuropsychological test battery: Theory and 
clinical interpretation. Neuropsychol. Press. 
Ricker, J.H., Hillary, F.G., DeLuca, J., 2001. Functionally activated brain imaging (O-15 PET and 
fMRI) in the study of learning and memory after traumatic brain injury. J. Head Trauma 
Rehabil. 16, 191–205. 
Rincon, F., Ghosh, S.M., Dey, S.M., Maltenfort, M., Vibbert, M., Urtecho, J., McBride, W., 
Moussouttas, M., Bell, R., Ratliff, J.K., Jallo, J., 2012. Impact of Acute Lung Injury and 
Acute Respiratory Distress Syndrome After Traumatic Brain Injury in the United States. 
[Miscellaneous Article]. Neurosurg. Oct. 2012 71, 795–803. 
doi:10.1227/NEU.0b013e3182672ae5 
Risch, N., Herrell, R., Lehner, T., Liang, K.-Y., Eaves, L., Hoh, J., Griem, A., Kovacs, M., Ott, J., 
Merikangas, K.R., 2009. Interaction between the serotonin transporter gene (5-HTTLPR), 
stressful life events, and risk of depression: a meta-analysis. JAMA J. Am. Med. Assoc. 
301, 2462–2471. doi:10.1001/jama.2009.878 
Ritter, C., Miranda, A.S., Giombelli, V.R., Tomasi, C.D., Comim, C.M., Teixeira, A.L., Quevedo, 
J., Dal-Pizzol, F., 2012. Brain-derived neurotrophic factor plasma levels are associated 
with mortality in critically ill patients even in the absence of brain injury. Crit. Care 16, 
R234. doi:10.1186/cc11902 
Romanczyk, T.B., Weickert, C.S., Webster, M.J., Herman, M.M., Akil, M., Kleinman, J.E., 2002. 
Alterations in trkB mRNA in the human prefrontal cortex throughout the lifespan. Eur. J. 
Neurosci. 15, 269–280. doi:10.1046/j.0953-816x.2001.01858.x 
Roozenbeek, B., Chiu, Y.-L., Lingsma, H.F., Gerber, L.M., Steyerberg, E.W., Ghajar, J., Maas, 
A.I.R., 2012. Predicting 14-Day Mortality after Severe Traumatic Brain Injury: 
Application of the IMPACT Models in the Brain Trauma Foundation TBI-trac ® New York 
State Database. J. Neurotrauma 29, 1306–1312. doi:10.1089/neu.2011.1988 
Rosenthal, M., Christensen, B.K., Ross, T.P., 1998. Depression following traumatic brain injury. 
Arch. Phys. Med. Rehabil. 79, 90–103. 
Rostami, E., Krueger, F., Plantman, S., Davidsson, J., Agoston, D., Grafman, J., Risling, M., 2013. 
Alteration in BDNF and its receptors, full-length and truncated TrkB and p75< sup> 
NTR</sup> following penetrating traumatic brain injury. Brain Res. 
Rostami, E., Krueger, F., Zoubak, S., Dal Monte, O., Raymont, V., Pardini, M., Hodgkinson, C.A., 
Goldman, D., Risling, M., Grafman, J., 2011. BDNF Polymorphism Predicts General 
Intelligence after Penetrating Traumatic Brain Injury. PLoS ONE 6, e27389. 
doi:10.1371/journal.pone.0027389 
  255 
Rothman, S.M., Griffioen, K.J., Wan, R., Mattson, M.P., 2012. Brain-derived neurotrophic factor 
as a regulator of systemic and brain energy metabolism and cardiovascular health. Ann. N. 
Y. Acad. Sci. 1264, 49–63. doi:10.1111/j.1749-6632.2012.06525.x 
Rubia, K., Lee, F., Cleare, A.J., Tunstall, N., Fu, C.H.Y., Brammer, M., McGuire, P., 2005. 
Tryptophan depletion reduces right inferior prefrontal activation during response inhibition 
in fast, event-related fMRI. Psychopharmacology (Berl.) 179, 791–803. 
doi:10.1007/s00213-004-2116-z 
Sabet, A.A., Christoforou, E., Zatlin, B., Genin, G.M., Bayly, P.V., 2008. Deformation of The 
Human Brain Induced By Mild Angular Head Acceleration. J. Biomech. 41, 307–315. 
doi:10.1016/j.jbiomech.2007.09.016 
Saha, R.N., Liu, X., Pahan, K., 2006. Up-regulation of BDNF in astrocytes by TNF-alpha: a case 
for the neuroprotective role of cytokine. J. Neuroimmune Pharmacol. Off. J. Soc. 
NeuroImmune Pharmacol. 1, 212–222. doi:10.1007/s11481-006-9020-8 
Salmond, C.H., Chatfield, D.A., Menon, D.K., Pickard, J.D., Sahakian, B.J., 2005. Cognitive 
sequelae of head injury: involvement of basal forebrain and associated structures. Brain J. 
Neurol. 128, 189–200. doi:10.1093/brain/awh352 
Sánchez-Benavides, G., Gómez-Ansón, B., Sainz, A., Vives, Y., Delfino, M., Peña-Casanova, J., 
2010. Manual validation of FreeSurfer’s automated hippocampal segmentation in normal 
aging, mild cognitive impairment, and Alzheimer Disease subjects. Psychiatry Res. 181, 
219–225. doi:10.1016/j.pscychresns.2009.10.011 
Sánchez-Carrión, R., Gómez, P.V., Junqué, C., Fernández-Espejo, D., Falcon, C., Bargalló, N., 
Roig-Rovira, T., Enseñat-Cantallops, A., Bernabeu, M., 2008. Frontal hypoactivation on 
functional magnetic resonance imaging in working memory after severe diffuse traumatic 
brain injury. J. Neurotrauma 25, 479–494. doi:10.1089/neu.2007.0417 
Santamaría, J., Tolosa, E., Valles, A., 1986. Parkinson’s disease with depression: a possible 
subgroup of idiopathic parkinsonism. Neurology 36, 1130–1133. 
Santarsieri, M., Niyonkuru, C., McCullough, E., Dobos, J., Dixon, C.E., Berga, S., Wagner, A.K., 
M.D., 2013. CSF Cortisol and Progesterone Profiles and Outcomes Prognostication after 
Severe TBI. J. Neurotrauma. doi:10.1089/neu.2013.3177 
Sashindranath, M., Samson, A.L., Downes, C.E., Crack, P.J., Lawrence, A.J., Li, Q.-X., Ng, 
A.Q.P., Jones, N.C., Farrugia, J.J., Abdella, E., Vassalli, J.-D., Madani, R., Medcalf, R.L., 
2011. Compartment- and context-specific changes in tissue-type plasminogen activator 
(tPA) activity following brain injury and pharmacological stimulation. Lab. Invest. 91, 
1079–1091. doi:10.1038/labinvest.2011.67 
Satz, P., Forney, D.L., Zaucha, K., Asarnow, R.R., Light, R., McCleary, C., Levin, H., Kelly, D., 
Bergsneider, M., Hovda, D., Martin, N., Namerow, N., Becker, D., 1998. Depression, 
cognition, and functional correlates of recovery outcome after traumatic brain injury. Brain 
Inj. BI 12, 537–553. 
Sawaguchi, T., Goldman-Rakic, P.S., 1991. D1 dopamine receptors in prefrontal cortex: 
involvement in working memory. Science 251, 947–950. doi:10.1126/science.1825731 
Scanlon, J.M., Price, J., Ricker, J.H., Conley, Y.P., Becker, C., Burkhardt, J.N., Dixon, C.E., 
Wagner, A.K., 2009. Response to Methylphenidate Administration and Dopaminergic 
Function in Persons with TBI and Healthy Controls., in: 8. J. Neurotrauma, p. A–23. 
Scanlon, J.M., Price, J., Ricker, J.H., Conley, Y.P., Becker, C., Lopresti, B., Drewencki, L.L., 
Deslouches, S., Fabio, A., Wagner, A.K., 2007. Striatal dopamine transporter and D2 
  256 
receptor binding and executive functioning after TBI: an initial PET study, in: 
Neuroscience, 262.7/S5. Presented at the Society for Neuroscience, San Diego, CA. 
Schmitter-Edgecombe, M., 2006. Implications of basic science research for brain injury 
rehabilitation: a focus on intact learning mechanisms. J. Head Trauma Rehabil. 21, 131–
141. 
Schneider, E.B., Sur, S., Raymont, V., Duckworth, J., Kowalski, R.G., Efron, D.T., Hui, X., 
Selvarajah, S., Hambridge, H.L., Stevens, R.D., 2014. Functional recovery after 
moderate/severe traumatic brain injury A role for cognitive reserve? Neurology 82, 1636–
1642. doi:10.1212/WNL.0000000000000379 
Seamans, J.K., Robbins, T.W., 2010. Dopamine Modulation of the Prefrontal Cortex and 
Cognitive Function, in: Neve, K.A. (Ed.), The Dopamine Receptors, The Receptors. 
Humana Press, pp. 373–398. 
Seamans, J.K., Yang, C.R., 2004. The principal features and mechanisms of dopamine modulation 
in the prefrontal cortex. Prog. Neurobiol. 74, 1–58. doi:10.1016/j.pneurobio.2004.05.006 
Sen, S., Duman, R., Sanacora, G., 2008. Serum Brain-Derived Neurotrophic Factor, Depression, 
and Antidepressant Medications: Meta-Analyses and Implications. Biol. Psychiatry 64, 
527–532. doi:10.1016/j.biopsych.2008.05.005 
Sesack, S.R., Hawrylak, V.A., Matus, C., Guido, M.A., Levey, A.I., 1998. Dopamine axon 
varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse 
immunoreactivity for the dopamine transporter. J. Neurosci. 18, 2697–2708. 
Shalev, I., Lerer, E., Israel, S., Uzefovsky, F., Gritsenko, I., Mankuta, D., Ebstein, R.P., Kaitz, M., 
2009. BDNF Val66Met polymorphism is associated with HPA axis reactivity to 
psychological stress characterized by genotype and gender interactions. 
Psychoneuroendocrinology 34, 382–388. doi:10.1016/j.psyneuen.2008.09.017 
Sharp, D.J., Beckmann, C.F., Greenwood, R., Kinnunen, K.M., Bonnelle, V., De Boissezon, X., 
Powell, J.H., Counsell, S.J., Patel, M.C., Leech, R., 2011. Default mode network functional 
and structural connectivity after traumatic brain injury. Brain 134, 2233–2247. 
Sheline, Y.I., Gado, M.H., Kraemer, H.C., 2003. Untreated depression and hippocampal volume 
loss. Am. J. Psychiatry 160, 1516–1518. 
Shimada, R., Abe, K., Furutani, R., Kibayashi, K., 2014a. Changes in dopamine transporter 
expression in the midbrain following traumatic brain injury: an immunohistochemical and 
in situ hybridization study in a mouse model. Neurol. Res. 36, 239–246. 
doi:10.1179/1743132813Y.0000000289 
Shimada, R., Abe, K., Furutani, R., Kibayashi, K., 2014b. Changes in dopamine transporter 
expression in the midbrain following traumatic brain injury: an immunohistochemical and 
in situ hybridization study in a mouse model. Neurol. Res. 36, 239–246. 
doi:10.1179/1743132813Y.0000000289 
Sidaros, A., Engberg, A.W., Sidaros, K., Liptrot, M.G., Herning, M., Petersen, P., Paulson, O.B., 
Jernigan, T.L., Rostrup, E., 2008. Diffusion tensor imaging during recovery from severe 
traumatic brain injury and relation to clinical outcome: a longitudinal study. Brain 131, 559 
–572. doi:10.1093/brain/awm294 
Siironen, J., Juvela, S., Kanarek, K., Vilkki, J., Hernesniemi, J., Lappalainen, J., 2007. The Met 
Allele of the BDNF Val66Met Polymorphism Predicts Poor Outcome Among Survivors of 
Aneurysmal Subarachnoid Hemorrhage. Stroke 38, 2858–2860. 
doi:10.1161/STROKEAHA.107.485441 
  257 
Silhol, M., Bonnichon, V., Rage, F., Tapia-Arancibia, L., 2005. Age-related changes in brain-
derived neurotrophic factor and tyrosine kinase receptor isoforms in the hippocampus and 
hypothalamus in male rats. Neuroscience 132, 613–624. 
doi:10.1016/j.neuroscience.2005.01.008 
Siuciak, J.A., Lewis, D.R., Wiegand, S.J., Lindsay, R.M., 1997. Antidepressant-like effect of 
brain-derived neurotrophic factor (BDNF). Pharmacol. Biochem. Behav. 56, 131–137. 
doi:10.1016/S0091-3057(96)00169-4 
Social Security Death Index [WWW Document], n.d. . GenealogyBank.com. URL 
http://www.genealogybank.com/gbnk/ssdi/ (accessed 12.9.13). 
Soeiro-De-Souza, M.G., Bio, D.S., David, D.P., Missio, G., Lima, B., Fernandes, F., Machado-
Vieira, R., Moreno, R.A., 2013. Gender effects of the COMT Val 158 Met genotype on 
verbal fluency in healthy adults. Mol. Med. Rep. 8, 837–844. doi:10.3892/mmr.2013.1564 
Stroop, J., 1935. Studies of interference in serial verbal reactions. J. Exp. Psychol. 18, 643–662. 
doi:10.1037/h0054651 
Stroop, J.R., 1935. Studies of interference in serial verbal reactions. J. Exp. Psychol. Exp. Psychol. 
18, 643–662. doi:10.1037/h0054651 
Susman, M., DiRusso, S.M., Sullivan, T., Risucci, D., Nealon, P., Cuff, S., Haider, A., Benzil, D., 
2002. Traumatic brain injury in the elderly: increased mortality and worse functional 
outcome at discharge despite lower injury severity. J. Trauma 53, 219–223; discussion 
223–224. 
Tang, L., Todd, R.D., O’Malley, K.L., 1994. Dopamine D2 and D3 receptors inhibit dopamine 
release. J. Pharmacol. Exp. Ther. 270, 475. 
Tanriverdi, F., Senyurek, H., Unluhizarci, K., Selcuklu, A., Casanueva, F.F., Kelestimur, F., 2006. 
High Risk of Hypopituitarism after Traumatic Brain Injury: A Prospective Investigation of 
Anterior Pituitary Function in the Acute Phase and 12 Months after Trauma. J. Clin. 
Endocrinol. Metab. 91, 2105–2111. doi:10.1210/jc.2005-2476 
Tao, X., Finkbeiner, S., Arnold, D.B., Shaywitz, A.J., Greenberg, M.E., 1998. Ca2+ Influx 
Regulates BDNF Transcription by a CREB Family Transcription Factor-Dependent 
Mechanism. Neuron 20, 709–726. doi:10.1016/S0896-6273(00)81010-7 
Tapia-Arancibia, L., Aliaga, E., Silhol, M., Arancibia, S., 2008. New insights into brain BDNF 
function in normal aging and Alzheimer disease. Brain Res. Rev. 59, 201–220. 
doi:10.1016/j.brainresrev.2008.07.007 
Tate, D.F., Bigler, E.D., 2000. Fornix and Hippocampal Atrophy in Traumatic Brain Injury. Learn. 
Mem. 7, 442 –446. doi:10.1101/lm.33000 
Tate, D.F., Bigler, E.D., 2000. Fornix and hippocampal atrophy in traumatic brain injury. Learn. 
Mem. 7, 442–446. 
Teasdale, G., Jennett, B., 1974a. Assessment of coma and impaired consciousness. A practical 
scale. Lancet 2, 81–84. 
Teasdale, G., Jennett, B., 1974b. Assessment of coma and impaired consciousness. A practical 
scale. Lancet 2, 81–84. 
Teasdale, G.M., Murray, G.D., Nicoll, J.A.R., 2005. The association between APOE epsilon4, age 
and outcome after head injury: a prospective cohort study. Brain J. Neurol. 128, 2556–
2561. doi:10.1093/brain/awh595 
Temkin, N.R., Dikmen, S.S., Wilensky, A.J., Keihm, J., Chabal, S., Winn, H.R., 1990. A 
randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. 
N. Engl. J. Med. 323, 497–502. doi:10.1056/NEJM199008233230801 
  258 
Terracciano, A., Piras, M.G., Lobina, M., Mulas, A., Meirelles, O., Sutin, A.R., Chan, W., Sanna, 
S., Uda, M., Crisponi, L., Schlessinger, D., 2013. Genetics of serum BDNF: Meta-analysis 
of the Val66Met and genome-wide association study. World J. Biol. Psychiatry Off. J. 
World Fed. Soc. Biol. Psychiatry 14. doi:10.3109/15622975.2011.616533 
Thompson, J., Thomas, N., Singleton, A., Piggott, M., Lloyd, S., Perry, E.K., Morris, C.M., Perry, 
R.H., Ferrier, I.N., Court, J.A., 1997. D2 dopamine receptor gene (DRD2) Taq1 A 
polymorphism: reduced dopamine D2 receptor binding in the human striatum associated 
with the A1 allele. Pharmacogenetics 7, 479–484. 
Toker, L., Amar, S., Bersudsky, Y., Benjamin, J., Klein, E., 2010. The biology of tryptophan 
depletion and mood disorders. Isr. J. Psychiatry Relat. Sci. 47, 46–55. 
Tomaiuolo, F., Carlesimo, G.A., Paola, M.D., Petrides, M., Fera, F., Bonanni, R., Formisano, R., 
Pasqualetti, P., Caltagirone, C., 2004. Gross morphology and morphometric sequelae in 
the hippocampus, fornix, and corpus callosum of patients with severe non-missile traumatic 
brain injury without macroscopically detectable lesions: a T1 weighted MRI study. J. 
Neurol. Neurosurg. Psychiatry 75, 1314–1322. doi:10.1136/jnnp.2003.017046 
Torres, G.E., Carneiro, A., Seamans, K., Fiorentini, C., Sweeney, A., Yao, W.D., Caron, M.G., 
2003. Oligomerization and trafficking of the human dopamine transporter. J. Biol. Chem. 
278, 2731. 
Tunbridge, E.M., Harrison, P.J., Weinberger, D.R., 2006. Catechol-o-Methyltransferase, 
Cognition, and Psychosis: Val158Met and Beyond. Biol. Psychiatry 60, 141–151. 
doi:10.1016/j.biopsych.2005.10.024 
Turken, A.U., Whitfield-Gabrieli, S., Bammer, R., Baldo, J., Dronkers, N.F., Gabrieli, J.D.E., 
2008. COGNITIVE PROCESSING SPEED AND THE STRUCTURE OF WHITE 
MATTER PATHWAYS: CONVERGENT EVIDENCE FROM NORMAL VARIATION 
AND LESION STUDIES. NeuroImage 42, 1032–1044. 
doi:10.1016/j.neuroimage.2008.03.057 
Udekwu, P., Kromhout-Schiro, S., Vaslef, S., Baker, C., Oller, D., 2004a. Glasgow Coma Scale 
score, mortality, and functional outcome in head-injured patients. J. Trauma 56, 1084–
1089. 
Udekwu, P., Kromhout-Schiro, S., Vaslef, S., Baker, C., Oller, D., 2004b. Glasgow Coma Scale 
score, mortality, and functional outcome in head-injured patients. J. Trauma 56, 1084–
1089. 
Vakil, E., 2005. The effect of moderate to severe traumatic brain injury (TBI) on different aspects 
of memory: a selective review. J. Clin. Exp. Neuropsychol. 27, 977–1021. 
doi:10.1080/13803390490919245 
Van Dyck, C.H., Malison, R.T., Staley, J.K., Jacobsen, L.K., Seibyl, J.P., Laruelle, M., Baldwin, 
R.M., Innis, R.B., Gelernter, J., 2004. Central serotonin transporter availability measured 
with [123I]beta-CIT SPECT in relation to serotonin transporter genotype. Am. J. 
Psychiatry 161, 525–531. 
Van IJzendoorn, M.H., Caspers, K., Bakermans-Kranenburg, M.J., Beach, S.R.H., Philibert, R., 
2010. Methylation matters: interaction between methylation density and serotonin 
transporter genotype predicts unresolved loss or trauma. Biol. Psychiatry 68, 405–407. 
doi:10.1016/j.biopsych.2010.05.008 
VanNess, S.H., Owens, M.J., Kilts, C.D., 2005. The variable number of tandem repeats element 
in DAT1 regulates in vitro dopamine transporter density. BMC Genet. 6, 55. 
doi:10.1186/1471-2156-6-55 
  259 
Vidaurre, O.G., Gascón, S., Deogracias, R., Sobrado, M., Cuadrado, E., Montaner, J., Rodríguez-
Peña, A., Díaz-Guerra, M., 2012. Imbalance of neurotrophin receptor isoforms TrkB-
FL/TrkB-T1 induces neuronal death in excitotoxicity. Cell Death Dis. 3, e256. 
doi:10.1038/cddis.2011.143 
Vijayraghavan, S., Wang, M., Birnbaum, S.G., Williams, G.V., Arnsten, A.F.T., 2007. Inverted-
U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat. 
Neurosci. 10, 376–384. doi:10.1038/nn1846 
Vinogradov, S., Fisher, M., Holland, C., Shelly, W., Wolkowitz, O., Mellon, S.H., 2009. Is serum 
brain-derived neurotrophic factor a biomarker for cognitive enhancement in 
schizophrenia? Biol. Psychiatry 66, 549–553. doi:10.1016/j.biopsych.2009.02.017 
Voisey, J., Swagell, C.D., Hughes, I.P., Morris, C.P., van Daal, A., Noble, E.P., Kann, B., Heslop, 
K.A., Young, R.M., Lawford, B.R., 2009. The DRD2 gene 957C>T polymorphism is 
associated with posttraumatic stress disorder in war veterans. Depress. Anxiety 26, 28–33. 
doi:10.1002/da.20517 
Wagner, A.K., 2010. TBI translational rehabilitation research in the 21st Century: exploring a 
Rehabilomics research model. Eur. J. Phys. Rehabil. Med. 46, 549–556. 
Wagner, A.K., 2010. TBI translational rehabilitation research in the 21st Century: exploring a 
Rehabilomics research model. Eur. J. Phys. Rehabil. Med. 46, 549–556. 
Wagner, A.K., 2011. Rehabilomics: a conceptual framework to drive biologics research. PM R 3, 
S28–30. doi:10.1016/j.pmrj.2011.04.013 
Wagner, A.K., Amin, K.B., Niyonkuru, C., Postal, B.A., McCullough, E.H., Ozawa, H., Dixon, 
C.E., Bayir, H., Clark, R.S., Kochanek, P.M., Fabio, A., 2011a. CSF Bcl-2 and cytochrome 
C temporal profiles in outcome prediction for adults with severe TBI. J. Cereb. Blood Flow 
Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 31, 1886–1896. 
doi:10.1038/jcbfm.2011.31 
Wagner, A.K., Bayir, H., Ren, D., Puccio, A., Zafonte, R.D., Kochanek, P.M., 2004. Relationships 
between cerebrospinal fluid markers of excitotoxicity, ischemia, and oxidative damage 
after severe TBI: the impact of gender, age, and hypothermia. J. Neurotrauma 21, 125–136. 
Wagner, A.K., Chen, X., Kline, A.E., Li, Y., Zafonte, R.D., Dixon, C.E., 2005. Gender and 
environmental enrichment impact dopamine transporter expression after experimental 
traumatic brain injury. Exp. Neurol. 195, 475–483. doi:10.1016/j.expneurol.2005.06.009 
Wagner, A.K., Drewencki, L.L., Chen, X., Santos, F.R., Khan, A.S., Harun, R., Torres, G.E., 
Michael, A.C., Dixon, C.E., 2009. Chronic methylphenidate treatment enhances striatal 
dopamine neurotransmission after experimental traumatic brain injury. J. Neurochem. 108, 
986–997. doi:10.1111/j.1471-4159.2008.05840.x 
Wagner, A.K., Hatz, L.E., Scanlon, J.M., Niyonkuru, C., Miller, M.A., Ricker, J.H., Conley, Y.P., 
Ferrell, R.E., 2012. Association of KIBRA rs17070145 polymorphism and episodic 
memory in individuals with severe TBI. Brain Inj. BI. doi:10.3109/02699052.2012.700089 
Wagner, A.K., Kline, A.E., Ren, D., Willard, L.A., Wenger, M.K., Zafonte, R.D., Dixon, C.E., 
2007a. Gender associations with chronic methylphenidate treatment and behavioral 
performance following experimental traumatic brain injury. Behav. Brain Res. 181, 200–
209. doi:10.1016/j.bbr.2007.04.006 
Wagner, A.K., McCullough, E.H., Niyonkuru, C., Ozawa, H., Loucks, T.L., Dobos, J.A., Brett, 
C.A., Santarsieri, M., Dixon, C.E., Berga, S.L., Fabio, A., 2011b. Acute serum hormone 
levels: characterization and prognosis after severe traumatic brain injury. J. Neurotrauma 
28, 871–888. doi:10.1089/neu.2010.1586 
  260 
Wagner, A.K., McCullough, E.H., Niyonkuru, C., Ozawa, H., Loucks, T.L., Dobos, J.A., Brett, 
C.A., Santarsieri, M., Dixon, C.E., Berga, S.L., Fabio, A., 2011c. Acute serum hormone 
levels: characterization and prognosis after severe traumatic brain injury. J. Neurotrauma 
28, 871–888. doi:10.1089/neu.2010.1586 
Wagner, A.K., Miller, M.A., Scanlon, J., Ren, D., Kochanek, P.M., Conley, Y.P., 2010. Adenosine 
A1 receptor gene variants associated with post-traumatic seizures after severe TBI. 
Epilepsy Res. 90, 259–272. doi:10.1016/j.eplepsyres.2010.06.001 
Wagner, A.K., Ren, D., Conley, Y.P., Ma, X., Kerr, M.E., Zafonte, R.D., Puccio, A.M., Marion, 
D.W., Dixon, C.E., 2007. Sex and genetic associations with cerebrospinal fluid dopamine 
and metabolite production after severe traumatic brain injury. J. Neurosurg. 106, 538–547. 
doi:10.3171/jns.2007.106.4.538 
Wagner, A.K., Ren, D., Conley, Y.P., Ma, X., Kerr, M.E., Zafonte, R.D., Puccio, A.M., Marion, 
D.W., Dixon, C.E., 2007b. Sex and genetic associations with cerebrospinal fluid dopamine 
and metabolite production after severe traumatic brain injury. J. Neurosurg. 106, 538–547. 
doi:10.3171/jns.2007.106.4.538 
Wagner, A.K., Scanlon, J.M., Becker, C.R., Ritter, A.C., Niyonkuru, C., Dixon, C.E., Conley, 
Y.P., Price, J.C., 2014. The influence of genetic variants on striatal dopamine transporter 
and D2 receptor binding after TBI. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. 
Blood Flow Metab. doi:10.1038/jcbfm.2014.87 
Wagner, A.K., Scanlon, J.M., Becker, C.R., Ritter, A.C., Niyonkuru, C., Dixon, C.E., Conley, 
Y.P., Price, J.C., 2014. The influence of genetic variants on striatal dopamine transporter 
and D2 receptor binding after TBI. J. Cereb. Blood Flow Metab. 34, 1328–1339. 
doi:10.1038/jcbfm.2014.87 
Wagner, A.K., Zitelli, K.T., 2012. A Rehabilomics focused perspective on molecular mechanisms 
underlying neurological injury, complications, and recovery after severe TBI. 
Pathophysiol. Off. J. Int. Soc. Pathophysiol. ISP. doi:10.1016/j.pathophys.2012.02.007 
Wagner, A.K., Zitelli, K.T., 2013. A Rehabilomics focused perspective on molecular mechanisms 
underlying neurological injury, complications, and recovery after severe TBI. 
Pathophysiol. Off. J. Int. Soc. Pathophysiol. ISP 20, 39–48. 
doi:10.1016/j.pathophys.2012.02.007 
Walton, M.R., Dragunow, M., 2000. Is CREB a key to neuronal survival? Trends Neurosci. 23, 
48–53. doi:10.1016/S0166-2236(99)01500-3 
Wang, H., Zhou, X.-F., 2002. Injection of brain-derived neurotrophic factor in the rostral 
ventrolateral medulla increases arterial blood pressure in anaesthetized rats. Neuroscience 
112, 967–975. 
Wang, Y., Neumann, M., Hansen, K., Hong, S.M., Kim, S., Noble-Haeusslein, L.J., Liu, J., 2011. 
Fluoxetine increases hippocampal neurogenesis and induces epigenetic factors but does not 
improve functional recovery after traumatic brain injury. J. Neurotrauma 28, 259–268. 
doi:10.1089/neu.2010.1648 
Wan, R., Weigand, L.A., Bateman, R., Griffioen, K., Mendelowitz, D., Mattson, M.P., 2014. 
Evidence that BDNF regulates heart rate by a mechanism involving increased brainstem 
parasympathetic neuron excitability. J. Neurochem. doi:10.1111/jnc.12656 
Warden, D.L., Gordon, B., McAllister, T.W., Silver, J.M., Barth, J.T., Bruns, J., Drake, A., Gentry, 
T., Jagoda, A., Katz, D.I., Kraus, J., Labbate, L.A., Ryan, L.M., Sparling, M.B., Walters, 
B., Whyte, J., Zapata, A., Zitnay, G., 2006. Guidelines for the Pharmacologic Treatment 
  261 
of Neurobehavioral Sequelae of Traumatic Brain Injury. J. Neurotrauma 23, 1468–1501. 
doi:10.1089/neu.2006.23.1468 
Warner, M.A., de la Plata, C.M., Spence, J., Wang, J.Y., Harper, C., Moore, C., Devous, M., Diaz-
Arrastia, R., 2010. Assessing spatial relationships between axonal integrity, regional brain 
volumes, and neuropsychological outcomes after traumatic axonal injury. J. Neurotrauma 
27, 2121–2130. 
Warner‐Schmidt, J.L., Duman, R.S., 2006. Hippocampal neurogenesis: Opposing effects of stress 
and antidepressant treatment. Hippocampus 16, 239–249. doi:10.1002/hipo.20156 
Washington, P.M., Forcelli, P.A., Wilkins, T., Zapple, D.N., Parsadanian, M., Burns, M.P., 2012. 
The Effect of Injury Severity on Behavior: A Phenotypic Study of Cognitive and Emotional 
Deficits after Mild, Moderate, and Severe Controlled Cortical Impact Injury in Mice. J. 
Neurotrauma 29, 2283–2296. doi:10.1089/neu.2012.2456 
Webster, M.J., Herman, M.M., Kleinman, J.E., Shannon Weickert, C., 2006. BDNF and trkB 
mRNA expression in the hippocampus and temporal cortex during the human lifespan. 
Gene Expr. Patterns 6, 941–951. 
Wendland, J.R., Martin, B.J., Kruse, M.R., Lesch, K.-P., Murphy, D.L., 2006. Simultaneous 
genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR 
and rs25531. Mol Psychiatry 11, 224–226. 
Whitnall, L., McMillan, T.M., Murray, G.D., Teasdale, G.M., 2006. Disability in young people 
and adults after head injury: 5-7 year follow up of a prospective cohort study. J. Neurol. 
Neurosurg. Psychiatry 77, 640–645. doi:10.1136/jnnp.2005.078246 
Whyte, J., Hart, T., Vaccaro, M., Grieb-Neff, P., Risser, A., Polansky, M., Coslett, H.B., 2004. 
Effects of methylphenidate on attention deficits after traumatic brain injury: a 
multidimensional, randomized, controlled trial. Am. J. Phys. Med. Rehabil. Assoc. Acad. 
Physiatr. 83, 401–420. 
Willmott, C., Ponsford, J., McAllister, T.W., Burke, R., 2013. Effect of COMT Val158Met 
genotype on attention and response to methylphenidate following traumatic brain injury. 
Brain Inj. 27, 1281–1286. doi:10.3109/02699052.2013.809553 
Willmott, C., Withiel, T., Ponsford, J., Burke, R., 2014a. COMT Val158Met and Cognitive and 
Functional Outcomes after Traumatic Brain Injury. J. Neurotrauma. 
doi:10.1089/neu.2013.3308 
Willmott, C., Withiel, T., Ponsford, J., Burke, R., 2014b. COMT Val158Met and cognitive and 
functional outcomes after traumatic brain injury. J. Neurotrauma. 
doi:10.1089/neu.2013.3308 
Willmott, C., Withiel, T., Ponsford, J., Burke, R., 2014c. COMT Val(158)Met and Cognitive and 
Functional Outcomes after Traumatic Brain Injury. J. Neurotrauma 31, 1507–1514. 
doi:10.1089/neu.2013.3308 
Wilson, J.T., Hadley, D.M., Wiedmann, K.D., Teasdale, G.M., 1995. Neuropsychological 
consequences of two patterns of brain damage shown by MRI in survivors of severe head 
injury. J. Neurol. Neurosurg. Psychiatry 59, 328–331. 
Wilson, J.T., Pettigrew, L.E., Teasdale, G.M., 1998. Structured interviews for the Glasgow 
Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J. 
Neurotrauma 15, 573–585. 
Wilson, M.S., Hamm, R.J., 2002. Effects of fluoxetine on the 5-HT1A receptor and recovery of 
cognitive function after traumatic brain injury in rats. Am. J. Phys. Med. Rehabil. Assoc. 
Acad. Physiatr. 81, 364–372. 
  262 
Wise, E.K., Hoffman, J.M., Powell, J.M., Bombardier, C.H., Bell, K.R., 2012. Benefits of exercise 
maintenance after traumatic brain injury. Arch. Phys. Med. Rehabil. 93, 1319–1323. 
doi:10.1016/j.apmr.2012.05.009 
Woolf, P.D., 1992. Hormonal responses to trauma. Crit. Care Med. 20, 216–226. 
Wozniak, G., Georgoulias, P., Iliadis, C., Valotasiou, V., Papadopoulos, G., Bagiatis, V., Tsougos, 
I., Paterakis, K.N., Fountas, K.N., 2010. Serotonin and Neuron-specific Enolase. 
Neurosurg. Q. 20, 297–303. doi:10.1097/WNQ.0b013e3181732399 
Xiao, L., Becker, J.B., 1994. Quantitative microdialysis determination of extracellular striatal 
dopamine concentration in male and female rats: effects of estrous cycle and gonadectomy. 
Neurosci. Lett. 180, 155–158. 
Xie, P., Kranzler, H.R., Poling, J., Stein, M.B., Anton, R.F., Brady, K., Weiss, R.D., Farrer, L., 
Gelernter, J., 2009. Interactive effect of stressful life events and the serotonin transporter 
5-HTTLPR genotype on posttraumatic stress disorder diagnosis in 2 independent 
populations. Arch. Gen. Psychiatry 66, 1201–1209. 
doi:10.1001/archgenpsychiatry.2009.153 
Xie, T., Ho, S.L., Ramsden, D., 1999. Characterization and implications of estrogenic down-
regulation of human catechol-O-methyltransferase gene transcription. Mol. Pharmacol. 56, 
31–38. 
Yang, A.C., Chen, T.-J., Tsai, S.-J., Hong, C.-J., Kuo, C.-H., Yang, C.-H., Kao, K.-P., 2010. BDNF 
Val66Met polymorphism alters sympathovagal balance in healthy subjects. Am. J. Med. 
Genet. Part B Neuropsychiatr. Genet. Off. Publ. Int. Soc. Psychiatr. Genet. 153B, 1024–
1030. doi:10.1002/ajmg.b.31069 
Yang, B., Slonimsky, J.D., Birren, S.J., 2002. A rapid switch in sympathetic neurotransmitter 
release properties mediated by the p75 receptor. Nat. Neurosci. 5, 539–545. 
doi:10.1038/nn853 
Yang, L., Zhang, Z., Sun, D., Xu, Z., Yuan, Y., Zhang, X., Li, L., 2010. Low serum BDNF may 
indicate the development of PSD in patients with acute ischemic stroke. Int. J. Geriatr. 
Psychiatry. doi:10.1002/gps.2552 
Yan, H.Q., Kline, A.E., Ma, X., Hooghe-Peters, E.L., Marion, D.W., Dixon, C.E., 2001. Tyrosine 
hydroxylase, but not dopamine beta-hydroxylase, is increased in rat frontal cortex after 
traumatic brain injury. Neuroreport 12, 2323. 
Yan, H.Q., Kline, A.E., Ma, X., Li, Y., Dixon, C.E., 2002. Traumatic brain injury reduces 
dopamine transporter protein expression in the rat frontal cortex. Neuroreport 13, 1899. 
Yan, H.Q., Kline, A.E., Ma, X., Li, Y., Dixon, C.E., 2002. Traumatic brain injury reduces 
dopamine transporter protein expression in the rat frontal cortex. Neuroreport 13, 1899–
1901. 
Yasuda, S., Wehman, P., Targett, P., Cifu, D., West, M., 2001. Return to work for persons with 
traumatic brain injury. Am. J. Phys. Med. Rehabil. Assoc. Acad. Physiatr. 80, 852–864. 
You, Z., Luo, C., Zhang, W., Chen, Y., He, J., Zhao, Q., Zuo, R., Wu, Y., 2011. Pro- and anti-
inflammatory cytokines expression in rat’s brain and spleen exposed to chronic mild stress: 
involvement in depression. Behav. Brain Res. 225, 135–141. 
doi:10.1016/j.bbr.2011.07.006 
Zafonte, R.D., Cullen, N., Lexell, J., 2002. Serotonin agents in the treatment of acquired brain 
injury. J. Head Trauma Rehabil. 17, 322. 
Zalsman, G., Huang, Y., Oquendo, M.A., Burke, A.K., Hu, X., Brent, D.A., Ellis, S.P., Goldman, 
D., Mann, J.J., 2006. Association of a Triallelic Serotonin Transporter Gene Promoter 
  263 
Region (5-HTTLPR) Polymorphism With Stressful Life Events and Severity of 
Depression. Am J Psychiatry 163, 1588–1593. doi:<p>10.1176/appi.ajp.163.9.1588</p> 
Zawarynski, P., Tallerico, T., Seeman, P., Lee, S.P., O’Dowd, B.F., George, S.R., 1998. Dopamine 
D2 receptor dimers in human and rat brain. FEBS Lett. 441, 383–386. 
Zeng, L.-L., Shen, H., Liu, L., Wang, L., Li, B., Fang, P., Zhou, Z., Li, Y., Hu, D., 2012. Identifying 
major depression using whole-brain functional connectivity: a multivariate pattern 
analysis. Brain 135, 1498–1507. doi:10.1093/brain/aws059 
Zhan C, Miller MR, 2003. EXcess length of stay, charges, and mortality attributable to medical 
injuries during hospitalization. JAMA 290, 1868–1874. doi:10.1001/jama.290.14.1868 
Zhang, Y., Bertolino, A., Fazio, L., Blasi, G., Rampino, A., Romano, R., Lee, M.-L.T., Xiao, T., 
Papp, A., Wang, D., Sadée, W., 2007. Polymorphisms in human dopamine D2 receptor 
gene affect gene expression, splicing, and neuronal activity during working memory. Proc. 
Natl. Acad. Sci. 104, 20552–20557. doi:10.1073/pnas.0707106104 
Zhang, Z.-Y., Zhang, Z., Fauser, U., Schluesener, H.J., 2007. Global hypomethylation defines a 
sub-population of reactive microglia/macrophages in experimental traumatic brain injury. 
Neurosci. Lett. 429, 1–6. doi:10.1016/j.neulet.2007.09.061 
Zhu, X., Wang, X., Xiao, J., Liao, J., Zhong, M., Wang, W., Yao, S., 2012. Evidence of a 
dissociation pattern in resting-state default mode network connectivity in first-episode, 
treatment-naive major depression patients. Biol. Psychiatry 71, 611–617. 
doi:10.1016/j.biopsych.2011.10.035 
 
